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ALTERED PATTERNS OF HEPARAN SULPHATE
PROTEOGLYCAN EXPRESSION IN HUMAN EPITHELIAL
OVARIAN CANCER EJ Davies1, A McGown1, J Shanks2, G David3, JT
Gallagher4 and G Jayson4, 1Department of Drug Development and Imaging,
Paterson Institute for Cancer Research, Manchester, UK, 2Dept
Histopathology, Christie Hospital, Manchester UK, 3Centre for Human
Genetics, University of Leuven, Belgium, 4CRC Department of Medical
Oncology, Christie Hospital, Manchester, UK
Heparan sulphate proteoglycans (HSPG) have been implicated in a number of
processes related to the malignant phenotype, including malignant transformation,
metastasis and angiogenesis. Changes in expression of HSPG have been reported in
certain cancers, but most studies have only looked at syndecan 1 expression. The
present study reports the immunohistochemical expression and cell localisation of
syndecan 1, 2, 3 and 4, glypican and perlecan in human ovarian cancer using specific
monoclonal antibodies and relates the findings to established prognostic factors. We
performed immunostaining on formalin and frozen sections of normal ovary (n=9),
benign ovarian tumours (n=15), borderline tumours (n=3) and epithelial ovarian
cancer (n=90). Preliminary findings suggest altered expression and distribution of
syndecan 1 in ovarian cancer tissue, which may suggest a role in metastasis. Scanning
confocal microscopy suggests that syndecan 1 is present in the cytoplasm of epithelial
cancer cells and this finding may represent internalisation or increased secretion of
syndecan 1. Syndecan 4 also shows moderate cytoplasmic staining on light
microscopy. The results indicate altered expression of HSPG in ovarian cancer, and
increased intracellular localisation of syndecan 1 and syndecan 4. There is also intense
reactivity for syndecan 3 and perlecan in tumour vessels, possibly suggesting a role in
angiogenesis. This and the results of further studies including the prognostic signifi-
cance of these changes by univariate and multivariate analysis will be presented.
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THE INTERACTION OF VEGF165 WITH HEPARAN SULPHATE
Chris Robinson*+, Sally Stringer*+ & John Gallagher+, The Cancer
Research Campaign Department of Drug Development* and the CRC and
University of Manchester Department of Medical Oncology+, Paterson
Institute for Cancer Research, Christie Hospital, Manchester M20 4BX, UK
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for cultured
endothelial cells, and a potent stimulator of angiogenesis in vivo. The ability of the
most abundant VEGF isoform, VEGF165, to bind heparin and the related cell surface
glycosaminoglycan heparan sulphate (HS) has been shown to play a significant role in
the functioning of this growth factor. In light of the central role of VEGF in patholog-
ical conditions which are angiogenesis-dependent, notably the neovascularisation
observed in growing tumours, the regulation of VEGF by heparin-like molecules is
attracting much interest as a possible target for therapeutic intervention.
Heparan sulphate (HS) is a linear sulphated polysaccharide found covalently
linked to core proteins in the extracellular matrix and on the surface of almost all
mammalian cell types. It has a unique molecular structure consisting of short regions
of high sulphation level (S-domains) interspersed by longer, predominantly non-
sulphated  N-acetyl-rich stretches. The complex structure of HS is the key to its biolog-
ical activities as the regions of sulphation confer on this polymer the ability to bind
specific protein ligands and through this binding modulate their functions.
We are studying the interaction of VEGF165 with heparin/HS in order to charac-
terise the sequence requirements within these polysaccharides that are responsible for
their effects on VEGF function. Initially, Scatchard analysis of the VEGF165-HS inter-
action revealed that binding occurs in a 1:1 ratio of VEGF165 dimers to HS chains.
Whilst in-solution VEGF165-binding studies using specifically cleaved HS species
showed that the interaction requires both highly sulphated ‘S-domain’ regions of the
HS chains as well as the predominantly non-sulphated N-acetyl-rich sequences. These
results support a model for the VEGF165-HS interaction where S-domain regions inter-
acting with the two heparin-binding sites of the VEGF165 dimer are connected by a
stretch of largely unsulphated sequence. Competitive inhibition studies and work with
HS oligosaccharides suggest that the S-domain regions may have to be at least 8
monosaccharides in length and that 2-O-sulphation appears to be particularly impor-
tant for the VEGF165 interaction.
Currently, affinity chromatography and HPLC are being used to identify specific
S-domain sequences capable of VEGF165 binding and preliminary results appear to
confirm the importance of 2-O-sulphation. Meanwhile, enzyme protection assays and
oligosaccharide binding experiments are in progress to isolate the entire binding
sequence from within HS. Attempts are also underway at transforming a HS-deficient
cell line with the VEGF-receptor KDR to set up a biological activity assay system for
potentially interesting HS fragments identified in these studies.
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DIFFERENTIAL REGULATION OF VEGF FAMILY MEMBERS BY
C-ERBB LIGANDS IN HEAD AND NECK SQUAMOUS CELL
CARCINOMA (HNSCC) P O-charoenrat*1, P Rhys-Evans1, and SA Eccles2,
1Royal Marsden Hospital, 2Institute of Cancer Research, Sutton, Surrey SM2
5NG, UK
Aberrant expression of (proto)-oncogenic tyrosine kinases such as c-erbB receptors
contributes to the progression of HNSCC. We have previously shown that EGFR/c-
erbB activation potentiates invasion via upregulation of tumour cell motility and
matrix metalloproteinase activity. However, in addition, upregulation of vascular
endothelial growth factor-A (VEGF-A) expression via EGFR and/or c-erbB-2
signalling has been described in other tumour types. This raises the possibility that
potentiation of angiogenesis might also contribute to the pathogenesis of HNSCC
which overexpress members of the c-erbB family. Using semiquantitative RT-PCR,
we found that all four known members of the VEGF family (VEGF-A, VEGF-B,
VEGF-C and VEGF-D) were expressed in a panel of 15 HNSCC lines. We found a
direct correlation between EGFR and VEGF expression levels in tissue specimens
from HNSCC patients. To determine whether erbB activation was directly linked to
VEGF expression we studied the effects of three major ligands with different selec-
tivity of binding to c-erbB receptors; namely TGF-a, betacellulin (BTC) and hereg-
ulin-b1 (HRG-b1). All ligands upregulated all four isoforms of VEGF-A (most
notably isoform 121) and also VEGF-C (BTC optimum concentrations 1–10 nM;
TGF-a and HRG-b1 10–100 nM) but had no effect on VEGF-B. All ligands simulta-
neously down-regulated the expression of VEGF-D. An antagonistic EGFR antibody
(ICR62) reduced the basal mRNA levels of VEGF-A (all isoforms) and VEGF-C but
had no detectable effects on VEGF-B and VEGF-D. ICR62 also reversed the effects
(whether stimulatory or inhibitory) of all three c-erbB ligands on VEGF-A, VEGF-C
and VEGF-D expression. An anti-c-erbB-2 mAb (ICR12) had no effect on basal or
ligand-modulated expression of any VEGF in these cell lines, although they co-
express this receptor, which is a preferred heterodimerization partner for all receptors.
The VEGF-C results are particularly interesting since this ligand has been implicated
in lymphangiogenesis, and its expression correlates with lymph node metastasis in
these HNSCC patients. Our results show that the four VEGF genes are regulated by c-
erbB signalling pathways in a strikingly different manner, suggesting that they serve
distinct, although perhaps complimentary (VEGF-A and VEGF-C) or antagonistic
(VEGF-D) functions. The EGFR signalling pathway plays a major role in VEGF
regulation in HNSCC, even in response to ligands which bind primarily (HRG-b1) or
additionally (BTC) to other family members, notably c-erbB-4, presumably by
forming active heterodimers.
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IMMUNOHISTOCHEMICAL EXPRESSION OF VASCULAR
ENDOTHELIAL GROWTH FACTOR (VEGF) AND VESSEL
COUNTING AS PROGNOSTIC INDICATORS IN NODE-NEGATIVE
COLORECTAL CANCER E Tsiompanou, GM Boxer, T Levine & RHJ Begent,
Oncology Dept, Royal Free Campus, UCL Medical School, London NW3
2PF, UK
Current tumour staging practices in colorectal cancer are proven inadequate to iden-
tify those patients with node-negative disease that will eventually relapse. New prog-
nostic markers are needed to help us select high risk patients that will subsequently
benefit from treatment at an earlier stage when there is minimal residual disease. The
present study was designed to assess the VEGF expression and the microvascular
count in node-negative colorectal cancers and to investigate the correlation of these
two parameters with survival rate. Formalin-fixed, paraffin sections from 56 patients
with primary colorectal carcinomas (12 Dukes A, 44 Dukes B) that have been
completely excised, were immunostained for VEGF (R & D Systems) and CD34 (for
blood vessel identification). VEGF reactivity was examined at or adjacent to the inva-
sive margin and was graded on a scale of 0 to 3+. In addition, for each case, binding to
vascular endothelium was noted. Vessel counts were also assessed at the invasive edge
of the tumour, following the criteria of Weidner et al for assessing microvessel density
in human tumour specimens1. Findings were correlated to survival in days and to
outcome (dead/alive). Kaplan-Meier plots were generated and in Dukes B patients a
statistically significant difference was demonstrated between VEGF+ve and
VEGF–ve group (p=<0.05). The presence of VEGF reactivity was significantly corre-
lated with patient outcome (p=<0.03) by Fishers Exact Test, as was the presence of
VEGF reactivity within the vascular endothelium (p=0.018), both tests indicating that
VEGF expression is an indicator of poor prognosis. The maximum vessel density per
case, recorded for the Dukes B patient group (median=32.5, range 9–60,) was shown
to be lower for those cases with a poor outcome (Mann Whitney U-test: p=0.019).
These results suggest that assessment of VEGF expression by immunohistochemistry
in Dukes B patients may be used to identify patients at risk of relapse. Moreover,
using this assay it may be possible to select node-negative patients for therapeutic
intervention, using treatment modalities such as chemotherapy or antibody-directed
cancer therapy. Our results, which suggest that a low microvascular count is a marker
of poor prognosis, are contrary to the findings of most other investigators. Further
studies are required to establish the significance of this parameter. This work was
supported by the Cancer Research Campaign.
1 Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumour angiogenesis
and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1–8
British Journal of Cancer (2000) 83(Suppl 1), 29–84
© 2000 Cancer Research Campaign
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A COMPARISON OF SERUM AND PLASMA LEVELS OF
VASCULAR ENDOTHELIAL GROWTH FACTOR DURING THE
MENSTRUAL CYCLE IN HEALTHY FEMALE VOLUNTEERS C Mcllhenny*,
JC Doughty, WD George, University Department of Surgery, Western
Infirmary, Glasgow G11 6NT, UK
Aims It has been suggested that serum levels of the angiogenic cytokine VEGF may
alter with the menstrual cycle and be responsible for the reported increase in recur-
rence rate in breast cancer patients operated on during the follicular phase. However,
it is now apparent that many haematological cells are capable of releasing VEGF,
especially platelets. The extent to which these cells normally contribute to the circu-
lating VEGF pool in vivo and the physiological relevance of this is not known. The
measurement of serum concentrations of VEGF has therefore been speculated upon as
being an artificial situation, which measures both the freely circulating VEGF and that
released by platelets upon activation during the clotting process. We therefore
conducted the first prospective trial to compare serum and plasma levels of VEGF in
healthy pre-menopausal volunteers.
Methods 20 healthy premenopausal women were recruited and had blood samples
were taken over one menstrual cycle with an average of 8 samples taken per patient.
Plasma and serum samples were then analysed for sex hormones and VEGF 165.
Results Serum VEGF levels were found to be significantly higher than plasma
VEGF levels (p<0.005). The majority of the measurements for plasma levels of
VEGF at all phases of the cycle were under the limit of detection of the VEGF ELISA
kit. We found no significant difference between serum and plasma VEGF in the luteal
and follicular phases of the cycle. We found no significant correlation between plasma
or serum levels of VEGF and either FSH, LH, Oestradiol or Progesterone levels.
Discussion We conclude that varying levels of serum VEGF are not responsible
for any possible survival advantage of being operated on for breast cancer during the
follicular phase of the cycle. Plasma VEGF levels are much lower than serum levels
and are usually beneath the limit of the ELISA assay utilised in our study.
Development of a more sensitive assay is required before conclusions can be reached
about its physiological significance. In addition, with no cyclical variation in circu-
lating VEGF demonstrated, menstrual phase need not be taken into account if serum
or plasma VEGF is to be used as a prognostic factor in the future.
P6
IMAGING VASCULAR ENDOTHELIAL GROWTH FACTOR IN VIVO
WITH POSITRON EMISSION TOMOGRAPHY VA Carroll1,2, M
Glaser1, E Aboagye1, D Brown1, S Luthra1, F Brady1, R Bicknell2, AL Harris2
and P Price1, 1CRC PET Research Group, Hammersmith Hospital, ICSM,
London and 2ICRF Molecular Oncology labs, Institute of Molecular Medicine,
University of Oxford, Oxford, UK
Tumour growth and spread is dependent on angiogenesis – defined as the growth of
new blood vessels from the pre-existing vasculature. Blocking antibodies to vascular
endothelial growth factor, an important angiogenic factor are currently in phase II/III
clinical trials for anti-angiogenic therapy. We are developing quantitative assays to
image expression of the target molecule VEGF in vivo by positron emission tomog-
raphy (PET), initially in animal models.
An anti-VEGF monoclonal antibody denoted VG76e was shown to completely
inhibit VEGF stimulated endothelial cell growth. Iodine 124 was chosen as a suitable
positron emitter due to its long half-life (t1/2=4days) and was generated by the 124Te
(p,n) reaction. VG76e was radiolabelled with 124I both directly by the iodogen tech-
nique or via lysine residues with ‘Bolton-Hunter’ labelling reagents. Following iodi-
nation, immunoreactivity was analysed by binding to VEGF in a radioimmunoassay.
Immunoreactivity of VG76e was less than 10% after direct labelling with iodogen, but
increased to 45% when conjugated to iodinated succinimidyl esters. HT-1080
fibrosarcoma cells that secrete high levels of VEGF and are known to form secondary
lung tumours were injected sc into nude mice. Once tumours had reached a diameter
of 0.7 mm 124I-VG76 was injected intravenously and mice were scanned 24 h later in
a HIDAC animal scanner. PET images showed localisation to the tumour as well as
the thoracic cavity. Tumour and normal tissue including heart, lung, liver, kidney,
intestine and spleen were excised and radioactivity was determined by gamma
counting. Ex vivo biodistribution confirmed antibody localisation to the tumour (5.9%
id/g) and lung (3.5% id/g). PET may be one useful strategy for effective monitoring of
antiangiogenic therapy with VG76e in vivo and in addition, to assess the role of VEGF
in the growth of secondary cancer.
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A POSITRON EMISSION TOMOGRAPHY (PET) STUDY ON THE
EFFECTS OF COMBRETASTATIN A4 ON MURINE LIVER
METASTASES AT McGown1, JV Moore1, S Zhao1, JA Hadfield1, DL
Hastings2, ML Waller2 and GR Pettit3, 1CRC Paterson Institute, 2Christie
Hospital, Manchester M204BX, 3Arizona State University, USA
The combretastatins have been shown to be capable of causing the destruction of
tumour vasculature in model systems (Dark et al., (1997), BJC, 77, 1829; Grosios et
al., (1999), BJC, 81, 1318). We have used positron emission tomography (PET) as a
non-invasive measurement of tumour biology and therapeutic response in liver metas-
tases (murine T50/80 breast) following treatment with combretastatin A4. This has
allowed us to study the outcome of therapy in individual animals in a clinically rele-
vant internal body site. [18F]-Fluorodeoxyglucose ([18F]-FDG) was used as an indi-
cator of metabolism and scanning was carried out using high-density avalanche
chamber (HIDAC) detection. The distribution of [18F]-FDG in the absence of disease
was characterised, showing clear delineation of the brain, heart, and urinary bladder.
In untreated mice with liver metastases a strong correlation (r2=0.98) was found
between the estimation of [18F]-FDG by PET and ex vivo counting. The spatial reso-
lution of the instrument (2.6 mm FWHM) allowed us to distinguish total metastatic
tumour masses of 200 mm3, although smaller individual deposits could be seen.
Single i.p. treatment with combretastatin A4 (75–140 mg/kg) resulted in an
average 30% decrease in tumour volume 24 hours following administration. A histo-
logical examination of these tumours showed extensive necrosis consistent with
vascular damage. This technology is now being used to study other combretastatin
analogues. In conclusion PET imaging with [18F]-FDG provides a non-invasive assay
of cellular metabolism. The ability to sequentially scanned the same animal both
before and after treatment, and to study the effects of therapy in clinically relevant
internal sites makes this extremely powerful tool in the development of novel anti-
cancer therapies. This has been used to demonstrate the anti-vascular effect of
combretastatin A4 on metastatic deposits of the liver.
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DESIGN AND SYNTHESIS OF NOVEL COMBRETASTATIN
ANALOGUES K Gaukroger*1,3, JA Hadfield1,2, NJ Lawrence3 and AT
McGown1, 1CRC Drug Development Group, 2CRC Radiochemical Targeting
and Imaging, Paterson Institute for Cancer Research, Christie Hospital NHS
Trust, Manchester M20 4BX, 3Department of Chemistry, UMIST, PO Box 88,
Sackville Street, Manchester M60 1QD, UK
The combretastatins are stilbenes isolated from the South African tree Combretum
caffrum. These agents are characterised for their ability to interact with tubulin and
cause catastrophic destruction of blood vessels (vasculature) within tumours.
Tumours are thus deprived of oxygen and nutrients, leading to death of the cancer
cells. The simplicity of the combretastatins offers promise for the rational design of
new chemotherapeutic agents and we are currently studying the structure-activity
relationship of substituted stilbene derivatives of this type based on the lead
compound, combretastatin A-4. The main synthetic approaches to combretastatin A-4
and analogues are based on Witting reactions from which both E and Z stereoisomers
are isolated. A series of novel analogues with substitution both in the A and B rings of
combretastatin have been synthesised. We are also investigating the effect of func-
tionalising the olefinic bond. The Heck reaction has been utilised to synthesis stil-
benes with a methyl group on the olefinic bond. These modified stilbenes have been
characterised by their ability to inhibit the growth of P388 and K562 cells in vitro.
This study has shown that altering the trimethoxy aryl motif on the A ring and
changing the configuration of the olefinic bond of the stilbene from Z to E leads to a
large loss in cytotoxic activity. The ability of these compounds to interact with tubulin
and to disrupt the microvasculature is currently being studied. These data are being
used to design new analogues with improved antivascular activity.
The funding for this project comes from the Association for International Cancer
Research.Poster Presentations 31
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IN VITRO CHARACTERIZATION OF THE NOVEL TUMOUR
VASCULAR TARGETING AGENT ZD6126 AL Holder1, GM Tozer1, C
Kanthou1, PD Davis*2, S Douglas3 and D Blakey3, 1Gray Laboratory CRT,
Northwood, HA6 2JR, 2Angiogene Pharmaceuticals Ltd, 1Oxfordshire, OX9
5SX, 3AstraZeneca plc, Macclesfield, SK10 4TG, UK
Certain tubulin-binding agents such as colchicine and vinca alkaloids disrupt tumour
vasculature at doses approaching their maximum tolerated dose. ZD6126, a phosphate
prodrug of N-acetylcolchinol, is a new tubulin binding agent which, unlike colchicine
and the vinca alkaloids, has selective tumour vascular damaging activity at well
tolerated doses. These studies aimed to help characterise the properties of ZD6126
(ANG453) responsible for its in vivo activity using in vitro assays to measure
toxicity/antiproliferation, permeability changes to cell monolayers and cell shape
changes.
The toxicity/antiproliferative effects were measured in proliferating human
endothelial cells (HUVECs), which were drug treated for 2 hours, washed, given fresh
medium and then incubated for a further 4 days. Viability was then assessed by neutral
red staining. For permeability studies, HUVECs were plated on to fibronectin coated
microporous filter cell culture inserts to give a confluent monolayer. The passage of
FITC-Dextran was then measured through both treated and untreated cell monolayers
and unseeded inserts to enable a % change in permeability to be calculated.
Immunofluorescence studies were performed using HUVECs stained with an anti b-
tubulin antibody followed by an FITC-linked conjugate in order to evaluate effects on
the microtubule cytoskeleton and changes in cell shape.
The toxicity/antiproliferative effects of both N-acetylcolchinol and ZD6126 in
HUVECs were found to occur at concentrations >100 mM. In contrast, changes to the
microtubule cytoskeleton leading to changes in cell shape and permeability were
observed at concentrations much lower than those causing toxicity. Depolymerization
of the microtubules and increased permeability (20–30%) of cell monolayers were
seen at 0.01 mM ZD6126. These results suggest that, at concentrations of active drug
which cause anti-vascular activity in vivo, change in endothelial cell shape and func-
tion, rather than direct endothelial cell cytoxicity, are likely to be responsible for the
selective anti-vascular activity of ZD6126.
P10
ZD6126: A NEW AGENT CAUSING SELECTIVE DAMAGE OF
TUMOUR VASCULATURE Davis PD*1, Hill SA2, Galbraith SM2,
Chaplin DJ2, Naylor MA2, Nolan J2 and Dougherty GJ1, 1Angiogene
Pharmaceuticals Ltd., Oxfordshire OX9 5SX, UK and 2Gray Laboratory
Cancer Research Trust, Northwood HA6 2JR, UK
Tubulin-binding agents such as colchicine, vinca alkaloids and combretastatins
disrupt tumour vasculature by a direct effect on immature endothelium. Only the
combretastatins, however, have been reported to have significant vascular damaging
activity below maximum tolerated doses. We have developed a new class of tubulin
binding agents with selective tumour vascular damaging activity at well tolerated
doses. ZD6126 (ANG453), a phosphate prodrug of N-acetylcolchinol, is synthesised
in four steps from colchicine. Treatment of non-confluent, proliferating HuVEC
cultures (as a model of immature endothelium) with ZD6126 produces changes in cell
shape at concentrations that are without effect on confluent, quiescent cultures. At one
thirtieth of the maximum tolerated dose ZD6126 causes marked reduction in the func-
tional vascular volume of CaNT tumours in CBA mice, 6 h after drug administration.
Widespread necrosis is induced in these tumours, leaving only a rim of viable cells.
ZD6126 at well tolerated doses has significant anti-tumour activity in both syngeneic
tumour (CaNT) and xenograft (FaDu) models.
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ANTI-TUMOUR ACTIVITY OF ZD6474, A VEGF RECEPTOR
TYROSINE KINASE INHIBITOR J Kendrew1, SR Wedge1, DJ
Ogilvie1, M Dukes1, LF Hennequin2, ESE Stokes1 and B Curry1, 1Cancer and
Infection Research, AstraZeneca Pharmaceuticals, Alderley Park,
Macclesfield, Cheshire SK10 4TG, UK; and 2AstraZeneca Pharma, Centre de
Recherches, Z.I. La Pompelle, B.P. 401, 51064 Reims, France
ZD4190, a small molecular weight VEGF receptor tyrosine kinase inhibitor (RTKI),
has previously been shown to elicit broad-spectrum anti-tumour activity in human
tumour xenografts, following chronic oral daily dosing (Wedge et al., Cancer Res, 60:
970–975, 2000). ZD6474, another VEGF RTKI, also demonstrates significant activity
in a histologically diverse panel of human tumour models (lung, breast, ovarian,
vulval, prostate, colon). This profile is consistent with inhibition of VEGF signalling
and an indirect (i.e. anti-angiogenic) anti-tumour effect.
The effect of ZD6474 treatment on established tumours of varying sizes was inves-
tigated. ZD6474 (100 mg/kg/day, p.o.) was administered to groups of mice bearing
CaLu-6 human NSCLC tumours, with mean volumes of 0.3, 0.5, 1.0 and 1.5 cm3 (n =
10). ZD6474 was found to inhibit the growth of all tumours, irrespective of the tumour
volume at start of treatment. A similar experiment was performed with mice bearing
different sized PC-3 human prostate tumours (mean volumes of 0.3, 0.5, 0.9 and 1.4
cm3). In contrast to the responses observed in the CaLu-6 model (growth-inhibition),
ZD6474 was found to induce regression in all PC-3 tumours with the most
pronounced effects being evident in the largest tumours.
The PC-3 tumour model was further used to examine the effect of intermittent
ZD6474 treatment (50 mg/kg/day, p.o.). Mice bearing PC-3 tumours were treated with
ZD6474 for 2 weeks. Treatment was then withdrawn and tumours allowed to re-grow
for 4 weeks until reaching a volume of ~ 0.7 cm3. Upon re-treatment with ZD6474 for
4 weeks, all tumours were observed to regress to a volume of ~ 0.2 cm3. This study
indicates that human tumour xenografts remain responsive to re-treatment with an
inhibitor of VEGF signal transduction.
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A PHASE II STUDY OF HIGH DOSE ORAL THALIDOMIDE IN
PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
(RCC) OR METASTATIC MELANOMA (MM) J Stebbing1, C Benson1*, T
Eisen2, I Mak3, L Pyle1, K Smalley2, ME Gore1, 1Dept. of Medical Oncology,
Royal Marsden Hospital, London SW3 6JJ, 2Dept of Oncology, Royal Free &
University College Medical School, London W1P 8BT, 3 Dept of Clinical
Neurophysiology, Chelsea & Westminster Hospital, London SW10 9NH, UK
Angiogenesis is an important new target for anti-cancer drugs. Thalidomide
suppresses levels of the angiogenic factors, tumour necrosis factor-a (TNFa) and
basic fibroblast growth factor (bFGF). We have performed a phase II study in previ-
ously treated patients with metastatic RCC (20 patients) and MM (19 patients). The
median age of patients (pts) was 51 years, range 26–74 years. All pts had pre-treat-
ment sensory nerve action potential (SNAP) testing, repeated every 3 months. We also
measured levels of TNFa, bFGF, vascular endothelial growth factor (VEGF), IL-6
and IL-12, before and during treatment. Pts were treated with escalating doses of
thalidomide over 6 weeks to a target dose of 600 mg po daily.
Results: The response rate in pts with metastatic RCC was 10% (2 pts). However,
an additional 10 pts achieved stable disease (SD) ³ 12 weeks, 7 of these had SD ³ 24
weeks. There were no objective responses in pts with MM although 1 patient achieved
SD ³ 12 weeks. Tumours were heterogenous and mean cytokine levels did not corre-
late with response to treatment. Further analysis is awaited. Main toxicities (WHO)
were lethargy (13 pts grade II, 2 pts grade III), constipation (10 pts grade II, 2 pts
grade III) and neuropathy (3 pts grade II, 1 pt grade III). In pts with RCC, 17/20
reached 600 mg od and only 4 required dose reductions due to toxicity. Conclusions:
Thalidomide has activity in patients with metastatic RCC. We are currently engaged
in a phase III study comparing its efficacy against medroxyprogesterone acetate.32 Poster Presentations
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LOCALISATION OF HYPOXIC CELLS USING A POLYCLONAL
ANTISERUM WHICH RECOGNISES PROTEIN ADDUCTS OF
THE 2-NITROIMIDAZOLE PROBE SR4554 Anthea Hardcastle, Sue Clinton,
Phyllis Goddard, Lisa Brunton, Melanie Valenti, Paul Workman and G Wynne
Aherne, CRC Centre for Cancer Therapeutics, Institute of Cancer Research,
Sutton, Surrey SM2 5NG, UK
Hypoxia within solid malignant tumours causes lack of response to both radiotherapy and
conventional chemotherapy. Additionally it is associated with the development of
metastatic disease. Detection of hypoxia would therefore be an important advance in the
treatment of some cancers. SR4554 N-(2-hydroxy-3,3,3,-trifluoropropyl)-2-2-(2-nitroimi-
dazoyl) acetamide, a new non-invasive probe for hypoxia, undergoes selective nitroreduc-
tion and forms adducts to macromolecules in hypoxic cells that can be detected by
Magnetic Resonance Spectroscopy (MRS). It has been approved for Phase I trial as a
tumour hypoxia probe. Immunochemical detection of SR4554 adducts would provide an
additional methodology for validation of the compound as a hypoxia marker.
Ten rabbits were immunised with a variety of SR4554-protein (bovine serum
albumin, Bowman’s Birk Inhibitor and ovalbumin) conjugates prepared by different
methodologies under radioreduction. Antisera production was monitored by a sensitive
antigen coated enzyme linked immunosorbent assay (ELISA) with time resolved fluores-
cent end point detection (Delfia). The ELISA was also used for preliminary characterisa-
tion of the antisera. The SR4554 conjugate used for coating in the ELISA was different
from that used for immunisation. All animals showed an immune response in this screen
by binding to the coated conjugate. This indicates that the animals had produced anti-
bodies that recognise an epitope on SR4554 protein conjugates which is not the protein
moiety of the conjugate used as immunogen. This is possibly an SR4554 adduct since
competitive displacement experiments showed that the antisera did not recognise uncon-
jugated SR4554.
Nude mice carrying xenografts of human tumours (CH1, SKOV3, BE, HN5, HT29 and
COLO26) were dosed with SR4554 (80 mg/kg ip) and tumour obtained at various time-
points. Tumours from undosed animals were used as controls. The antiserum showing the
best titre in the ELISA has been used for immunohistochemical detection of SR4554
adducts in sections cut from these tumours using a biotinylated secondary antibody
followed by a preformed avidin/biotin/horse radish peroxidase complex and subsequent
visualisation with diaminobenzidine (ABC/DAB Vector Laboratories). The same sections
have been stained for platelet/endothelial cell adhesion molecule-1 (Pecam 1/CD31) and
Ki67 antigen (Mib1) to co-localise tumour angiogenesis and proliferation with the pres-
ence of SR4554 adducts. Compared to untreated controls, areas of brown immunoperoxi-
dase staining of varying intensity were visible in the tumours. These reagents in
conjunction with other techniques are presently being used to validate the use of SR4554
as a marker of hypoxia in ongoing preclinical studies and in the forthcoming Phase 1 trial.
Supported by the Cancer Research Campaign Programme Grant SP2330/0201.
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BLOOD OXYGEN LEVEL DEPENDENT (BOLD) MRI IMAGING: A
NON INVASIVE ASSESSMENT OF HYPOXIA AND PERFUSION
IN SOLID TUMOURS N Shah*1, P Hoskin1, A Sibtain1, H Baddeley2, J
Taylor2, MI Saunders2, Marie Curie Research Wing & The Paul Strickland
Scanner Centre, Mount Vernon Hospital, Northwood HA6 2RN, UK
Purpose Non invasive MRI evaluation of changes in tumour oxygenation using
carbogen (5% CO2, 95%O2) breathing to enhance oxygen uptake in vivo.
Background Gradient recalled echo (GRE) MRI imaging can assess blood flow
changes in vivo. MRI can utilise the respective paramagnetic and diamagnetic proper-
ties of tissue deoxyhaemoglobin and oxyhaemoglobin providing a functional
sequence of blood oxygen level dependent (BOLD) contrast scans to study the modi-
fication of tissue hypoxia.
Methods Subjects underwent GRE MRI for BOLD enhancement whilst breathing
a sequence of air (5 minutes), carbogen (10 minutes) and air (10 minutes). Specified
regions of interest in solid tumours and normal tissues were analysed pre and post
carbogen breathing. A BOLD signal change of more than 5% of the whole region was
interpreted as a significant change due to carbogen breathing.
Results 35 patients with solid tumours (pre-treatment) were successfully assessed.
In 15 other subjects, technical difficulties including patient movement, intolerance of
carbogen, mask displacement and magnetic disruption artefacts did not allow a full
assessment. Patients with head and neck tumours constituted approximately 50% of
the technical failures.
BOLD enhancement during carbogen breathing was observed in 20 patients
(57%). By histological subtype these included 6/8 SCC head and neck, 2/4 NHL, 1/6
rectal carcinoma, 5/8 bladder carcinoma, 2/3 prostate carcinoma and 4 other sites
(sacral osteosarcoma, buttock melanoma, breast carcinoma and prostatic leiomyosar-
coma). A reduction in signal was observed in 1 patient with a head and neck carci-
noma.
Conclusion Changes in BOLD MRI sequences have been observed in 57% of
patients during carbogen breathing supporting other work using direct measurements
which demonstrate an increase in tumour oxygenation. The relative components of
perfusion change and oxygenation cannot be evaluated. Modifications in the gas
mixture and breathing apparatus are being assessed to reduce technical failure. Studies
are necessary to correlate the above findings with clinical outcome and the suitability
of this technique for assessing therapies modifying hypoxia.
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RADIOIMMUNOTHERAPY IS MORE EFFECTIVE IN SMALL
TUMOURS DUE TO HIGHER DOSE AND DOSE RATE
A Mayer*1, AA Flynn2, E Tsiompanou2, RB Pedley2, J Dearling2, R Boden2,
RHJ Begent2, 1Oncology Centre, Addenbrooke’s NHS Trust, Cambridge CB2
2QQ, 2Cancer Research Campaign Targeting and Imaging Group, Royal
Free and University College Medical School, London NW3 2PF, UK
We report an experiment to investigate the potential reasons for the enhanced thera-
peutic effect of radioimmunotherapy (RIT) in small tumours. Theoretically a greater
proportion of viable radiosensitive areas in small tumours, higher antibody uptake or
a higher dose and dose rate may account for this.
Six mice per group bearing small (median tumour size 0.06 cm3, range 0.02–0.11
cm3) and large LoVo xenografts (median tumour size 0.38 cm3, range 0.16–0.57 cm3)
received either RIT using a 131I labelled anti-CEA antibody A5B7, 5-FU modulated
with leucovorin (LV) or no treatment at all. Tumour size was measured for 22 days.
The %injected activity/gram was determined by a laboratory gamma counter in a
separate study. Radioluminography was used to assess the distribution of the antibody
in viable and necrotic areas as defined on the corresponding digitised histological
section. Beta point dose kernels were then used to generate the dose distribution from
each radioluminograph. High power microscopy images of small and large tumours
were reconstructed to form a mosaic of the original section to estimate the proportion
of viable areas in the tumour volume.
Mice with large (p=0.002) and small (p=0.0003) xenografts grew significantly less
when treated with RIT compared to the control group. 5-FU was found ineffective in
this experiment. Comparison of the groups with small and large tumours treated with
RIT showed that small tumours grew significantly less compared to large tumours
(p<0.02), while there was no significant difference of small and large tumour growth in
the group treated with 5-FU and the control group. The total amount of radioactivity in
small and large tumours was not significantly different, but a significantly higher
amount of % injected activity per gram of tumour was found in small tumours (median
26.6%, range 19.9–59.2% vs median 8.1%, range 1.6–12.5%, p=0.0007). In addition, a
significantly greater % injected activity per gram was found in both viable (47.7% vs
11.1%, p=0.007) and necrotic (18.8% vs 3.9%, p=0.006) parts of small tumours
compared to large tumours. Consequently, a significantly higher dose rate at 24 hours
post injection was calculated for viable (56.2+/–23.7 vs 13.3+/–7 cGy/h) and necrotic
parts (19.2+/–16.3 vs 4.9+/–4.7 cGy/h) of small tumours compared to large tumours
(p=0.0007). Mosaics of images of tumour morphology showed that a significantly
larger % of the total volume was viable for larger tumours (85.2% vs 71.6%, p=0.039).
Our experiment confirms that RIT is more effective in small tumours due to higher
dose and dose rate throughout the tumour. The improved tumour control rate in small
tumours favours RIT as an attractive option for adjuvant treatment in colon cancer.Poster Presentations 33
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OPTIMISING CORONARY ARTERY RADIATION USING
TARGETED RADIOIMMUNOTHERAPY, EC Sims1*, MEB Powell2,
MT Rothman3, TD Warner1, 1Dept of Vascular Inflammation, William Harvey
Research Institute, St. Bartholomew’s & The Royal London School of
Medicine and Dentistry, 2Dept of Clinical Oncology & 3Dept of Cardiology,
Bart’s & The London NHS Trust, UK
Introduction Coronary artery disease is the leading cause of mortality in the West
with over 1.2 million angioplasties performed annually. Despite the introduction of
stents, restenosis occurs in 20–35% of vessels. Intracoronary artery radiation has
emerged as potential therapy for the prevention of restenosis. Targeted radiation using
radiolabelled antibody would optimise delivery and fractionation of radiotherapy and
minimise radioprotection issues.
Aims To assess the feasibility of coating a stent with antigen and to evaluate the
qualitative and quantitative uptake of antigen specific antibody in vitro and in vivo.
Method Lengths of polythene tubing (similar to coated intracoronary stents) were
incubated in either biotinylated bovine serum albumin (experimental arm) or phos-
phate buffered saline (control). A circuit mimicking the circulatory system was
devised. It incorporated the tubes (vessels), a peristaltic pump (heart) and a 20 ml
reservoir of heparinised human blood containing fluorescein-tagged antibiotin anti-
body (5 mg/ml). After 24 hours in this circuit the tubes were incubated with trypsin to
recover bound antibiotin antibody. Uptake of antibiotin antibody was then quantified
using curves created from fluorescence measurement of standard pre-prepared anti-
body dilutions in 0.5% trypsin.
Results Uptake of anti-biotin antibody by tubes is shown in the table. The reading
of 14050 was estimated to equate to antibody uptake of 3.7 mg per tube.
Antigen Fluorescence Standard error
reading
Tube + Biotin-BSA (n=4) 14050 ±469
Tube + PBS (control) (n=4) 147 ±8
Assay Background (0.5% trypsin) (n=4) 145 ±6
Conclusion Polythene tubing can be readily coated with antigen. Using an in vitro
flow system antibody may be specifically targeted to this antigen. No uptake of
labelled antibody to tubes lacking antigen occurred. Further results using an in vivo
system will be presented.
These results show for the first time that highly selective targeted radioim-
munotherapy in vascular brachytherapy using radio-labelled antibody has important
therapeutic potential.
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PATTERN OF LOCAL RECURRENCE AFTER CONSERVATIVE
SURGERY AND RADIOTHERAPY FOR SOFT TISSUE
SARCOMA Susan Cleator1*, Chris Cottrill2, Clive Harmer1, 1Sarcoma Unit,
Royal Marsden Hospital NHS Trust, London SW3 6JJ, 2Dept of
Radiotherapy, St Bartholomew’s Hospital, London EC1A 7BE, UK
Purpose Over the past two decades our centre has adopted a policy of conservative
surgery followed by adjuvant radical-dose radiotherapy for all medium- and high-
grade soft tissue sarcomas. Low grade tumours are treated post-operatively only if
they demonstrate multiple recurrences or if complete resection is not technically
feasible. From the patients treated in this manner at the Royal Marsden Hospital over
the last 15 years we studied 16 who had relapsed locally. We discuss technical factors
which may have contributed to local relapse in some cases and the geographical rela-
tionship between sites of recurrence and the phase 1 and 2 radiotherapy volumes.
Patients and methods We examined those cases recorded on our soft tissue
sarcoma database between January 1986 and September 1999 who had recurred
locally following surgery and radical post-operative radiotherapy. We excluded
patients with residual macroscopic disease following surgery and any patients with
metastatic disease at presentation. We recorded details relating to original tumour
stage, histological type, grade and surgical margins. The cohort included 7 patients
with T1 (44%) and 9 patients with T2 tumours (56%). The tumours were grade 1, 2
and 3 in 2 (13%), 5 (31%) and 9 (56%) cases respectively. The majority of patients
were treated with a phase I volume corresponding to the entire muscle compartment
which received 50 Gy in 25 fractions over 5 weeks. The phase II was a reduced
volume corresponding to the tumour bed and received 10 Gy in 5 fractions during the
sixth week of treatment.
Results Mean time to local recurrence was 26 months. Four recurred within the
phase I volume (25%), 8 (50%) recurred within the phase II volume and 4 (25%)
outside the irradiated volume. Seven patients who relapsed had positive surgical exci-
sion margins originally; of these, 2 recurred in the phase I volume, 4 in the phase II
and I outside the irradiated volume. Nine patients had clear operative margins origi-
nally; of these, 2 recurred within the phase I, 4 in phase II and 3 outside the field. With
a mean follow-up time since completion of radiotherapy of 63 months, 7 patients have
died, of whom 6 were disease-related.
Conclusion Prospective, multi-centre data collection and ideally a randomised
trial are required to formulate an improved treatment policy.
Keywords: sarcoma, post-operative radiotherapy, recurrence, conservative
surgery.
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RADIOTHERAPY TO LIMB PROSTHESES: A NEW METHOD TO
IMPROVE DOSE HOMOGENEITY Dr KE Sherwin*1, R
Kestelman2, SJ Thomas2, AR Geater2, Dr NG Burnet, Dr CB Wilson1, Dr MV
Williams1, Departments of 1Oncology and 2Medical Physics, Addenbrooke’s
Hospital, Cambridge CB2 2QQ, UK
A metal prosthesis within the target volume adversely affects the homogeneity of the
radiotherapy dose distribution. In rare cases when radiotherapy is required after pros-
thetic replacement of a bone tumour, a significant shadow is cast by the prosthesis.
We report a novel technique devised in our department to deliver radiotherapy to a
limb and its metal bone prosthesis to homogenise dose distribution and minimise the
risk of underdosage in the ‘shadow’ of the prosthesis. Radiotherapy is delivered using
parallel opposed fields to the limb with sparing of a lymphovascular corridor and the
area in the shadow of the prosthesis boosted using a ‘negative’ keyhole cutout of the
prosthesis. To date we have treated four patients with this technique, with no local
failures, median follow-up 2 years.
Standard dosimetry calculations use an estimate of the electron density of titanium
alloy to be four times that of tissue. Using a ‘Modified Batho’ algorithm the treatment
planning system suggested a 10% dose deficit either side of the prosthesis. In vivo exit
dosimetry was consistent with this estimate. The keyhole cutout boost was used to
deliver 10% of the daily fraction size to correct for this. Due to the high density of the
prosthesis, it was clearly visible using on-line portal imaging, allowing interactive
positioning of the boost field.
We have been able to carry out in vitro dosimetry experiments to estimate the
attenuation of megavoltage photons caused by the shaft of the prosthesis following the
generous loan of a non-extendable prosthesis by a patient, which was replaced when
he unexpectedly grew. The dose beyond the prosthesis in ‘tissue’ has been measured
using a Roos parallel-plate ion chamber in a water tank. This confirms that both
‘Effective Depth’ and ‘Modified Batho’ algorithms give a good approximation to the
measured dose using an electron density of 3.4 for titanium alloy.
We believe that this is a valuable technique which improves homogeneity of radio-
therapy to a site which includes a metal prosthesis. In typically similar relatively
radioresistant tumours a 10% dose attenuation could have a significant impact on local
control and hence overall outcome for the patient.
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AUTOCRINE STIMULATION OF EWING’S SARCOMA GROWTH
J Withey* and SA Burchill, Candlelighter’s Children’s Cancer
Research Laboratory, ICRF Cancer Medicine Research Unit, St. James’s
University Hospital, Leeds LS9 7TF, UK
Growth factors and their receptors are important in normal cell growth, activating
signalling pathways which can stimulate or inhibit cell division, differentiation and
migration. Aberrant expression of these proteins can contribute to tumorigenesis by
modulating tumour cell attachment, growth and angiogenesis. The aim of this study
was to determine whether growth factors and their receptors provide a growth advan-
tage in the neural-crest derived Ewing’s Sarcoma (ES).
Six ES cell lines were studied (TC-32, RD-ES, TTC-446, SK-ES-1, A673, SK-N-
MC). Growth of four cell lines was examined under normal, reduced and serum-free
conditions. A neuroblastoma cell line (SK-N-SH) was used as a control. To determine
if cell survival was due to a secreted factor, four ES cell lines were used to condition
flasks of media for 1 or 2 days. ES cells were then cultured in this conditioned media
and cell number determined at 0, 48 and 72 h. Atlas cDNA arrays (Clontech) were
used to look at the range of growth factors and receptors expressed by all 6 ES cell
lines to identify potential autocrine and paracrine loops.
All four ES cell lines studied maintained their cell number in serum-free media for
up to 72 h; in contrast the neuroblastoma cell line showed a significant decrease in cell
number (p<0.001). Conditioned media from all 4 ES cell lines increased cell number,
indicating that ES cells secrete a factor or factors which have a survival and/or mito-
genic effect. Using cDNA arrays we identified 4 growth factors which are abundantly
expressed in all 6 cell lines and a further 11 which are expressed in more than half the
cell lines. Expression of growth factors and receptors of interest has been confirmed
by RT-PCR and/or western blot analysis.
In summary autocrine and/or paracrine loops provide ES cells with a
growth/survival advantage. These loops are potential targets for modulating ES
behaviour and may provide a new therapeutic strategy for ES.34 Poster Presentations
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EXPRESSION OF TRANSFORMING GROWTH FACTOR
RECEPTORS TYPE1 AND TYPE2 IN SUPERFICIAL
TRANSITIONAL CELL CARCINOMA OF THE BLADDER P Maheshkumar1*,
JE Martin2, VH Nargund1 and DM Berney2, 1Dept of Urology and 2Dept of
Histopathology and Morbid Anatomy, Barts and The London NHS Trust,
London ECIA 7BE, UK
Objectives Transforming growth factor-beta (TGFb) is a potent inhibitor of cellular
proliferation in cells of epithelial origin. It acts through two membrane receptors
(TGFbRI and TGFbRII). It has been shown in colonic, gastric and head and neck
malignancies that there is decreased expression of TGFbRII due to genetic mutations
leading to initiation and progression in these tumours. Previous studies in transitional
cell carcinoma (TCC) bladder have shown conflicting results on the role of TGFb
receptors in the biology of this disease.
Materials Formalin fixed tumour tissue from 49 patients with newly diagnosed
superficial TCC bladder (pTa=16 and pT1=33) were analyzed by immunohistochem-
istry for TGFbRI and TGFbRII following microwave antigen retrieval.
Results TGFbRI and TGFbRII were both present in all superficial TCC’s irrespec-
tive of grade and stage. TGFbRI was strongly expressed in the basal layer and
TGFbRII was strongly expressed in both basal and superficial layers, similar to
normal urothelium. TGFbRI was moderately expressed in superficial TCC in contrast
to TGFbRII, which was strongly expressed as in normal urothelium. Both receptors
were also expressed in invasive areas.
Conclusion We suggest that loss of TGFb receptors is infrequent in superficial
bladder cancer and plays little part in the oncogenesis of the early stages of TCC
bladder.
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INDUCTION OF EXPRESSION OF FGF RECEPTOR 2-IIIB IN
OVARIAN CANCER IA Steele*1, RJ Edmondson2, B Bolger3, J
Bulmer4, HY Leung1, BR Davies1, 1Dept of Surgery. The Medical School,
University of Newcastle-upon-Tyne, 2Northern Gynaecological Oncology
Centre, Queen Elizabeth Hospital, Gateshead, 3Obstetrics and Gynaecology
and 4Pathology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
Introduction Ovarian cancer is the leading cause of death from gynaecological
malignancy in the UK today. Due to its asymptomatic progression, little is known
about the early stages of the disease, however, the majority of ovarian carcinomas
arise from the ovarian surface epithelium (OSE). The fibroblast growth factors (FGFs)
are a family of structurally related polypeptides, implicated in a wide range of solid
tumours. They act through a series of high-affinity membrane receptors whose
response is mediated by multiple ligands. FGFR2-IIIb is a spliced variant of FGFR2
which binds the ligands FGF-1 and FGF-7 with high affinity. Epithelial ovarian
cancers are more highly committed to an epithelial phenotype than the relatively
uncommitted OSE from which they arise. For instance induction of E-cadherin and
CA125 expression observed in the majority of ovarian cancers. Thus, we hypothe-
sised that expression of the epithelial marker FGFR2-IIIb may accompany metaplasia
in the malignant transformation of ovarian surface epithelium.
Methods and Materials Primary cultures of human OSE were generated by
scraping the surface of ovaries from women undergoing surgery for benign conditions.
Total RNA was isolated from cells and samples of epithelial ovarian cancers snap
frozen at the time surgery. Expression of FGFR2-IIIb, FGF-1 and FGF-7 mRNA was
determined by RT-PCR. Formalin fixed, paraffin-embedded sections of normal and
tumour tissue were stained with antisera to FGF-1 and a mouse anti-human FGFR2-
IIIb immunoglobulin chimera. The proliferative effects of FGF-1 and FGF-7 on normal
(n=3) and cancer cell lines (n=3) was determined using a DNA synthesis assay.
Results The expression of FGFR2-IIIb mRNA was undetectable in normal OSE,
whilst expression of both FGF-1 and FGF-7 mRNA was positive. Conversely, expression
of FGFR2-IIIb mRNA was clearly detectable in 8/16 (50%) of ovarian cancers. FGF-7
mRNA expression was retained in 90% of ovarian cancers, whereas only 8/16 (50%)
expressed FGF-1 mRNA. Imunocytochemistry demonstrated a similar pattern of results
for expression of the receptor and FGF-1 proteins. Ovarian cancer cell lines expressing
the receptor showed a significant increase in cellular proliferation in response to FGF-1
and FGF-7, whereas primary cultures of normal OSE failed to respond to the ligands.
Discussion Expression of FGFR2-IIIb was induced in a significant proportion of
the epithelial ovarian cancers and ovarian cancer cell lines that express this receptor
responded to its ligands, FGF-1 and FGF-7. Signalling through this receptor may be
mediated via an autocrine or paracrine mechanism and may represent an important
stage in epithelial ovarian cancer development.
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GONADOTROPHINS DIRECTLY STIMULATE THE
PROLIFERATION OF HUMAN OVARIAN SURFACE EPITHELIAL
CELLS RJ Edmondson,1 JM Monaghan1, BR Davies2, 1Northern
Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead,
Tyne and Wear; 2Dept of Surgery, University of Newcastle upon Tyne, UK
Introduction Over 85% of ovarian cancers arise from the ovarian surface epithelium.
Epidemiological evidence suggests that high levels of the gonadotrophins, LH and
FSH may be associated with the development of ovarian cancer. Although it has been
shown in a mouse model in vivo that gonadotrophins can stimulate proliferation of the
epithelium(1), little is known about the effects of gonadotrophins on the human
ovarian surface epithelium.
Methods We have established primary cultures of ovarian surface epithelium, by
scaping the surface of the ovaries, from patients undergoing oopherectomy for benign
disease(2). Epithelial phenotype was confirmed by staining with a panel of cytoker-
atin antisera. Total RNA was isolated and the presence or absence of LH and FSH
receptor mRNA was determined using RT-PCR. The effects of gonadotrophins on
DNA synthesis was determined by 3H thymidine incorporation assay.
Results We have shown that the mRNA encoding the LH receptor is expressed by
6 of 6 primary cultures. Only 1 of 6 cultures appears to express the FSH receptor. LH
causes a modest but significant induction of DNA synthesis in all cultures when given
at physiological doses. FSH induces a smaller but significant induction of DNA
synthesis in cultures which express the FSH receptor mRNA.
Conclusions We have shown that physiological doses of gonadotrophins can cause
direct stimulation of human ovarian surface epithelium. These observations lend
support, at the cellular level, for the gonadotrophin theory of ovarian carcinogenesis.
We are currently studying other physiological effects of gonadotrophins on the OSE,
including the rate of apoptosis.
1 Davies B, et al (1999) Administration of gonadotropins stimulates proliferation
of normal mouse ovarian surface epithelium. Gynecol Endocrin 13: 74–81
2 Kruk P, Maines-Bandiera S and Auersperg N (1990) A simplified method to
culture human ovarian surface epithelium. Lab invest 63: 132–136
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PROFILE OF EGFR EXPRESSION IN HUMAN MALIGNANCIES:
EFFECTS OF EXPOSURE TO EGF AND ITS BIOLOGICAL
INFLUENCE ON ESTABLISHED HUMAN TUMOUR CELL LINES Nouri
AME, Thompson C, Cannell H, Symes M, Amirghofran Z, Uro/Oncology
Research Unit, The Royal London, London E1 1BB, UK
The aim of this study was to compare the profile of EGFr expression in transitional
cell carcinoma of the bladder (TCC) and in oral squamous cell carcinoma (OSCC). In
addition, to study the influence of EGF stimulation on the expression of major histo-
compatibility complex (MHC) class I antigens, placental alkaline phosphatase
(PLAP) as well as changes in tumour cell sensitivity to cisplatin using immunocyto-
chemical staining, a colorimetric assay and SDS-gel electrophoresis.
The results showed that:
1. Strong EGFr expression in could be seen in 22/88 (27%) cases of TCCs. In oral
tumours the values for non-invasive ameloblastoma and invasive OSCC were
4/25 (16%) and 30/41 (73%) respectively.
2. EGFr expression in tumour cell lines paralleled that of tumour biopsies. The
number of lines expressing high and low EGFr expression amongst TCCs were 4
and 4 and in OSCCs were 3 and 1 respectively.
3. Exposure of tumour cell lines to EGF led to:
i. An increase in EGFr expression (stimulatory indices SI, ranged from 1.06 to
2.58) for TCCs but a decrease in the case of OSCCs (SI ranged from 0.01 to
0.85). The corresponding SI values for class I antigens were 0.95 to 1.16 and
0.10 to 0.84.
ii. A significant reduction in expression of PLAP by OSCC cell lines.
iii. An increased susceptibility of OSCC cell lines to cisplatin by as much as
14% (p<0.001).
These data demonstrated the over expression of EGFr in a significant proportion of
TCCs. As for oral tumours it depended on whether they were of an invasive or non-
invasive type. In the invasive cases the majority over-expressed EGFr. The exposure
of OSCC but not TCC tumour cells to EGF resulted in down regulation of EGFr and
class I antigens. The expression of PLAP was also significantly reduced. Exposure of
OSCC cell to EGF resulted in their increased susceptibility to cisplatin. The data
supports the notion that the mitogenic activation of some tumour cells by EGF
resulted in a reduction of their immune visibility, differentiation status and an increase
in chemo-sensitivity.Poster Presentations 35
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KINETIC AND IN VIVO ANALYSIS OF THE SOLUBLE IGF2
RECEPTOR J Morrice*1, G Groeger1, MH Brown2, AN Barclay2, CF
Graham1 & AB Hassan1, 1Department of Zoology & 2Sir William Dunn School
of Pathology, University of Oxford, South Parks Road, Oxford OX1 3PS UK
The aim of this study was to engineer IGF2R constructs that would bind IGF-II with
high affinity and affect IGF-II driven growth. The insulin-like growth factor 2
receptor (IGF2R) binds and internalises mannosylated proteins and IGF-II. Loss of
IGF2R would therefore be expected to increase circulating levels of IGF-II, mannosy-
lated proteins and proteolytic enzymes. Latent TGFb binds to IGF2R before activa-
tion by plasmin hence a decrease in IGF2R would also reduce levels of active TGFb,
a potent growth inhibitor. IGF2R may therefore be a tumour suppressor gene,
evidence supporting this includes early onset LOH and IGF2R gene mutation in hepa-
tocellular, breast, ovarian and colorectal cancer.
IGF2R is composed of 15 homologous extracellular domains. Mannosylated
proteins bind to domains 3 and 9 and IGF-II binds to domain 11. Domain 13 is thought
to enhance IGF-II binding. sIGF2R (domains 1–15) was cloned and its affinity for
IGF-II was compared with peptides designed around domain 11 using BIAcore.
sIGF2R bound IGF-II with the highest affinity, 9.55 ´10–9 M (see table). The lower
affinities of domains 10–12, 11–12 and 11 for IGF-II, compared to domains 11–13 and
10–13, supports the observation that domain 13 enhances IGF-II binding. A point
mutation (T to C converting Ile1572 to Thr) abolished IGF-II binding and was used as a
control. Insulin and IGF-I did not bind. b-glucuronidase bound with high affinity to
the full length construct but did not bind to construct 10–13. The effect of pH on IGF-
II affinity was also analysed: ka was not significantly affected by pH however kd was
significantly reduced at pH 5.5, the approximate pH of lysosomes. No binding was
observed at pH 4.5. The pH within a tumour environment is approximately pH 6.8.
Domains ka (M/s) kd (/s) KD (M)
1–15 1.18 ´ 106 0.0113 9.55 ´ 10–9
10–13 1.64 ´ 105 8.08 ´ 10–3 4.93 ´ 10–8
11–13 1.0 ´ 105 4.26 ´ 10–3 4.26 ´ 10–8
11–12 6.13 ´ 104 8.2 ´ 10–3 1.34 ´ 10–7
10–12 2.48 ´ 104 8.6 ´ 10–3 3.46 ´ 10–7
11 9.0 ´ 104 0.0138 1.53 ´ 10–7
The effect of the IGF2R constructs on IgF2-dependent cell lines (tera-2 and T3/73)
is currently being investigated and will be presented.
This work is supported by the CRC Grant 2390/0201.
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THE SOLUBLE IGF2 RECEPTOR REDUCES SMALL INTESTINE
ADENOMA NUMBER IN THE APCMIN/+ MOUSE JA Howell and AB
Hassan*, Cell and Development Group, Department of Zoology, University of
Oxford, South Parks Road, Oxford OX1 3PS, UK
The ApcMin/+ mouse develops multiple, small intestinal, adenomas that progress to
invasive tumours depending on genetic background. Insulin-like growth factor-II
(IGF-II) is an embryonic growth factor which is ubiquitously expressed in human
cancer and whose gene is imprinted, with expression from the paternal allele. IGF-II
appears to be the most abundant mRNA in colorectal cancer, with frequent biallelic
expression. Genetic manipulation of IGF-II supply modifies the growth of intestinal
adenoma in ApcMin/+ (Hassan and Howell 2000 Cancer Res 60; 1070–76). IGF-II
supply can also be altered by the IGF-II/M6P receptor (IGF2R), which normally func-
tions to internalise IGF-II for degradation. There is frequent LOH (6q26–7) and
IGF2R gene mutation in hepatocellular, breast, ovarian and colorectal cancer.
In the present study, we investigate whether limiting the supply of IGF-II, by
expressing a soluble form of the IGF2R, modifies adenoma growth in the intestine of
ApcMin/+ mutant mice. Female ApcMin/+ (isogenic C57BL6J) were mated with male mice
over-expressing a soluble IGF2R transgene delivered with a keratin 10 promoter
transgene, K10sIgf2r/+ (Zaina et al 1998 Endocrinology, 139: 3886–95, inbred onto
129/JSv). Transgene expression is mainly confined to the colon, uterus, skin, with
lower expression in the small intestine. Animals were housed with sex matched litter-
mates and were fed normal chow (3.5% fat). Genotypes were determined by PCR and
the small intestine and colon processed as previously described (Hassan and Howell
2000 Cancer Res 60; 1070–76). Combination of K10sIgf2r/+ and ApcMin/– resulted in a
3 fold reduction in small intestine adenoma number by post-natal day 150, when
compared to ApcMin/+ littermate controls (6.35±1.4, n=34, vs 18.1±2.6 n=24, respec-
tively, mean±SEM adenoma/mouse, p=0.0001 Mann Whitney). Although transgene
expression reduced small intestine surface area (K10sIgf2r/+, ApcMin/+, 26.7±0.7 cm2 vs
ApcMin/+, 31.8±1.1 cm2, mean±SEM, p=0.0003), it failed to result in equivalent effects
on adenoma diameter. We conclude that soluble IGF2R receptor can modify the
effects of small intestinal adenoma growth. Expression of the transgene has been
previously shown to be greater in the mouse colon, and experiments are now in
progress which investigate the effect of soluble IGF2R on colorectal adenoma
progression.
Experiments were performed following approval of the Home office and
Departmental ethics committee and following the guidelines of the UKCCR.
*Supported by Senior Clinical Research Fellowship Grant (2390/0101) of the Cancer
Research Campaign.
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THE IN VITRO METABOLISM OF ANTAGONIST G, A BROAD
SPECTRUM GROWTH FACTOR ANTAGONIST, IN THE LIVER
CYTOSOL OF MOUSE, RAT AND MAN MA Mark*, S Clive, AJ MacLellan, J
Cummings, JF Smyth, DI Jodrell, ICRF Medical Oncology Unit, University of
Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK
Antagonist G (NH2-Arg-DTrp-MePhe-DTrp-Leu-Met-NH2), a substance P analogue,
is a broad spectrum neuropeptide antagonist being developed clinically as treatment
for small cell lung and other cancers. The enzyme involved in the metabolism of
Antagonist G is widely distributed, the highest specific activity being detected in
cytosolic fractions of the liver (Jones et al, 1995, Biochem. Pharmacol., 50(5), 585).
The enzyme is capable of both deamidation (optimal at neutral pH) and carboxypepti-
dase activity (optimal at acidic pH). The in vitro metabolism of Antagonist G proceeds
from the c-terminus via deamidation to form Metabolite (Met) I and then removal of
methionine to form Met II. In pharmacokinetic (PK) studies of Antagonist G, admin-
istered by i.v. infusion, in female Wistar rats the relationship between dose and steady
state concentration appears to be non-linear suggesting clearance is saturable and
suggesting metabolism is a significant mechanism of drug clearance. Liver cytosol
preparations (LC preps) from mice, rats and humans were prepared and incubated
with Antagonist G to investigate species differences in metabolism. Incubations were
performed at neutral pH to favour deamidation to Met I and to limit the formation of
Met II. Experiments were performed in triplicate with rodent LC preps being a mix of
at least 2 animals. Mouse livers were obtained from female nu nu mice, and rat livers
from female Wistar rats. Human liver specimens were obtained fresh during hepatic
surgery (n=4). Previous PK studies with Antagonist G utilised electrochemical detec-
tion, but we have developed a new reverse phase HPLC method using UV photo-
diode array detection which allows the simultaneous determination of both Antagonist
G and its metabolites (Cummings et al, 1999, J. Chromatog. B, 732 277). When used
to analyse LC preps, the mean retention times of Antagonist G and Met I and Met II,
were 15.1 mins, 13.4 mins and 12.3 mins respectively. The rate of formation of Met I
was equivalent to the disappearance of Antagonist G and conformed to Michaelis
Menten kinetics in all 3 species. However, estimates of Vmax (the maximum produc-
tion rate of metabolism) and Km (the concentration of substrate at which half of the
active sites are filled), estimated using GraphPad Prism™ differed between species.
Vmax was greater in the human LC preps (2110 ± 497 (mean ± 95% C.I.) mmoles
min–1 mg protein–1) compared to the mouse (849 ± 167) and rat (832 ± 69), the rodent
species giving similar estimates. Km also varied between species (rat 19.3 ± 6.2 mM,
compared to mouse, 39.6 ± 25.4 and human, 133 ± 80.3). Non-linear PKs have been
identified in the phase I clinical trial but a PK model has not been fully defined,
perhaps because the plasma concentrations achieved (≤ 46 mM) are less than 50% of
the estimated Km for the LC prep.
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RAPID DETECTION OF CIN STATUS IN HUMAN TUMOUR CELL
LINES USING A CENTROMERIC FISH 3 PROBE SYSTEM
Jaffrey RG*, Marsh S, Cassidy J, McLeod HL, Oncology Group Dept of
Medicine and Therapeutics, University of Aberdeen AB25 2ZD, UK
Chromosome instability (CIN) is a characteristic that is seen, as aneuploidy, in a
majority of tumour types. The role of CIN is poorly understood in the progression to
malignancy and in chemotherapy resistance. The loss or gain of chromosomes (aneu-
ploidy) is generally viewed in the early stages of tumour evolution, accumulating as
the tumour becomes increasingly advanced. Several recent studies have focused their
attention to the possible mechanisms of action of this CIN phenotype. We have
proposed a model for the rapid detection of the CIN phenotype in human cancer.
Analysis of centromeric probes by FISH was performed in 11 human cancer cell lines
with defined CIN status: 7 CIN+ (BE, CACO2, H630-R10, H630, HT29, L-DAN and
MCF-7), and 4 CIN- (RKO, DLD-1, LOVO and WIL-2) and a normal leukocyte
control. Primary analysis of these cell lines used 11 centromeric probes and clearly
separated the two subgroups based on mean centromeric signal per cell (p<0.001). All
CIN+ cell lines had a mean centromere number >2.8 and all CIN-cells were <2.1.
Analysis of predictive performance identified several probes with a high ability to
predict CIN status (k=1). Use of data from probes for centromeres 11, 17 and 18 gave
100% ability to rapidly determine CIN phenotype in human cancer cell lines. This
centromeric CIN model will help researchers to accelerate the pursuit of the complex
and subtle mechanisms involved in chromosome catastrophe.36 Poster Presentations
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DETECTION OF AMPLIFIED AND TRANSCRIBED SEQUENCES
AT THE CHROMOSOME 12Q13–15 LOCUS IN NGP
NEUROBLASTOMA CELLS BY ALU-PCR LIB Pinto1, ADJ Pearson2, R
Perry3, J Lunec1, 1Cancer Research Unit, 2Dept Child Health, 3Dept
Pathology, University of Newcastle NE2 4HH, UK
Alu-PCR fingerprinting has been used to disclose genetic abnormalities in cancer that
may be associated to activation of oncogenes or inactivation of tumour suppressor
genes. This technique is based on polymerase chain reaction (PCR) amplification of
genomic DNA with primers specific for the Alu repeat sequences, which are distrib-
uted ubiquitously throughout the genome. Several types of primers based on the
consensus Alu sequence have been designed. This primers can be used alone or in
combination with other Alu primers or primers to other interspersed repeat elements
to amplify inter-Alu sequences from human DNA. We have used this strategy to study
7 neuroblastoma cell lines compared to 8 normal samples (4 blood samples and 4
cerebellum samples). Amplification of 2 DNA fragments was detected in the NGP
cell line. The fragments have been cloned into the p-GEM-T-easy vector (Promega)
and automated sequenced. The sequences were flanked by Alu repeat elements and
the inter-Alu sequences were searched against the GENEBANK database. A novel
623 bp sequence was disclosed and the other sequence was revealed to be part of the
advillin gene. The 623 bp fragment and a 808 bp PCR product from the advillin gene
were used as probes for Southern-blot analysis of genomic DNA of the NGP cell line
and confirmed the amplification observed by Alu-PCR fingerprinting. Both fragments
were also used as probes for Northernblot and increased expression on filters carrying
total RNA from the NGP cell line was disclosed when compared with total RNA from
the cell lines SHEP and SKNSH. Radiation hybrid mapping revealed that the 623 bp
fragment was amplified from a region of chromosome 12q13–15, where the MDM2
and the advillin loci have been previously mapped. The results indicate that Alu-PCR
fingerprinting is useful for the detection and cloning of amplified genomic regions and
the subsequent identification of amplified genes in tumour cells.
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EXPRESSION OF GENES PAX-3 AND PAX-7 IN NEURAL
CREST LINEAGE TUMOURS C Parker1,* W Wang2, I Hart3, K
Sisley4, S Kumar5 and P Kumar1, 1Manchester Metropolitan University,
Manchester M13 9PT, 2Aberdeen University, Aberdeen, 3St. Thomas’
Hospital, London SE1 7EH, 4Royal Hallamshire Hospital, Sheffield,
5Manchester University, Manchester M13 9PT, UK
The developmental genes Pax-3 and Pax-7 have been shown to be expressed in the
early embryo in developing muscle and elements of the brain and nervous system.
Recent studies have shown expression of these genes in both alveolar and embryonal
forms (RMS-A and RMS-E) of Rhabdomyosarcoma. In the study here RT-PCR was
used to screen melanoma cell lines and primary malignant ocular melanoma tissue
along with small cell lung cancer (SCLC) cell lines, all of which are neural crest
lineage related. Eleven out of thirteen melanoma cell lines were found to express Pax-
3 but not Pax-7. Two cell lines from ocular melanomas, did not express Pax-3
although one of the cell line did express Pax-7. All 8 occular melanoma tissue samples
screened also expressed Pax-3 along with 2/3 of the SCLC cell lines. Interestingly a
non tumorigenic cell line melan A, did not show Pax-3 expression but did express
Pax-3 after transfection with ras.
These results indicate that Pax-3 and Pax-7 may have important role in the devel-
opment and progression of neural lineage tumours and may serve as prognostic
markers for these tumour types. Furthermore the results show that Pax-3 may be
involved in the ras transformation of neural lineage tumours.
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PREVALENCE OF BRCA1 AND BRCA2 MUTATIONS IN A
LARGE POPULATION BASED SERIES OF BREAST CANCER
CASES Bettina Kuschel*, For the The Anglian Breast Cancer Study Group,
University of Cambridge Dept of Oncology, Strangeways Research
Laboratories, Worts Causeway, Cambridge CB1 8RN, UK
Background Estimates of the contribution of BRCA1 and BRCA2 to breast cancer
incidence in outbred populations have been based on studies that are either small or
have selected for cases diagnosed at an early age. Only one of these has reported an
estimate of the breast cancer risk associated with a mutation in these genes, and there
is no published ovarian cancer risk estimate derived from a population based case
series.
Method A population-based series of breast cancer cases Anglian Cancer Registry
comprising a prevalent series of cases diagnosed under age 55 was screened for muta-
tions in BRCA1 and BRCA2 by multiplex heteroduplex analysis. In order to assess the
importance of survival bias, we also screened the subgroup of an incident population
based case series diagnosed under age 35 together with the incident cases with the
strongest family histories. Pedigree information from mutation carriers was used to
estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1
and BRCA2.
Results We identified 8 (0.7%) BRCA1 and 15 (1.2%) BRCA2 mutation carriers in
1220 prevalent breast cancer cases. Mutation prevalence was substantially higher in
cases diagnosed before 35 years of age and with increasing number of relatives
affected with breast or ovarian cancer. However, most mutation carriers were diag-
nosed in the older age groups, and a minority reported a first degree relative with
breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI
7–82%) for BRCA1 mutation carriers and 74% (7–94%) for BRCA2 mutation carriers.
Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6–65%) by
age 80. Seventeen per cent of the familial risk of breast cancer was attributable to
BRCA1 and BRCA2. At birth, the estimated prevalence of BRCA1 mutation carriers
was 0.07%–0.09% and 0.14%–0.22% for BRCA2. Updated results, with data from the
mutation analysis of 288 incident cases will also be presented.
Conclusions Mutations in the breast cancer susceptibility genes BRCA1 and
BRCA2 are rare in the population and account for a small fraction of all breast cancer
in Britain, even in a population based series of young diseased patients without any
survival bias.
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ESTROGEN RECEPTOR GENE POLYMORPHISMS AND MALE
BREAST CANCER IE Young*1, KM Kurian1, MAF MacKenzie1, IH
Kunkler2, BB Cohen3, CM Steel3, 1/C.R.C. Laboratories, Molecular Medicine
Centre & 2/Dept. of Clinical Oncology, Western General Hospital, Crewe
Road, Edinburgh EH4 2XU, 3/School of Biomedical Sciences, University of
St. Andrews, St. Andrews, Fife KY16 9TS, UK
In a previous study we have shown an association between a polymorphism in the CYP17
gene and male breast cancer[1]. Other studies, looking at polymorphisms in the estrogen
receptor gene, have not shown a consistent association with female breast cancer[2]. The
aims of this study were to investigate the frequencies of two estrogen receptor gene poly-
morphisms in a group of male breast cancer patients from South East Scotland.
Cases were a consecutive series of 76 male breast cancer patients treated in S.E.
Scotland between 1974 and 1998. 64 DNA samples were available (from blood
samples in 25 cases, archival tissue in 39). Control DNA samples were obtained from
77 healthy males representative of the S.E. Scotland population. The relevant frag-
ments of intron 1 and exon 2 containing the polymorphic sites were amplified by poly-
merase chain reaction (PCR). The intron 1 products were digested overnight by Pvull at
37°C and the exon 2 products by BstUI at 60°C. The products were then separated on
4% agarose gels, stained with ethidium bromide and visualised under ultraviolet light.
The distribution of alleles of exon 2 of the estrogen receptor gene is shown in the table:
Allel Cases (n=63*) Controls (n=77)
W:W 46 67
W:P 16 10
P:P 1 0
(W=Wild type, P=Polymorphic i.e. cut by BstUI)
*PCR unsuccessful with one DNA sample
27% of males with breast cancer carry a polymorphic allele in exon 2 compared to
13% of controls. This difference is statistically significant (c2=4.361, 1 df, p=0.0368).
The odds ratio for the risk of developing breast cancer in a male with a polymorphic
allele in exon 2 is 2.476 (95% CI 1.041 to 5.890). There were no significant differ-
ences between cases and controls in the distribution of intron 1 alleles (data not
shown).
We have demonstrated an association between a polymorphism in exon 2 of the
estrogen receptor gene and male breast cancer. This is now the second modifying
polymorphism that we have associated with an increased risk of male breast cancer.
We believe that this further illustrates the potential importance of these low-pene-
trance genes in the development of breast cancer.
1 Young et al (1999) Br J Cancer 81:(1) 141
2 Andersen et al (1994) Hum Genet 94: 665Poster Presentations 37
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IMMUNOHISTOCHEMICAL DETECTION OF ESTROGEN
RECEPTOR b IN PARAFFIN-EMBEDDED HUMAN BREAST
TISSUES GP Skliris*1, PJ Carder2, J Askaa3, AF Markham1 and V Speirs1,
1Molecular Medicine Unit, 2Pathology, St. James’s University Hospital, Leeds
LS9 7TF, 3DAKO A/S Denmark
Estrogen receptor (ER) is a prognostic marker for predicting response to endocrine
therapy in breast cancer. The cloning of a novel ER, ERb, has been reported and has
been implicated in breast cancer. The presence of ERb has been provided from in situ
hybridisation studies and RT-PCR, but little is known concerning the protein. For ERb
to have potential as a diagnostic tool, optimisation of immunostaining for use on
paraffin sections is required as most clinical material is processed in this way. The aim
of this study was to investigate the expression and distribution of ERb protein in
breast tumours. Twenty tumour breast biopsies, mostly invasive ductal carcinomas,
were randomly selected. Five mm sections were cut, mounted on silanised slides and
dried overnight, before being microwaved in the presence of citrate buffer pH 6.0.
ERb staining was performed using two different antibodies, of monoclonal and poly-
clonal origin, while staining for ERa, which acted as a reference point was conducted
using the monoclonal antibody ER1D5. Specific strong staining was mainly exhibited
in nuclei of epithelial cells using both ERb antibodies, while occasional cytoplasmic
staining was sometimes detected in stromal cells. When the monoclonal ERb antibody
was applied, stronger staining intensity was observed in the nuclei, accompanied with
less background. Additionally, ERb was co-expressed with ERa in most tumours,
confirming previous mRNA studies. Specificity of ERb staining was confirmed in
sections where primary antibodies were omitted, substituted with PBS, or pre-
absorbed with 5 times excess of blocking peptide. Our results indicate that ERb
protein is detectable in human breast tumours using immunohistochemical tech-
niques. Routine measurement of ER subtypes in these tumours is likely to enhance the
ability to individualise therapy and offer a more selective approach in defining the
most appropriate initial hormonal intervention. Supported by Yorkshire Cancer
Research
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BCL-2, ANGIOGENESIS, NECROSIS AND MACROPHAGES IN
EARLY BREAST CANCER KJ O’Byrne*1, RD Leek3, RA Walker2
and AL Harris3, University Depts of 1Oncology and 2Pathology, Leicester
Royal Infirmary, LE1 5WW; 3Imperial Cancer Research Fund Medical
Oncology Unit, Churchill Hospital, Oxford OX3 9DS, UK
Bcl-2 is an anti-apoptotic factor the expression of which is paradoxically associated
with a favourable outcome in solid tumours including breast cancer. A number of
studies have shown a consistent inverse relationship between bcl-2 expression and
apoptosis and tumour necrosis (TN). Angiogenesis, the formation of new blood
vessels from an existing vasculature, is necessary for a tumour to grow beyond 1–2
mm in diameter and is associated with both macrophage infiltration (MphiI) and TN
in breast cancer. An inverse correlation between bcl-2 expression and angiogenesis,
assessed by the Chalkley microvessel counting method (MVC), has been found in
non-small cell lung cancer (NSCLC). We evaluated the inter-relationships between
bcl-2 expression and MVC, p53, estrogen receptor (ER), epidermal growth factor
receptor (EGFR), vascular endothelial growth factor (VEGF), thymidine phosphory-
lase (TP), and tumour necrosis factor(TNF)-a expression, TN, MphiI and clinico-
pathological features in a retrospective study of 82 patients with operable breast
cancer. An inverse relationship was found between Bcl-2 and MVC (p=0.02), tumour
grade (p=0.01), p53 (p=0.005), EGFR expression (p=0.048), TN (p=0.002) and MphiI
(p=0.02). Bcl-2 was positively correlated with post-menopausal status (p=0.04),
increasing patient age (p=0.03) and ER immunopositivity (p<0.0001). Bcl-2 was not
associated with tumour size, nodal status or the expression of VEGF, TP and TNF-a.
In conclusion, although not of prognostic significance, bcl-2 immunopositivity was
associated with favourable prognostic indices in operable breast cancer. In particular
bcl-2 expression may result in the inhibition of apoptosis and necrosis induced by
tumour hypoxia with a consequent reduction in macrophage infiltration and subse-
quent angiogenesis.
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LOCALLY ADVANCED BREAST CANCER IS ASSOCIATED WITH
A HIGH RATE OF HER2 OVEREXPRESSION, *Bartlett J,
 Anderson A, *Watters A,  Leonard R and  Cameron D, Medical Oncology
Unit, Western General Hospital, Edinburgh and *Department of Surgery,
Glasgow Royal Infirmary, UK
In different series of breast cancer the overexpression of HER2 protein varies from
around 9% to 39%, depending on the antibody selected and the patient group.
Overexpression is associated with more aggressive behaviour, is inversely correlated
with ER expression and presents a target for antibody therapy with the humanised
mouse monoclonal antibody, trastuzumab. In many studies there is a close correlation
between protein overexpression and gene amplification (Robertson et al, 1996). There
is also controversial data that suggests that overexpressing tumours show a dose
response effect when exposed to anthracycline chemotherapy in the clinic [Muss et al
1996; Thor et al 1999; Cameron et al 1999]. A series of Edinburgh patients presenting
with inoperable breast cancer was treated with infusional 5 fluorouracil and anthracy-
clines or cyclophosphamide/methotrexate with conventionally adequate outcomes
[Davidson et al 1999].
A random selection of 32 patients with T4 disease has been studied for HER2 gene
amplification using the Pathyvision FISH diagnostic technique which is reproducible
and quantifiable and is superior to IHC which is semiquantitative and may produces
either false positives or false negatives [Allred AJCP 2000].
Results
Inflammatory ER+VE Grade 3 Size>5 cm 3 yr survival
FISH+ve(14) 17% 49% 66% 67% 57%
FISH–ve(18) 44% 79% 59% 75% 89%
Grade and size are not different between the groups but there is an inverse rela-
tionship between ER and HER2 +ve patients as expected. Neither disease free nor
overall survival is significantly different but there is a trend (p=0.06) to improved
survival in the HER2 –ve group. The rate of gene amplification in this series of T4
tumours is 44% which is markedly higher than published rates for gene amplification
in breast cancer (Salmon et al, 1987, Mitchell & Press, 1999). It appears that in addi-
tion to the high stage of disease in this patient group the rate of amplification is also a
factor in the poor outcome for patients. These data have important implications for the
prognosis and management of patients with locally advanced breast cancer.
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PERSISTENCE OF C-ERBB-2 OVEREXPRESSION AFTER
NEOADJUVANT CHEMOTHERAPY FOR PRIMARY BREAST
CANCER, RJ Burcombe*1, A Makris1, PI Richman2, F Daley2, S Noble2, GD
Wilson2, 1Marie Curie Research Wing & 2The Gray Laboratory, Mount Vernon
Hospital, Northwood HA6 2RN, UK
Overexpression of the c-erbB-2 (HER-2) proto-oncogene in breast cancer patients is
associated with worse prognosis and has been implicated in resistance to chemothera-
peutic agents, including anthracyclines. The use of neoadjuvant chemotherapy
provides an in vivo model to study the effects of treatment on c-erbB-2 expression.
48 women with primary breast cancer (mean age 57 years, range 27–78) were
studied. All patients underwent diagnostic core biopsy prior to 6 cycles of
neoadjuvant FEC chemotherapy (5-Fluouracil 600 mg/m2, Epirubicin 60 mg/m2,
Cyclophosphamide 600 mg/m2). Surgery was performed after clinical and radiolog-
ical assessment of response. Tamoxifen was commenced post-operatively in patients
with ER positive tumours.
Immunohistochemical analysis for c-erbB-2 was performed on core biopsies and
subsequent surgical specimens using a monoclonal mouse anti-c-erbB-2 antibody
(Zymed laboratories). Two independent observers assessed the specimens. Membrane
staining in > 10% of tumour cells was scored positive.
Tumours from eight patients (17%) were c-erbB-2 positive on both the core biopsy
and surgical specimen. All other tumours stained negative for c-erbB-2 before and
after treatment. Clinical response to treatment (CR and PR) was observed in 6/8
(75%) and 28/40 (70%) of c-erbB-2 positive and negative tumours respectively.
Conclusion Overexpression of c-erbB-2 was not affected by neoadjuvant anthra-
cycline-based chemotherapy and in this cohort of patients did not predict for resis-
tance to treatment.38 Poster Presentations
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THE P53 STATUS OF SPORADIC BREAST TUMOURS
ASSESSED BY DIFFERENT METHODS PM Duddy*1, AM Hanby2,
DM Barnes2 and RS Camplejohn1, 1Richard Dimbleby Dept. of Cancer Res.,
St. Thomas’ Hospital, London SE1 7EH, 2ICRF Clinical Oncology Unit, Guy’s
Hospital, London SE1 9RT, UK
Indirect methods of assessing p53 do not give an accurate assessment of the mutation
status of tumours. In sporadic tumours, p53 mutations commonly are found in hot-
spot regions of the gene, such as the core DNA-binding domain. As a result, direct
sequencing of the p53 gene has concentrated on exons 5–8, although a significant
minority of mutations have been found in other parts of the gene such as the
oligomerisation domain (Hainaut et al. Nucleic Acids Res. 1998; 26: 205–213).
The aim of this investigation was to examine the ability of the yeast-based func-
tional assay, the FASAY, to detect p53 mutations in breast cancers when compared
with immunohistochemistry and automated sequencing of the whole p53 gene (exons
1–11). To achieve this, all 3 methods were carried out on a cohort of aggressive breast
tumours. In those tumours, in which the FASAY analysis indicated the presence of a
mutation, cDNA was extracted from red yeast colonies and was sequenced in order to
identify the base change in the p53 gene. The FASAY detected all 24 mutations found
in the series of 48 tumours, whilst initial automated sequencing of genomic DNA
detected 18/24 mutations. A second round of automated sequencing, carried out using
an independent source of genomic DNA, detected mutations in 3 of the 6 tumours
which originally appeared to lack a mutation in genomic DNA. All but 1 of the muta-
tions originally missed by sequencing of genomic DNA were point mutations. Five
mutations in this series (21%) were outside the commonly investigated exons 5–8,
reinforcing the need to extend sequencing beyond this region. All 14 tumours with
strong immunohistochemical staining had p53 mutations; the majority of mutations
missed by immunohistochemistry produced a truncated protein. Strong staining was
never seen in tumours lacking a p53 mutation. The FASAY proved to be a rapid, reli-
able and effective method for identifying those breast tumours harbouring p53 muta-
tions and could well provide the ‘gold-standard’ for detection of these genetic defects.
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EXPRESSION OF CYCLOOXYGENASE 2 (COX-2) IN HUMAN
BREAST CARCINOMAS CJ Witton*, LF Clark, TG Cooke and JMS
Bartlett, Dept of Surgery, Queen Elizabeth Building, Glasgow Royal Infirmary,
Alexander Parade, Glasgow G31 2ER, UK
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been found to be protective
against colorectal cancer. These compounds inhibit the catalytic activity of cyclooxy-
genase (COX) which is involved in the regulation of prostaglandin synthesis(1).
Prostaglandins in turn control the production of vascular endothelial growth factor
(VEGF) and this growth factor promotes angiogenesis. This process is important for
tumour growth and metastasis. Aberrant or increased expression of COX-2 has been
reported in colorectal, lung, oesophageal and breast cancers. COX-2 has previously
been found to be localised to tumour cells in breast (2). In colorectal cancer it has been
suggested that COX-2 expression is regulated by HER2 (3).
We have examined COX-2 in formalin fixed tissue from a randomly selected
cohort of patients who were treated in Glasgow for breast cancer between 1984 and
1997. Follow up data was available for all these patients. COX-2 expression was
analysed with immunohistochemistry (IHC) using a monoclonal antibody to COX-2.
COX-2 staining was carried out using the NexES II IHC Staining System. This is a
fully automated, temperature controlled staining system which eliminates variations
in results due to temperature variations in the laboratory. Epitope retrieval was
performed within a microwave pressure cooker in Tris-EDTA (TE) buffer. COX-2
staining was assessed independently by two investigators using a histoscore based on
percentage and intensity of staining with 300 representing a very high intensity stain
in all tumour cells and 0 representing no tumour cells stained.
COX-2 staining was localised to the cytoplasm of tumour cells with low to
medium intensity (histoscores 120–220). The mean COX-2 histoscore for tumours
scored as positive for HER2 by Fluorescent in situ hybridisation (FISH) (n=22,
mean=153, sd=20.08) was higher those scored negative (n=55, mean=163, sd=23.30)
but this was not significant. The mean histoscores of those patients who had died from
their disease (n=42, mean=161, sd=28.71) and those who hadn’t (n=58, mean=160,
sd=21.25) were also not significantly different.
COX-2 staining therefore did not correlate with HER2 status, in contrast to
evidence in colorectal cancer (3), or survival. However since this enzyme has been
found in all tumours, treatment with NSAIDs or specific COX-2 inhibitors to decrease
COX-2 may have potential in the treatment of breast cancer. Future work will
examine expression of VEGF in breast cancer to relate it to this COX-2 data.
1 Shiff SJ, Rigas B (1999) J Exp Med 190: 445–450
2 Hwang D, Scollard D, Byrne J, Levine E (1998) J Natl Cancer Inst 90:
455–460
3 Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R
(1999) Oncogene 18: 305–314
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LOSS OF EXPRESSION OF THE HIC-1 GENE
(HYPERMETHYLATED IN CANCER) FROM 17P13.3 IN BREAST
CANCER G Nicoll, DN Crichton, AM Thompson*, Department of Surgery &
Molecular Oncology, University of Dundee DD1 9SY, UK
In addition to the p53 gene, a new cancer gene, HIC-1 (Hypermethylated In Cancer)
on chromosome 17p may be of clinical importance in sporadic breast cancer. HIC-1
lies in band 17p13.3 telomeric to p53 at 17p13.1, where loss of heterozygosity studies
have suggested clinically significant involvement of a gene associated with poor prog-
nosis in breast cancer. Regional DNA hypermethylation (resulting in suppression of
gene expression) of 17p13.3 has been shown to precede 17p structural changes in
human carcinogenesis. Thus, loss of HIC-1 expression and p53 malfunction may be
common synergistic events in sporadic breast cancer.
Using RT-PCR, HIC-1 transcripts were identified in MCF7 (wild type p53) but not
in MDAMB231 (mutant p53), which were used as positive and negative controls
respectively. Mdm2 and actin were used as internal controls for the integrity of the
RT-PCR process.
HIC-1 expression was sought in the RNA extracted from 31 primary, untreated
human breast cancers and was detected in only 6/31 (19%) cancers despite positive
internal controls for mdm2/actin and repeat testing of samples.
These data suggest that loss of function of the HIC-1 gene on 17p13.3, a chromo-
somal region associated with poor prognosis, occurs in a substantial majority (81%) of
breast cancers. This presents the opportunity for therapeutic manipulation of the
methylation status of genes such as HIC-1 as a novel approach to breast cancer treat-
ment.Poster Presentations 39
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CHROMOSOMAL RADIOSENSITIVITY IN G2-PHASE
LYMPHOCYTES IS ASSOCIATED WITH GOOD PROGNOSIS IN
BREAST CANCER A Riches1, P Bryant1, AM Thompson2*, PE Preece2, CM
Steel1, 1School of Biology, University of St Andrews, 2Department of Surgery
& Molecular Oncology, University of Dundee DD1 9SY, UK
Patients who are cancer-prone as a result of certain genetic disorders exhibit a high G2
chromosomal radiosensitivity. It has been demonstrated that peripheral blood lympho-
cytes from some breast cancer patients also have an increased sensitivity to radiation
damage in G2 compared with age matched controls.
The aims of this study were to evaluate the frequency of lymphocyte G2 radiation
sensitivity in breast cancer patients in our region and to compare G2 sensitivity to
clinical and pathological parameters.
Pretreatment blood samples were collected from 65 women with breast cancer and
lymphocytes set up in culture for analysis by the G2 assay. Chromatid aberrations per
100 metaphase spreads (with the unirradiated background subtracted) were deter-
mined.
Thirty patients (46%) exhibited an increased radiation sensitivity of peripheral
blood lymphocytes compared with 14% (9/66) of control samples (patients under-
going minor surgery with no history of malignancy). In the high G2 group, 81% of
cancers were oestrogen receptor positive, while only 45% were oestrogen receptor
positive in the low G2 group. Patients with a high G2 score were more likely to be
axillary node negative, had smaller cancers and a better prognosis (based on the
Nottingham Prognostic Index) than breast cancer patients with a low G2 score.
These data suggest that a high G2 assay score (increased radiation sensitivity)
distinguishes a group of women with breast cancer who have a good prognosis. The
gene or genes underlying this increased sensitivity to radiation may play an important
role in the pathogenesis of breast cancer.
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DOXORUBICIN-CMF CHEMOTHERAPY FOR MULTIPLE NODE-
POSITIVE BREAST CANCER – UK EXPERIENCE *A Anderson,
*DA Cameron, *RCF Leonard, Department of Clinical Oncology, Western
General Hospital, Edinburgh, Scotland on behalf of the UK Breast Cancer
Collaborative Group
Sequential doxorubicin and CMF chemotherapy, as designed by Bonadonna et al
[JAMA 1995; 273: 542–547], has the best non-myeloablative medium and long term
results in the treatment of multiple node-positive breast cancer. Between 1994 and
1998, 75 patients (pts) [median age 48, range 26–62] with operable multiple node
positive breast cancer [median 10 nodes; 3 nodes, 2 pts; 4–9 nodes, 35 pts; and 10+
nodes, 38 pts,] were treated with doxorubicin 75 mg/m2 ´ 4 followed by intravenous
CMF [cyclophosphamide 600 mg/m2; 5-fluorouracil 600 mg/m2 and methotrexate 40
mg/m2], ´ 8 cycles; both q 21 days. Adjuvant locoregional radiotherapy was given to
61 pts using standardised fractionation at 4500–6000 cGy between cycles 2 and 3 of
the CMF regimen. Tamoxifen 20 mg/day for 5 years was given to 57 ER-positive pts
on completion of chemotherapy.
The projected overall survival is 95% at 3 years for the 4–9 node group and 70%
for the 10+ node group [difference between groups; Kaplan Meier statistic p=0.027],
similar to that reported by Bonadonna. Tumour grade [15 grade 1 or 2; 60 grade 3],
estrogen receptor status and use of tamoxifen are not significant factors in survival
analysis. Disease-free survival for the same groups and follow-up periods are 62%
and 60%. Site of first relapse was locoregional in 8, distant (with or without local) 18.
Local control at 3 years is 80%. Toxicity was generally acceptable in all age-groups.
60 had treatment delays 1–6 weeks, 11 had dose reductions and 9% pts were admitted
for neutropenic sepsis. There were no toxic deaths and no clinical cardiac toxicity has
been observed.
The regimen has been tested more widely in the UK with 6 centres providing a
total of 280 patients. This is the largest series of patients treated with the regimen and
the outcomes will be presented.
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ANASTROZOLE (ARIMIDEX™) VERSUS TAMOXIFEN AS 1ST-
LINE THERAPY FOR ADVANCED BREAST CANCER (ABC) IN
POST-MENOPAUSAL (PM) WOMEN – COMBINED ANALYSIS FROM TWO
IDENTICALLY DESIGNED MULTICENTER TRIALS JFR Robertson, On
behalf of the Arimidex 1st-Line study group, Dept of Surgery, Nottingham City
Hospital, UK
Anastrozole (‘Arimidex’) (AN) is a non-steroidal aromatase inhibitor used to treat
ABC in PM women whose tumors recur/progress on tamoxifen (TAM). We report on
two randomized, double-blind trials (performed in the US and Canada [T30] and
Europe/rest of the world [T27]), which compared AN 1 mg od and TAM 20 mg od as
first-line therapies for ABC in PM women with ER+ve and/or PR+ve or unknown
tumor receptor status. The design allowed for combined data analysis. Primary
endpoints were time to progression (TTP), objective response (OR), and tolerability.
1021 patients (n=353 [T30]; n=668 [T27]) were included in the combined analysis.
Median duration of follow-up was 18.2 months. Median TTP was 8.5 months for AN
and 7.0 months for TAM with an estimated hazard ratio relative to the control arm,
TAM, of 1.12 (lower 95% CL, 1.00) showing AN to be at least equivalent to TAM.
OR (defined as complete or partial response [CR+PR]) was 29% for AN and 27% for
TAM. Efficacy of AN relative to TAM was explored within subgroups defined retro-
spectively by receptor status, prior hormonal treatment, site of disease and age. These
analyses showed a significant prolongation of TTP in the AN arm (median values of
10.7 and 6.4 months for AN and TAM, respectively, 2-sided p=0.022) in patients
confirmed as ER+ve and/or PR+ve (57.7% of combined trial population). In patients
with visceral lesions, AN was equivalent to TAM in terms of TTP. Both AN and TAM
were well tolerated by most patients. However, both thromboembolic events and
vaginal bleeding were reported in half as many patients treated with AN as those
treated with TAM [4.5 versus 7.6% (thromboembolic) and 1.2 versus 2.9% (vaginal
bleeding), respectively].
In conclusion, in PM women with hormonally-sensitive ABC, these data suggest
that AN should be considered as an alternative first-line treatment to TAM.
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ADJUVANT FEC AND CMF CHEMOTHERAPY DOSE INTENSITY
IN THE LEEDS BREAST UNIT RA Popescu*1, A Henry2, DJ Dodwell2
and TJ Perren1, 1ICRF Cancer Medicine Research Unit, St. James’s Hospital
Leeds LS9 7TF, 2Radiotherapy Dept, Cookridge Hospital LS16 6QV, UK
A clear relationship exists between dose intensity of a variety of adjuvant
chemotherapy regimens and outcome in patients with early breast cancer. However,
the number of clinical trials that report the achieved dose intensity in this population is
small, and data is scarce on dose intensity delivered in routine clinical practice.
Between 1 March 1998 and 30 September 1999, 160 patients received adjuvant cyto-
toxic treatment in the Leeds Breast Unit. Using the computerised chemotherapy
prescription records, we identified all women scheduled to receive 6 courses of adjuvant
Bonadonna CMF or FEC chemotherapy, and assessed the number of chemotherapy
cycles administered, treatment delays, toxicity and dose intensity achieved.
Adjuvant FEC chemotherapy (Fluouracil 600 mg/m2 iv d1, Epirubicin 60 mg/m2 iv
d1 and Cyclophosphamide 600 mg/m2 iv d1 every 3 weeks) was administered to 86
women (mean age 46, range 31–63). 84 patients were given 6 cycles, one patient 5 and
another 4 cycles of treatment (mean 5.97 cycles). 49 patients (57%) completed their
treatment without any delays, 17 were delayed for one week and 13 for two weeks; 2
patients were delayed for 4 or more weeks. Of all cycles, 11% were delayed, of which
4/5th due to neutropenia or sepsis. Likelihood of dose reductions increased as
chemotherapy courses were accumulating, but 82% of patients receiving a sixth
course had 95% or more of the planned dose given. Relative dose intensity (DI)
administered was on average 95% of planned DI, the median relative DI was 100%.
Of all 86 patients, 12 (14%) achieved less than 90% of planned DI, and 7 (8%) were
given less than 80% of planned DI.
Bonadonna CMF was given to 33 patients (mean age 55, range 32–75). Twenty-four
patients completed the planned 6 cycles, but 7 patients (21%) received 5 cycles and 2
(6%) 4 cycles (mean 5.64 cycles). Of all chemotherapy cycles administered, 26% were
delayed, 19% due to neutropenia or sepsis and 6% due to radiotherapy scheduled after the
3rd course. Dose reductions were necessary in 25 patients (76%). The average relative
dose intensity achieved was 82% (median 83%, minimum 50%). Two thirds of patients
(22) had less than 90% of planned DI, one third less than 80% and 4 patients (12%) less
than 65%. In 11 patients, planned radiotherapy given after the 3rd chemotherapy cycle
significantly prolonged total treatment duration, thus contributing to reducing achieved
DI. For the remaining 22 patients, relative achieved DI was WW%.
There was no correlation between age of patients or nadir blood counts after the
first cycle of FEC (where available) and the achieved DI. Patients with early occur-
rence of delays or dose reductions were most likely to attain a lower DI. In conclusion,
a high relative dose intensity is achievable in the majority of patients treated with FEC
chemotherapy in routine clinical practice. In our small series, CMF was more toxic
and patients achieved lower relative DI.40 Poster Presentations
P45
THE ROLE OF ZOLADEX IN THE PREVENTION OF OVARIAN
DAMAGE DURING CHEMOTHERAPY FOR PRIMARY BREAST
CANCER EF Shah*1, J Woodside1, R Chatterjee2, R Stein3, C Saunders1,
1Dept of surgery, 2Dept of Reproductive Medicine, 3Dept of Oncology,
University College London, 67–73 Riding House St, London W1P 7LD, UK
Aims The aim of this study was to determine whether temporary interruption of the
hypothalamic-pituitary axis by administration of a luteinising hormone releasing
hormone agonist, goserelin, during cytotoxic chemotherapy, would diminish the inci-
dence of chemotherapy-induced premature ovarian failure in premenopausal women
with breast cancer.
Methods A retrospective analysis was carried out on women selected from the
Cancer Research Campaign Adjuvant Breast Trial for women under fifty years old.
Twelve patients, aged 33–48 years at diagnosis, were evaluated at a mean interval of
2.4 years after completion of treatment. Six had been treated with goserelin during
their course of adjuvant chemotherapy and the other six, who served as controls,
received only the chemotherapy. Chemotherapy consisted of cyclophosphamide,
methotrexate and 5-fluorouracil in both groups. At interview, patients completed
questionnaires on their menstrual and reproductive history. Serum oestradiol, follicle-
stimulating hormone (FSH) and luteinising hormone levels were measured in all
patients. Ovulation was assessed by mid-luteal serum progesterone peak levels.
Results Eight patients, three in the control and five in the study group, developed
biochemical evidence of premature ovarian failure with low serum oestradiol and high
FSH levels. Questionnaire evaluation showed four patients, three in the control and
one in the study group, retained their menstrual cycles, and three of these had positive
ovulation tests.
Conclusions Goserelin did not prevent chemotherapy-induced premature ovarian
failure in women with breast cancer. However the results are inconclusive as patients
in the goserelin group were perimenopausal. The study should be repeated prospec-
tively in a larger sample of patients below 40 years old.
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CHEMOTHERAPY USAGE IN WOMEN UNDER 35 WITH
BREAST CANCER Richard Sainsbury* and Bob Haward,
Huddersfield Royal Infirmary HD3 3EA and NYCRIS University of Leeds
LS16 9QB, UK
Introduction There is debate as to whether all young women require chemotherapy.
Young age is often taken as an independent risk factor although it is known to be asso-
ciated with an excess of Grade 3 lesions. A recent paper from Denmark (1) suggests
that survival rates can be improved if all women under 35 receive chemotherapy.
Methods We used the Yorkshire Cancer Registry to look at chemotherapy rates for
the years 1980–1994 and examined at the relationship with survival.
Results 1534 patients under 35 were treated over this time of whom 304 (19.8%)
received adjuvant chemotherapy.
The 5-year overall survival for this group was 60% (95% confidence intervals
54.8–65.8) for those receiving chemotherapy and 63% (60.6–66.0) for those who did
not. Forty-one patients presented with overt metastatic disease, if they are excluded
from the analysis the 5-year survival rates increased to 63% and 64% respectively.
The paper from Denmark does not give 5-year survival rates and thus direct compar-
isons of 5-year survival are not possible.
There was no significant improvement in survival for those receiving
chemotherapy for either the individual time cohorts or the group as a whole. A
Wilcoxon (Breslow) test for equality of survivor functions showed no significant
differences between the groups receiving chemotherapy and those who did not
(p=0.31). The percentage of chemotherapy usage in this age group increased from 8%
in the years 1980–84 to 17% in 1985–1989 and to 32% in 1999–1994.
Conclusion The amount of chemotherapy given over this time period was low but
increased significantly year-on-year. There is no evidence from our large data set that
the addition of chemotherapy affected five-year survival rates.
1 Kroman N, Jensen M-B, Wohlfahrt J, et al (2000) Factors influencing the effect
of age on prognosis in breast cancer: a population based study. BMJ 320: 474–9
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CORE BIOPSY IN BREAST CANCER – AN ANALYSIS OF THE
OPTIMUM NUMBER OF CORES FOR ACCURATE
ASSESSMENT OF HISTOLOGICAL GRADE C McIlhenny*1, JC Doughty1,
WD George1, EA Mallon2, 1University Department of Surgery, 2Department of
Pathology, Western Infirmary, Glasgow, G11 6NT, UK
Aims Core biopsy is well established in the investigation of breast disease and is
increasingly used in patients with locally advanced breast cancer prior to commencing
neoadjuvant chemotherapy. Histological grade is one of the important prognostic
factors in these patients, and accurate assessment of this by core biopsy is important in
predicting outcome. To date no author has reported on the number of cores required to
accurately grade a tumour pre-operatively. This prospective single-blind study was
carried out to determine the number of passes required to establish both a histological
diagnosis of cancer and for accurate determination of the grade of the tumour.
Methods Twenty mastectomy specimens were examined immediately after
surgery. These were orientated as they would have been in vivo and biopsied percuta-
neously. Ten consecutive core biopsies were taken using a spring-loaded device and
labelled sequentially. Sections were then labelled randomly, to blind the investigators.
The tumour was then processed for final histology.
Results A single Core Biopsy achieved an accurate histological diagnostic rate of
73.7%. This figure rose to 89.5% with a second pass and did not become any more
accurate with subsequent passes. To accurately reflect tumour grade, a single needle
pass predicted grade in only 31.6%. This rose to 68.4% for three needle passes, and to
73.7% for four passes. These differences were statistically significant (p < 0.05).
Conclusions From our study, two core biopsies are sufficient to accurately diag-
nose breast disease, and additional passes do not increase this figure. If core biopsies
are being used to grade a tumour, then a minimum of 4 cores are recommended for a
diagnostic accuracy of 75%.
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PATTERNS OF SUPRACLAVICULAR FOSSA FAILURE IN EARLY
BREAST CANCER NJ Thorp*, I Syndikus, Dept. of Radiotherapy,
Clatterbridge Centre for Oncology, Wirral, Merseyside CH63 4JY, UK
Isolated supraclavicular fossa (SCF) relapse following treatment for early breast
cancer is a rare event but can be difficult to manage and impacts on the individual’s
quality of life. It is common practice to treat this area with prophylactic adjuvant
radiotherapy in high risk patients. This requires an anterior field to be matched to the
tangential fields, leading to a higher risk of radiation related toxicity. Some authors
therefore dispute the need for routine SCF irradiation. Until recently the standard
radiotherapy technique used at our centre for the adjuvant treatment of early breast
cancer employed two long tangential fields with no additional anterior field. In vivo
dosimetry studies have demonstrated an adequate axillary dose but a subtherapeutic
dose to the SCF.
We undertook a retrospective study of patients with early breast cancer treated
using this technique in 1993 recording tumour and treatment characteristics. We then
determined the overall rate of SCF relapse and the rate of isolated SCF relapse in this
group of patients in whom the SCF was suboptimally treated.
A total of 361 patients were identified. There were fourteen cases of ipsilateral
SCF recurrences (3.9%) of which 6 had distant metastases diagnosed at the time of the
SCF relapse. The remaining 8 patients had isolated SCF disease at the time of diag-
nosis but 1 patient developed distant metastases 19 months later. Of the 7 patients with
distant metastases 6 have died and 3 of the 7 with isolated SCF recurrence are dead.
Hence 4 of the 7 patients with isolated SCF recurrences remain alive and disease free
and 1 patient with associated bone metastases remains alive 24 months following the
diagnosis of SCF disease.
This study confirms the low rate of isolated SCF recurrence in patients who have
not received prior optimal radiotherapy to the SCF. However, 3 of these patients died
with no other sites of documented disease, suggesting an impact on survival. Data
remains sparse and a large randomised controlled study would be required to clarify
the situation.Poster Presentations 41
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ONCOLOGICAL SAFETY OF SKIN SPARING MASTECTOMY
AND IMMEDIATE RECONSTRUCTION BY BREAST SURGEONS
KL Kirkpatrick, C Choy, ACA Leris, K Mokbel, N Williams, C Kouriefs, A
Mostafa and R Carpenter, St. Bartholomew’s Hospital, West Smithfield,
London EC1A 7BE, UK
Aims To assess the oncological safety, complication rate and patients’ satisfaction
after skin sparing mastectomy (SSM) and immediate reconstruction for breast cancer.
Methods We retrospectively reviewed the records of 136 patients who had Becker
implant (N=100), Latissimus Dorsi Flap (N=28) or TRAM Flap (N=8) breast recon-
struction after skin sparing mastectomy. All data was collected prospectively as part
of continuing audit of reconstructive procedures at this institution.
Results The median age was 52 years (27–74). After a median follow-up of 4
years, there were 6 locoregional recurrences, 20 breast cancer related deaths and one
death unrelated to breast cancer. The overall implant loss rate was 18% (23/128).
There was no flap loss, however recipient breast skin necrosis occurred in 2 patients
and wound infection was observed in 19 patients (14%). 87% of patients were satis-
fied with the cosmetic outcome (median satisfaction score=9, range 0–10). Two
patients who underwent TRAM flap reconstruction developed incisional hernias
(25%). Capsule formation occurred in 35 patients and capsulotomy was performed in
these 35.
Conclusions SSM with immediate reconstruction by breast surgeons appears to be
an oncologically safe procedure and is associated with satisfactory cosmesis at 4
years. However the complication rate is significant and should be taken into consider-
ation when consenting patients during surgical budget planning.
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DOES RADIOTHERAPY IMPACT ON THE OUTCOME OF
IMPLANT-ONLY AND LD FLAP/IMPLANT RECONSTRUCTIONS?
Landau D*1,3, Sacks N2,3, Gui G2, A ‘Hern R4, Ross G1,3, Depts. of
1Radiotherapy, 2Surgery, and 4Computing, The Royal Marsden Hospital,
London, and 3St. George’s Hospital, London, SW3 6JJ, UK
Background The impact of adjuvant post-mastectomy radiotherapy (RT) on disease-
free and overall survival in breast cancer has been demonstrated in two recent
randomised trials. With increasing use of immediate breast reconstruction there has
been variability in referral for locoregional RT. The aim of this study was to investi-
gate the impact of RT on the frequency of surgical revision of breast reconstructions,
either implant-only or latissimus dorsi (LD) flap, after mastectomy.
Procedure Notes were reviewed of patients who had undergone postmastectomy
reconstruction by NS and GG to identify the frequency of removal of prostheses or
other surgical revision of the reconstructions. Indications for mastectomy, type of
reconstruction, details of prior or subsequent RT and details and timing of surgical
revision were recorded.
Major findings 216 patients underwent 253 reconstructions from August 1994 to
April 1999. 199 reconstructions were immediate and 17 delayed, 129 were implant
only and 124 latissimus dorsi flap and implant. The indications for mastectomy were
multifocal invasive disease (63 breasts), DCIS (47), prophylactic (44), recurrent inva-
sive carcinoma (37), advanced disease (17), extensive intraductal component (14),
retroareolar tumour (9), positive margins (5), patient choice (5), inflammatory carci-
noma (4), unknown (4), palliative (2), large phylloides tumour (1) and patient not suit-
able for RT (1). Median follow-up was 14 months. 50 reconstructions were on
previously irradiated chest walls and another 40 went on to receive RT. All patients
received either 2 Gy/# to 46–60 Gy, 40 Gy in 15# or 45 Gy in 25#. 34 implants were
removed and 10 required other surgical revision.
The addition of RT to LD flap reconstruction did not increase the need for surgical
revision (11%). For the implant only group the surgical revision rate was 41% with RT
vs 18% without RT (p=0.049). Timing of RT and RT dose did not affect the revision
rate. The mean time to implant removal was 8 months (range 0.3–55) for all cases; for
infected prostheses the mean time to removal was 2 months and for
capsule/cosmesis/pain 11 months. 59% of removals were within 6 months and 79%
within 12 months post-op.
Conclusion RT has previously been shown to increase the revision rate following
implant-only reconstruction. We have demonstrated that this is not the case for LD
flap reconstructions. Possible explanations for this difference are improved vascu-
larity of the periprosthetic tissue and increased ‘padding’ with the LD flaps compared
with implant-only reconstructions.
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THE ROLE OF ADJUVANT RADIOTHERAPY IN SMALL
INVASIVE BREAST CANCERS JCC Hu, ACA Athow, ACA Leris,
NJ Williams, C Kouriefs, C Choy, C Wells, K Mokbel and R Carpenter, St.
Bartholomew’s Hospital, West Smithfield, London ECIA 7BE, UK
Aims To analyse outcome of patients with small tumours (less than or equal to 1 cm),
managed by breast conserving surgery with or without radiotherapy.
Patients and methods 110 patients with tumours equal to or less than 1 cm in
maximum diameter were identified from the St. Bartholomew’s Hospital database.
The notes, histology reports and mammograms were retrospectively reviewed. During
this period policy on the management of small tumours changed and those less than 1
cm in diameter with negative axillary lymph nodes and no adverse histological
features were managed with breast conserving surgery alone; i.e. no adjuvant radio-
therapy was given. The final surgical margins were clear in all cases in both groups.
Results The median age at diagnosis for patients treated by local resection alone
(group 1) was 59 years (45–81) and in group 2, 57 years (38–80). Median tumour size
was 7 mm in group 1, and 9 mm in group 2. Seventy-eight (71%) of 110 patients
underwent axillary surgery (clearance or sampling). Four patients were found to have
lymph node metastases, all of whom received radiotherapy. After a median follow-up
of 4 years for group 1, there were 2 local recurrences, these occurred at 4 and 6 years
from date of diagnosis. In group 2 after a median follow up of 6 years there were no
local or distant recurrences.
Conclusions We conclude that a highly selective policy of avoiding the use of
adjuvant radiotherapy in small, invasive, node-negative breast cancers without
adverse histological has an acceptably low local recurrence rate. These patients
require continued follow up to ensure local control is maintained long term.
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INCREASED BREAST TEMPERATURE IN THE ‘AT RISK’
BREAST L Hayes*1, P Wilson2, J Affen2, R Greenhalgh2, J Cooley5,
DG Evans3, L Tetlow4, A Howell2, Departments of Surgery1, Medical
Oncology2, Genetics3, Biochemistry4, Physics5, University Hospital of South
Manchester, Nell Lane, Manchester M20 2LR, UK
Breast surface temperature rises during the luteal phase of the menstrual cycle to a
greater extent than core body temperature.1 We wished to test the hypothesis that this
breast specific temperature might be higher in women at increased risk of breast
cancer. We have therefore compared the breast temperature throughout the luteal
phase of the menstrual cycle in 12 control breasts and in 8 breasts at risk related to
contralateral breast cancer.
Patients and methods Brassieres fitted with 12 temperature sensors were supplied
by Professor Hugh Simpson in Glasgow. The sensors were worn for 90 minutes each
evening through one luteal phase. Subjects also measured their daily oral temperature
and collected daily saliva for progesterone assay. Breast temperature data were
analysed by fitting a cosine function with a period of 14 days to the grouped data
enabling the two series to be summarised into three parameters – phase, amplitude and
level. Cycles were synchronised based on progesterone peak. Two sets of data from
the controls were excluded due to presumed instrument fault or poor subject compli-
ance.
Results The contralateral breasts of patients with a history of breast cancer showed
a higher mean breast surface temperature (35.90° C) than the controls (35.41° C), the
amplitude of cyclical temperature fluctuation was significantly reduced in the
contralateral breasts (0.127° C compared to 0.255° C) and there was a lower proba-
bility of detecting a luteal rhythm in these breasts.
Conclusion These results support the data of Simpson et al1 and suggest a real
difference in the temperature profile of the contralateral breast in breast cancer
patients, independent of body temperature. This leads to the hypothesis that a ‘high
risk’ breast may also exhibit this type of temperature profile. The mechanism by
which this alteration in local temperature is brought about is unclear but is likely to be
a result of local hormonal influences over-riding basal body temperature. Further
investigation of these phenomena is warranted.
1 HW Simpson, K Griffiths, C McArdle, AW Pauson, P Hume, A Turkes (1993)
The luteal heat cycle of the breast in health. Breast Cancer Research &
Treatment 27: 23942 Poster Presentations
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MAPPING STUDY OF A POST-MORTEM LUNG SHOWS
GENETIC CHANGES OF CANCER IN ADJACENT BRONCHIAL
EPITHELIUM M Ocejo-Garcia*, JM Coulson, PJ Woll, CRC Academic
Department of Clinical Oncology, Nottingham City Hospital NG5 1PB, UK
Lung cancer is believed to develop through an accumulation of genetic alterations
which lead to morphological changes of increasing disorder. Deletions, shown by 
loss of heterozygosity (LOH) at polymorphic loci on different chromosomes, are
frequently seen in both small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). Here we investigated genetic alterations in samples taken during autopsy at
specific distances from the tumour in a lung from a female heavy smoker (20 cpd, 50
years) with SCLC. This kind of mapping study is often difficult to undertake in SCLC
since post-mortem samples are rarely available.
Methods We compared the alterations found in the tumour with its corresponding
pre-invasive lesions. The samples analysed included a tumour sample, bronchial
epithelium at 1 cm and at 5 cm from the tumour and normal lung tissue from the other
healthy lung. After genomic DNA extraction of the human samples, these were
analysed for LOH at a number of microsatelite loci by radioactive (g32P) PCR and gel
analysis. Microsatellite markers included D3S4103 within the FHIT gene at locus
3p14.2, D3S1289 at locus 3p21, D3S1293 at locus 3p25, D13S153 within the
retinoblastoma (RB) gene at locus 13q14.3 and D17S513 within the p53 gene at
17p13.1. Results were visualised by autoradiography.
Results Normal lung and distant (5 cm) samples were heterozygous for the
microsatellite markers studied whereas their corresponding tumour sample showed
LOH for the same markers. The sample adjacent to the tumour (1 cm) showed LOH
for the microsatellite marker D3S4103 located within the FHIT gene (3p14.2). The
same allele was shown to be lost in the tumour and its paired adjacent (1 cm) sample
indicating a common clonal origin.
Discussion Loss of function of the tumour suppressor FHIT has been previously
reported to be common in lung cancer and especially frequent in smokers. It has also
been suggested as a marker for the early detection of lung cancer (Sozzi et al., Cancer
Research, v.58, p.5032; 1998). Using a mapping approach, we have shown that
normal bronchial epithelium adjacent to the tumour shows LOH at the microsatellite
marker D3S4103, suggesting a field effect of carcinogens. We propose that LOH at
this locus could be used as a potential early marker for the detection of SCLC. The
understanding of tumour development will enable its early detection, an improved
staging of lung cancer and the identification of new therapeutic targets. We are
currently expanding this study to include a larger number of patients and further
markers.
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MULTICENTRE PHASE II STUDY OF CARBOPLATIN (AUC 5)
AND VINORELBINE IN SMALL CELL LUNG CANCER (SCLC)
DJ Dunlop*1, ME O’Brien2, SM Lee3, S Hill4, N Thatcher5, 1ST Mungo
Institute, Glasgow, 2Royal Marsden Hospital, London, 3Middlesex/UCL
Hospital, London 4Pierre Fabre Ltd, Winchester, 5Christie Hospital,
Manchester, UK
Based on existing data suggesting efficacy and tolerability of carboplatin and vinorel-
bine in poor prognosis SCLC, (Gridelli et al, 1997. Proc Am Soc Clin Oncol 16, ab
1620), 4 centres in the UK collaborated to establish further safety and efficacy using
an AUC calculated dose of carboplatin, (AUC´5)mg intravenously on d1 q28 days,
and vinorelbine 30 mg/m2 on days 1 and 8 of a 28 day cycle. Chemonaive patients
with an ECOG performance status 0–2 were eligible with poor prognosis SCLC or
good prognosis disease medically unfit for intensive chemotherapy. Dose modifica-
tions were based on nadir blood counts on treatment days or grade 3/4 myelosuppres-
sion morbidity. Evaluable patients for response had to complete 2 cycles of therapy.
All patients were evaluable for toxicity and survival. 58 patients were enrolled over a
12 month period. Patient characteristics included; mean age 65 yrs, (range 45–86 yrs),
39 patients had poor prognosis disease, 19 patients had good prognosis SCLC, mean
ECOG performance status was 2. 10 patients were inevaluable for response due to
early withdrawal due to disease progression or toxicity. 202 cycles of therapy were
administered. 50% of patients experienced WHO grade 4 neutropenia but over the
whole study ther were only 3 septic deaths. Only 4 patients (7%) experienced WHO
grade 3/4 platelet toxicity, all of these cycles being uncomplicated. Non-haematolog-
ical toxicity was observed in <5% of patients, (3/58 grade 3/4 nausea/vomiting, 2/58
grade 3 alopecia, 1 patient grade 3 diarrhoea, 1 patient grade 3 neuropathy). 6/48
(12.5%) achieved CR, 20/48 (42%) achieved PR, 10/48 (20.5%) had SD, and 12/48
(25%) had PD. The overall response rate was 54.5%. Median survival for all patients
was 26 weeks, (95% confidence interval 15–37 weeks). 17 patients are still alive. 
Conclusion; The regimen is well tolerated with good clinical efficacy comparable
to that reported with other combinations. Despite significant myelotoxicity, morbidity
related to this was minimal. This AUC calculated dose of carboplatin produced signif-
icantly more myelosuppression than the mg/m2 dose used in previous studies.
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PHASE II STUDY OF OCTREOTIDE PLUS STANDARD
CHEMOTHERAPY IN THE TREATMENT OF SMALL CELL LUNG
CANCER MP Decatris*, A Thomas, L Fresco, K Jeffries, S Conray, A
Benghiat and KJ O’Byrne, University Dept Oncology, Leicester Royal
Infirmary LE1 5WW, UK
Octreotide is an octapeptide somatostatin analogue routinely employed in the treat-
ment of neuroendocrine tumours. Octreotide inhibits small cell lung cancer (SCLC)
growth in vitro and in vivo. Recent work has shown that somatostatin analogues
enhance the cytotoxicity of chemotherapy agents whilst reducing their side effects.
We are evaluating the efficacy and tolerability of Octreotide, 100 mcg tds s/c daily, in
combination with standard cytotoxic chemotherapy – (adriamycin, cyclophos-
phamide, etoposide [ACE]; vincristine, adriamycin, cyclophosphamide; [VAC];
cisplatin, etoposide [CE]) in previously untreated patients with SCLC in an ongoing
phase II study. Octreotide is continued for 6 months. Eleven patients (pts), 9 male and
2 female, median age 61 years (range 50–73) and median ECOG performance status =
1, have been recruited to date. Seven pts had extensive and 4 limited disease. The 11
pts have received a total of 47 cycles of chemotherapy. Neutropenic pyrexia occurred
in 4 patients on one occasion only (9% of treatment cycles). Other grade 3/4 toxicities
seen were nausea (1 pt), vomiting (1 pt), diarrhoea (1 pt), constipation (1 pt), lethargy
(1 pt), anaemia (1 pt), and thrombocytopenia (1 pt). Three patients with bulky disease
and tumour obstruction of the main airway developed evidence of pulmonary abscess
formation in the right upper lobe. After a median of 4 chemotherapy cycles (range
1–6), 9 of 11 pts were evaluable for response. A radiological objective tumour
response was seen in 8 pts (2 CR and 6 PR). The remaining patient had stable disease
after 3 cycles of VAC chemotherapy. Two pts have died, one 8 months after initial
treatment while on second line chemotherapy for relapsed disease and the other with a
pulmonary abscess whose general condition deteriorated after 2 cycles of
chemotherapy. After a median follow up time of 4 months, 9 patients are alive of
whom 2, with limited disease at presentation, are disease free (1 by CT scan and 1 by
CXR). These preliminary results suggest that the combination of Octreotide with stan-
dard cytotoxic chemotherapy regimens has acceptable toxicity and activity in SCLC
justifying continued recruitment of patients to the study.
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WEEKLY CHEMOTHERAPY IN POOR PROGNOSIS SMALL CELL
LUNG CANCER (SCLC): A SINGLE CENTRE PHASE II TRIAL
HE Innes*, DB Smith, PI Clark and E Marshall, Department of Medical
Oncology, Clatterbridge Centre for Oncology, Merseyside CH63 4JY, UK
Many patients with small cell lung cancer present with poor prognostic features (poor
performance status and/or extensive disease). Current treatment for this group with
the CAV regimen (cyclophosphamide, doxorubicin and vincristine) remains unsatis-
factory; median survival is typically only 6 months but associated with significant
toxicity. Studies have also highlighted a risk of early mortality (up to 10%) following
the first cycle of chemotherapy, possibly related to sepsis.
VAPEC-B is a weekly low dose combination chemotherapy initially developed for
intermediate grade non-Hodgkin’s lymphoma (NHL). We have found this regimen it
to be particularly well tolerated by patients irrespective of age or performance status
and weekly administration enables close monitoring of patients. It also appears to be
as effective as CHOP chemotherapy in NHL, a regimen that is almost identical to
CAV. We have conducted a phase II study using a modified version of this regimen
consisting of: adriamycin 35 mg/m2 weeks 1 and 3, cyclophosphamide 350 mg/m2
week 1, vincristine 1.4 mg/m2 weeks 2 and 4 and etoposide 50 mg bd for 5 days in
week 3. This is repeated 3 times to give a total duration of 12 weeks. All patients
receive prophylactic ciprofloxacin and a reducing schedule of oral steroids.
Entry criteria included: patients with poor prognostic features but considered
eligible for palliative chemotherapy, creatinine <1.5 ´ normal, bilirubin <2.5 ´ normal,
measurable disease and no CNS disease. Primary end-points were response rate and
toxicity with time to disease recurrence and overall survival as secondary end-points.
During the first phase 12 eligible patients were entered (March to August 1999). The
median age was 68 y (57–77 y). 8 of the patients were poor performance status; 4 were
good performance status but were elderly and/or had extensive stage disease.
Treatment was generally poorly tolerated. Only 1 patient completed treatment
according to the planned schedule, the rest terminated the regimen early and/or
required treatment delays or dose reductions. The median duration of treatment was 6
weeks (3–12). Reasons for early discontinuation were toxicity (4), progressive disease
(3) and early death (2). Two patients were converted to alternative treatment (1 to
CAV and 1 to oral etoposide). The main toxicities were haematological, 5 patients
having grade 3 or 4 neutropenia although only 1 required hospitalisation. Mucositis
was generally mild, with only 1 patient having ³ grade 3. 10 patients were assessable
for response. There was 1 complete response, 6 partial responses and 3 patients with
progressive disease. The median overall survival was 26 weeks.
In summary, weekly low dose chemotherapy does not appear to improve tolera-
bility or survival in this group of patients with small cell lung cancer with poor prog-
nostic features. Of note is that the median survival is comparable with previously
published data despite the very brief median duration of treatment.Poster Presentations 43
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A RANDOMISED PILOT STUDY OF SRL172 (MYCOBACTERIUM
VACCAE) IN PATIENTS WITH SMALL CELL LUNG CANCER
(SCLC) TREATED WITH CHEMOTHERAPY L Assersohn1, BE
Souberbielle3, L Spencer1, R Bass2, R Mendes1, IE Smith1, MER O’Brien1,2,
1Royal Marsden NHS Trust, Sutton, Surrey, 2Kent Cancer Centre, Maidstone,
Kent, 3Dept of Molecular Medicine, King’s College, London, UK
Introduction SRL172 is a preparation of heat killed Mycobacterium vaccae. When
used with autologous cells in animal models, it proved to be a very potent immuno-
logical adjuvant. In human studies, promising results with SRL172 have been
obtained in NSCLC and mesothelioma when used in combination with chemotherapy.
An interim analysis was performed in July 1999.
Methods Patients were randomised to receive chemotherapy with (n=14) or
without (n=14) SRL172. The chemotherapy was either platinum-based (MVP, n=9) or
anthracycline-based (ACE, n=19). SRL172 was given intradermally on Day 0, weeks
4, 8 and then 3–6 monthly. The response was assessed using CT scanning every 2
courses.
Results The treatment arms were well balanced with respect to disease extent (LD
vs ED). A median survival of 8.5 months was obtained with chemotherapy alone and
13.8 months with chemotherapy and SRL172 (p=0.07). The trend was the same with
both chemotherapy regimens in combination with SRL172. 26 of the 28 patients in
this pilot study have now died.
Conclusions In this pilot study with SCLC patients, the trend seen in improved
median survival, with the combination of chemotherapy and SRL172, is the same as
that previously reported for NSCLC and mesothelioma patients. This trend was seen
for both platinum- and anthracycline-based regimens. The final report will be avail-
able for the meeting.
We are grateful to SR Pharma for their support.
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IS THERE A RELATIONSHIP BETWEEN PRE-TREATMENT
HAEMOGLOBIN AND OUTCOME IN NON-SMALL CELL LUNG
CANCER TREATED WITH RADIOTHERAPY? A Sibtain,* N Shah, MI
Saunders, PJ Hoskin, Marie Curie Research Wing, Mount Vernon Hospital,
Northwood HA6 2RN, UK
Introduction There is accumulating evidence that haemoglobin levels correlate with
outcome in head and neck, bladder, anal, prostate, and cervical cancer treated with
radiotherapy. This effect may be due to impaired oxygen delivery in anaemic patients,
increasing tumour hypoxia and thus radioresistance, although other mechanisms may
also be implicated e.g. Haemolysis, malnutrition, advanced disease etc.
Aim To assess the effect of the pre-treatment haemoglobin level in patients with
non-small cell lung cancer treated with radiotherapy.
Methods and Materials A retrospective review of patients treated with radical
radiotherapy for non-small cell lung cancer between 1990 and 1999, analysing pre-
treatment haemoglobin levels, disease-free and overall survival for each presenting
stage and for each sex.
Results In 165 identified patients, the median age was 66 (range 35–78) years and
the sex ratio was 123 male: 42 female. Thirty-two patients were stage I, 24 stage II, 55
stage IIIa and 54 were stage IIIb. Forty-six patients were treated by conventionally
fractionated radiotherapy, 27 by CHART and 76 by CHARTWEL. Sixteen patients
received chemotherapy and CHARTWEL. Median follow-up time was 16.2 months.
One hundred and twenty-seven patients have died, and 4 are alive with disease. The
median overall survival for male patients was 18.3 months and for females 16.4
months. Haemoglobin levels ranged from 17.4 to 10 g/dl in the male patients and from
16.6 to 8.6 g/dl in the female patients. 27% (33/123) of the males and 23% (10/42) of
the females had a level below the lower limit of the normal range (13–17 g/dl) in
males and 11.5–16.5 g/dl in females). There was no correlation between haemoglobin
and local disease free survival (males r=0.10, females r=0.003), metastasis free
survival (males r=0.11, females r=0.28), or overall survival (males r=0.12, females
r=–0.46). No significant correlation coefficient emerged when each stage or method
of fractionation was individually analysed, except in females with stage I disease,
when a negative correlation was found (r=–0.81). Kaplan Meier survival analyses
revealed no significant differences in disease-free or overall survival when the
patients were classified by the haemoglobin level being either within or below the
normal range.
Conclusion No correlation between pre-treatment haemoglobin has been observed
in this cohort of patients, implying factors other than anaemia-related hypoxia influ-
ence treatment outcome.
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DOES TREATMENT DELAY AFFECT SURVIVAL IN NON-SMALL
CELL LUNG CANCER (NSCLC)? A RETROSPECTIVE ANALYSIS
OF DELAY AND OTHER FACTORS H Bozcuk, WMC Martin, Department of
Oncology, Norfolk & Norwich Hospital, Norwich NR1 3SR, UK
The Joint Council for Clinical Oncology and British Thoracic Society have made
recommendations on waiting times for patients with lung cancer1,2 and the Department
of Health is introducing from April 2000 a policy by which patients suspected of lung
cancer are to be seen within two weeks, yet to date there is no evidence that early
treatment is associated with improved survival.
Objectives We studied adherence to delay targets and survival in relation both to
these targets and to other clinical and laboratory parameters.
Subjects A cohort of 189 NSCLC patients presenting in year 1998 to Norfolk &
Norwich Hospital.
Outcome Measures
1. Waiting times in patients’ pathway recorded were: time from GP to starting
treatment, time from GP to first hospital appointment, time to see surgeon, time to
surgery (from decision to operate), time to see oncologist, time to starting radio-
therapy (RT) (from decision), time to chemotherapy from decision.
2. Other parameters recorded were patient and tumour demographic data, labora-
tory parameters, nature of treatment received and survival.
Results In multivariate analysis, waiting time to start treatment did not affect
survival. Combined-modality treatment, laboratory abnormality, stage and bone/liver
metastases were highly significant survival predictors (p<0.001, <0.001, 0.001, 0.007
resp). Median time to treatment was 50 days. Compliance with 4-week standard of
time to surgery was 80% but most patients had waited over 7 weeks to see the
surgeon. There was 53.5% compliance with 1-week standard to see oncologist, 42%
with 4-week standard to starting radical RT, 62% with 2-week standard to palliative
RT, 28% and 84% respectively with 1-week (good practice) and 3-week (max accept-
able) to starting chemotherapy.
Conclusion Since combined treatment significantly improves survival, NSCLC
results will be benefited more by improving resources especially oncology (equip-
ment, drugs, personnel) and in thoracic surgery than by attempting to reduce waiting
time to see a physician in 2 weeks.
1 Joint Council for Clinical Oncology (1993) Reducing delays in cancer
treatment
2 The Lung Cancer Working Party of BTS. Roy Coll Phys London (1993) Thorax
1998; 53:(Suppl 1) S1–8
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PALLIATIVE CHEMOTHERAPY FOR MESOTHELIOMA –
SIGNIFICANCE OF PERFORMANCE STATUS (PS) RK Gregory*,
MER O’Brien, S Ashley, IE Smith, Lung Unit, Royal Marsden Hospital (RMH),
Fulham Road, London SW3 6JJ, UK
Chemotherapy can provide useful palliation in malignant mesothelioma (1). However
not all patients benefit and the decision on who to treat is based on a number of factors
including rate of progression of disease, PS and patient preference. Oncologists are
often reluctant to offer palliative chemotherapy to patients of poor PS (>2).
Methods We performed a retrospective analysis of patients with mesothelioma
treated at the RMH with palliative MVP (mitomycin C, vinblastine, cisplatin) with
respect to PS, response to chemotherapy and time to disease progression.
Results Data were available for 94 patients. Of these 3 were PS 0, 53 were PS 1, 31
were PS 2 and 7 were PS 3. Overall objective response rate was 15%, symptomatic
response rate was 71%. In particular, 6/7 of the PS 3 patients had a symptomatic
response. Median duration of symptom relief was 4 months and there was no differ-
ence between the different PS groups. All patients had symptomatic progression
within 18 months of commencing treatment, PS did not predict for rapid symptom
progression following treatment.
Summary Symptomatic response to palliative chemotherapy in mesothelioma is
high at >70% and the benefit does not appear to be confined to patients of good PS. It
may be that patients who could potentially benefit from treatment are not being
offered chemotherapy on the basis of a poor PS.
1 GW Middleton, IE Smith, MER O’Brien et al (1998) Good symptom relief with
palliative MVP chemotherapy in malignant mesothelioma. Annals of Oncology
9: 269–27344 Poster Presentations
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INVESTIGATION OF LOSS OF HETEROZYGOSITY AT THE
FOLLOWING LOCI: 1P36, 5 Q(APC LOCUS), 7Q31, 17 P(P53
LOCUS) AND 18 Q(DCC LOCUS) IN HUMAN COLON, OESPHAGEAL AND
STOMACH CANCER RN Hourihan*1, E Baird2, GC O’Sullivan3, JG Morgan1,
Departments of Microbiology1, Medicine2, and Surgery3, National University
of Ireland, Cork, Ireland
Simultaneous analysis of loss of heterozygosity (LOH) in adenomatous polyposis coli
(APC), deleted in colon cancer (DCC) and p53 genes, in addition to microsatellite
markers on chromosomes 1 p and 7 q has not yet been reported. The objective of this
study was to determine the frequency of LOH at each of the 5 distinct loci. DNA was
extracted from 68 patients’ tumour and matched normal mucosa. 53%, 29% and 18%
of these patients had colon, oesophageal and stomach cancers respectively.
A VNTR polymorphism (DCC) and RFLP analysis of Dde1 and BstU1 sites were
investigated in order to determine heterozygosity of APC and p53 respectively.
It was shown that 40%(27/69), 14%(8/58) and 26%(11/41) were heterozygous for
DCC, APC and p53 respectively. LOH analysis of the paired samples showed
frequencies of 26%, 36% and 0% for DCC, p53, and APC in that order.
Regarding microsatellite markers, D1S228 on 1 p and D7S522 on 7 q, DNAPCR
products were subjected to high-resolution spreadex electrophoresis, stained with
syber green nucleic acid stain and illuminated at 254 nm. It was shown that
42%(26/62) were heterozygous for D1S228 and 54%(34/63) were heterozygous for
D7S522. LOH analysis showed frequencies of 4%(1/26) and 9%(3/34) for D1S228
and D7S522 respectively. Two of the three D7S522 LOH positives were oesophageal
samples. This is the first study to demonstrate LOH of microsatellites using this tech-
nique. LOH frequencies were confirmed using ABI prism 310 and gene scan analysis.
It was shown that two patients exhibited LOH at both DCC and p53. One patient
was shown to display LOH at both 1 p and p53.
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THE ANALYSIS OF COPY NUMBER CHANGES IN BARRETT’S
OESOPHAGUS USING COMPARATIVE GENOMIC
HYBRIDISATION J Croft*1, E Parry1, J Baxter2, T Brown2, P Griffiths2, JM
Parry1, 1Centre for Molecular Genetics and Toxicology, UWS, Swansea,
2Morriston Hospital, Morriston, Swansea, Wales
The technique of Comparative Genomic Hybridization (CGH) has been used to char-
acterise genome wide changes that occur during the progression of Barrett’s meta-
plasia through low-grade dysplasia (LGD) and high-grade dysplasia (HGD) to
adenocarcinoma. Biopsies were obtained from 10 patients with LGD, 15 HGD and 5
adenocarcinomas. CGH allows the global analysis of the genome for net loss or gain
of chromosome regions in a single hybridization, by competitive binding of test and
genomic reference DNA to normal metaphase chromosomes. Hybridization of the
DNA samples is visualised by the use of two different fluorochromes. The ratio of
fluorescence intensities along each chromosome reflects the relative ratios of test and
reference sequences. Thus, CGH produces a map of DNA sequence copy number as a
function of chromosomal location.
The data demonstrates that high grade dysplasia is a stage of substantial karyotypic
instability, with the amplification seen on 4 q present in 60% of samples. By contrast,
adenocarcinomas show less widespread chromosome changes with amplification of
chromosome 8 q being the most common feature, indicating the presence of multiple
copies of the myc-C oncogene in the adenocarcinomas.
Despite ongoing efforts to characterize the molecular changes in Barrett’s oesoph-
agus, its pathogenesis remains poorly understood. It is hoped, that this work will lead
to a greater understanding of the host/cell factors involved, subsequently helping to
identifying a clinically useful marker for the progression of this condition and there-
fore allowing clinicians to stratify patients into high versus low risk groups.
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SENESCENCE-ASSOCIATED BETA-GALACTOSIDASE
ACTIVITY IN NORMAL, METAPLASTIC AND DYSPLASTIC
MUCOSAE OF THE UPPER GI TRACT AJ Fletcher-Monaghan*, M Downey,
R Stuart, JJ Going and WN Keith, CRC Dept of Medical Oncology, University
of Glasgow, CRC Beatson Labs, Glasgow G61 1BD, UK
Background: Increased beta galactosidase (BGal) activity at pH 6 has been associated
with senescence of cells in culture and in vivo. Neoplastic transformation is associated
with escape from senescence, and dysplasia and neoplasia could therefore be associ-
ated with downregulation of senescence-associated beta-galactosidase activity (SA-
BGal). Aims: To investigate senescence-associated (SA) beta galactosidase activity in
normal, metaplastic, dysplastic and neoplastic mucosae of the upper GI tract,
including Barrett’s oesophagus. Patients and methods. Histochemical staining for
non-specific (pH 4) and SA-BGal (pH 6) was performed on frozen sections of 350
endoscopic biopsies from 46 patients (26 with long segment Barrett’s oesophagus, 15
with gastric cancer, 2 with Barrett’s adenocarcinoma and 3 with squamous
oesophageal carcinoma). An intensity and extent-weighted staining score (range 0–6)
was assigned to surface (luminal), intermediate and basal mucosal/epithelial compart-
ments in all biopsies. 
Results Squamous epithelium was consistently negative for SA-BGal. Strongest
expression was detected in the luminal compartment of duodenal mucosa (mean score
3.7 ± 0.5, n=18), ‘specialised’ Barrett’s mucosa (mean 2.2 ± 0.12, n=105) and gastric
intestinal metaplasia (mean 2.37 ± 0.40. n=16). Neither low grade (n=5) nor high
grade (n=3) Barrett’s dysplasia correlated directly or indirectly with decreased SA-
BGal activity but invasive adenocarcinomas showed significantly reduced activity
(mean 1.3 ± 0.29, n=17), with no activity detectable in 6. Conclusions: SA-Bgal
expression marks intestinal differentiation in the upper GI tract. It is not downregu-
lated in dysplastic Barrett’s mucosa but is in invasive gastric and oesophageal adeno-
carcinomas, and may therefore represent a late event in the oesopagogastric
dysplasia/carcinoma sequence, associated with invasion.
P64
ADENOCARCINOMAS OF THE GASTROOESOPHAGEAL
JUNCTION AND DISTAL STOMACH ARE GENETICALLY
DIFFERENT SC Stocks1,2, FA Carey2, AM Thompson*3, D Johnston3, NM
Kernohan2, NR Pratt1, 1Departments of Human Genetics, 2Molecular &
Cellular Pathology, 2Surgery & Molecular Oncology, University of Dundee
DDI 9SY, UK
The incidence of adenocarcinoma arising at the gastro-oesophageal junction is rapidly
increasing in the West and may reflect the increasing prevalence of Barrett’s oesoph-
agus. In contrast, the incidence of histologically similar cancers arising in the body
and antrum of the stomach is declining. The epidemiological data suggest that the
aetiology and pathogenesis of these cancers is distinct.
The aim of this study was to investigate the pattern of genetic abnormalities in
adenocarcinomas of the gastrooesophageal junction (n=11) and distal stomach (n=17)
by screening genomic DNA recovered from histologically confirmed frozen cancer
samples. Regions of chromosomal imbalance (amplification or deletion) were deter-
mined by screening the genomic DNA by comparative genomic hybridisation (CGH).
Amongst the 28 cancers, genetic loss was frequent at chromosomes 17 p and 22 q
while amplification was identified at 3 q, 5 q, 8 q, 12 q, 13 q, 20 p and 20 q. The most
notable difference between the two tumour sites was at the DCC (Deleted in Colon
Cancer) locus on 18 q which was deleted in 4/11 (36%) gastrooesophageal cancers but
deleted in only 1/17 (6%) of the distal gastric cancers.
This novel difference between adenocarcinomas of the gastrooesophageal junction
and distal stomach suggests a genetic mechanism may underlie the known epidemio-
logical differences between these two tumour sites.Poster Presentations 45
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GSTM1 AND CYP1A1 POLYMORPHISMS AND INCIDENCE OF
COLORECTAL ADENOMA M Gunter1*, M Watson2, S Bingham1,
W Atkin3, N Day4, A Loktionov1, 1MRC Dunn Human Nutrition Unit, Hills
Road, Cambridge CB2 2XY; 2Norfolk and Norwich Hospital; 3ICRF, London;
4Strangeways Research Laboratory, Worts Causeway, Cambridge, UK
GSTM1 and CYP1A1 metabolise a number of important environmental carcinogens
and polymorphisms in these genes have been associated with several cancers (Zhong
et al, 1993; Carcinogenesis, 14, p1821 and Sivaraman et al, 1994; Cancer Res, 54,
p3692). There is controversy as to whether homozygosity for the GSTM1 null allele
confers increased risk for colorectal cancer and no evidence to date regarding
colorectal adenomas. In addition, there is little information regarding association of
CYP1A1 exon 7 and Msp I polymorphisms with colorectal adenoma. Our aim was to
investigate any association between these polymorphisms and incidence of colorectal
adenoma.
Methods GSTM1 genotypes were examined by RFLP analysis in 716 subjects
with colorectal adenoma and 724 polyp-free controls. CYP1A1 genotypes were simi-
larly examined in 674 of these individuals from one arm of the cohort (319 cases, 355
controls).
Results GSTM1 63% of the cohort were homozygous for the GSTM1 null allele,
37% displayed an active allele. Following statistical analysis, an unadjusted OR of
1.20 (95% confidence interval: 0.97–1.49) was observed for null vs active alleles.
Individuals carrying at least one GSTM1 A allele appeared to be protected: OR=0.76
(0.58–0.99)
CYP1A1 As expected, the Msp I and exon 7 polymorphisms were in complete
linkage disequilibrium. The putative high risk genotype Val/Val was rare (0.2%) in
this group. 94% of individuals were Ile/Ile homozygotes, and 5.8% were Ile/Val
heterozygotes. Carriers of the Val allele were not shown to be at risk of colorectal
adenoma: OR=0.58 (0.30–1.10). Homozygous carriers of the Msp I polymorphism
(m1/m1) were also rare (0.74%) in this group. 83.7% of individuals were homozygous
carriers of the wild-type (w1/w1) allele and 15.6% were heterozygotes. Possession of
the putative high risk allele did not confer increased risk of adenoma: OR=0.84
(0.56–1.27).
Conclusions Any associations between GSTM1 and CYP1A1 polymorphisms and
risk of colorectal adenoma appear to be weak. The analyses of interactions between
these genes with various lifestyle variables, such as diet are in progress.
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EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN
PRIMARY COLORECTAL CANCER AND SECONDARY LYMPH
NODE METASTASES *McKay JA, Murray LJ, Ross VG, Curran S, Murray
GI, Cassidy J, McLeod HL, Department of Medicine and Therapeutics, and
Pathology, University of Aberdeen, Aberdeen, AB25 2ZD, UK
Colorectal cancer is a common malignancy, and at present patient prognosis is deter-
mined primarily by extent of tumour spread at presentation. However, patients with an
identical pathological disease stage can display widely differing outcomes in terms of
survival and response to chemotherapy. Therefore it is fundamentally important to
identify molecular markers of more aggressive tumour phenotypes in order to adjust
patient treatment accordingly. The epidermal growth factor receptor (EGFR) is a
major regulator of several distinct, diverse cellular pathways, and a wide range of
human tumours overexpress EGFR in vivo. EGFR is the focus of various anticancer
agents currently under investigation, but little information is available on EGFR
expression in colorectal cancer. To assess EGFR as a target for colorectal cancer, this
study examined EGFR protein expression in a large series of 249 primary colorectal
cancer samples for which uniform clinicopathological data is available. EGFR expres-
sion in lymph node metastases from a subset of 42 patients was also evaluated to
examine the role of EGFR in invasion. We have used immunohistochemistry to deter-
mine the in situ localisation of EGFR protein within these samples. Seventy three
percent (181/249) of primary tumours displayed EGFR immunostaining, the majority
of which showed immunoreactivity in >50% of tumour cells (123/181 tumours).
EGFR expression was localised primarily to the cell membrane (73/181, 40%), in
some cases accompanied by cytoplasmic staining (94/181, 52%). In a small number of
samples, immunoreactivity was observed solely in the cytoplasm of tumour cells
(14/181, 8%). Using preliminary outcome data, patients whose tumours expressed
EGFR protein were found to have a significant survival advantage (P<0.05), which
remained following adjustment for Dukes’ stage. In addition, the degree of EGFR
expression in colorectal tumours was correlated with differentiation grade (P<0.05),
with poorly differentiated tumours tending to express EGFR to a lesser degree than
moderately/well differentiated tumours. No relationship was observed between EGFR
expression levels and Dukes’ stage, site or age of the patient. EGFR protein expres-
sion was observed in 22/42 (52%) of the lymph node metastases, and using a 5% cut-
off point for positive expression, 25/42 (60%) samples showed agreement with the
corresponding primary colorectal tumour (P>0.05). The majority of non-concordant
cases (15/17, 88%) showed EGFR expression in the colorectal but not the lymph node
tumour, suggesting that loss of EGFR protein may be involved in the metastatic
process. Ongoing work will update the survival information available, and also inves-
tigate any relationship between EGFR protein and possible interacting factors (e.g. c-
erbB-2, b-catenin) in colorectal cancer.
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DUAL-PROBE IS MORE EFFECTIVE THAN SINGLE-PROBE
CRYOTHERAPY FOR HEPATIC METASTASES Huang A*, Mathur
P, McCall J1, Weston M2, Quinn H, Glover C, Henderson DC3 and Allen-Mersh
TG, Department of Surgery, 1Radiology, 2Anaesthesiology & 3Immunology,
Chelsea & Westminster Hospital, 369 Fulham Rd, London SW10 9NH, UK
Aims Cryotherapy for colorectal liver metastases may result in a fall in serum carci-
noembryonic antigen (CEA) that is thought to be predictive of survival. Cytokines are
released that may be beneficial in stimulating the immune system leading to an antitu-
mour response. This study determined whether dual- or single-probe percutaneous
cryotherapy was more effective in reducing CEA and stimulating immune responses.
Methods Between July 1996 and December 1999 twenty-two single-probe treat-
ments were given to 15 patients and fourteen dual-probe treatments to 7 patients with
unresectable colorectal liver metastases. Single-probe cryotherapy was performed with
either 3.6 mm or 6.3 mm probes (ice-ball volumes 18 cm3 & 59 cm3 respectively;
Spembley Medical Ltd); dual-probe was performed with two 6.3 mm probes simulta-
neously (ice-ball volume 205 cm3). Each percutaneous treatment was performed for
one freeze/thaw cycle (20 mins each) under computed tomography guidance. Serum
levels of CEA, interleukin 2 soluble receptor a (IL-2sRa), soluble necrosis factor
receptor I (sTNF RI), interleukin 6 (IL-6) and C-reactive protein (CRP) were measured
pre-operatively, at day 1, day 14, day 28 and at more than 40 days from cryotherapy.
Results Single-probe cryotherapy resulted in significant increases in IL-6 and CRP
(p=0.001 & p<0.0001 respectively) that returned to basal levels by 14 days. The rise
in sTNF RI was significant on day one (p=0.04) with no significant changes in IL-
2sRa at any time. There was no significant fall in CEA and serum levels more than 40
days from cryotherapy were significantly higher than pre-treatment levels (p=0.008).
In contrast dual-probe cryotherapy stimulated significant rises in IL-2sRa, sTNF RI,
IL-6 and CRP (all p<0.05) on day one that returned to basal levels between 14 and 28
days after cryotherapy. These changes were accompanied by a significant rise in CEA
(p=0.003) on day one that fell to below pre-treatment levels between 14 and 28 days
(p=0.008 & p=0.005 respectively). CEA levels more than 40 days from cryotherapy
were not significantly different from pre-treatment levels (p=0.5).
The rise in IL-2sRa in the dual-probe group was significantly higher than the
single-probe group at 14 days (p=0.04) as was the increase in CRP at day one (p=0.02).
The initial rise in CEA and subsequent fall between 14 and 28 days were significantly
different between the two groups (p=0.0001, p=0.04 & p=0.003 respectively).
Conclusion Dual-probe compared with single-probe cryotherapy produced a signif-
icant fall in CEA suggesting the former was more effective at destroying tumour. Acute
phase immune reaction as reflected by elevated IL-6 and CRP levels were seen in both
groups but dual-probe cryotherapy also stimulated a significant IL-2sRa rise indicating
a lymphocytic response. Thus a large ice-ball was necessary to reduce CEA and stimu-
late a lymphocytic response in the cryotherapy of colorectal liver metastases.
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A PHASE II STUDY OF CAELYX™ (LIPOSOMAL DOXORUBICIN)
IN THE TREATMENT OF ADVANCED GASTRIC CANCER AL
Thomas*, K Jeffries, WP Steward, KJ O’Byrne, University Dept of Oncology,
Leicester Royal Infirmary, UK
Treatment of advanced gastric cancer remains disappointing. Anthracycline-
containing chemotherapy regimes have response rates of 9–40% but are associated
with significant toxicity. This is confounded by the fact that these patients (pts) are
frequently elderly and have poor performance status. In other solid tumours (breast
and relapsed ovarian cancer), Caelyx™, stealth liposomal doxorubicin, has docu-
mented objective response rates equivalent to standard single-agent therapies. In addi-
tion significantly fewer side-effects such as alopecia, nausea and vomiting, mucositis
and neutropenic sepsis are seen. We conducted a phase II study to evaluate the effi-
cacy and tolerance of Caelyx™ in advanced gastric cancer. Twenty previously
untreated pts with locally advanced (4 pts; 20%) or metastatic (16 pts; 80%) gastric
cancer have been enrolled. Median age: 70 years (range 41–82) and performance
status (WHO) 0 in 6, 1 in 9 and 2 in 5 pts. Caelyx™ was administered at 45 mg/m2 IV
every four weeks. To date median event free survival in all 20 pts is 63 days (range
1–291 days) and median overall survival is 155 days (range 16–415). A total of 63
cycles have been given with a median of 3 cycles per pt. All pts were evaluable for
toxicity. Although grade 3 nausea was seen in 1 pt, nausea and vomiting were rare
metoclopramide being used as emesis prophylaxis. Grade 3 constipation was seen in
1, grade 3 mucositis in 1, grade 3/4 lethargy in 2 and an allergic drug reaction in 1 pt.
The most severe side-effect were grade 3 pneumonitis in 1 pt and grade 4 hand-foot
syndrome in another. No other grade 3/4 toxicities were seen including alopecia or
myelosuppression. Fifteen pts were evaluable for response: 1 pt had a partial
response, 6 stable disease and 8 progressive disease. The 5 pts not evaluable for
response included 1 pt with an allergic reaction to the Caelyx™ infusion who was
withdrawn from the study, 3 with clinical deterioration after 1 cycle and a fifth who
awaits initial re-staging. In conclusion Caelyx™ is safe and well tolerated in pts with
advanced gastric cancer. Survival data are comparable to other regimens but with the
advantage of minimal toxicity. Recruitment is ongoing and updated information will
be presented.46 Poster Presentations
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THE COMBINATION OF RALTITREXED (TOMUDEX) AND
MITOMYCIN-C IN THE TREATMENT OF ADVANCED
COLORECTAL CANCER: A PHASE-II-STUDY JE Michels1, M Harvey1, A
Darby1, AM Iveson2, L Nokes1, TJ Iveson1,2, Royal South Hants Hospital,
Southampton1, Salisbury District Hospital, Salisbury2, UK
5FU based chemotherapy is now established treatment for advanced colorectal cancer.
There is a move to combination treatment and the combination of Mitomycin-C with
infusional 5FU has been shown to be superior to infusional 5FU alone. The specific
thymidylate inhibitor Raltitrexed has been shown to have equal efficacy to bolus 5FU
and folinic acid.
This phase II study therefore evaluated the combination of Raltitrexed (3 mg/m2 iv
every 3 weeks) with Mitomycin C (7 mg/m2 every 6 weeks) as chemotherapy treat-
ment for advanced colorectal cancer. Patients initially received 12 weeks treatment
before assessment with CT scan and those responding received a further 12 weeks
treatment. It was planned to enter 29 patients into the study but the study was closed
after 22 patients had been entered because of 3 unexpected deaths. Patient characteris-
tics were as follows: 15 male and 7 female with a median age 64 years (range 27–75).
15 had a colonic primary and 7 a rectal primary. Sites of metastases were: liver (16),
lymph nodes (8), peritoneum (4), other (4). 7 patients had >1 site of metastatic
disease.
There were 4 partial response (18%), 8 (36%) had stable disease, 8 (36%) progres-
sive disease and 2 (9%) were not evaluable. The median time to disease progression
was 3.1 months (95% CI 2.5–3.7). The median overall survival was 11.6 months (95%
CI 6.1–17.2).
There was significant grade 3/4 toxicity: nausea/vomiting (27%), diarrhoea (18%),
neutropenia (18%), thrombocytopenia (14%), renal impairment (9%), and anaemia
(5%).
There were 3 deaths due to a combination of prolonged diarrhoea, neutropenic
sepsis and renal failure. While the combination of Raltitrexed and Mitomycin-C is
active in advanced colorectal cancer in view of the marked toxicity seen in some
patients we would not advocate the use of this combination in phase III studies of
combination chemotherapy for advanced colorectal cancer.
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PRE-OPERATIVE CHEMORADIOTHERAPY FOR LOCALLY
ADVANCED CARCINOMA OF THE RECTUM R Cooper1, P
Finan2, P Sagar2, D Johnston2, H Sue-Ling2, P Quirke2 and D Sebag-
Montefiore1, Leeds Cancer Centre, Cookridge Hospital1, Leeds LS16 6QB,
and Leeds General Infirmary2, Leeds LS1 3EX, UK
Purpose To evaluate the effectiveness of chemoradiotherapy (CRT) prior to surgery
in locally advanced carcinoma of the rectum, treated in a single centre.
Patients and methods Between February 1996 and August 1999 29 patients with
locally advanced rectal carcinoma were treated with pre-operative CRT. Radiotherapy
was delivered using a three/four field prone technique giving a dose of 45 Gy in 25
fractions over 5 weeks. Folinic acid (20 mg/m2, as a bolus) and 5-Fluorouracil (350
mg/m2, as a short infusion) was administered, for the first and last five days of radio-
therapy.
Results 26/29 patients (93%) completed CRT as scheduled. Grade 3/4 toxicity was
experienced by 3 patients (10%). Resection, following CRT was performed in 25/29
patients (87%) and in 23/29 (79%) the intent was curative. In 4 patients no resection
was performed due to unresponsive/progressive disease. Of the 23 curative resections
6 patients (26%) had a histopathological complete response, 3 (13%) TIS-T2, 11
(48%) T3 and 3 (13%) T4. Four (17%) were node positive and 19 (83%) node nega-
tive. The circumferential resection margin was involved in 4/23. For all patients who
underwent curative resection the Mandard score of pathological response was
performed and correlated with outcome. Perioperative morbidity was also evaluated
for this group of patients. At a median follow-up of 30 months (range 4–44) 19/23
(83%) are alive, 2/23 (8%) have local recurrence and 3/23 (13%) metastases.
Conclusion The CRT regimen evaluated in this study is associated with a high
curative resection rate. Furthermore, toxicty was low and compliance high. At a
median follow-up of 30 months outcome measures are encouraging.
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CHEMORADIATION FOLLOWED BY IMMEDIATE BOOST IN
SQUAMOUS CELL CARCINOMA OF THE ANUS Dr M Osborne*,
Dr R Glynne-Jones, Dr A Makris, Mount Vemon Hospital, Northwood,
Middlesex HA6 2RN, UK
Chemoradiation (CRT) is now established as the primary treatment for anal carci-
noma, allowing avoidance of colostomy in the majority of patients. Standard treat-
ment in the UK (UKACCCR-Anal cancer trial) involves initial CRT followed by
reassessment at 6 weeks and subsequent radiotherapy (RT) boost in responders. This
practice contrasts with the recognised detrimental influence of gaps in treatment in
cervical and head and neck cancer. We therefore report on 27 patients with anal carci-
noma in whom the gap has been abandoned and a reduced boost delivered immedi-
ately on completion of CRT.
27 consecutive patients (11 m, 16 f), mean age 67 years (range 37–85), with anal
carcinoma (26 scc, 1 adenosquamous) have been treated since 1995. Stage at diag-
nosis was T1 (2), T2 (10), T3 (6), T4 (9), N+ (4). RT was delivered in three phases at
1.8 Gy per fraction daily. Phase 1-parallel opposed fields including the inguinal nodes
to a dose of 30.6 Gy/17 fractions,phase 2-reduced pelvic field to a total dose of 45 Gy.
Phase 3 (boost)-planned volume to the primary achieving a total dose of 50.4 Gy/28
fractions (9 patients), 52.2 Gy/29 fractions (12 patients), 54 Gy/30 fractions (6
patients) according to stage. Inguinal region treated to the same dose where nodes
involved. Concurrent chemotherapy (CT) was given with 5FU 750 mg/m2 d1–5,
21–25 and either Mitomycin C 12 mg/m2 d1 (15 patients) or Cisplatin 20 mg/m2 d1–5,
21–25 (12 patients).
Mean follow up 12 months (range 2–35 months). 2 patients failed to complete RT
as planned. 1 due to Grade 4 bowel toxicity limiting total dose to 43.2 Gy/24 fractions,
1 patient developed a rectovaginal fistula and completed 50.4 Gy/28 fractions/112
days. No haematological delays with CT. Acute toxicity: Skin grade 3- 26/27 (96%),
Diarrhoea grade 4- 1/27 (4%), grade 3- 2/27 (7%), grade 2- 21/27 (77%), Vomiting
grade 1- 3/27 (11%). Late toxicity to date: anal stenosis 1, sphincter disturbance 1.
Responses: clinical CR 20 (74%), PR 6 (22%), PD 1 (4%). Relapses: 5 (19%), 2 at
primary site, 2 primary and distant, 1 distant alone.
Chemoradiation in anal carcinoma and boosting without a gap is shown in this
group of patients to be feasible with acceptable toxicity.
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ANORECTAL IRRADIATION IN PELVIC RADIOTHERAPY: AN
ASSESSMENT USING IN-VIVO DOSIMETRY *D Hayne1, U
Johnson2, DD’Souza2, H Payne3, PB Boulos1, 1Dept of Surgery, University
College London W1P 7LD, 2Dept Medical Physics and 3Dept Of Oncology,
Middlesex Hospital W1N HAA, UK
Objectives To compare in vivo techniques of measuring radiation doses received by
the anorectum during pelvic radiotherapy with the dose predicted by a GE TARGET™
treatment planning system.
Background Radiation damage to the anorectal region following pelvic radio-
therapy is a cause of severe morbidity in some patients. Functional and structural
changes in the anorectum, in relation to the site and dose of pelvic radiation received,
have not been fully investigated. For this purpose an accurate technique for measure-
ment of the dose has been developed.
Methods and study design Five patients with cancers of the prostate, cervix and
uterus were CT planned using the TARGET™ system. A Scanditronix rectal probe
containing 5 n-type photon-detecting diodes was placed in the anorectum during the
planning CT. The probe position was standardised with the 5 diodes at 2 cm intervals
from the anal verge. The probe diodes were calibrated for 10 MV photons. Doses were
measured for each diode on 5 consecutive fractions in the first patient. The anal canal
was included in the target volume because of local invasion. The probe was then used to
measure radiation doses during 2 fractions in the remaining 4 patients. Thermo-lumines-
cent devices (TLDs) were also attached over the sites of the diodes to further verify
measured doses. TARGET™, diode measured and TLD measured doses were compared.
Results Diode measured doses in the first patient, were reproducible (SD<1% of
mean. Range 0.2–0.9%). Diode measured doses were all within 2.5% of TARGET™
predicted doses. TLD measured doses on the same 5 occasions were less reproducible
than diode measured doses (SD<5% of mean. Range 2.4–4.7%) and were all within
5% of TARGET™ predicted doses.
Diode read consistently lower than predicted doses, on average by 2%. TLDs read
consistently higher than predicted doses on average by 2.8%.
In the other 4 patients diodes and TLDs within the target volume were within 7% of
predicted doses. Outside the target volume diodes and TLDs agreed but were less compa-
rable with predicted doses. Greatest variability was seen at the edges of the target volume
where dose varies widely across small distances. (Range –68% to +54% of predicted dose).
Conclusions The results in the first patient suggest that TARGET™ planned doses
are accurate. The reproducibility of results can be explained by all of the diodes being
in the target volume. Anal canal stenosis in this patient may also have minimized
probe movement.
Changes in the position of the probe at CT planning and between readings prob-
ably accounts for measured differences in the other patients. Measurement on more
than 2 fractions might improve results.Poster Presentations 47
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PERIPHERAL RIM ENHANCEMENT (PRE) OF HEPATIC
COLORECTAL CANCER (CRC) METASTASES DURING
ENHANCED COMPUTED, TOMOGRAPHY (CT): A NEW PROGNOSTIC
INDICATOR D Farrugia*1, D Elias2, I Vlahos2, C Mulatero1, J Kellaway1, P
Wilson1, A Martin2, ML Slevin1, RH Reznek2, Departments of Medical
Oncology and Radiology, St. Bartholomew’s Hospital, London, ECIA 7BE, UK
PRE of hepatic CRC metastases during contrast enhanced imaging is a recognised
phenomenon possibly relating to new vessel formation (angiogenesis) at the growing
edge of tumour masses. We used dynamic CT to evaluate PRE in hepatic CRC metas-
tases and to correlate this with prognosis. Fifty one patients (pts) with metastatic
disease underwent baseline CT scanning before (20 pts), or after commencing (30 pts)
palliative chemotherapy (timing unspecified in 1 pt). Single level dynamic CT scans
were performed at 3 second intervals after intravenous iohexol (300 mg/ml, 6 mls/sec)
from early arterial to late portal phase. Parameters measured included morphology of
PRE in terms of definition, thickness and intensity of rim enhancement, total hepatic
metastatic volume (TMV), % hepatic replacement by tumour (PHR) and hepatic
perfusion index (HPI): a ratio of hepatic arterial to total hepatic blood flow in normal
liver. Median age of pts was 66 years, 72% had performance status (PS) 0–1, and 46
received or were receiving chemotherapy. Median survival from baseline PRE evalu-
ation was 350 days (range: 13–1210) and 22 pts were alive at analysis. It was possible
to consistently group PRE into 4 categories: absent (group 0, n = 12), illdefined blush
(group 1, n = 18), well-defined thin rim (group 2, n = 11) and well-defined thick rim
(group 3, n = 10). Univariate analysis using Kaplan-Meier test identified high PRE
score (³2), TMV > median, low PS and high primary tumour grade as adverse prog-
nostic factors. Median survival was 240 days (95% CI: 177–303) in PRE groups 0–1
(n=30) compared to 146 days (95% CI: 54–238, p=0.035) in groups 2–3 (n = 21). Age,
gender, Dukes stage, PHR, HPI and plasma CEA levels are not significant at this
stage. Inclusion of serial scans over time from 19 pts (total: 76 scans from 51 pts)
increased adverse prognostic significance of higher PRE score (p=0.0035). Thus the
morphology of PRE on CT has potential prognostic value. A multivariate analysis is
planned with continued recruitment. We are evaluating the impact of chemotherapy
on PRE and possible correlation between PRE and other parameters of tumour angio-
genesis.
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NO ASSOCIATION BETWEEN THE GSTMI, GSTTI, AND GSTPI
GENE POLYMORPHISMS, SQUAMOUS CELL CANCER OF THE
HEAD AND NECK AND SECOND PRIMARY TUMOURS S Jefferies*1, Z
Kote-Jarai1, R Houlston1, M-J Frazer-Williams1, R A’Hern2, MPT
Collaborators and R Eeles1
Individuals who have had an index squamous cell cancer of the head and neck (SCCHN)
have a 10–20% chance of developing a second primary tumour (MPT). Traditionally any
familial clustering of head and neck cancer has been attributed to sharing of the same envi-
ronmental risk factors, such as tobacco and alcohol. However, there is some preliminary
evidence that there may be a genetic component to SCCHN. There is an increased risk of
cancer in first-degree relatives of individuals with SCCHN and this risk rises markedly when
the affected individual has had two primary tumours. Carcinogens are detoxified by the
phase II enzymes glutathione S-transferases (GST) which may have an important role in the
development of tumours. These enzymes, due to the presence of polymorphisms causing loss
of function, may provide some explanation for observed individual variation in cancer
susceptibility. GSTM1 and GSTT1 null genotypes have been associated with increased risk
of developing SCCHN. The GSTP1 gene has a polymorphism at nucleotide 313 resulting in
a Ile to Val substitution which consequently lowers the enzymatic activity of the protein.
This has also been suggested to increase cancer susceptibility.
We investigated the association between genetic polymorphisms in GST genes and
patients with index squamous cell cancer of the head and neck who developed second
primary tumours (SPT) in a case-control study. GSTM1, GSTT1, and GSTP1 genotypes
were determined in 52 cases of MPT and for 280 controls by PCR and RFLP. The associa-
tions between specific genotypes and the development of MPT were examined by use of the
Chi-squared test.
The results for this study did not show any increased risk for the development of MPT
with the presence of null genotypes for GSTM1, GSTT1 or heterozygous or homozygous
polymorphism of the GSTP1 gene. We therefore conclude that polymorphisms in the
GSTM1, GSTT1 and GSTP1 genes do not play a major role in cancer susceptibility in this
group. Tobacco and alcohol exposure and metabolic enzyme genotype may affect risk for
development of MPT and we are currently assessing this for the MPT cases versus matched
controls.
MPT Collaborators: J Henk2, M Gore2, P Rhys-Evans2, D Archer2, K Bishop2, E
Solomon3, S Hodgson3, M McGurk3, J Hibbert3, MO’Connell3, M Sauders4, M Partridge3, E
Chevretton3, F Calman3, K Shotton5, A Brown6, S Whittaker7, D Goldgar8, W Foulkes9.
1Cancer Genetics, Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey. 2The Royal
Marsden Hospital Trust, Downs Rd, Sutton, Surrey, SM2 5PT. 3Guys and St Thomas’ and
Kings Hospital Trusts. 4Mount Vemon Hospital Trust, Rickmansworth Road, Northwood,
Middlesex, HA6 2RN. 5Mid-Kent Oncology Centre, Hermitage Lane, Maidstone, Kent,
ME16 9QQ. 6Queen Victoria Hospital, East Grinstead. 7Royal Surrey County Hospital,
Egerton Road, Guildford, GU2 5XX. 8IARC, Lyon, France. 9McGill University, Montreal,
Canada.
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THE USE OF IRIDIUM 192 IMPLANTS FOR T1/T2 NO
SQUAMOUS CELL CARCINOMA OF THE TONGUE AND FLOOR
OF MOUTH – CONTROL AND COMPLICATIONS S Sothi*, J Townley, J
Glaholm and A Goodman, The Cancer Centre, Queen Elizabeth Hospital,
Birmingham, UK
We present the results of patients with T1 and T2 N0 squamous cell carcinoma of the
tongue and floor of mouth treated with iridium 192 implantation at our centre between
1994 and 1998. Thirty four patients were treated by two consultants. Twenty six had
T1 tumours, 8 had T2. Median age was 61 years (range 35 to 84 years). Median
tumour size was 2.0 cm (range microscopic to 3.5 cm). All patients had histologically
proven squamous cell carcinoma. Seven had muscle invasion. Seven patients had
laser excision prior to brachytherapy, five with incomplete excision and 2 with close
margins. The other 27 were biopsied only. Twenty seven patients were treated with
brachytherapy alone and all received 60Gy with a median dose rate of 0.52 Gy/hr
(range 0.34 to 0.87 Gy/hr). Seven patients were treated with a combination of
brachytherapy (30 Gy) and external beam radiotherapy (41.25 Gy in 15 fractions) to
primary site and first station nodes. Six had brachytherapy followed by external beam
treatment starting 1–6 weeks after implantation (median 2 weeks). In one patient
brachytherapy was performed two weeks after completion of external beam radio-
therapy.
Median follow up was 35 months (range 3 to 62 months). Two out of 34 (6%)
patients have recurred locally, both had simultaneous regional node recurrence. Both
were treated with brachytherapy alone. Six patients (18%) developed regional node
recurrence, five were treated with brachytherapy alone. Two patients with regional
recurrence have been successfully salvaged with surgery. Five patients have died,
three with recurrent disease. Actuarial two year survival was 85% and two year cause
specific survival was 91%. Sixteen patients developed soft tissue necrosis. Fifteen had
mild to moderate necrosis healing with conservative treatment. One patient had
persistent symptomatic tongue ulceration which healed after hyperbaric oxygen. None
required surgery. Four patients had osteoradionecrosis. Three had been treated with
brachytherapy alone. One healed with conservative treatment, two after hyperbaric
oxygen and the other required surgery and hyperbaric oxygen. All four remain alive
and well.
In conclusion, interstitial therapy with iridium 192 is effective treatment for small
T1 and T2 N0 squamous carcinomas of the tongue and floor of mouth. Supraregional
specialisation is required in view of small patient numbers.
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PLASMA TRANSFORMING GROWTH FACTOR BETA 1 (TGFb1)
LEVELS AND ACUTE RADIATION MORBIDITY IN PATIENTS
RECEIVING RADICAL RADIOTHERAPY TO THE HEAD AND NECK
REGION J Dickson, 1CML West, 2N Slevin, 2AJ Sykes, 1CRC Experimental
Radiation Oncology Group, 2Christie Hospital NHS Trust, Wilmslow Road,
Manchester M20 4BX, UK
Introduction There is increasing evidence that plasma TGFb1 levels can be used as a
predictor of both prognosis and acute radiation morbidity in a number of malignancies
including breast cancer NSCLC. This prospective study was designed to investigate
the relationship between plasma TGFb1 levels and acute radiation morbidity in a
group of patients receiving radical radiotherapy for carcinomas of the head and neck
region.
Materials and methods Plasma was obtained prior to the start of and in the final
week of a course of radical radiotherapy. TGFb1 levels were measured by sandwich
ELISA, using a commercially available kit. Data on the severity of the acute reaction
were available at the end of treatment and at six week follow-up. Plasma TGFb1
levels were correlated with acute reaction score (as measured by the LENT SOMA
scale) using non-parametric tests.
Results Plasma TGFb1 levels were available on 75 patients prior to the start of
treatment and in 68 patients in the final week of treatment. 19 patients had elevated
pre-treatment values and 13 patients had elevated values in the final week of treatment
(normal 2.59 ng/ml). There was a weak positive correlation between end of treatment
TGFb1 levels and acute reaction score at first follow up (p = 0.057). Patients whose
TGFb1 levels had normalised at the end of treatment had a significantly lower median
reaction score those whose TGFb1 level remained elevated (6 versus 31.5, p = 0.003).
Conclusion Plasma TGFb1 levels show promise in predicting those patients who
develop severe acute radiation morbidity following radical radiotherapy for head and
neck malignancies.
This work was supported by the Christie Hospital Endowment Fund and the
Cancer Research Campaign.48 Poster Presentations
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A PILOT STUDY OF POSTOPERATIVE CHART AND CHARTWEL
IN HEAD AND NECK CANCER N Shah*, M Saunders, S Dische,
Marie Curie Research Wing, Mount Vernon Hospital, Northwood, HA6 2RN
UK
Purpose A phase 2 feasibility study of CHART (Continuous hyperfractionated accel-
erated radiotherapy) and CHARTWEL (CHART weekend less) in the post operative
treatment of patients with squamous cell carcinoma of the Head and Neck.
Methods 24 patients (17M:7F) with a median age of 64 years (range 34–80) were
treated with postoperative radiotherapy from 1991 to 1999. All patients presented
with primary squamous cell carcinoma which at surgery had shown adverse patholog-
ical factors for recurrence. Patients were treated using a CHART (n=11) or
CHARTWEL (n=13) schedule from 49.5 Gy to 54 Gy.
Results Adjuvant radiotherapy was given to 17 patients following radical surgery
as initial management. In 7 other patients, recurrence after surgery had occurred and
was treated by further surgery and postoperative radiotherapy (1 primary tumour
recurrence, 4 nodal recurrences and 2 recurrent primary and nodal disease). Primary
tumour sites included oral cavity (9), oropharynx (8), pinna (3), larynx (2), columnella
(1) and unknown primary (1).
Treatment was commenced from a median time of 6.9 weeks (range 4.4–16.6) after
radical surgery. All patients completed treatment, with one patient’s treatment
extended by one day due to gastrostomy tube complications.
A confluent radiation mucositis occurred in 20/23 evaluable patients, and
mucositis settled in four to ten weeks after commencing radiotherapy. Moderate to
severe dysphagia occurred in 15/23 patients. Narcotic analgesics were given in 14/23
patients during the period of mucositis. Skin erythema was noted in all patients with
dry and moist desquamation appearing from 2 weeks in the region of the high dose
field. Resolution of the desquamation occurred in all patients from 4 weeks. Mild
subcutaneous oedema was observed in 11 patients from 12 weeks after treatment. All
mucosal reactions have healed with no consequential late necrosis. No cases of tran-
sient or permanent radiation myelitis have been observed.
Over a median follow up period of 16 months, local control is maintained in 17
patients (70%). 7 patients have relapsed and died of disease. A mean survival of 49
months (range 1–75 months) is observed.
Conclusion This pilot study demonstrates acceptable morbidity for
CHART/CHARTWEL in the postoperative setting. A prospective multicentre
randomised trial using an accelerated schedule of radiotherapy versus conventional
fractionation for the radical postoperative treatment of primary Head and Neck cancer
is currently in preparation.
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THE TIME SPAN BETWEEN SYMPTOM ONSET AND THE
START OF RADIOTHERAPY IN THE TREATMENT OF HEAD
AND NECK TUMOURS – A RETROSPECTIVE REVIEW E Pettet*, H
Phillips, S Jackson & MI Saunders, Mount Vernon Hospital, Rickmansworth
Road, Northwood HA6 2RN, UK
Introduction The importance of the overall duration of a course of radiotherapy for
head and neck cancer has been emphasised in the past 10 years. Very little importance
has however been given to the time that the patient spends between onset of symptoms
and commencement of radiotherapy treatment. This research has set out to investigate
the time span between symptom onset and the start of radiotherapy in patients with
head and neck cancer.
Patients and Methods The time span between the onset of symptoms and the
commencement of radiotherapy in patients with head and neck cancer was assessed
over a one year period. During this time patients were interviewed and their hospital
records reviewed. The duration of delays experienced at the various stages of patient
management was noted. The time spans identified were:
[1] Patient delays – the time taken for the patient to seek professional advice
usually from a general practitioner or dentist.
[2] Specialist delays, that is the time taken for the patient to be referred to the
hospital specialist usually an ENT or orofacial maxillary surgeon for the diagnosis to
be made and a management decision taken with the clinical oncologist.
[3] Planning delays – the time taken from seeing an oncologist to the first day of
radiotherapy treatment.
Patients were then subdivided into 6 sites of malignancy: nasopharynx, larynx,
hypopharynx, oropharynx, oral cavity and “other”. The data analysed as to whether
the patients underwent surgery and post-operative radiotherapy or radiotherapy only.
Results The findings of this study show that on an average a head and neck patient
takes 94 days (13.5 weeks) to seek professional advice from the onset of symptoms
and then spends a further 123 days (17.5 weeks) in the system before receiving radio-
therapy. On an average 44 days elapsed between first seeing the clinician and referral
to the hospital, 20 days were taken to achieve a diagnosis and a further 10 days to
make the management decision towards surgery, radiotherapy or a combined modality
approach. Once referred to the oncologist 49 days elapsed between that consultation
and commencement of radiotherapy. Analysis at the time delays for individual sites
will be given in detail and their relevance as to outcome.
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INTERSTITIAL PHOTODYNAMIC THERAPY IN HEAD AND
NECK CANCER Hopper C*, Suhr M, Jones L, Nakanishi H, Jaeger
R, Brookes J, National Medical Laser Centre and University College London
Hospitals NHS Trust
Background For many years, the mainstay of treatment for oral squamous cell carci-
noma has been surgery and radiotherapy. Photodynamic therapy (PDT) is a local treat-
ment that can be applied to such tumours and has the advantage of being a repeatable,
tissue-sparing treatment that leaves no lasting damage. The depth of photodynamic
effect is limited by the ability of the activating light to penetrate through tissue. In
practice, this has resulted in PDT being of value only in the management of thin
tumours.
Aim The aim of this study was to see if light could be delivered into tumour tissue
to produce a photodynamic effect.
Procedure All patients received 0.15 mg/kg Foscan and 4 days later had their
tumours treated with laser light of 652 nm delivered intratumorally from a point
source laser fibre at 10–20 Joules/cm2. 38 treatments on 26 patients with advanced
head and neck cancer have been carried out, initially by direct fibre placement, latterly
under ultrasound, CT and MRI control.
Major findings The treatment was well tolerated in all patients and produced
consistent tumour necrosis. No specific neurotoxicity was seen even when tumour
was treated around nerves such as the hypoglossal, vagus and brachial plexus. The
most important limiting factor was the proximity of the tumour to major blood
vessels. In one patient, there was a rarely encountered event of tumour erosion
through the carotid artery, and a blow-out was seen 8 days following treatment.
Significance No tumour type was immune to the PDT effect and normal tissue
recovered well following treatment. This is a repeatable treatment with no cumulative
toxicity and is an option when other treatments have failed
Conclusion Interstitial PDT offers a minimally invasive, local treatment for malig-
nant disease which is potentially applicable to any site in the body.
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COST UTILITY OF TAXOTERE VS VINORELBINE OR TAXOL IN
ADVANCED BREAST CANCER Brown R1, Hutton J1, 1MedTap
International, London, UK
The objective of this study was to capture the costs and quality of life (QOL) related
outcomes for advanced breast cancer (ABC) patients management with Taxotere
(TAX) in comparison to vinorelbine (VIN) and taxol (TOL). An updated version of
the Hutton et al. (Pharmacoeconomics 1996) model was used to simulate the experi-
ences (associated costs and outcomes) of patients undergoing treatment for ABC,
from the onset of chemotherapy to death. Published clinical trials were used to estab-
lish response rate, time to progression, median survival, rate of grade four febrile
neutropenia, and toxicity rate related to chemotherapeutic agent. Costs were taken
from published sources and reflect the UK National Health Service and were
discounted at 6%. Average patient costs were found to be £4268 for VIN, £7817 for
TAX and £7645 for TOL. The estimated Quality Adjusted Life Year values were 0.48
for VIN, 0.73 for TAX and 0.65 for TOL. This means that VIN produces an additional
175 days of good quality life, TAX produces an additional 266 days and 237 days for
TOL. The incremental cost per quality adjusted life year (QALY) for TAX were
£14,500 compared with VIN and £1,990 compared with TOL. Various sensitivity
analyses were undertaken and did not change the findings greatly. The cost-effective-
ness ratios are within the range of generally acceptable technologies. Patients
managed with TAX have improved QOL in comparison to these alternative
chemotherapies and a longer median survival.Poster Presentations 49
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COSTS OF FAILURE OF 1ST LINE CHEMOTHERAPY FOR
ADVANCED BREAST CANCER IN THE UK Tran G1 Burrell AD2*,
Jackson DL2*, 1Lewin Group, Bracknell UK, 2Aventis Pharma, West Malling,
Kent, UK
Objective The objective of this study was to summarise medical resource utilisation
and estimate the overall costs of treatment failure following first-line chemotherapy in
patients with advanced breast cancer in the UK.
Design The study was designed to abstract data from medical notes of patients who
had withdrawn from 1st line chemotherapy for advanced breast cancer. The medical
notes of these patients were retrieved and clinical outcomes, as well as medical
resource utilisation data were abstracted from date of study treatment failure (with-
drawal) to 200 days following withdrawal, or up to the date of last contact or death.
All data was abstracted by trained nurses onto specifically designed case report forms.
The main analytic framework was an assessment of the overall costs of treatment
failure associated with the 23 patients withdrawn due to disease progression, adverse
events or other reasons. The cost evaluation only included direct costs as the study
perspective was the UK NHS.
Study end points Medical resource utilisation measures were anti-tumour therapy
and setting in which these therapies were administered, hospitalisation days (days
spent in each type of ward), consultations and location in which patients attended
these consultations, tests/procedures and setting in which these were performed.
Results
Reason for Withdrawal Number of Patients Median cost per Patient (£)
Disease progression 9 5,590.8
Adverse Event 8 2,959.22
Other 6 1,726.12
All patients 23 3,728.44
The overall cost of treatment failure was found to be high, with a significant propor-
tion of this cost (55.8%) attributable to hospitalisation. Disease progression implied
the greatest associated costs. However, the small sample size of this study does not
allow a definitive conclusion.
Conclusions Treatment failure due to progression appears to incur additional
costs. Cost offsets may be possible from therapies which prolong time to progression
or are associated with less adverse events which require treatment discontinuation.
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A SYSTEMATIC REVIEW OF DOCETAXEL, PACLITAXEL AND
VINORELBINE IN THE TREATMENT OF ADVANCED BREAST
CANCER IN THE UK Lorna Anderson1, Jane Cox1, 1Anderson Cox
Consulting, 48 Hazeldene Road, Chiswick, London W4 3JB, UK
A systematic literature review was undertaken to help determine which is the most
effective therapy for treatment of advanced breast cancer within UK licensed treat-
ment regimens. As there is a lack of head to head Phase III randomized controlled
trials comparing docetaxel, paclitaxel, and vinorelbine. Cochrane Collaboration
methodology was followed to design a literature search. A cut-off point of 18 August
1999 was decided upon and the following databases were searched: EMBASE,
EMBASE Alert, HealthStar, CancerLit, and MEDLINE. Five Phase III trials (three
for docetaxel, one for paclitaxel, one for vinorelbine) were found within the pre-spec-
ified inclusion criteria. Study populations were similar, and dosing schedules were in
accordance with their UK licensed indications. Patient-weighted averages for efficacy
and safety from the docetaxel studies were calculated and compared with the pacli-
taxel and vinorelbine studies. When compared as single agents, docetaxel appears to
produce a greater overall response rate than paclitaxel or vinorelbine in this patient
population. Docetaxel is also associated with greater median time to progression and
median survival than vinorelbine, although complete response rates appear similar for
the two agents. Grade III/IV safety outcomes, where comparisons allowed, were
largely similar, with docetaxel associated with a higher incidence of neutropenia,
asthenia, and diarrhoea, but a lower incidence of anemia compared to vinorelbine.
Comparable data for paclitaxel were not available from the publication. A quantitative
meta-analysis of data from these studies is ongoing. Whilst indirect comparisons from
disparate studies should be interpreted with caution, this represents the best currently
available evidence, and suggests that docetaxel may be more effective in terms of
overall response rate, time to progression, and survival in this patient population.
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AN AUDIT OF DOCETAXEL AS A SECOND LINE AGENT IN
TREATMENT OF METASTATIC BREAST CANCER IN SOUTH
EAST WALES S Mukherjee*1, IJ Robbie2, D Allen,1 CC Gaffney, 1DWO
Tilsley1, PJ Barrett-Lee1, 1Velindre Hospital, Cardiff CF4 7XL, 2Bro Taf Health
Authority
Background Docetaxel, a semi-synthetic agent of the taxoid family has shown great
potential in the management of advanced breast cancer, and is now widely used as a
second line agent in the treatment of metastatic breast cancer. To the best of our
knowledge, this is the first audit of the use of this drug in a hospital setting.
Funding for the use of docetaxel as a second line agent for metastatic or locally
advanced breast cancer was obtained from Bro Taf Health Authority, SE Wales, in
September 1998, which agreed to fund 24 patients per year from the Bro Taf popula-
tion.
Patients aged less than 65 years with metastatic or locally advanced breast cancer,
who had received prior anthracyclines, and had an anticipated survival greater than 3
months, were considered eligible.
We have audited the use of this drug at the end of one year of its use.
Results 15 patients were treated (Mean age 47.5 years, range 31–61 years), all of
whom had prior anthracyclines and 13 of whom (87%) had more than one site of
metastasis. 9 of the patients (60%) completed 6 cycles, and 8 (53%) of them started on
100 mg/m2.8 of the 15 patients (53%) showed response to the drug with a median
survival of 204 days. 6 of the patients (40%) required admission due to neutropenic
sepsis, one of whom was admitted on 5 occasions. 1 patient died of neutropenic
sepsis. Interestingly, 5 of the 6 patients (83%) with neutropenic sepsis responded to
docetaxel chemotherapy.
Conclusion The response rate and the duration of survival achieved using
docetaxel in our hospital are at least comparable to that reported in literature1.
However there has been a higher incidence of patients admitted with neutropenic
sepsis. Neutropenic sepsis may be a more significant problem than encountered in the
trials and may be more common in patients with multiple sites of involvement and
liver disease. It might also be a predicator of response. Further studies are necessary to
elucidate this aspect of docetaxel chemotherapy.
1 O’Brian MER, Leonard RC, Docetaxel in the community setting: An analysis
of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK
Barrett-Lee PJ, Eggietor SPH, Bizzari JP, on behalf of UK Study Group (1999)
Annals of Oncology 10: 205.
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LARGE VARIATIONS IN UK MANAGEMENT OF INTRADUCTAL
CARCINOMA OF THE BREAST, D Landau*1, E Hall2, G Ross12, The
Royal Marsden Hospital and Institute of Cancer Research London SW3 6JJ, UK
Background Ductal carcinoma in situ (DCIS) accounts for 20% of screen-detected
breast cancers. There are however a lack of mature clinical trial data and consequently
many unresolved issues in the area of clinical management.
Aim We performed a national survey of current UK practice in the management of
DCIS in order to investigate variations in such practice and to inform the design of
any future national prospective randomised trials in DCIS.
Methods A questionnaire was sent on 17/11/1999 to 271 consultant surgeons to
whom the UK breast screening centres refer breast cancer patients and to 203 consul-
tant clinical oncologists treating breast cancer patients at UK radiotherapy centres. It
was re-sent to non-responders on 18/1/2000. The results of questions related to work-
load and current clinical practice are presented here.
Results 182 (67%) surgeons and 131 (65%) clinical oncologists returned
completed questionnaires. The combined results are as follows:
Workload: new patients Indications for Indications for
per month (n=308) Radiotherapy (n=298) Tamoxifen (n=280)
<1 26% None 14% None 21%
1–2 44% All DCIS 14% All DCIS 26%
3–4 19% All HG/comedo 45% All postmenopausal 10%
5 or more 10% Specific size 29% All ER+ 27%
Indications for Close margin 34% All HG/comedo 11%
Mastectomy (n=302) Family history 5% Widespread or
>1 quadrant 78% Microinvasion 48% multifocal DCIS 16%
Specific size 51% Combin.factors 45% Microinvasion 31%
Family history 12% Radiotherapy: Bilateral 15%
Combin. factors 44% Use of boost* (n=117) Family history 15%
Axillary Surgery (n=298) Not used 76% Combination of
No patients 59% Routine 9% factors 18%
Selected patients 41% Close margins only 15%
Re-excision if margins *surgeons not asked this question
involved (n=296) n = number of respondents to each question
Yes 97%
Conclusions We believe this to be a representative overview of current UK prac-
tice. It reveals large variations in the management of a common form of breast cancer
regarding indications for mastectomy, radiotherapy and tamoxifen and confirms the
need for evidence-based guidelines.50 Poster Presentations
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SPECIALIST PALLIATIVE CARE IN CANCER OUTPATIENTS:
WHAT ROLE? V Lidstone*, C Sinnott, T Beynon, M Richards, Dept
of Palliative Medicine, St. Thomas’ Hospital, London SE1 7EH, UK
Aims To determine the views of Oncologists regarding functions and acceptability of
Specialist Palliative Care (SPC) in Oncology out-patients.
To determine the views of SPC staff regarding actual and potential role in
Oncology clinics.
To define the most effective and acceptable model of input to aid future service
planning.
Design Oncologists and SPC doctors and nurses regularly involved in Oncology
Clinics at Guys and St. Thomas’ Hospitals were asked to agree to semi-structured
interviews. The interview included general questions about current running of the
Clinics and specific questions about current and appropriate future provision of SPC.
Interviews were recorded on audio-cassette for internal validation.
Subjects 12 Oncology Consultants. 10 Oncology Specialist Registrars. 4 SPC
staff.
Results Interviews revealed a high level of interest in SPC involvement in the
clinics. Doctors found SPC input particularly beneficial when it provided a link with
the community service and an opportunity for information exchange. Symptom
control was highlighted by oncologists as an important function of the team particu-
larly when symptoms were multiple, difficult to control or related to poly-pharmacy.
Counselling/psychological support was also a valued role. These roles were recog-
nised by the SPC staff who also highlighted the building of relationships with
oncology staff, and introduction of patients to the concept of SPC as important func-
tions of their presence in the clinics. All but one of the oncologists interviewed felt
that further placement of SPC in their clinics would be beneficial, although SPC staff
currently placed in out-patients feel they are under-used. Most Oncologists would
prefer the support of a SPC Nurse rather than a SPC Doctor, and SPC staff themselves
agree nurses are probably more appropriate. Half favoured a parallel clinic model, half
joint clinics.
Conclusions SPC services in out-patients are highly valued and widely acceptable
to Oncologists, many of whom view it as an essential part of patient management and
would like expansion of this service in the future. However, despite this high level of
enthusiasm SPC staff who are currently placed in oncology clinics felt that
Oncologists were under-referring and this is likely to be related to the limited percep-
tion they had of the role of SPC. Expansion of the service in out-patients will require
education of both parties in order to provide the most efficient model of care for
patients.
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PROVISION OF SPECIALIST PALLIATIVE CARE IN CANCER
OUTPATIENT CLINICS: A NEEDS ASSESSMENT V Lidstone*, C
Sinnott, T Beynon, M Richards, Dept of Palliative Medicine, St. Thomas’
Hospital, London SE1 7EH, UK
Aim To define and prioritise the need for Specialist Palliative Care (SPC) in Cancer
Outpatient Clinics.
Design A validated 29-item Symptoms/concerns checklist.
Setting Guys and St. Thomas’ Hospitals out-patients departments.
Subjects 480 patients with a histologically proven diagnosis of cancer (n=60 for
each of: lung, breast, gastrointestinal (G.I), gynaecological, urological, genitourinary
(G.U), brain and lymphoma).
Results This study defined the prevalence and severity of 29 common symptoms
and concerns in an oncology out-patient population. Recruitment was trouble-free
(97%), and patients answered on average 27/29 of the questions, reporting around 10
items as current problems. The highest overall level of need, as defined by the highest
number and most severe symptoms/concerns, was reported by the patients with lung
tumours, followed by those with brain tumours. The lowest levels of need were
reported by those with lymphoma and G.U. tumours. Those with advanced disease
reported a higher level of need than those with non-advanced disease; those in remis-
sion had the lowest level of need. Those on current radio/chemotherapy had higher
levels of need than those not although the differences were not significant. Those aged
30–39 and 40–49 yrs had the highest level of need, and the need declined after the 
age of 50 yrs. Of the six symptoms known to be improved by SPC intervention the
group of patients with lung tumours reported the highest frequencies of
mild/moderate/severe symptoms for five of these, and highest frequencies of
moderate/severe symptoms for three. The group of patients with G.I. tumours reported
the second highest levels for three of these symptoms.
Conclusions The checklist represents a feasible and acceptable tool for audit of
symptoms/concerns in cancer out-patients. A high proportion of these patients have
multiple problems. Some may be alleviated by treatment/care. More than half of the
sample studied reported one or more moderate/severe problem that may benefit from
SPC intervention. With regards to the tumour groups studied there is no single agreed
measure of need in this context. However, using a variety of approaches patients with
lung cancer appear to have the highest level of need followed by those with brain
tumours, G.I. tumours, breast tumours and head and neck cancer. Patients with
lymphoma and gynaecological or G.U. primaries and appear to have lowest levels of
need, though individual patients may have high levels of need. Advanced patients are
likely to benefit more from intervention but this is relative and non-advanced and
patients in remission should not be excluded.
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CAN THE ADMISSION OF MEDICAL ONCOLOGY PATIENTS TO
INTENSIVE CARE BE JUSTIFIED? G Hall*1, E Harrer1, T Perren1,
P Selby1, 1ICRF Cancer Medicine Research Unit, St James’s University
Hospital, Leeds, UK
The use of intensive care beds in the UK has recently been the focus of considerable
interest. The admission of any patient receiving cancer treatment to the intensive care
unit (ICU) frequently causes considerable debate regarding whether such an admis-
sion can be justified in view of the underlying diagnosis. We have therefore reviewed
the medical oncology admissions to the ICU at our centre.
Medical oncology admissions to ICU between January 1993 and July 1999 were
identified by comparing the electronic databases of both units. Admission to our ICU
reflects a need for ventilatory support whereas other acutely ill patients are managed
on the general oncology ward. Case notes were reviewed to identify the reason for
admission to exclude patients admitted to ICU following primary surgical resection.
Patient age, diagnosis, duration of admission, outcome (death or discharge from ICU)
and survival from date of admission were subsequently recorded. A comparison of
these data with all patients recorded within both the oncology and ICU databases were
made.
41 patients were identified with a median age of 48.2 years (range – 18 to 74
years). The three most common underlying diagnoses were lymphoma (12 patients),
breast (8 patients) and germ cell tumours (5 patients). The most frequent reason for
admission was respiratory support associated with neutropenic sepsis. A total of 316
‘bed-days’ were used by these admissions with an average of 8 days per patient.
Eighteen patients died on ICU, a further four within 7 days of discharge. Five patients
died more than one month after discharge from ICU and ten patients are still alive
(range – 6 to 77 months). 34.1% of patients therefore survived more than one month
following discharge from ICU. This compared favourably to the survival of other
patients admitted to ICU.
This review confirmed our impression that cancer patients admitted to ICU do not
have a uniformly poor prognosis. It reinforces the need to assess each seriously ill
patient on an individual basis to ensure that the stigmata of their diagnosis does not
restrict their access to life-saving facilities.
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LONG TERM OUTCOME OF PATIENTS WITH LOCALLY
ADVANCED THYROID CARCINOMA J Powles*, L Vini, RA ‘Hern,
C Harmer, P Rhys-Evans, Head, Neck and Thyroid Unit, Royal Marsden
Hospital, Fulham Road, London SW3 6JJ, UK
Aim This is a retrospective study to assess the long term outcome of patients with
locally advanced (pT4) differentiated thyroid carcinoma.
Patients Of 1404 patients with differentiated thyroid carcinoma treated at the
Royal Marsden Hospital over the last 60 years, we identified 255 who had locally
advanced tumours at diagnosis (pT4). Of these 94 were male and 161 female (M:F=
1:1.71), with a mean age at diagnosis of 56 (range: 7–85 years). Most patients (85%)
presented with a thyroid nodule or a palpable neck node. Mean follow up was 21 years
(range: 1–60 years).
Results There were 193 papillary, 52 follicular and 10 Hurthle cell carcinomas;
48% of all tumours were well differentiated and 25% poorly differentiated. 148
patients were recorded as having involved lymph nodes, 76 were ipsilateral (N1a), and
distant metastases were found in 46 cases (most commonly in lungs and bones). Initial
management included total thyroidectomy in 138 cases, lobectomy/hemithyroidec-
tomy in 59 and biopsy/enucleation in 59. A modified radical neck dissection was
performed in 50 patients while simple nodal excision occurred in 54. Radioactive
iodine was given to 238 patients, with 31 receiving an ablative dose and the rest
receiving more than 1 dose (cumulative activity: 8.5–24GBq). External beam radio-
therapy was given to 72 patients. Local recurrence (thyroid bed, neck nodes or medi-
astinum) occurred in 93 patients and was managed by further surgery, radioiodine or
external beam radiotherapy 46 patients (18.04%) relapsed at distant sites. Overall
cause specific survival at 10, 20 and 30 years was 60%, 45% and 45% respectively.
Age at diagnosis and extent of surgery were found to be independent prognostic
factors for local recurrence as well as for survival, while external beam radiotherapy
was a significant prognostic factor for local control.
Conclusions Locally advanced differentiated thyroid carcinoma is associated with
aggressive behaviour and should be managed with total thyroidectomy and selective
neck dissection (if involved) followed by radioactive iodine. Radiotherapy should be
also considered, especially in older patients, to reduce the risk of local recurrence.Poster Presentations 51
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AN AUDIT OF GERM CELL TUMOURS REFERRALS TO A
CANCER CENTRE VR Bulusu*1, J Robson1, MV Williams1, MA
Ward2, 1Oncology Centre, and 2Clinical Audit Department, Addenbrooke’s
Hospital, Cambridge CB2 2QQ, UK
Aims 1. To audit the time taken for a patient with suspected germ cell tumour (GCT)
of the testis from presentation to the GP to the treatment. 2. To identify the bottlenecks
if any, in the referral pathway. 3. To compare our data with the national guidelines for
GCT referrals.
Material and Methods 41 case records of patients with GCT of testis referred to
the Oncology centre, during the period 1998–1999, have been audited. The following
information was obtained from the GPs, surgeons and the oncologist. 1. Date of GP
referral 2. Date of surgical consult 3. Date of orchidectomy 4. Date of referral to
oncologist 5. Date seen by oncologist 6. Date decision made re. Treatment 7. Date
treatment commenced. The mean (± SD) and median were calculated for the waiting
times. These were compared with the national/departmental guidelines for GCT refer-
rals.
Results There were 66% patients with Stage I GCTs and 22% were recommended
surveillance. The mean duration of symptoms before attending the GP was 15.4 weeks
(range 1–104 wks). 78% had tumour markers done preoperatively and only 61% had
pre oncology referral CT scan of the chest, abdomen and pelvis. The mean, median
and st. deviations are given in the table I. 66% of the patients were seen by the oncol-
ogist within four weeks of the orchidectomy. As shown in the table, the total waiting
time is the composite effect of delays occurring at most steps of the referral pathway.
Days Total GP- Urology- Surgery- Oncology Oncol.OP Decis.
Waiting Uro surgery oncology referral- decision -Rx
time log y referral oncol. OP Rx start
Mean 71 17 7.5 14 11.5 10 11
Median73 10 6 9 10 7.5 7
SD 29.2 19 7 15.5 9 11 12.5
Conclusions We believe there are still significant delays occurring in the referral
pathway of patients with GCTs of testis. 77% of the total delay seem to occur prior to
oncology consultation. Only 66% of the patients were within the time frame recom-
mended by the COIN guidelines, 1999.(1). We propose a fast track referral process to
minimise the delays in the referral pathway. Patient education is essential in reducing
the delays in seeking medical advice.
1 Howard G & Mead GM et al (1999) COIN and SIGN Guidelines on the
management of adult testicular germ cell tumours.
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COLORECTAL CANCER REFERRALS TO A DISTRICT
HOSPITAL – DO WE NEED AN INTEGRATED CARE PATHWAY?
B Lovett*, D Hassanally, C Ingham-Clark, MR Lock, RAM Al-Mufti,
Department of Surgery, The Whittington Hospital, Royal Free and University
College Medical School, London N19 5NF, UK
Aim To evaluate the referral patterns and current clinical practice for colorectal cancer
patients referred to a colorectal cancer unit. To compare these to NHS Executive guid-
ance on improving outcomes in colorectal cancer1 and with the guidelines issued by
the Royal College of Surgeons of England2.
Method The clinical notes of all patients referred with colorectal cancer in a one
year period were reviewed retrospectively by a single observer. Recorded factors
included the time from GP referral to first consultation, time from first symptoms to
diagnosis, pre-operative diagnostic investigations, urgency of surgery, speciality of
operating surgeon, requirement for stoma formation, use of adjuvant therapy and
mortality rate.
Results The case notes of all 49 patients referred with colorectal cancer were
reviewed. 68% of cases were seen within 2 weeks of referral. The longest delays in
diagnosis, (median 4.5 months) was due to the prolonged interval between onset of
symptoms and GP consultation. 36% of patients presented as emergencies. 17% of
patients underwent full colonoscopy before surgery, 45% prepared Ba enema and 15%
unprepared Ba enema. 39% of cases were biopsied preoperatively. 89% of elective
cases and 56% of emergency cases were performed by a colorectal surgeon. The
procedure was regarded as curative in 63% of cases and a stoma was required in 30%.
Histology confirmed 6% Dukes A, 41% Dukes B and 41% Dukes C tumours. 34% of
patients received adjuvant chemotherapy, 9% received radiotherapy and 4% received
both. 55% of patients were discharged within 14 days of admission. Mortality was
6%.
Discussion Our current practice in the management of colorectal cancer referrals
does not meet NHS executive guidelines. We identified a need for an integrated care
pathway designed to streamline colorectal cancer diagnosis and treatment.
1 NHS Executive (1997) Guidance on commissioning cancer services. Improving
outcomes in colorectal cancer. Department of Health
2 The Royal College of Surgeons of England and Association of Coloproctology
of Great Britain and Ireland (1996) Guidelines for the management of
colorectal cancer.
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MANAGEMENT OF MALIGNANT PHAEOCHROMOCYTOMA: A
RETROSPECTIVE REVIEW OF THE USE OF MIBG AND
CHEMOTHERAPY IN THE WEST MIDLANDS Hartley A*1, Spooner D1,
Brunt AM2, Lewington V3, 1Queen Elizabeth Centre for the Treatment of
Cancer, Birmingham B15 2TH, 2Staffordshire Oncology Centre, Stoke-upon-
Trent, 3Department of Nuclear Medicine, Southampton General Hospital, UK
Introduction Phaeochromocytoma is a rare disorder with no randomised and little
prospective data to facilitate choice between the two main treatment modalities,
chemotherapy and radiolabelled monoiodobenzylguanidine(mIBG). In the last decade
the latter modality has been preferred and radiological response rates of 30% have
been reported. There are fewer patients reported in the literature who have received
chemotherapy but one prospective trial of chemotherapy reported radiological
response rates of 57%. A recent prospective trial combining the two modalities has
been disappointing with only one patient completing the treatment schedule. We
present six patients with malignant phaeochromocytoma or paraganglioma who
received mIBG therapy. Four patients also received chemotherapy. 
Method A retrospective review of the case notes was performed. Radiological and
hormonal responses were determined. Time to progression after each modality were
calculated. 
Results One partial hormonal response was seen with mIBG treatment. One
complete and one partial hormonal response and one radiological partial response
were seen with chemotherapy. The median time to disease progression from
commencement of mIBG was 12 months (range 3–44) and from commencement of
chemotherapy used as 1st or 2nd line was 22.5 months (range 7–25). 
Conclusions Chemotherapy may be a more active modality in this disease than
previously considered. MIBG uptake may increase following a partial radiological
response to chemotherapy enabling subsequent mIBG therapy. Future trials looking at
combined therapy should consider administering chemotherapy prior to mIBG for
reasons we outline.
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MANAGEMENT OF LUNG CANCER IN ABERDEEN:
COMPARISON OF TREATMENT AND OUTCOMES WITH THE
NATIONAL AVERAGE Marianne C. Nicolson*, Donald Bissett, Muriel Reid
and Robin Legge, ANCHOR Unit, Aberdeen Royal Infirmary, on behalf of the
Aberdeen Lung Cancer Group
Introduction We know from the data presented last year that lung cancer is under-
treated in Scotland. The practice in Aberdeen differs in that all patients treated come
through this hospital and for five years now we have had a multidisciplinary group
who meet weekly to discuss the new patients’ diagnoses and management in addition
to having bimonthly research meetings. The treatments and outcomes were audited for
1994, before the arrival of oncologists interested in lung cancer, and again in 1997.
There has been a marked change in practice in the stable population in the North East
of Scotland and this is reflected in outcomes here and in comparison with the rest of
the country.
The number of patients diagnosed was 422 in 1997. The demographics are unre-
markable with 265 males to 157 females and age range 35 to 95 years with mean 69
years. The diagnosis was confirmed histologically or cytologically in 71.3% of cases
(62% in Scotland 1995). Squamous and adenocarcinoma histologies were equal in
incidence, each accounting for 26.8% of patients. Small cell was diagnosed in 15.2%
only. Primary treatment was chemotherapy in 22.3% of patients with non-small cell
lung cancer compared with 16.6% in the national study. The majority of these patients
were treated in a clinical trial. The percentage resected was 17% compared with
11.6% in Scotland in 1995. For small cell lung cancer, only 61% received
chemotherapy as primary treatment, and a further 8 patients (12.5%) received second
line chemotherapy.
In 1994, no patients in Grampian with non-small cell lung cancer received
chemotherapy. Survival data for the 1997 audit will be available and further compara-
tive data will be presented.52 Poster Presentations
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SCOTTISH AUDIT OF SURGICAL MORTALITY: AUDIT OF 182
DEATHS FROM PANCREATIC CANCER MA Jahan*1, H Burton2,
SJ Nixon2, AM Thompson1,2, 1Department of Surgery & Molecular Oncology,
University of Dundee DD1 9SY, 2Scottish Audit of Surgical Mortality, Royal
College of Physicians and Surgeons, Glasgow G2 5RJ, UK
The Scottish Audit of Surgical Mortality (SASM) conducts peer review of the
management of all patients who die in surgical wards. The first round of audit of 334
patients who died with pancreatic cancer (1994–1996) identified a high rate of emer-
gency admission, adverse surgical management and poor utilisation of perioperative
monitoring resulting in some 25% of deaths being potentially avoidable. The aim of
this study was to conduct a second round of audit using the most recent SASM data
(1997–98) to evaluate changes.
During 1997–1998, 182 patients died with pancreatic cancer on surgical wards in
Scotland. Compared with the previous audit (1994–1996 figures in italics), 77(42%)
were emergency admissions (qv 75%) and 94 (40%) had terminal care (qv 28%).
There was a reduction in potentially avoidable causes of death to 37/182 (20%) from
25% Nineteen (10%) deaths followed endoscopic procedures under sedation (qv
23/334, 7%). Adverse factors in surgical management (usually post-operative compli-
cations, detected too late and managed by inexperienced staff) were identified in 7
(11%) patients who underwent surgery (qv 12%).
Since the last audit, there has been a reduction in emergency admission rate and
deaths due to potentially avoidable causes, but an increase in the proportion of
patients receiving terminal care for pancreatic cancer on a surgical ward. However,
endoscopic procedures, currently the subject of more detailed audit, and adverse
factors in surgical management remain causes for concern.
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A PROSPECTIVE AUDIT OF THE DELAYS IN REFERRAL AND
TREATMENT OF MALIGNANT SPINAL CORD COMPRESSION
SG Russell1 and LT Tan1, 1Dept of Oncology, Addenbrooke’s Hospital,
Cambridge CB2 2QQ, UK
Introduction Malignant spinal cord compression (MSCC) is a common condition and
a major cause of morbidity in patients with cancer. The outcome depends on the func-
tional status at the time of treatment. Delay is associated with loss of neurological
function which may be irreversible. This prospective audit assesses the delays in
presentation, investigation and treatment of MSCC at Addenbrooke’s Oncology
Centre.
Methods 40 consecutive patients with MSCC were interviewed with a structured
questionnaire. The following data was collected: dates of onset of symptoms, presen-
tation to GP, admission to District General Hospital, admission to Addenbrooke’s,
commencement on dexamethasone, MRI and definitive treatment. Functional status
was also assessed at each of these times.
Results The median age was 66 (range=38–94) years. The commonest malignancy
was prostate followed by breast and lung. The median delay from onset of symptoms
to first consultation was 8 (range=0–38) days. The median delay after presentation to
the GP was 2 (range=0–28) days. The median delay at the District General Hospital
was 1 (range=0–5) day. The median delay at the Cancer Centre was 0 (range=0–2)
day. 93% of patients were treated on the day of referral. Deterioration in functional
status followed a similar pattern to the delays in referral: 25% of patients deteriorated
before consulting a doctor, 10% after presentation to the GP and 5% at the District
General Hospital. MRI was performed on the same working day on 38/40 (95%)
patients; 1 patient was scanned the next working day while the other refused due to
claustrophobia. 36/40 (90%) patients were started on dexamethasone the same day the
clinical diagnosis of MSCC was made.
Conclusion The main delay in referral of MSCC in this audit was by the patient. It
would therefore seem logical to target specific groups with a relatively high proba-
bility of developing MSCC for patient education. This may include patients with
breast, prostate and lung cancer, myeloma and those with known bone metastases.
These patients could be given an advice card outlining the symptoms of MSCC (pain,
weakness, sensory disturbance, ataxia and bladder dysfunction) and advertising a
direct referral route to the Cancer Centre. We feel that the relatively short delays expe-
rienced after the patient had presented to a doctor was in part due to the implementa-
tion of a co-ordinated multi-disciplinary approach involving oncology, neurosurgery
and radiology with the aim of reducing delay.
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MALIGNANT SPINAL CORD COMPRESSION: A SCOTTISH
AUDIT P Levack1, I Kunkler2, J Graham2, R Grant2, A Gibson2, D
Collie2, P Statham2, R Rampling3, L Slider3, D Hurman4, 1Royal Victoria
Hospital, Dundee; 2Lothian Univ Hospitals NHS Trust, Edinburgh; 3Western
Infirmary, Glasgow; 4Aberdeen Royal Infirmary, Aberdeen, UK
Early diagnosis and treatment of malignant spinal cord compression (MSCC) are
important in optimising the outcome of treatment. Delay in diagnosis or treatment
may compromise neurological outcome. Little is known on a national basis of the
process of care of MSCC. A prospective multidisciplinary audit was carried out of
300 patients in three Scottish cancer centres including the onset of symptoms and
signs of MSCC and institution of radiological investigations and treatment. A prelim-
inary analysis is presented on 200 patients. 80% had evidence of malignancy at least 2
weeks before the diagnosis of MSCC. Predominant primary sites were
lung>prostate>breast. At presentation 14% were ambulant, 37% were ambulent with
assistance and 44% were unable to walk (see Table). Radicular pain occurred in 83%
at diagnosis and in one third was 10/10 on the VAS scale of severity. The median time
from first reporting symptoms to a medical practitioner to diagnosis of MSCC was 75
days. 86% first reported symptoms to their GP. Most patients were initially investi-
gated by their GP with plain radiographs. Many with thoracic MSCC (70% of all
compressions) had had lumber spine films only. An additional 40% of patients had
bone scans incurring further delay in diagnosis of MSCC. 90% were diagnosed-on-
MRI. Eleven of the 30% referred for a neurosurgical opinion underwent surgery (2%
for biopsy and 9% for definitive surgery). 86% were treated with radiotherapy of
whom 7% received postoperative radiotherapy.
Ambulation Lung Prostate Breast GI Kidn NK
None 32 32 27 12 8 11
With help 27 23 14 12 10 7
Walks alone 9 11 14 7 3 6
Conclusions 1. A high proportion of patients present with MSCC unable to walk
despite a long history of severe root pain suspicious of epidural disease. 2. Rapid
access to MRI for patients with known malignancy and root pain might lead to earlier
diagnosis and more effective treatment by surgery and/or radiotherapy.
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AN AUDIT OF CLINIC CONSULTATION TIMES IN A CANCER
CENTRE – IMPLICATIONS FOR NATIONAL MANPOWER
PLANNING RJ Benson*, NG Burnet, MV Williams and LT Tan, Oncology
Centre, Addenbrooke’s Hospital NHS Trust, Cambridge CB2 2QQ, UK
Introduction A departmental audit was conducted to assess the frequency, extent and
causes of late completion of oncology clinics.
Methods Data were collected prospectively from clinical, medical, haematological
and multidisciplinary oncology clinics. Factors recorded included clinic start and
finish time, number of patients seen, type of consultation, number of doctors in each
clinic, time spent by the doctor with the patient and other factors that may have
contributed to late completion of clinics.
Results 848 patient consultations were recorded in 81 clinics. Of 67 clinics in
which finish time was recorded, 19 (28%) were completed on time while 48 (72%)
were late by a mean of 49 minutes. The mean time spent by consultants with new,
follow-up and chemotherapy patients was 37, 21 and 22 minutes respectively. This
time did not include time spent reviewing notes, dictation or ordering investigations.
There was no significant difference in the time spent by specialist registrars compared
to consultants, or clinical oncologists, medical oncologists and haematologists.
Unforeseen problems such as difficult consultations (e.g. breaking bad news, difficult
symptom control) occurred in 228/848 (27%) consultations while delays due to
missing information occurred in 33/848 (3.9%) consultations. Unplanned interrup-
tions occurred in 48/81 (59.3%) clinics and late starts in 13/67 (19.4%) clinics. 10/81
clinics (12%) were overbooked. There was no significant difference in the time lost to
unforeseen factors between those clinics which finished late and those which finished
on time. The mean delay of multidisciplinary clinics was longer than for non-multi-
disciplinary clinics (59 and 31 minutes respectively), despite a higher ratio of doctors
to patients in the former (1:5.4 and 1:7 respectively).
Conclusion The audit found that the main cause of delay in clinics in our depart-
ment was the longer than anticipated time spent by doctors with patients.
Consultations are taking longer because of the increasing complexity of non-surgical
cancer treatment and the greater emphasis placed on patient information and informed
consent. The Royal College of Radiologists (RCR) has calculated that if a consultant
oncologist sees a maximum of 315 new patients per year, the time available for each
follow-up consultation would be 10 minutes. Our audit showed that follow-up consul-
tations took an average of 21 minutes. These results suggest that the RCR recommen-
dations for consultant expansion substantially underestimates the true number of
consultants required for the treatment of cancer patients in the U.K.Poster Presentations 53
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THE EFFECTS OF RADIOTHERAPY WAITING TIMES ON THE
TREATMENT OF GLIOBLASTOMA M Kwok1, JW Adlard*1, G
Gerrard1, 1Yorkshire Centre for Clinical Oncology, Cookridge Hospital, Leeds
LS16 6QB, UK
Introduction Glioblastoma is an aggressive intracerebral glioma with a median
survival of 9 months and a 5-year survival approaching 0%. Treatment with high
doses of radiotherapy (RT) improves median survival by several months. A standard
RT regimen is 60 Gy in 30 fractions over 6 weeks. A hypofractionated regimen of 30
Gy in 6 fractions over 2 weeks with a similar Radio-Biological Effectiveness has
previously been piloted in poor prognosis high grade gliomas (1).
Method At the Authors’ centre, patients with glioblastoma with poor prognosis
(low Karnofsky Performance Status (KPS)/elderly) are treated with the hypofraction-
ated (HF) regimen and the remainder with the standard (SD) regimen. Prior to a recent
increase in linear accelerator capacity the RT waiting time has been longer for patients
offered the more fractionated regimen. A retrospective study was performed to
compare the survival outcome of the two groups, to determine whether patients dete-
riorate prior to treatment and to assess the potential impact of increased radiotherapy
waiting times.
Results A total of 72 cases (43 SD group, 29 HF group) treated between March
1998 and January 2000 were reviewed. Pretreatment prognostic factors were worse
for the HF group compared with the SD group (Mean age 60.8 years vs. 50.2 years,
KPS 50–60 vs. 70–90). The mean RT waiting time was shorter for the HF group (17
days vs. 38 days). In the SD group two patients died and 8 deteriorated prior to
starting RT compared with and one death and 2 deteriorations in the HF group. There
was no significant difference in survival between the two groups (Median survival:
HF group 8.3 months vs. SD group 10.9 months).
Conclusion This study suggests that increased radiotherapy waiting times are
deleterious in glioblastoma and may eliminate any potential benefit of more fraction-
ated regimens. Where resource limitations lead to unavoidable prolonged waiting
times the hypofractionated regimen may be useful, but should be compared to stan-
dard regimens in randomised trials.
(1) Thomas R, James N, Guerrero D, et al (1994) Radiotherapy and Oncology
33(2): 113–6
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AUDIT OF SHORT COURSE PREOPERATIVE RADIOTHERAPY
FOR OPERABLE RECTAL CANCER A Hartley*, S Giridharan, JI
Geh, The Cancer Centre at the Queen Elizabeth Hospital Birmingham B15
2TH, UK
Introduction Short course (25 Gy in 5 fractions over one week) preoperative radio-
therapy (RT) has been shown to reduce the risk of local recurrence and improve
overall survival in patients with operable rectal cancer. However, in view of improved
surgical techniques, this advantage may be lessened. In addition, preoperative RT may
not be necessary in all patients and there is a potential risk of postoperative complica-
tions, late toxicity and impaired functional results using this approach. The aim of this
audit was to identify the proportion of patients in whom either short course RT may
have been avoided or a prolonged fractionation may have been more appropriate.
Method An audit of all rectal cancer patients treated in this centre with pre opera-
tive RT during 1998 was performed. Information from clinical notes, surgical findings
and pathology reports were obtained. All patients who received short course RT were
included.
Results A total of 88 patients were identified; 70 patients with clinically operable
tumours received short course RT, 13 patients with fixed tumours received prolonged
fractionation, information on 5 patients pending. Of these 70 patients 64 (91%) had
curative resection, 5 had palliative resection (3 had liver or peritoneal metastasis) and
1 was unresectable. Of the 64 who had curative resection, 57 (89%) had clear circum-
ferential margins, 7 (11%) had positive margins. Pathological staging identified Dukes
A 9 (14%), Dukes B 29 (45%) and Dukes C 26 (41%). Four (6%) patients died within
3 months of commencing RT and there were 26 treatment related early complications
in 20 (29%) patients (wound complications (11); thromboembolic episodes (4); pelvic
abscess (4); anastamotic leak (1); others (6)).
Conclusion A significant proportion of the 70 patients receiving pre-op RT were
found to be incurable (9%) or to have Dukes A disease (13%). In addition, the 10% of
patients who had positive circumferential margins may have had greater benefit from
a more prolonged course of RT. Therefore, 32% of patients may have received short
course RT inappropriately. In future, to avoid the problems identified, a greater
emphasis on more accurate pre-operative assessment and staging is desirable. The
results of the MRC CR07 trial, comparing short course preoperative RT with selective
postoperative chemoradiation may help to resolve these uncertainties.
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AN AUDIT TO COMPARE PLANNING TARGET VOLUMES
USING CONVENTIONAL CT SCAN GREY SCALES PLANNING
AND THE CT ACQSIM SYSTEM FOR RADICAL RADIOTHERAPY OF
CARCINOMA OF THE PROSTATE D Power, JF Money-Kyrle, S Allen, RSD
Brown & HA Payne, Meyerstein Institute of Oncology, Middlesex Hospital,
London W1N 8AA, UK
Aims of Study To evaluate the accuracy of target definition in prostatic carcinoma
using AcQSim virtual simulation computer software and a Picker PQ 5000 CT
Simulator (Picker, Ohio, USA) compared with our existing method of conventional
CT grey scale planning. Study endpoints were the size of margin around clinical target
volume (CTV), the size of planning target volume (PTV), and the possibility of
geographical miss.
Methods Concurrent AcQSim and conventional grey scales CT planning was
performed on 19 sequential patients. PTV’s were calculated and compared for both
groups.
Results For AcQSim plans, PTV were smaller in 14 patients and larger in 5
patients. The mean reduction in area when planned with AcQSim was 4.5% (246
mm2). The maximum area reduction was 35.1% with a maximum increase of 22.9%.
Length of PTV by AcQSim was reduced in 15 cases (maximum reduction 18 mm),
unchanged in 2 cases and increased in 2 cases. Change in the PTV were largely deter-
mined by the smaller field length on AcQSim rather than the difference in area
outlined. There was little difference in the posterior border (rectal) using the two
methods. One partial geographical miss was seen with grey scale planning.
Conclusions The AcQSim gives a comparable PTV to the grey scales, but by
using smaller CT cuts, the length of the volume is more accurately determined. The
composite shape appeared to be more accurate on AcQSim, although this had less
impact clinically. The system was easy to use and beam’s eye lead can be applied to
reduce rectal toxicity.
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DO ENQUIRERS TO CANCER INFORMATION SERVICE
HAVE SUPPORT AT HOME? M Boudioni1*, J Mossman1, A
Jones2, M Boulton3, K McPherson4, 1CancerBACUP, 3 Bath Place, Rivington
Street, London EC2A 3DR; 2Royal Free Hospital, Pond Street, London NW3
2QG; 3Social Science. & Law, Oxford Brookes University, Gipsy Lane
Campus, Oxford OX3 0BP; 4Epidemiology & Population Health, LSHTM,
London WC1E 7HT, UK
Aims The aim of the study was to ascertain whether people living alone are more
likely than those in multi-person households to contact independent cancer informa-
tion services. It was postulated that the availability of support from others within a
household would diminish the need for support from an organisation such as
CancerBACUP.
Methods An Enquirer Record Form (ERF) is completed for every fifth enquirer to
the Cancer Information Service. Demographic characteristics, subjects of enquiry and
advice given are systematically and routinely recorded, but information on living
arrangements is not collected.
A questionnaire was developed to record living arrangements of enquirers who
were patients, relatives or friends. It was used in association with the routine ERF, for
a five-week period (13/07/98 to 14/08/98). The Information nurse specialists were
briefed on the purpose of the survey and how to apply it. Those callers who were too
upset or emotional were not asked.
Main findings Of the 677 people who constituted the sample, 552 (82%) callers
specified whether they were living alone or not. 250 (45%) of them were diagnosed
patients and 302 (55%) were relatives/friends. 481 (87%) were living with someone,
while 71 (13%) were living alone. These data were compared to the Great Britain
Population1 and it was found that a slightly higher percentage of people living alone
contacted the service than those in the general population (13% Vs 11%). Living alone
or with others was significantly associated with type of enquirer. 72% of those living
alone were diagnosed patients compared with 41% of those living with others (chi-
square=21.952, p=0.000). The recorded subjects of enquiry were also analysed and it
was found that patients and relatives/friends living alone had different concerns from
those living with others.
Conclusions This analysis provides an insight into the characteristics and needs of
people using independent support services. Although there are no significant differ-
ences in the living arrangement of enquirers compared with the GB population as a
whole, there are differences in the needs between those living alone and those living
with others. These findings may enable healthcare professionals to begin to identify
groups where there is a greater need for support.
1. Household and Families (1998, 1999) Social Trends 28 & 29. Office for
National Statistics, London54 Poster Presentations
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SPECIAL SCREENING OF FAMILY HISTORY PATIENTS –
DOES IT MEET GENERAL SCREENING STANDARDS? K
Hogben*, J Viggers, J Davey, G Curling, N Burch, B Kirkman, Newman M, G
Walsh and G Gui, Breast Diagnostic Unit, The Royal Marsden Hospital NHS
Trust, London SW3 6JJ, UK
Women with a significant family history of breast cancer attend specialist clinics for
high risk screening, usually selected by a calculated lifetime risk greater than 1:8
compared to the population risk of 1:12. Such women are screened annually from age
35 years but there is currently no data to support the practise or to compare results
against the National Health Breast Screening Programme (NHSBP). Women with a
risk between 1:8 and 1:12 are considered low risk and advised to attend the NHSBP
from age 50 years.
Women were categorised into lifetime risk of between 1:12 and 1:8 (low risk) and
greater than 1:8 (moderate/high risk), based on Claus predictive tables. 2578 women
were seen between June 1993 and August 1994 with a mean follow up of 120 (range
8–357) months in this retrospective study. Screening consisted of annual review and
mammography.
Low risk High risk Total
Patients, n 1500 1078 2578
Follow-up in women years 5902 4328 10230
Median age at diagnosis 54.5 (38–63) 45 (26–66)
DCIS, n 0 2 2
Invasive cancers <10 mm, n 2 4 6
10–20 mm, n 7 10 17
21–30 mm, n 3 1 4
Unknown, n 0 2 2
As all women were already attending for screening at the start of the study, the
cancer incidence was 2/1000 per year in Group 1 and 4.4/1000 per year in Group 2.
NHSBP targets are to detect 4/1000 cancers per three yearly screen, which is equiva-
lent to 1.3/1000 years. 24% of all invasive cancer in Group 2 were <10 mm.
The screening of high risk women meets and exceeds the rigorous targets set for
the detection of invasive cancer in the incident screens of the NHSBP directed at the
general population. The annual screening of high risk women with clinical examina-
tion and mammography is justified.
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RESULTS OF THE NORTH THAMES DEANERY TRAINEE
SATISFACTION SURVEY FOR CLINICAL AND MEDICAL
ONCOLOGY SHO’S & SPR’S 1999 RSD Brown1, D Power1, M Aitken2 & E
Paice2, 1SpR in Clinical Oncology, Middlesex Hospital, London W1A 8AA,
2North Thames Postgraduate Medical and Dental Education, 33 Milman
Street, London WC1N 3EJ, UK
Introduction The North Thames deanery is the UK’s largest, where 25% of all UK
specialist registrars are trained. In November 1998 to January 1999 a North Thames
deanery survey was widely distributed to North Thames hospitals to assess trainee
satisfaction as part of the Calman training reforms. Results were available for all main
medical subspecialties.
Methods 25 questions relevant to Clinical and Medical Oncology trainees were
analysed. Tests for significant differences from other medical specialities were
performed using Chi squared and students t-tests. Nine key questions were used to
rank trainee satisfaction across the range of medical specialties.
Results Oncology SpR’s ranked in the top half of medical specialty trainee satis-
faction in 4 of 9 comparisons; night time rest [1st/13, p=0.03], nursing support
[4th/13], hands on experience [5th/13] & overall post rating [5th=/13]. In 5 of 9
comparisons satisfaction was in the lower range; hours of formal education [7th/13],
consultant supervision [10th/13], job intensity [10th/13], induction to post [12th/13,
p=0.04], & feeling forced to cope [13th/13].
Oncology SHO’s also ranked in the top half of medical specialty trainee satisfac-
tion in 4 of 9 comparisons; feeling forced to cope [1st/13], nursing support [2nd/13,
p=0.01], night time rest [5th/13, p<0.05], consultant supervision [6th/13, p=0.03]. In 5
of 9 comparisons, satisfaction was in the lower range; job intensity [8th/13], induction
to post [11th/13], overall post rating [13th/13, p<0.05], hands on experience [13th/13]
& hours of formal education [13th/13, p=0.04].
Conclusion Overall satisfaction scores among North Thames oncology trainees
are generally high. Areas for possible improvement compared with other medical
specialties are defined.
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WOMEN WITH OVARIAN CANCER: THEIR PERCEPTIONS
OF CT SCANNING BA Crosse*1, J Spencer2, TJ Perren3,
1Huddersfield Royal Infirmary, HD3 3EA,2 Department of Clinical Radiology
and 3Imperial Cancer Research Fund Cancer Medicine Research Unit, St
James’s University Hospital, Leeds LS9 7TF, UK
Abdomino-pelvic CT scanning makes an important contribution to the management
of women with ovarian cancer. The optimum method of disease monitoring is much
debated. 1Women may undergo several CT scans during the course of their disease. In
clinical practice, this procedure appeared to cause anxiety for some, and considerable
distress for a few. The impact of scanning on cancer patients has been studied infre-
quently,2 and there is no published work in the context of ovarian cancer. A semi-
structured questionnaire was designed to elicit the views of women with ovarian
cancer on the experience of CT scanning. 61 fixed response items were derived from
unstructured interviews with 6 women, and with clinical and radiology personnel.
Items were ordered chronologically, covering the period prior to the scan, preparation
for the scan, the scan procedure and the period afterwards. Items included anxieties
occasioned by the scan, physical symptoms, knowledge of the procedure, and issues
of consent and control. Women were asked to refer to their most recent scan when
responding. Open responses were invited to questions about change of experience
with repeated scanning, the best and worst aspect of scanning and areas for improve-
ment. 50 women received the questionnaire, and 45 responded. Their ages ranged
from 38 to 83 years (median 58) and the number of scans per woman from 1 to 12
(median 4). 33% of women dreaded the scan because it was so unpleasant. Physical
symptoms occasioned by the oral and intravenous contrast fluids (particularly diar-
rhoea and vomiting), and the unpleasant nature of the oral contrast were distressing
aspects. Anxieties related to ignorance of the procedure, invasive elements of the
process, physical consequences, the scan environment, and waiting to hear the results.
Important minorities of women felt they had no choice about having a scan, or that
they had no control over unpleasant or invasive aspects. Fear of the procedure gener-
ally lessened with repeated scanning, but physical symptoms did not. Women
expressed confidence in the accuracy of scanning and its contribution to their manage-
ment.
Ovarian cancer is an unpleasant and distressing disease. This study presents
evidence that CT scanning causes distress for some women, and this should be consid-
ered when decisions about disease monitoring are made.
1. Rustin GJ, Nelstrop AE, McClean P et al. (1996) J Clin Oncol; 14: 1545
2. Peteet JR, Stomper PC, Ross DM, Cotton V, Truesdell P, Moczynski W (1992)
Radiology 182: 99.
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WEIGHT GAIN DURING CHEMOTHERAPY MAY BE A
SIGNIFICANT PROBLEM FOR BREAST CANCER PATIENTS
– AND SHOULD BE ADDED TO INFORMATION SHEETS KJ Lankester*,
PA Lawton, JE Phillips, Centre for Cancer Treatment, Mount Vernon Hospital,
Rickmansworth Rd, Northwood HA6 2RN, UK
Several reports in the literature have shown that weight gain can occur during adju-
vant chemotherapy for breast cancer. Despite this, current dietary advice in many
centres is to eat small frequent snacks (such as biscuits) to combat nausea, which
could contribute to weight gain. We conducted an audit to investigate weight change
in our own centre and to examine possible contributory factors.
Methods Case notes from 50 patients who had received either adjuvant or neoad-
juvant FEC or CMF chemotherapy for breast cancer were studied. Cancer stage,
menopausal status, type of chemotherapy, weight at each cycle of chemotherapy, use
and dose of steroids, antiemetics and tamoxifen were recorded.
Results The mean weight change was a gain of 3.9 kg (range –3.2 kg to 17.9 kg,
standard deviation 3.7 kg). This was highly significant with a p-value of <0.001.
Weight gain in this study appeared to be independent of steroid use, antiemetics,
menopausal status and tamoxifen.
Gaining a few kilograms may be dismissed as a trivial side effect. However, it can
impact significantly on self-image and hence quality of life and general health. We
propose that patients should be made aware of possible weight gain and that the
current dietary advice should be modified.Poster Presentations 55
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AUDIT OF A NURSE LED PERIPHERALLY INSERTED
CENTRAL VENOUS CATHETER (PICC) PRACTICE
K Clayton*, S Hummerston, JD White, PJ Woll, J Carmichael, Cancer
Research Campaign Dept. of Clinical Oncology, Nottingham City Hospital,
Nottingham, UK
Introduction Due to the costs and complications of Hickman lines in our unit we
introduced peripherally inserted central catheter (PICC) lines in preference.
Methods A retrospective audit of our experience using PICCs was undertaken. A
database (using SPSS version 8.0, Chigaco, IL.) was established. This included indi-
cation for insertion, complications and their management, time remaining in situ.
Protocol for insertion included a check CXR.
Results 47 PICCs were inserted in 41 pts (22 M and 19 F) over a 34-month period,
median age 56 years (19–82). Underlying tumours were colorectal 27, breast 5,
pancreas, sarcoma, germ cell, cholangiocarcinoma each 3 and 3 other tumours.
Indications for PICC insertion were intermittent continuous infusion chemotherapy
45%, continuous infusion chemotherapy 34%, poor peripheral access 17% and 4%
other. Regimes administered were 45% De Gramont, 28% continuous infusion 5-FU
and 28% 12 other regimes 83% of PICCs were single lumen. The left arm was used
for 64% of insertions. 62% of PICCS were inserted successfully at first attempt, 22%
needed two, 13% three and 2% required 4 attempts to cannulate. Complications occur-
ring at the time of insertion 59% nil, 27% inability to cannulate leading to repeat
attempts, median 1 (1–4), 5% of PICCs were mal-positioned and 7% could not be
advanced. Indications for removal of line were 60% completion of treatment, 8% each
for thrombosis, patient choice and mal-position and 3% each for fracture, occlusion
and leakage. PICC fracture occurred at the hub (1) and entry site (1), necessitating
repair and removal. Line removal (2) and systemic anticoagulation (1) treated the
three cases of thrombosis, axillary (2) and subclavian (1). One PICC complicated by
leakage was treated by removal. PICC infections consisted of 2-exit site (treated 1
with oral and one with oral and i.v. antibiotics) and a probable bacteraemia treated
with oral antibiotics. There were no proven cases of bacteraemia. 7 PICCs were
complicated by mechanical phlebitis. PICC occlusion occurred twice one treated by
urokinase bolus and one by removal. There was a trend to longer PICC survival for
lines placed in the right arm. Whilst not achieving statistical significance the mean
time catheters remained in situ was longer for single lumen PICCs compared to
double lumen. Median overall PICC survival was 76 days (2–212); corresponding
figures for PICCs removed due to complications and those removed on completion of
treatment were 44.5 (2–128) and 107 (16–212).
Conclusion This method facilitates easy recording and audit of our PICC practice
and in the future other central venous access devices.
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METHYLATION AT THE TELOMERASE RNA GENE
PROMOTER, INDUCES ALTERNATIVE METHODS OF
TELOMERE LENGTH MAINTENANCE IN HUMAN CELLS SF Hoare*, L
Bryce, S Muir and WN Keith, CRC Department of Medical Oncology,
University of Glasgow, CRC Beatson Laboratories, Bearsden, Glasgow G61
1 BD, UK
We have studied methylation of the promoters of the telomerase genes hTERC (the
RNA component) and hTERT (the catalytic subunit). Telomerase is present and active
in most tumours but absent in normal somatic cells. It acts by maintaining telomere
length, thus preventing cells from senescing. Both genes have promoter regions with a
high CpG content, so have the potential to be regulated by methylation. Methylation
was studied by both Southern blotting and methylation specific pcr (m.s.p.) on DNA
samples from tumour and normal tissues and cell lines. Methylation status was
confirmed by sequencing. Of the normal samples tested none showed methylation for
either gene, suggesting that the absence of telomerase was not due to promoter methy-
lation. The tumours types studied were lung, breast, colon, cervix, ovarian and brain.
No methylation of the hTERT gene was observed in any tumour sample, but 7/49
ovarian tumour samples showed partial hTERC methylation. None of the other
tumours showed hTERC methylation. 21 cell lines were tested, of the 18 cell lines
which expressed telomerase, the hTERC promoter was unmethylated in 11 and
partially methylated in 7. Full methylation of the hTERC promoter was only seen in
the three ALT Cell lines, SUSM -1, KMST -6 and W138 -SV40, none of which
express telomerase. Two other ALT cell lines were both unmethylated, but these cell
lines express hTERC. This suggests that methylation might be the mechanism used by
some ALT cell lines to switch off telomerase expression, forcing telomere length to be
maintained by alternative methods. hTERT results, however, did not correlate with
telomerase expression. Of the 20 cell lines tested, 1 cell line (SUSM -1) showed
complete methylation, 5 cell lines were unmethylated and 14 were partially methy-
lated. 10/20 cell lines showed similar methylation status in the promoters of both
genes. We conclude that promoter methylation is unlikely to be involved in the regu-
lation of telomerase expression except possibly in the ALT cell lines, where promoter
methylation necessitates telomere length to be maintained by methods other than
telomerase. Further studies are underway to investigate whether telomerase expres-
sion can be reactivated in the ALT cell lines by treatment with the demethylating agent
5-aza-cytidine.
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METHYLATION STATUS OF P16 IN BREAST CANCER CELL
LINES, NORMAL BREAST TISSUE, BREAST TUMOURS AND
LYMPHOCYTES VH Deshmane*1,2, S Droufakou1, AM Hanby2, WH Harris2,
IS Fentiman2 and IR Hart1, The Richard Dimbleby Dept of Cancer
Research/ICRF Laboratory1, St Thomas’ Hospital & Breast Unit, Guy’s
Hospital2, London, UK
The cell cycle is strictly controlled by a complex system of molecules, which regulate
the progress of the proliferating cell through various checkpoints. These include the
retinoblastoma gene product (pRB), cyclins, cyclin dependent kinases (CDKs), and
CDK inhibitors (CDKIs). One such CDKI is p16INK4 which controls progress from G1
to S phase. Inactivation of p16 occurs commonly in human neoplasia. It is the
predominant tumour suppressor gene located on 9p21, a region frequently affected by
LOH. However, homozygous deletions and mutations of p16 are rare, which raises
questions as to how this gene is inactivated. Methylation of the promoter region of this
gene provides one possible mechanism.
We have analysed the methylation status of the p16 promoter following modifica-
tion by sodium bisulphite. Using Methylation Specific PCR (MSP) cell lines (n=4),
normal breast tissue (n=8), breast cancer tumours (n=65) and circulating lymphocytes
(n=6), all have been examined. MSP with the T47D cell line demonstrated a methy-
lated promoter with a product of 150 bp, whereas MDA MB 435, BT474 and ZR75
cells have an unmethylated promoter generating a product of 15 bp. Specificity of
MSP products was confirmed by sequencing, demonstrating the conversion of all
cytosines to uracil in the unmethylated promoter. Normal breast specimens all (8/8)
appeared to have a methylated promoter, in circulating lymphocytes 4/6 (67%) were
unmethylated while in 2/6 (33%) there was some degree of methylation, along with a
strong unmethylated signal. Among tumour samples 52/65 (80%) were methylated,
while 13/65 (20%) were unmethylated. On further analysis grade I tumours, lymph
node-negative tumours, patients with <3 positive lymph nodes and ER/PR positive
tumours showed a definite trend to have only unmethylated alleles i.e. active p16.
However, after a median follow-up of 10 years, methylation status of the p16
promoter did not correlate with disease free survival (p=0.738) or overall survival
(p=0.879). Our results indicate that while p16 appears to be activated to a greater
degree in those with apparently good prognosis tumours, this does not associate with
survival. These findings suggest that while inactivation of p16 gene expression by
methylation may appear to provide a frequent means of silencing this CDK1 in breast
cancers this also occurs in normal tissues.
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THE ROLE OF P21CIP1/WAF1 AND P27KIPI IN THE GROWTH
INHIBITION OF COLON CARCINOMA CELLS BY
TRANSFORMING GROWTH FACTOR-b1 JL Limer*, JA Royds and J Lawry,
Institute for Cancer Studies, Division of Oncology and Cellular Pathology,
Sheffield University Medical School, Beech Hill Road, Sheffield, South
Yorkshire S10 2RX, UK
Transforming Growth Factor-b1 (TGF-b1) is a potent repressor of epithelial cell
proliferation, inducing cell cycle arrest at the G1 restriction point. Neoplastic transfor-
mation of colonic epithelia is frequently associated with the acquisition of a TGF-b1
resistant phenotype. At present, the molecular mechanisms responsible for this occur-
rence are poorly understood. In order to investigate TGF-b1 insensitivity we have
identified two adenocarcinoma cell lines (HT29 and SW742) with opposing responses
to the cytokine. The HT29 cell line is significantly growth inhibited by 1 ng/ml TGF-
b1, demonstrating concurrent G1 accumulation and decreased S-phase synthetic
activity. TGF-b1 exposure induced upregulation of the cyclin dependent kinase
inhibitor (CDKI) proteins p21CIP1/WAF1 and p27KIPI, as detected by flow cytometry.
Immunoprecipitation studies confirmed increased CDKI interaction with CDK2 and
CDK4 in the presence of TGF-b1. Contrastingly, SW742 demonstrates insensitivity
the cytokine, exhibiting an increase in S-phase progression and decreased G1 accu-
mulation. The SW742 cell line expresses elevated basal levels of p27KIPI, however
minimal CDKI-CDK binding was observed in response to TGF-b1. In summary, our
results suggest a direct correlation between TGF-b1 insensitivity and a failure to
inhibit G1 cyclin-CDK activity. We are currently utilising antisense oligonucleotide
techniques to further investigate the role of p27KIPI in the TGF-b1 inhibitory response.
This work is funded by Yorkshire Cancer Research.56 Poster Presentations
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RAPID PROTEOSOME-DEPENDENT DEGRADATION OF P21
IN HUMAN TESTICULAR GERM CELL TUMOURS Bate, TE*,
Hickman, JA† & Chresta, CM, School of Pharmacy, University of Manchester
M13 9PT, UK †Institut Servier, 92150 Suresnes, Paris, France
Overexpression of wtp53 is a frequent alteration in human testicular germ cell
tumours (TGCT). Following etoposide treatment, cells derived from these tumours
continue to proliferate with damaged DNA. We have investigated whether defects in
the p21waf-1/cip-1 pathway allow TGCT to tolerate these high levels of wtp53. In the
TGCT cell line (833K) with wild-type p21, transcripts are unregulated in a p53-
dependent manner in response to DNA damage. However, p21 protein is expressed at
negligible levels and Rb remains in the inactive hyperphosphorylated form. The low
levels of p21 protein resulted from reduced stability of the protein, as treatment with
cycloheximide revealed the p21 of TGCT has a shorter half-life than that of bladder
carcinoma cells (RT4) which undergo a stable cell cycle arrest. The reduced p21
stability results from enhanced proteolysis in the presence of proteosome inhibitors
(MG132 and lactacystin) p21 protein accumulates to high levels. The effect of proteo-
some inhibitors on p21 stability is much greater in TGCT than in a wild-type p53
containing RT4 cells which has stable p21 protein. However, stabilisation of p21 in
TGCT by proteosome inhibitors did not result in a functionally active protein as cell
cycle analysis by bromodeoxyuridine staining showed no G1 phase accumulation.
Additionally, analysis of Rb after proteosome inhibition showed no evidence of the
hypophosphorylated form which would be consistent with a G1 arrest. We conclude
that low levels of p21 protein occur in TGCT due to its rapid degradation by the
proteosome: it may therefore act as an assembly factor, rather than an inhibitor of
cyclin/CDK complexes. However, proteosome inhibitor treatment of TGCT does not
result in the production of a functionally active p21 protein.
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CELL PROLIFERATION AND APOPTOSIS CONTROL IN NON-
HODGKIN’S LYMPHOMA SF AI-Othman1, JR Goepel2, H Al-
Husaini–3, J Martin4, Olivia Smith2, J Lawry1, 1Division of Oncology and
Cellular Pathology, 2Department of Pathology, University of Sheffield Medical
School, Beech Hill Road, Sheffield, S102RX. 3Department of Histopathology,
Riyadh Armed Forces Hospital; Riyadh; KSA, 4Department of Histopathology,
King Faisal Specialist Hospital & Research Centre, Riyadh, KSA
Aims To investigate by flow cytometry and immunohistochemistry, the expression of
four regulatory proteins having a key role in the processes of cell proliferation &
apoptosis control (p53, bcl-2, bcl-6 and cyclin D3) in non-Hodgkin’s Lymphoma.
Methods 1– Three human cell lines were used: Raji, (Burkitt’s) MC116 (undiffer-
entiated lymphoma) and WILCL (normal B cell). All cells were maintained in suspen-
sion culture in RPMI-1640 supplemented with 10% fetal bovine serum. Cells were
analysed by flow cytometry for expression of the four regulatory proteins.
2 – Paraffin wax embedded tissue was used in a parallel study from 35 cases of
non-Hodgkin’s Lymphomas (14 follicular lymphoma, 11 diffuse large B-cell
Lymphoma of primary lymph node and 10 diffuse large B-cell lymphoma of primary
gastric origin). Tissues have been stained with specific antibodies using immunohisto-
chemical techniques. Samples were scored for staining distribution and intensity using
appropriate controls.
Preliminary results (1) Cyclin D3 & bcl-6 were negative in all three-cell lines, but
bcl-2 was positive in both WILCL and Raji, and very high expression of p53 in Raji.
(2) Immunohistochemistry showed positive Cyclin D3 & p53 in about 50% cases of
both nodal and gastric non-Hodgkin’s Lymphoma, being more common in high grade.
Bcl-6 was more commonly expressed in diffuse large B-cell lymphoma of primary
gastric origin than its nodal counterpart. Bcl-2 staining was positive in 70–90% of the
cases tested and was also more commonly expressed in follicular lymphoma.
Conclusions In-vitro studies indicated that the cell lines were a good model for the
in-vivo studies, and apoptosis inhibition may be the key to this cancers development.
Low-grade disease was characterised by the lack of Cyclin D3 and p53 and
conversely, by the presence of bcl-2. The reciprocal expression of these proteins may
provide the “switch” from low grade to high grade B-cell non-Hodgkin’s Lymphoma
and also the cancers’ apoptotic response.
Bcl-6 however, may play a more important role in the pathogenesis of gastric large
B-cell lymphoma as these cases were characterised by elevated expression of bcl-6
compared to follicular and diffuse nodal lymphoma.
The Kingdom of Saudi Arabia and Yorkshire Cancer Research provided funding.
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CELL CYCLE CONTROL AND APOPTOSIS IN
NEUROBLASTOMA SL Hankin*1, M Gerrard2, S Variend2 & J
Lawry1, 1Division of Oncology and Cellular Pathology, University of Sheffield,
Beech Hill Road, Sheffield, S10 2RX, 2Sheffield Children’s Hospital, Sheffield
S10 2TH, UK
Introduction Neuroblastoma is the most common extracranial malignant tumour in
childhood, displaying a wide range of behaviour from spontaneous regression to
highly malignant disease. The reasons for this diversity have yet to be elucidated
using either growth control and/or apoptotic mechanisms.
Aims This study aims to decipher the specific growth control mechanisms that
govern both the cell cycle control and apoptotic processes in neuroblastoma. We are
trying to combine behaviour observed ‘in vivo’, using immunohistochemical
methods, to an ‘in vitro’ analysis using two established neuroblastoma cell lines.
Methods Initial studies involved an ‘in vivo’ assessment of archival paraffin wax
embedded tumours, with a panel of antibodies using immunohistochemical tech-
niques. The antibody panel included cell cycle players such as CDK4, CDK6, and
apoptotic associated-proteins such as Bax, Bcl-2 and CD95. Other antibodies
employed included the prognostic markers N-Myc, NB84 and CD44. This same anti-
body panel was then used as part of an ‘in vitro’ investigation, which quantified
protein expression using flow cytometry on the two cell lines Kelly and SK. N.SH.
Results were expressed as fold increases, using the median fluorescence index (MFI)
of each test protein, compared to the negative isotype control. The cell cycle phases
(propidium iodide staining) and apoptosis (Annexin V staining) were also assessed in
normal culture conditions and serum-deprived conditions.
Results Amongst other findings, preliminary results with immunohistochemistry
indicate that neuroblastoma growth may be particularly associated with CDK4, as
opposed to CDK6. Flow cytometry on the cell lines showed increased expression of
CDK4 (Kelly MFI=3.5, SK.N.SH MFI=4.6) compared to CDK6 (Kelly MFI=1.7,
SK.N.SH MFI=2.8). In addition, N-Myc protein was highly expressed (MFI=5.9) in
both cell lines. N-Myc positivity was also evident in each clinical stage of neuroblas-
toma tested by immunohistochemistry, including the patients with no recorded N-Myc
gene amplification.
Conclusions Initial data suggest that N-Myc protein expression, as opposed to
gene amplification, may be a more valuable prognostic factor. It is anticipated that this
dual approach of both cell cycle control and apoptotic analysis will provide essential
data on an exact mechanism of growth control in neuroblastoma, which may provide
information for therapeutic intervention.
Research is funded by Yorkshire Cancer Research.
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DIFFERENTIAL EFFECTS OF ESTRONE- AND ESTRONE-3-
O-SULFAMATE DERIVATIVES ON MITOTIC ARREST,
APOPTOSIS AND MICROTUBULE ASSEMBLY IN HUMAN BREAST
CANCER CELLS Graham Packham*1, MacCarthy-Morrogh2, PA Townsend1,
A Purohit2, HAM Hejaz3, BVL Potter3 and M Reed2, 1CRC Wessex Medical
Oncology Unit, Cancer Sciences Division, School of Medicine, University of
Southampton, Southampton, SO16 6YD, 2Endocrinology and Metabolic
Medicine and Sterix Ltd, Imperial College School of Medicine, St Mary’s
Hospital, London W2 1NY, 3Wolfson Laboratory of Medicinal Chemistry and
Sterix Ltd, Department of Pharmacy and Pharmacology, University of Bath,
Bath BA2 7AY, UK
There is considerable interest in the potential use of estrogen derivatives for treatment
and prevention of breast cancer. The naturally occurring estradiol metabolite, 2-
Methoxyestradiol (2-MeOE2) does not bind the estrogen receptor, but does interact
with tubulin and induce mitotic arrest in breast cancer cells, and has anti-angiogenic
activity. We previously synthesised the sulfamoylated estrone derivative, 2-
Methoxyestrone-3-O-Sulfamate (2-MeOEMATE), and demonstrated that this
compound induced G2/M arrest and modest levels of apoptosis in breast cancer cells
in vitro whereas the parent estrone derivative, 2-Methoxyestrone (2-MeOE1), did not,
suggesting that sulfamoylation may be a useful way to increase the anti-cancer
activity of estrogen derivatives (Purohit et al., 2000, Int J Cancer, 85, 584). 2-
MeOEMATE also induced breast tumor regression in vivo in intact rats. To further
explore the significance of sulfamoylation on the anti-cancer activity of estrone deriv-
atives and to elucidate their mechanism of action, we synthesised two additional
agents, 2-Ethylestrone (2-EtE1) and 2-Ethylestrone-3-O-Sulfamate (2-EtEMATE). 2-
MeOEMATE and 2-EtEMATE inhibited the growth of a panel of estrogen receptor
negative and positive breast cancer cell lines in vitro, induced mitotic arrest and apop-
tosis and suppressed the long term clonogenic potential of MCF7 and CAL51 breast
cancer cells. In each assay, the sulfamoylated estrone derivatives were greater than 10-
fold more potent than their parent compounds. The sulfamoylated estrone derivatives
were also significantly more potent inhibitors of cell growth than 2-MeOE2. 2-
MeOEMATE and 2-EtEMATE functioned as anti-microtubule agents and inhibited
the ability of paclitaxel to promote tubulin assembly in vitro. Like other anti-micro-
tubule agents, the sulfamoylated estrone derivatives induced BCL-2 and BCL-XL
phosphorylation and increased p53 expression. 2-MeOEMATE and 2-EtEMATE are
novel anti-microtubule agents that have potent anti-cancer activity in breast cancer
cells in vitro and may be beneficial as anti-cancer agents in vivo.Poster Presentations 57
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FUNCTIONAL AND MOLECULAR CHARACTERISATION OF
THE VOLUME-REGULATORY CHLORIDE CURRENT IN THE
EPITHELIAL DERIVED HUMAN BREAST CANCER CELL LINE ZR-75–1
J Killey*, AJ Nicholl, MW Saul, C Garner, Dept of Chemical and Biological
Sciences, University of Huddersfield HD1 3DH, UK The Isle of Man
Government has funded this project.
When a cell in isotonic solution is exposed to a hypotonic solution water will move into
the cell causing it to swell due to the higher osmotic pressure in the cell. As a cell will
always try to remain at a constant volume, under these conditions it will activate volume
regulatory channels, resulting in a loss of specific ions, Cl– and K+, from the cell and
subsequently a loss of water. The molecular equivalent of the volume-regulatory Cl–
current, Iclvol has been proposed as either P-glycoprotein, the putative Cl– channel or Cl–
channel regulator (pIcl), or a member of the Cl– channel family (CIC). (Duan et al.,
1997). The aim of this work was to identify the volume-regulatory Cl– currents in the
ZR-75-1 cells using a hypertonic pipette solution in the whole-cell patch-clamp config-
uration. The molecular identity of this channel was also investigated using RT-PCR.
Cells bathed in NaCl isotonic saline (pH7.4; 285 mOsm/kgH2O) and dialysed with
hypertonic pipette solution (pH7.4; 370 mOsm/kgH2O) containing 5 mM ATP,
displayed an initial maximum outward Cl– current of 1.7±0.4 pA/pF (n=7, mean
±SEM). After 10–15 m the maximum outward Cl– current increased to 8 ±0.86 pA/pF
(P<0.001 paired t-test). The current was outwardly rectifying and inactivated at depo-
larising potentials. The reversal potential, –40 mV was the same as the equilibrium
potential for Cl–, indicating the current was carried by Cl–. The maximum outward
current was inhibited by 100 mM DIDS 60–80% (n=3). Total RNA from ZR-75-1
cells was reversibly transcribed into first strand cDNA in an oligo (dT) primed reac-
tion using AMV RT and PCR carried out using the specific primers for CIC2, CIC3,
CIC5, CIC6 and pIcl. Products were identified for all except CIC6.
This study identifies a functional volume-regulatory Cl– current in the ZR-75-1
cells and the mRNA for the ClC2, ClC3, ClC5 and pIcl. P-glycoprotein and pIcl are not
thought to be Cl– channels or part thereof, and previous results have shown that the
ZR-75-1 cells do not possess the mRNA for the MDR1 P-glycoprotein (Killey et al.,
1999). When expressed in apical membrane vesicles of HT29 cells, the characteristics
of ClC2 differ from native Iclvol. The properties of expressed ClC3 and ClC5, however,
have been shown to be similar to native Iclvol. This means that the most likely candidate
for Iclvol is ClC3 and/or ClC5 (Hagos et al., 1999). Future work will investigate the
characteristics of the volume regulatory Cl– conductance in ZR-75-1 cells to confirm
the molecular identity.
Duan D, Winter C, Cowely S, Hume JR, Horowitz B (1997) Nature 390: 417–421
Hagos Y, Krick W, Burckhardt G (1999) Eur J Physiology 437: 724–730
Killey J, Nicholl AJ, Saul MW, Garner C (1999) J Cancer Research: 40P, 46P
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VOLUME REGULATION IN BREAST CANCER CELLS USING
A VIDEO-IMAGING TECHNIQUE AJ Nicholl*, J Killey and C
Garner, Dept of Chemical and Biological Sciences, University of
Huddersfield, Queensgate, Huddersfield HD1 3DH, UK
Most mammalian cells are able to regulate their volume when challenged with
changes in osmolality. A decrease in external osmolality causes cell swelling as water
enters. Transport pathways allow efflux of Cl– and K+ with water following passively,
this is known as regulatory volume decrease (RVD). An increase in external osmo-
lality causes cell shrinkage as water leaves. Transport pathways allow a net influx of
K+ and Cl– and water enters passively, this is known as regulatory volume increase
(RVI; Sachs, 1996).
This study investigates the mechanisms by which the epithelial derived human
breast cancer cell line ZR-75-1 regulates its volume. Cells were bathed in HCO3
–
buffered isotonic solution at 22 °C for 3 min, exposed to either a hypotonic or hyper-
tonic solution for 15 min before being returned to isotonic solution for a further 12
min. Photographs were taken every minute and the area in pixels measured using the
Scion Image computer software package. Volume was then calculated and expressed
as relative volume (mean ± SEM) with respect to control values (Park et al., 1994) and
% RVD or RVI was calculated. The role of ion channels, co-transporters and
exchangers was investigated using specific inhibitors.
In 30% hypotonic solutions the cells swelled to 1.23 ± 0.040 (n = 7) in 4 min and
recovered to 1.10 ± 0.026 within 15 min (56% RVD). RVD was reduced to 8.7% (n =
6) by 10 mM Tamoxifen and 10.7% (n = 7) by 100 mM DIDS suggesting the involve-
ment of a volume regulated Cl– channel. In 30% hypertonic solutions cells shrunk to
0.84 ± 0.004 (n = 7) in 3 min and recovered to 0.96 ± 0.010 within 15 min (75% RVI).
RVI was reduced to 40% (n = 6) by 500 mM DIDS, an inhibitor of the Cl–-HCO3
exchanger, 17.6% (n = 7) by 10 mM amiloride, an inhibitor of the Na+-H+ exchanger
and 13.3% (n = 7) by 20 mM bumetanide, an inhibitor of the Na+-K+-2Cl– co-trans-
porter. These results indicate the involvement of each of these exchangers and co-
transporters in RVI.
In conclusion, ZR-75-1 cells act as perfect osmometers and are capable of both
RVD and RVI. RVD involves volume regulated Cl– channels and probably K+ chan-
nels. RVI involves uptake of Na+ and Cl– via the coupled Na+-H+ and Cl–-HCO3
–
exchangers or via the Na+-K+-2Cl– co-transporter. The accumulated Na+ is then
exchanged for external K+ via the Na+K+ ATPase pump, resulting in the net accumula-
tion of KCl (Sachs, 1996).
Sachs JR (1996) Molecular Biology of membrane transport disorders, edited by SG
Schultz et al. Plenem Press, New York 379
Park KP, Beck JS, Douglas IJ Brown PD (1994). Journal of Membrane Biology 141:
193
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ABROGATION OF SIGMA-MEDIATED SURVIVAL LEADS TO
APOPTOTIC DEATH OF TUMOUR CELLS BA Spruce1, J
Samson1, D McLean1, L Copeland2, L Campbell1 J Howie1, D Belelli2, J
Lambert2, A Thompson1, S Eccles3, 1Depts of Surgery and Molecular
Oncology, and 2Pharmacology and Neurosciences, University of Dundee,
Ninewells Hospital and Medical School, Dundee DD1 9SY; and 3Institute of
Cancer Research, McElwain Laboratories, Sutton, Surrey SM2 5NG, UK
Sigma receptors, once classed as members of the opioid receptor family, are now
known to be molecularly distinct; a functional relationship exists, nonetheless. We
have discovered that opioid systems participate in regulation of the apoptotic cell
death programme and are dysregulated in tumorigenesis. Sigma receptors (subtypes 1
and 2), which reside at least partly on the endoplasmic reticulum, are widely present in
human tumours in vivo and in vitro; an overabundance of sigma receptors in tumour
compared to non-tumour tissues has permitted specific sigma ligands to be used in
PET scanning for diagnostic tumour imaging. The biological significance of sigma
receptors in the genesis of tumours is unknown.
We have shown that sigma ligands which are generally perceived to be antago-
nistic in their action (such as rimcazole and haloperidol) induce programmed cell
death in tumour cell lines. Death induction by sigma antagonists does not require the
presence of functional p53 protein, although modestly overexpressed p53 enhances
their pro-apoptotic effect. Although death is induced in a range of tumour cell types,
we have chosen to focus on breast carcinoma, in particular hormone insensitive, cells.
This was partly because some oestrogen receptor negative breast cancer cells have
constitutively activated NFkappaB which enhances sigma ligand-induced death. RT-
PCR analysis has revealed that breast carcinoma cell lines express the sigma-1
receptor subtype; radioligand binding assays have confirmed the existence of high
affinity sigma ligand binding sites on breast carcinoma cell membranes. We are
extending these analyses to excised human breast tumour specimens.
Transient overexpression of the sigma-1 receptor, cloned from human breast
cancer cells, markedly protects transformed human epithelial cells from p53-and Bax-
induced apoptosis. In vivo experiments are underway to address anti-tumour proper-
ties of sigma ligands. These data indicate an anti-apoptotic function of the sigma-1
receptor, on which tumour cells have become reliant. This may provide a new thera-
peutic opportunity, particularly applicable to tumours which are resistant to existing
treatments.
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5 ASA UPREGULATES 5FU INDUCED BAX EXPRESSION IN
COLON CANCER CELLS IN VITRO *D Adeyemo, S Toffa, M
Lowdell¶ and M Winslet, Academic Departments of Surgery and
Haematology¶, Royal Free and UCL Hospital Pond Lane, London NW3 2QG,
UK
Background 5FU action in advanced colon cancer is by induction of apoptosis.
Apoptosis in mammalian cells is regulated by the Bcl-2 class of proteins comprising
the anti-apoptotic Bcl-2, Bcl-x, Mc1 and the pro-apoptotic Bax, Bad, Mad, Bak etc
(1). NSAIDs induce apoptosis and reduce proliferation in colon cancer cell lines,
lower incidence of colorectal cancer in humans while cause colon polyp regression
(2). Epidemiological studies also found lower incidence of colon cancer in inflamma-
tory bowel disease patients managed on 5 aminosalicylic acid or sulphasalazine than
in the population at large(3).
Aim To evaluate additive effects if any, of 5 Aminosalicylic acid at colon concen-
trations on 5FU induced upregulation of Bax expression in colon cancer cells in vitro.
Materials and Methods Colo 201 and Colo 205 cells were cultured for 72 hours
with 5 ASA, 5FU alone or combination of 5FU and 5 ASA. The cells were
trypsinised, fixed, permeabilised and stained with anti-Bax antibody. Phycoerythrin
labelled secondary was added. 104 cells were analysed by flow cytometry. Bax expres-
sion was recorded as the difference between test and isotype control fluorescent
values. Upregulation of Bax expression was calculated as test: control ratio.
Concentrations used: 5 ASA 7 mM, 5FU-0.1 mM for Colo 201 and 1 mM for Colo
205.
Results
5FU only 5 ASA 5 ASA + 5FU
Colo 201 1.1 (0.1) 1.1 (0.3) 3.3 (0.1)
Colo 205 1.0 (0.1) 0.9 (0.03) 4.1 (0.7)
Bax fluorescence ratios n = 3 sd – ().
Conclusion Apoptosis is associated with significant upregulation of Bax expres-
sion. The above findings suggest additive pro-apoptotic effects of 5 ASA and 5FU in
vitro. 5 ASA absorption is minimal, therefore concentrations employed in this study
far exceed serum levels. Well tolerated and better absorbed NSAIDs may however
augment 5FU chemotherapy in the systemic management of advanced colon cancer.
1 Oltvai NZ, Milliman CL, Korsmeyer SJ (1993) Cell 74: 609
2 Goldgerg Y, Nassif I, Pittas A, et al (1996) Oncogene 12: 893
3 Moody G, Probert J, Kay H, Mayberry J (1996) Euro. Jo. Of Gastroenter and
Hepatol 8(12): 1179
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ANTIOXIDANTS AUGMENT 5FU UPREGULATION OF BAX
EXPRESSION IN COLON CANCER CELLS IN VITRO
*D Adeyemo, S Toffa, M Lowdell1 and M Winslet, Academic Departments of
Surgery and Haematology1, Royal Free and UCL Hospital, Pond Street,
London NW3 2QG, UK
Background Chemotherapeutic action of 5FU in advanced colon cancer is by induc-
tion of apoptosis. Alteration of cell thymidylate metabolism by Folinic acid improves
its poor response rate (1).
Apoptosis in mammalian cells is regulated by the Bcl-2 class of proteins
comprising the anti-apoptotic Bcl-2, Bcl-x, Mc1 and the pro-apoptotic Bax, Bad,
Mad, Bak etc (3). Oxidative DNA damage in cells is implicated in oncogenesis and
continuing mutation possibly leading to drug resistance. Reactive oxygen species in
submicromolar concentrations also act as signal transducers in cancer cells (2).
Aim To evaluate the effect of oxidant quenching on 5FU induced upregulation of
Bax expression in colon cancer cells in vitro.
Materials and Methods Colo 201 and Colo 205 cells were cultured for 72 hours
with N Acetyl Cysteine, Vitamin E or 5FU alone or a combination of 5FU and one of
the antioxidants. The cells were trypsinised, fixed, permeabilised and stained with
anti-Bax antibody. Phycoerythrin labelled secondary was added. 104 cells were
analysed by flow cytometry. Bax expression was recorded as the difference between
test and isotype control fluorescent values. Upregulation of Bax expression was calcu-
lated as test: control ratio. Concentrations used: 25 mM NAC, 5 mM Vit. E, 5FU –0.1
mM for Colo 201 and 1 mM for Colo 205.
Results
5FU only NAC Vit. E NAC + 5FU Vit. E +
5FU
Colo 201 1.1 (0.1) 0.5 (0.1) 0.9 (0.2) 2.7 (0.4) 3.0 (0.4)
Colo 205 1.1 (0.1) 1.1 (0.5) 0.9 (0.3) 2.7 (0.4) 3.1 (0.6)
Bax fluorescence ratios n=4 sd –().
Conclusion Apoptosis is associated with significant upregulation of Bax expres-
sion. The above findings suggest that redox status alteration increase colon cancer cell
susceptibility to 5FU in vitro. This is consistent with published reports. Oxidant
quenching may act by abrogating continuing mutation and interfering with intracel-
lular signal transduction. If reproduced in vivo, with tolerated doses of antioxidants,
improved response rates and/or reduced toxicity or perhaps both may be achieved
with antioxidant/5FU combination.
1 Colucci G, Gebbia V et al (1999) Cancer 85(3): 535
2 Factor VM, Kiss A et al (1998) The Jo Of Biol Chem 273(25): 15846
3 Oltvai NZ, Milliman CL, Korsmeyer SJ (1993) Cell 74: 609
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bFGF-INDUCED CELL DEATH OF EWING’S SARCOMA IS
ASSOCIATED WITH ARREST OF CELLS AT THE G1
CHECKPOINT AND ACTIVATION OF PRB1 *G Westwood and SA Burchill,
Candlelighter’s Children’s Cancer Research Laboratory, ICRF Cancer
Medicine Research Unit, St. James’s University Hospital, Leeds LS9 7TF, UK
bFGF has been implicated in a multitude of physiological and pathological processes
including limb development, angiogenesis, wound healing and tumour growth. It has
been shown to be a potent mitogen for oligodendrocytes, schwann cells and astro-
cytes, and plays an important role in early neural crest development where it triggers
mitosis and later commits cells towards a neural lineage. However, we have recently
shown that bFGF decreases cell growth induced by cell death in the neural crest
derived Ewing’s sarcomas (1). The aim of this study was to investigate the effects of
bFGF on the cyclin complexes that exert positive and negative control on the progres-
sion of cells through the G1 phase of cell cycle in Ewing’s sarcoma cell lines.
To characterise the mechanism of bFGF-induced cell death, cultures were synchro-
nised and changes in cell cycle profile were identified by labelling with propidium
iodide and FACs analysis. Two Ewing’s sarcoma cell lines in which bFGF induced
cell death (TC-32 and TTC-466), and one that did not respond to bFGF (A673) were
studied. Regulation of cyclin complexes at the protein level was characterised by
Western blotting and densitometry using mouse monoclonal antibodies against p53,
p21, p27, cyclin D1, cyclin E, cyclin A, pRb1 and PCNA. In the TC-32 and TTC-466
cell lines, a significant decrease in the proportion of cells found in the G1 phase of cell
cycle was observed after treatment with bFGF (10 ng/ml) for 48 h (p<0.05) or 72 h
(p<0.001). This was characterised by the upregulation of p21, p27 and p53, downreg-
ulation of PCNA and cyclin A and dephosphorylation of pRb1. Cyclin D1 and cyclin
E levels were unchanged. bFGF (10 ng/ml) induced cell death was not observed in the
Ewing’s sarcoma cell line A673 (1) and had no effect on the proportion of these cells
in the G1 phase of cell cycle, phosphorylation state of pRb1 or the regulation of
PCNA.
In summary, proteins responsible for the control of G1 arrest are implicated in
bFGF-induced cell death in Ewing’s sarcoma, resulting in activation (dephosphoryla-
tion) of pRb1. We are currently investigating the expression of cell death associated
proteins and their relationship with cell cycle regulation.
1 Sturla, L et al (2000) Cancer Research. Submitted.
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THE DELAYED ACTION OF THE SPINDLE CHECKPOINT IN
P53 MUTATED LYMPHOID TUMOUR CELLS A Ivanov1, MS
Cragg2, TM Illidge2,3, Je Erenpreisa1, 1Laboratory of Tumour Cell Biology,
2Biomedicine Centre, University of Latvia, Riga; 2Tenovus Research
Laboratory; 3CRC Department of Oncology, Cancer Sciences Division,
Southampton General Hospital, Southampton University SO16 6YD, UK
After DNA damage p53 mutated tumours are associated with abrogation of the G1/S
checkpoint, delay and further adaptation of the G2 checkpoint and subsequent aber-
rant mitoses. Little is currently known regarding the fate of these mitoses. Given the
well-documented differences in DNA damage sensitivity of wild-type (wt) and mutant
(mut) p53 cells we therefore investigated these events in a variety of human
lymphoblastoid cell lines with differing p53 status after irradiation with doses of 5, 10
and 15 Gy.
After 5 Gy, TK6 (p53 wt) cells undergo partial arrest in metaphase at the first cycle
and then restitute normal mitotic events from day 5 onwards. After 10 and 15 Gy
however, the majority of cells fail to enter mitosis and subsequently die. In contrast,
the behaviour of p53 mut (W1-L2-NS) cells is strikingly different. Firstly, after 5 Gy,
cells exhibit delayed recovery from day 7 onwards. Secondly at all 3 doses of irradia-
tion p53 must cells undergo 2–3 cycles of aberrant mitoses followed by full arrest in
metaphase, starting from day 4. This arrest is prolonged and dose dependent.
Interestingly, cells arrested in metaphase have three potential fates. These include; (1)
release into anaphase, (2) apoptosis, and (3) restitution into polyploid interphase. The
first pathway occurs most frequently for p53 wt cells after 5 Gy, whilst the third
occurs only in p53 mutated cells. Furthermore, the accumulation of cells arrested in
metaphase appears directly proportional to the time spent in metaphasic arrest and is
inversely proportional to the rate of the diploid cell line recovery, as well as the length
of time spent arrested in G2. Such mitotic events may therefore be used as an indirect
indicator of the DNA damage repair efficiency at interphase checkpoints. Our data
indicate for the first time that the spindle checkpoint is delayed in p53 mutated cells.
We believe this delay is due to failure of the sensing machinery such that the check-
point is only engaged when the chromosome aberrations accumulated through several
cell cycles are finally sufficient to prevent the p53 mut cells from propagating the
grossly damaged genome. However, it would also appear that this control can be over-
ridden by mitosis restitution.Poster Presentations 59
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CAFFEINE TRIGGERS EXIT FROM M PHASE INTO
ENDOREDUPLICATION CYCLE AND APOPTOSIS AFTER
IRRADIATION IN P53 MUTATED BUT NOT P53 WILD TYPE CELLS
A Yiakouvaki1, MS Cragg2, Je Erenpreisa3, TM Illidge1,2 1CRC, Department of
Oncology, Cancer Sciences Division, Southampton General Hospital,
Southampton University S016 6YD UK; 2Tenovus Research Laboratory;
3Laboratory of Tumour Cell Biology, Biomedicine Centre, University of Latvia,
Riga
Caffeine is known to potentiate the cytotoxic effects of DNA damaging agents and
increase the sensitivity of p53-deficient cells to irradiation (IRR). We investigated the
cell cycle effects after IRR in the presence and absence of caffeine in haematological
cell lines with p53 mutant and p53 wild type status. p53 mutant lines displayed an
impaired G1 checkpoint and dose dependent G2/M arrest following IRR. This G2
delay was abrogated in the presence of 2.5 mM caffeine by inactivation of p34Cdc2
kinase leading to cycle progression. Interestingly the decrease in p34Cdc2 activity
correlated with an increase of cells in G1 and a highly significant (3-fold) increase in
the number of polyploid cells. This dramatic increase in polyploid cells initiated by
Caffeine suggests a switch from mitotic to endoreduplication cycle in these cells. The
subsequent breakdown of these polyploid giant cells represents the major source of
the highly significant (P<0.01) increase in apoptosis seen within the first 144 hours for
p53 mut cells treated with IRR in presence of 2.5 mM Caffeine but not seen with p53
wt cells. We have subsequently followed the fate of these polyploid cells with separa-
tion experiments and strongly believe that they represent an important source of mitot-
ically competent cells that bring about the recovery of the stem-line. Therefore these
results indicate that the cell cycle regulatory activities of caffeine are distinct from the
cytocidal activity reported and that p53 mutated cells are capable of switching from
mitotic to endoreduplication cycle and back again to mitotic cycle. Overall this data
suggest that this tumour specific switch may be a therapeutically exploited strategy for
overcoming the resistance of p53-deficient cancers to anti-cancer treatments.
P122
HYPOXIC ACTIVATION OF NFkB IN MCF-7 AND T47D CELLS
DOES NOT INVOLVE DEGRADATION OF 1kBA
CA Parker*, CE Lewis & JA Royds, Division of Oncology and Cellular
Pathology, University of Sheffield Medical School, Beech Hill Road, Sheffield
S10 2RX, UK
Hypoxia which occurs as a consequence of disorganised vasculature within solid
tumours, has been implicated in tumour progression and resistance to treatment. The
transcription factor NFkB responds to a diverse range of stress signals including
hypoxia and has a role in cell survival, protecting cells against apoptosis. 1kBa regu-
lates NFkB by sequestering it in the cytoplasm and Ubiquitin-mediated degradation of
1kBa allows NFkB to translocate to the nucleus. Activation of NFkB by hypoxia may
be one mechanism by which tumour cells can survive low oxygen conditions.
Nuclear and cytoplasmic extracts from T47D and MCF-7 breast carcinoma cell
lines cultured under normoxic and hypoxic (0.5%O2) conditions were assayed by
western blotting for RelA (a NFkB family member) and 1kBa protein levels.
RelA and 1kBa were confined to the cytoplasm in both cell lines under normoxic
conditions, but within 30 mins of hypoxia RelA appeared in the nucleus of T47D cells
and remained until after 24 hours. However, in MCF-7 cells nuclear expression of
RelA did not occur until 2 hours of hypoxia and only continued until 12 hours. 1kBa
was consistently present in the cytoplasm in both cell lines, but approximately 1 hour
following RelA expression in the nucleus 1kBa also appeared in the nucleus and
persisted until RelA was absent from the nuclear fraction.
Hypoxia causes nuclear translocation of NFkB and T47D cells exhibit a more
rapid and prolonged activation than that seen in MCF-7 cells. In contrast to reports for
other stimuli, hypoxia does not result in significant degradation of 1kBa. This could
suggest an alternative mechanism for 1kBa regulation of NFkB. The presence of
1kBa in the nucleus following RelA translocation may indicate that 1kBa may have
another level of regulation by directly attenuating the NFkB response.
This work is supported by Yorkshire Cancer Research.
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NUCLEAR FACTOR KAPPA B (NF-kB) AND PANCREATIC
CANCER TREATMENT Y Kyung Kang, JP Neoptolemos and E
Costello, Department of Surgery, University of Liverpool, UK
Pancreatic ductal adenocarcinoma shows especially poor responses to cytotoxic ther-
apies; the mortality at one year is 90% and nearly 100% at five years. A common clin-
ical problem in human cancer treatment is resistance of tumours to chemotherapy.
Apoptosis seems to be a principle means whereby anti-cancer therapies such as
chemotherapy and radiation exert their responses. Cell death induced by
chemotherapy and radiation requires the activation of the caspase cascade, leading to
proteolytic cleavage of a variety of important proteins and ultimately cleavage of
cellular DNA. The induction, in some cancer cell lines, of the transcription factor
NFkB however, in response to chemotherapy and radiation potently suppresses apop-
tosis. NFkB has been reported to be constitutively activated in pancreatic cancer
tissue but not in normal pancreas.
Aim To establish whether NFkB is further induced in response to cytotoxic drugs.
Methods Electrophoretic mobility shift assays were carried out with nuclear
extracts from six pancreatic cancer cell lines, Suit-2, MiaPaCa, BxPc3, Pancl,
CFPAC1 and AsPc1 treated with five different cytotoxic agents, TNFa, Gemcitabine,
5-Fluorouracil, Daunorubicin and CPT11.
Results NFkB activation was observed in all cell lines in response to treatment
with certain cytotoxic drugs. The level of NFkB induction varied from cell line to cell
line and was more pronounced with some cytotoxic drugs than with others in a cell-
line dependent manner.
Conclusions NFkB activation occurs in pancreatic cancer cell lines in response to
treatment with cytotoxic drugs. We are currently investigating whether the induction
of NFkB following cytotoxic drug treatment affects cell viability, and if so whether
inhibiting its activity, through a gene therapy approach, can enhance the efficiency
with which chemotherapeutic compounds kill pancreatic cancer cells.
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EXPRESSION OF CYCLIN D1, CYCLIN E AND P27KIP1 IN
SCHISTOSOMAL VERSUS NONSCHISTOSOMAL BLADDER
CANCER AA Khan1, KS Chaudhary1, PD Abel2, AM Shoma3, M El Baz3,
GWH Stamp1 and E-N Lalani1, Depts of 1Histopathology and 2Surgery,
Imperial College School of Medicine, Hammersmith Campus, London W12
0NN and 3Dept of Pathology; Mansoura University, Egypt
Schistosomal bladder cancer is considered clinically more aggressive than its
nonschistosomal counterpart but the molecular mechanisms underlying this difference
are not clear. Altered expression of the GI-S checkpoint regulators, cyclin D1, cyclin
E and p27Kipl is frequently observed in many human tumours, including bladder
cancer. We compared the immunohistochemical expression of these important cell
cycle regulators and the proliferation marker, Ki-67 in 29 invasive non-schistosomal
transitional cell carcinomas (TCC) with 20 invasive schistosomal bladder carcinomas,
including 10 squamous (SCC) and 10 transitional cell subtypes. Well-characterized
monoclonal antibodies were used. For each marker, the percentage of immunoreactive
tumour cell nuclei was determined and expressed as an index. Mean staining indices
were used to compare subgroups. Overall, the Ki-67 proliferative index was signifi-
cantly higher in the schistosomal group when compared with the nonschistosomal
group (P = 0.001). However, cyclin D1 and E expression was significantly lower in
the schistosomal group (P = 0.02 and 0.01, respectively). Within the schistosomal
group, TCCs displayed significantly higher expression of cyclin E (P = 0.006) when
compared with SCCs. In contrast, the Ki-67 index was higher for the SCC subgroup,
although this difference did not reach statistical significance. Schistosomal TCCs and
SCCs were comparable with respect to tumour grade, pathologic stage and expression
of p27Kipl and cyclin D1. Furthermore, no significant differences were observed
between nonschistosomal and schistosomal TCCs with regard to any of the markers
studied.
These results suggest that cyclin E expression is significantly associated with TCC
regardless of etiology. Moreover, the higher proliferative index of SCCs observed in
this study is consistent with their more aggressive clinical behaviour.60 Poster Presentations
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A NOVEL MDM2 BINDING PROTEIN (MTBP) INDUCES A G1
ARREST THAT IS SUPPRESSED BY MDM2 Nikolina
Vlatkovic, Conor Magee and *Mark T. Boyd, Dept of Surgery, University of
Liverpool, 5th Floor UCD, Daulby Street, Liverpool L69 3GA, UK
The MDM2 protein, through its interaction with p53 plays an important role in the
regulation of the G1 checkpoint of the cell cycle. In addition to binding to and
inhibiting the transcriptional activation function of the p53 protein, MDM2 binds,
inter alia, to RB and E2F-1 and in so doing may promote progression of cells into S-
phase. Mice transgenic for MDM2 possess cells that have cell cycle regulation defects
and develop an altered tumour profile independent of their p53 status. MDM2 also
blocks the growth inhibitory effects of TGF-b1 in a p53 independent manner. To iden-
tify the pathway/s that mediate these p53-independent (or downstream) effects of
MDM2 we have sought to identify novel MDM2 interacting proteins.
We have identified a novel gene that encodes an MDM2 binding protein hence
Mdm Two Binding Protein (MTBP). We have confirmed this interaction in yeast, in
vitro and in mammalian cells in culture. MTBP is a 104 kD protein with no extensive
detectable homology to other database sequences from higher eukaryotes. FASTA
analysis of the Sacharromyces cerevisiae genome database identified two proteins
Boi1p and Boi2p that possess 20–21% amino acid identity to MTBP in a 400 amino
acid stretch. These molecules are both part of a G-protein dependent signal transduc-
tion pathway that regulates bud formation. Ectopic expression of Boi1p and Boi2p
leads to growth arrest in yeast. Coincidentally, ectopic expression of MTBP leads to
growth arrest in a variety of human tumour cell lines to a similar degree to that
induced by p53. Flow cytometric analysis demonstrated that the growth inhibition
induced by MTBP is a result of an induction of G1 arrest. We therefore examined
whether MDM2 could abrogate this growth arrest much as it does for p53 and found
that this is indeed the case. We are currently investigating the normal function of
MTBP using anti-MTBP sera. We are also investigating the mechanism by which
MTBP induces growth arrest. These data will also be presented. Our results suggest
the existence of an additional growth control pathway that may be regulated, at least
in part, by MDM2.
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IN VIVO VARIATION OF P53 EXPRESSION IN RESPONSE
TO SERUM OESTROGEN CONCENTRATIONS IN MCF7
BREAST CANCER XENOGRAFTS D Ziyaie1, D Dornan2, TR Hupp2, NM
Kernohan2, AM Thompson1, 1Dept. of Surgery & Molecular Oncology, 2Dept
of Molecular & Cellular Pathology, University of Dundee DD1 9SY, UK
Functional inactivation of otherwise normal, wild-type p53, whereby the p53 tumour
suppressor activities could be inactivated by mechanisms other than p53 gene muta-
tion, has been described in many forms of human cancer. Models describing mecha-
nisms of p53 activation have demonstrated that, in response to cellular damage, p53
can (a) become activated and stabilised, (b) be activated in the absence of protein
stabilisation or (c) despite being activated, exhibit reduced p53 protein levels.
We have investigated the in vivo variation of p53 expression in response to serum
oestrogen concentrations in a xenograft model (ref) established from an MCF-7 breast
cancer cell line, which contains wild-type p53. Western blot analysis results have
demonstrated a distinctive pattern of p53 immuno-reaction in response to alterations
of serum oestrogen concentrations. We observed that p53 protein levels were reduced
in response to increasing levels of serum oestrogen, during which tumour kinetics in
terms of growth rate reached maximum; conversely, p53 levels rose concomitant with
the lowering levels of oestrogen, coinciding with static or minimal tumour growth.
This inverse correlation between p53 protein expression and serum oestrogen
concentration suggests that oestrogen may either act as an inhibitor for p53 activation
by promoting its degradation, or may be a p53 activator in a dose-dependent manner,
despite the initial apparent lower levels of the p53 protein.
These data highlight (a) the importance of serum oestrogen concentration as an
adjunct to p53 expression for in vivo studies and (b) the possibility of a dual role of
action for oestrogen in the pathogenesis of breast cancers, acting not only as a true
mitogen but also as a tumour behaviour-modifying agent.
AM Thompson, CM Steel, ME Foster, D Kerr, D Paterson, D Deane, RA Hawkins,
DC Carter & HJ Evans (1990) Gene expression in oestrogen-dependent human
breast cancer xenograft tumours. Br J Cancer 62: 78–80
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THE STUDY OF DNA-INDUCED P53 CLEAVAGE PRODUCT
WITH INDUCIBLE SYSTEM IN VIVO Ming Jiang* and Jo
Milner, p53 Research Group, Yorkshire Cancer Research, Department of
Biology, University of York, York YO10 5DD, UK
The p53 tumour suppressor gene plays a central role in the regulation of cell growth
and is inactivated by mutation in more than 50% of human cancers. The p53 protein is
activated in response to DNA damage by recognising and binding sides of DNA
damage, determining the cells towards arresting or apoptosis. The previous work has
found that the different damaged DNAs could induce different cleavages of p53 in
vitro, but they all generate a key product of 35 kDa peptide that encompasses the p53
DNA-binding domain (1,2). The p35 cleavage product has protease activity and is
able to cleave the N-terminus of full-length p53 to generate p50 (DN23) (2).
In order to investigate the functions of p53 cleavage products, we are using two
inducible systems: TET-ON and LAC-ON. Both TET-ON and LAC-ON expression of
p35 were shown to be dose dependent and reversible. Importantly the p35 core
domain adopted the ‘wild type’ conformation for p53 (246+/1620+/240) and was both
cytoplasmic and nuclear. Evidence that p35 can induce G1 arrest and trigger cell
apoptosis after DNA damage in p53-null fibroblasts will be presented. In addition, we
observed cleavage of full-length endogenous p53 in T3T3 cells expressing p35,
consistent with the amino peptidase activity previously observed in vitro (see above).
Our results indicate that the p35 cleavage product of p53 may function during the p53
responses to DNA damage in vivo.
1. Molinari M, Okorokov A and Milner J (1996) Interaction with damaged DNA
induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa
fragments competent for sequence-specific DNA binding. Oncogene 13:
2077–2086
2. Okorokov A, Ponchel F and Milner J (1997) Induced N- and C-terminal
cleavage of p53: a core fragment of p53, generated by interaction with damaged
DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA
induces C-terminal cleavage of p53. EMBO J 16(19): 6008–6017
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EVALUATION OF TYROSINASE STANDARD VS.
LIGHTCYCLERTM RT-PCR IN MELANOMA PATIENTS
1Konstantin Stoitchkov, 2Thierry Le Bricon, 1National Center of Oncology. Sofia,
Bulgaria, 2Laboratory of Biochemistry A, Saint-Louis Hospital, Paris, France
Malignant melanoma (MM) is the most aggressive skin cancer. There is still need of reliable
laboratory test for early detection of metastasis and residual disease to monitor therapy or to
contribute to individual and overall prognosis.
The development of RT-PCR has made the search of circulating melanoma cells in periph-
eral blood possible. Tyrosinase seems to be the most appropriate target by now. In a previous
study, we found RT-PCR positive in only 1 of 10 stage III and 3 of 20 stage IV melanoma
patients. In the present study we investigated the influence of different RT-PCR techniques on
tyrosinase positivity in melanoma patients with an emphasis on cDNA quality control.
Ten healthy subjects, six nonmelanoma skin cancer patients and 53 melanoma patients
from Sofia, Bulgaria entered the study. Longitudinal studies were performed in 47 melanoma
patients. A total number of 143 blood samples were analyzed. All samples after Ficoll treat-
ment were carried in Paris. France for acid guanidinium thiocyanate-phenol-chloroform
RNA extraction and reverse transcription. PCR were performed in 2 different laboratories
using different protocols: 1/ in Paris on an HYBAIDtm PCR machine and 2/ in Berlin.
Germany* on a LightCyclert.m. instrument (Roche). Total cellular RNA was reverse tran-
scribed with random hexamers and HTYR2 antisense primers for stage III and IV patients.
cDNA were stored at – 20°C before PCR. In both laboratories, blood mRNA integrity was
checked by PCR with primers for human b-2-microglobulin. PCR analysis of tyrosine tran-
scripts was performed using nested PCR as previously described by Smith et al. PCR
kinetics observed on the LightCycler system for b-2-microglobulin of tyrosinase RT-PCR
positive samples paralleled that of the positive control. Only 2 stage IV patients out of 11
were found tyrosinase positive by standard PCR and by the LightCyclertm system (one
reverse transcribed with random hexamers, one with specific antisense primer).
Cancer cell RNA from peripheral blood is generally obtained after gradient centrifugation
or whole blood processing. We obtained excellent RNA quality after storage of Ficoll-treated
samples at –80°C and transportation of samples in dry ice. While commercial kits work well
on cultured cell lines, we recommend the use of the Chomezynski method for RNA extraction
of clinical samples. The use of random oligo nuclcotide sequences as primers to generate
cDNA or gene-specific sequences could lead of detecting or loosing positive signals, so it
might be appropriate to do both. The LightCyclertm system allows the evaluation of cDNA
quality by following kinetic aspects of housekeeping gene PCR. Poor cDNA quality might be
considered as one of the possible reasons for low positivity rate of tyrosinase mRNA.
RT-PCR in peripheral blood as staging test for melanoma patients must be interpreted
cautiously. A consensus for standardization of the RT-PCR technique for tyrosinase mRNA
in peripheral blood is needed to make possible the comparison of results. It should include
reliable quality control assays for each step of the technique. The LightCyclert.m. system,
easy to run might be useful to monitor cDNA quality and further to quantify amplified PCR
products.Poster Presentations 61
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ADJUVANT INTERFERON a IN HIGH RISK RESECTED
MELANOMA APPEARS TO PROLONG DISEASE-FREE
SURVIVAL *DA Cameron1, MC Cornbleet1, RM Mackie2, JAA Hunter3, B
Hancock4, M Gore5, JF Smyth1 on behalf of the Scottish Melanoma Group,
1Western General Hospital & 3Royal Infirmary, Edinburgh, 2Western Infirmary
Glasgow, 4Weston Park Hospital Sheffield & 5Royal Marsden
Recent data suggest that for patients with stage II malignant melanoma, low dose
interferon a may result in a disease-free survival advantage1,2. In March 1989, the
Scottish melanoma group began a randomised study of a-Interferon for patients with
surgically treated primary malignant melanoma who were at high risk of subsequent
relapse. Patients were eligible if they had had a fully resected primary melanoma > 3
mm Breslow (stage II), or with regional node involvement (stage III). By August
1993, when the study was closed, 49 patients had been randomised to receive
Interferon  a 2b, 3MU (Schering-Plough) three times a week for six months, and 46
patients to observation only. The median age was 47 [range 16–79], with 35 (37%)
patients having stage II disease and 60 (63%) stage III. The two arms were well
balanced for age and stage. Patients were monitored monthly whilst on therapy, and
no serious toxicity was seen. At a minimum follow-up of 6 years, 70 (73%) of the
patients had relapsed (29% stage II, 71% stage III). Median disease-free survival was
extended from 9 months to 22 months for interferon treated patients, and median
overall survival from 27 to 38 months. These differences were not statistically signif-
icant, but are within the range reported from larger studies using higher doses and/or
longer duration of therapy.
Since the lack of a statistically significant survival advantage may be due to the
low number of patients recruited, these data suggest that even 6 months’ adjuvant
low-dose interferon may be beneficial in patients with high risk melanoma.
Confirmation of the possible survival advantage of this regimen can only come from
larger studies such as the AIM High trial, to which recruitment should be encouraged.
1 Grob JJ, Dreno B, de la Salmonière P, et al (1998) Randomised trial of
interferon a-2a as adjuvant therapy in resected primary melanoma thicker than
1.5 mm without clinically detectable node metastases. Lancet 351: 1905–1910
2 Pehamberger H, Soyer HP, Steiner A, et al (1998) Adjuvant Interferon Alfa-2a
treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:
1425–1429
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ADHESION-DEPENDENT CELL CYCLE CONTROL OF
MELANOCYTE-DERIVED CELL LINES R Gilchrist*, D
Jenkinson, RS Camplejohn, IR Hart, JF Marshall, Richard Dimbleby
Department of Cancer Research/ICRF Laboratory, Rayne Institute, St
Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK
We characterised a panel of C57/B1 mouse melanocyte-derived cell lines to study the
control mechanisms involved in adhesion-dependent and -independent growth (Br. J.
Cancer, 80(2), 25, 1999). Using BrdUrd labelling techniques we report that, in suspen-
sion, Melan-a (immortal melanocyte) cells arrest immediately in G1 whereas MT1.2
(polyoma middle T-transfected melanocytes), LTR Ras 3 (Ha-ras transfected
melanocytes) and B16F10 cells (melanoma) retain proliferative capacity of varying
degrees over a period of 24 hrs. G1-phase cell cycle control proteins have been exam-
ined during these adhesion-mediated changes. Western blotting revealed that p16 is
absent in all four cell lines (p16 is frequently deleted in melanoma). The pattern of Rb
expression and phosphorylation showed the expected correlation with adhesion-
dependent proliferation. In Melan-a cells, the unphosphorylated, hypophosphorylated
and hyperphosphorylated Rb bands are detectable after 24 hrs monolayer growth.
However, when cultured for 24 hrs in suspension, the hyperphosphorylated band is
absent leaving only hypophosphorylated and, to a lesser extent, unphosphorylated Rb
(60%:40%). No unphosphorylated Rb was detected in the remaining cell lines. In fact,
after 24 hrs monolayer growth, only hyperphosphorylated Rb was detected. Following
24 hrs suspension culture, the MT1.2 cells showed a reduction in hyperphosphory-
lated Rb with an increase in hypophosphorylated Rb (23%:77%) whereas the LTR Ras
3 and B16F10 cells expressed equal amounts of hyperphosphorylated and phosphory-
lated Rb. Melan-a cells appear to have a much reduced expression of total Rb
compared with the other three cell lines. P13-kinase activity has been implicated in
adhesion-independent cell survival and in the progression of growth factor-deprived
cells through the G1 phase of the cell cycle. We therefore analysed the role of P13-K in
adhesion-independent proliferation. Monolayer B16F10 and MT1.2 cells treated with
10 uM LY294002 for 16 hrs had reduced the S-phase fraction to 86% and 84% of the
control value respectively, whereas the S-phase fraction of non-adherent cells was
reduced to 41% and 43% respectively. These data correlated with a reduction in the
hyperphosphorylated form of Rb and an increase in hypophosphorylated Rb. Thus,
adhesion-independent growth of transformed cells of melanocytic origin appears to
require a P13K-activated pathway which may offer a means of targeting cancer cell
proliferation.
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THE ROLE OF MITOGEN ACTIVATED PROTEIN (MAP)
KINASES IN THE a-MSH MEDIATED MELANOGENIC AND
ANTI-PROLIFERATIVE RESPONSES OF B16 MELANOMA CELLS
KSM Smalley and T Eisen, Department of Oncology, University College
London, 91 Riding House Street, London W1P 8BT, UK
a-melanocyte stimulating hormone (a-MSH) is a 13-amino acid hormone which
exerts its physiological effects via interaction with a family of G protein coupled
melanocortin receptors (named MC1-MC5) (see Wikberg, Eur. J. Pharmacol. 375
295). A number of recent studies have implicated both the p38 and p44/42 mitogen
activated protein (MAP) kinases in cell differentiation. The aim of the current study
was to investigate the role of these kinases in the a-MSH-induced melanogenic and
proliferative responses of B16 murine melanoma cells.
Treatment of cells with a-MSH led to time-dependent phosphorylation of both p38
and p44/42 MAP kinases, albeit with differing kinetic profiles. Treatment of cells with
inhibitors of MEK1 (PD-98059, 10 mM) or phosphoinositide 3 (PI 3)-kinase, (wort-
mannin, 1 mM) inhibited a-MSH induced phosphorylation of p44/42 MAP kinase,
demonstrating that P13-kinase was activated upstream of MAP kinase. Incubation of
B16 cells in the presence of a-MSH (10 nM for 72 hours) was shown to induce
melanogenesis as measured by an extracellular melanin accumulation colormetric
assay (Siegrist & Eberle, Anal. Biochem. 159 191). Treatment of cells with inhibitors
of both protein kinase C (PKC) (Ro 31–8220, 2 mM) and p38 MAP kinase (SB
203580, 10 mM) were shown to significantly (P<0.05) inhibit the extent of a-MSH-
induced melanogenesis. Pre-treatment of cells with either wortmannin or PD-98059
did not significantly alter the extent of a-MSH induced melanogenesis. Application of
either kinase inhibitor alone induced increases in melanin production of 21.6 ± 6.4%
and 17.3 ± 4.7% of the response to a-MSH (10 nM), respectively. Incubation of B16
cells with increasing concentrations of a-MSH (10–10M – 10–6M) led to concentration
dependent inhibition of B16 cell growth (47.9 ± 4.1% of control values, pIC50 8.22 ±
0.08). Pre-treatment of cells with inhibitors of MEK1 or P1 3-kinase were shown to
potentiate the anti-proliferative effect of a-MSH (inhibition by 74.3 ± 4.5% and 71.6
± 1.1% of control values, respectively). In contrast, pre-treatment of cells with SB
203580 abolished the anti-proliferative effect of a-MSH. In addition, it was subse-
quently demonstrated that inhibition of either PKC or p38 MAP kinase in the absence
of a-MSH had no significant effects upon cell growth.
In summary, it appears that the a-MSH induced melanogenic and anti-proliferative
effects are transduced through activation of p38 MAP in B16 melanoma cells. It also
seems apparent that the constitutive activity of p44/42 MAP kinase is responsible for
B16 cell growth, as well as negatively regulating melanogenesis.
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THE ROLE OF P13-KINASE IN MIGRATION OF
MELANOCYTIC CELLS D Jenkinson*†, C Sawyer‡, IR Hart†, B
Vanhaesebroeck‡, JF Marshall†, † Richard Dimbleby/ICRF Laboratory,
Rayne Institute, St. Thomas’ Hospital, Lambeth Palace Road, London, 
‡Ludwig Institute for Cancer Research, Royal Free and University College
Medical School Branch, 91 Riding House Street, London, UK
PI3-kinase has been implicated in the control of cell migration, cell adhesion and
proliferation in various cell types. Recent work has indicated that the different PI3-
kinase p110 isoforms may control these different cellular functions. We have estab-
lished a panel of syngeneic mouse melanocyte derived cell lines which include
immortal melanocytes (Melan-a), transformed tumorigenic melanocytes (LTR Ras3
and MT1.2) and a metastatic melanoma (B16F10) and have examined the role that
PI3-kinase plays in the migration of these cells.
Using time-lapse video microscopy, combined with image analysis, we have
measured the rate of migration over 24 hours of these cells in ‘scratch wound’ assays.
Data showed B16F10 and MT1.2 had similar migratory rates (17.3 mm/hr and 18.0
mm/hr respectively), nearly double that of the LTR Ras3 (9.5 mm/hr) or Melan-a (10.9
mm/hr). Treatment with 10 mM of the PI3-kinase specific inhibitor, LY294002, did not
affect the rate of migration of either the LTR Ras3 (9.8 mm/hr) or Melan-a (9.8 mm/hr)
cell lines, whereas it reduced significantly the migration of both the MT1.2 (11.8
mm/hr) and B16F10 (10.3 mm/hr) cell lines. Confirmatory haptotactic migration
assays indicated that addition of LY294002 reduced the migration of B16F10 cells on
collagen types I and IV, but not on laminin substrates. These results imply that the
B16F10 and MT1.2 cells have both PI3-kinase dependent and PI3-kinase independent
migratory mechanisms. PI3-kinase reportedly signals through a variety of molecules,
including the protein kinases AKT/PKB and ERKs via Raf-1, as well as phospho-
inositide (3,4,5)-triphosphate. The expression levels of AKT/PKB, ERK1 and ERK2,
by Western blotting, was similar in all 4 cell lines. However, both AKT/PKB and
ERK2 showed lower levels of phosphorylation in B16F10 cells (30.4% and 19.8%
phosphorylated respectively) relative to MT1.2 cells (81.2% and 84.5% phosphory-
lated respectively). Taken together these data imply that the basis for PI3-kinase medi-
ated migration in melanocytic cell lines is not a consequence of these downstream
signalling events. Irrespective of this, these results show that PI3-kinase is responsible
for up to 50% of melanocytic cell migration and thus inhibition of PI3-kinase migra-
tion promoting signalling pathways represents novel target(s) to decrease the migra-
tory and therefore invasive capacity of melanomas.62 Poster Presentations
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MELANOMA INVASION THROUGH FIBRONECTIN AND
RECONSTRUCTED HUMAN SKIN R Molife*1,2 P Eves2, C
Layton2, P Lorigan1 and S. MacNeil2, 1Dept of Oncology, Weston Park
Hospital, Sheffield S10 2SJ, UK, 2University Section of Medicine, Northern
General Hospital, S5 7AU, UK
The escape of melanoma cells from the primary tumour through the basement
membrane (BM) is thought to be the first step in metastasis of melanoma. The process
of invasion is complex involving changes in cell/extracellular matrix (ECM) and
cell/cell interactions. Our aim was to investigate these interactions with 2 different in
vitro models of invasion. In the first model, cells invade through fibronectin (FN)
coated filters under serum free conditions over 20 hours and the total percentage of
cell invasion is calculated by harvesting all cells (1). This model attempts to reflect
simple melanoma/ECM interactions. We have developed the second model to shed
light on the more complex melanoma/cell/ECM interactions. Human skin is sterilised
and made acellular to form de-epidermised dermis (DED) but retain BM antigens, or
BM antigens can be removed by treatment with dispase (2). To the DED, dermal
fibroblasts (F), epidermal keratinocytes (K) and A375SM or HBL human melanoma
cells are added to BM+ or BM– dermis. The resultant composites are cultured at an
air-liquid interface for 2–3 weeks prior to histology and immunohistochemistry.
FN: %invasion ± Composites
SEM (n) –K –F +K +F
(n) (n)
HBL 54.1+4 (12) – (15) ++ (13)
A375SM 5 ± 0.7 (16) ++ (6) +/– (6)
–, no invasion; +/–, little invasion; ++, extensive invasion
We found the invasive behaviour of the 2 cell lines to differ significantly in the two
models. HBL cells invaded well through FN but failed to invade through the DED in
the absence of Ks and Fs. The presence of Ks and Fs facilitated HBL invasion.
A375SM cells in contrast were poorly invasive through FN, but invaded well through
DED on their own, with Ks and Fs reducing the extent of their invasion. Similar
results were obtained with and without BM for both cell lines. HBL cells were S100
negative but HMB45 positive. A375SM cells were S100 positive and only occasion-
ally HMB45 positive. The data suggests that different melanomas may invade by
different mechanisms and also illustrates the importance of cell/cell and cell/ECM
interactions. The composite model clearly illustrates that adjacent skin cells can influ-
ence melanoma metastasis and will be useful in exploring approaches to preventing
cells initially breaching the BM and invading the dermis.
1 Richardson B, Price A, Wagner M et al (1999) Br J Canc 80: (12) 2025
2 Eves P, Layton C, Hedley, S et al (2000) Br J Dermatol 142: 1
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INTEGRIN aVb6 PROMOTES MIGRATION OF SQUAMOUS
CELL CARCINOMA CELLS ON LOW CONCENTRATIONS OF
FIBRONECTIN THROUGH A PKC DEPENDENT MECHANISM
MR Morgan*, E Dex1, GJ Thomas1, SA Whawell1, PM Speight1, IR Hart and
JF Marshall, Richard Dimbleby Department of Cancer Research/ICRF Lab,
St. Thomas’ Hospital, London. 1Eastman Dental Institute, University of
London, UK
Upregulation of the fibronectin (Fn) receptor avb6 has been observed in squamous
cell carcinoma (SCC). In order to establish whether this could promote, rather than
merely be the consequence of, disease we have generated cell lines from the av-nega-
tive SCC line, H357. This parental line expresses only one fibronectin receptor, a5b1.
Using retroviral transfer of b6 cDNA we derived VB6, a cell line which expresses
similar levels of a5b1, which has 10 fold more avb6 than the control line C1. In
haptotactic migration assays the motility of C1 cells increased over coating concentra-
tions of 1–10 mg/ml plasma fibronectin (1 mg/ml=17.7%, 5 mg/ml=19.1%, 10
mg/ml=25.7%) whereas migration of VB6 cells decreased over the same concentration
range (1 mg/ml=34.9%, 5 mg/ml=26.2%, 10 mg/ml=17.1%). These data are consistent
with those of Palecek et al (Nature (1997)385:537–540) who showed maximal migra-
tion requires intermediate adhesiveness, which varies dependent upon integrin expres-
sion, integrin-ligand binding affinity and substrate concentration.
C1 cells migrated to a greater extent on cellular fibronectin than they did on plasma
fibronectin (cellular Fn 1 mg/ml=8.6%, plasma Fn 1 mg/ml=5.4%), whereas VB6 cells
were more migratory on plasma fibronectin (cellular Fn 1 mg/ml=5.9%, plasma Fn 1
mg/ml=16.8%). The reasons for this observation, which was highly repeatable, are
unclear, but may relate to differences in the proportion of splice variant fibronectin in
cellular, versus plasma, fibronectin.
Assays were repeated in the presence of integrin-blocking antibodies and/or
specific inhibitors of cell signalling. Thus, VB6 cell migration was reduced to 0% by
10 mg/ml of L230 (anti-av) but only to 67.4% by 10 mg/ml of P4C10 (anti-b1);
suggesting that VB6 migration on fibronectin is avb6-dependent principally.
Migration on fibronectin of H357 cells (av-negative) was inhibited completely by the
inhibition of a5b1 (P1D6 anti-a5). These data suggest that a5b1 activity is reduced in
VB6 cells, possibly due to increased avb6 expression, while reduction of migration to
7.8% in the presence of 100 nM Calphostin C (PKC inhibitor), suggest a PKC-
dependent role for avb6 mediated migration in VB6 cells.
The ability of avb6 to promote SCC cell migration on low concentrations of
fibronectin, possibly, could be involved in promoting a more invasive phenotype.
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FACTORS MODULATING INTEGRIN b1 EXPRESSION ON
THE BREAST CANCER CELL LINES MCF-7 AND MDA-MB-
231 CJ Pogson*1, CMW Chan2, L-A Martin2, GPH Gui1, Departments of
Academic Surgery1 and Biochemistry2, The Royal Marsden and Institute of
Cancer Research, Fulham Road, London SW3 6JJ, UK
The metastatic cascade describes a sequence of cellular events that forms the patho-
logical basis of tumour progression1. Integrins represent a large family of cell adhe-
sion receptors that are widely expressed and play a leading role in this complex
process. Integrin and growth factor dependent signals co-operate functionally in a
variety of biological processes2.
The objective of this study is to improve our understanding of the role of integrins
in breast cancer metastasis by investigating how growth factors (Epidermal Growth
Factor (EGF), Insulin-like Growth Factor-1 (IGF-1)), Oestradiol (E2) and Tamoxifen,
affect integrin b1 expression. The breast cancer cell lines MCF-7 and MDA-MB-231
were used and integrin expression measured by Western Blot. On the MDA-MB-231
cell line, we have demonstrated that EGF and IGF-1 up-regulate integrin b1 expres-
sion by 2.4 and 2.8 fold respectively. Integrin b1 expression was down-regulated by
tamoxifen, with a maximal effect at 10–6 M (34% reduction).
On the MCF-7 cell line E2 up-regulated integrin b1 expression at high concentra-
tions, whereas down-regulation occurred at lower concentration, with maximal effects
at 10–7 M (1.7 fold induction) and 10–11 M (29% reduction) respectively. Conversely,
high concentrations of tamoxifen resulted in a 26% down-regulation of integrin b1
expression at 10–8 M. Low concentrations of tamoxifen had no or minimal effect on
expression.
IGF-1 up-regulated integrin b1 expression on the MCF-7 cell line, with a peak
effect at 60 minutes, at a concentration of 25 ng/ml (1.8 fold induction). We have
demonstrated that EGF and IGF-1 up-regulate integrin b1 expression. Invading cancer
cells interact with the basement membrane, endothelial cells and the extracellular
matrix, a step requiring the up-regulation of adhesion receptors. Down-regulation of
integrin b1 expression by tamoxifen may render cancer cells less adhesive and there-
fore less invasive.
Tamoxifen effect on the oestrogen receptor (ER) negative cell line MDA-MB-231,
suggests signaling through an alternative pathway and may explain why some ER
negative patients respond well to tamoxifen.
Identification of factors that regulate integrin expression may lead to the develop-
ment of novel anti-metastatic agents.
1 Hart IR, Saini A (1992) Lancet 329: 1453
2 Giancotti FG (1997) Curr Opin Cell Biol 9: 691
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CHARACTERISATION OF A HUMAN COLON CELL LINE
POSSESSING ACQUIRED RESISTANCE TO FLAVOPIRIDOL
V Smith, P Workman and LR Kelland, CRC Centre Cancer Therapeutics,
Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Flavopiridol is a synthetic flavone closely related to a natural product found in the
bark of the Indian tree Dysoxylum binefactarum. It acts as a broad spectrum cyclin-
dependent kinase (cdk) inhibitor by competitively binding to the ATP binding cleft
and is currently in clinical trials. Mindful that drug resistance may limit its clinical
efficacy, the aim of this study was to establish a laboratory model of acquired resis-
tance and elucidate the underlying mechanism(s). Initially, the growth inhibition prop-
erties of Flavopiridol were assessed in a panel of colorectal cell lines by the
sulforhodamine B assay. The 96 hr IC50 ranged from 45 nM in HCT116 to 170 nM in
HT29 cells. Acquired Flavopiridol resistance was established in the HCT116 cell line
by continuous exposure to increasing amounts of drug. This resulted (after 4 months)
in the HCT116/8FP subline that is 8-fold resistant. Initial mechanistic studies have
focused on the multi-drug resistance efflux proteins PgP and MRP. HCT116/8FP cells
did not show crossresistance to chemotherapeutics that are known substrates for these
proteins (e.g. doxorubicin and etoposide). Moreover, western blotting did not show
any detectable PgP protein or MRP protein in either the parent or the resistant cell
lines. Comparison of growth inhibition by paclitaxel or doxorubicin in the presence of
non-toxic doses of PSC833, a PgP modulator, revealed no difference between the
resistant and parent cell line. Using a cell line stably transfected with MRP (versus its
vector control) no difference in growth inhibition after treatment with Flavopiridol
was observed indicating that Flavopiridol is not a substrate for MRP. In order to
exclude drug accumulation as a possible mechanism of resistance, uptake experiments
were carried out which showed that uptake is increased in the resistant cell line when
treated at equitoxic doses. To date, the most significant difference observed between
the pair of lines is an increase in cyclin E expression in the resistant line. In addition
no cross-resistance was observed to another cdk inhibitor, the aminopurine-based
compound, roscovitine. In summary these investigations indicate that, in the HCT116
cells, neither MRP nor PgP play a role in the acquired resistance to Flavopiridol.Poster Presentations 63
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ROLE OF THE FAS/FASL PATHWAY IN HORMONE
RESISTANT PROSTATE CANCER S Ganta*1,2, MJ
Thompson2, GA Choudry12, C Bradley12, GM Flannigan1, MC Bibby2,
Bradford Royal Infirmary1 & Clinical Oncology Unit2, University of Bradford,
UK
Introduction Fas is a cell-surface receptor involved in inducing apoptosis.
Alterations of the Fas gene can lead to the loss of its apoptotic function and contribute
to the pathogenesis of some cancers. Castration induced apoptosis in murine prostate
has been shown to involve the Fas apoptotic pathway. The aim of this study is to
define the expression of the factors in the Fas apoptotic pathway and to detect Fas
gene alterations in hormone resistant prostate cancers.
Materials and methods Components of the Fas/FasL apoptotic pathway were
analysed in 75 untreated samples of prostate cancer by immunohistochemistry, they
were categorised into complete and partial/non responders based on the PSA value 3
months following androgen withdrawal. Samples were also available for 20 patients
following relapse into an androgen resistant state. The paired samples were both
analysed using immunohistochemistry and for Fas gene alterations to examine the
role in acquired androgen resistance. The malignant cells were selectively micro-
dissected from H&E stained sections of the paired samples. Conformational changes
in a 150 bp segment of exon 9 (which codes for the functionally critical death domain)
were analysed by PCR-SSCP. The student T- test for equality of means, and Pearson’s
correlation were used to analyse the data.
Results Fas, FasL and FADD (a down-stream mediator) were identified in all the
tumour tissues, while FLIP (an inhibitor) was noted in only 45% of the tumours. There
was no difference in the expression of the factors in the Fas apoptotic pathway
between the paired samples. The expression of the factors did not assist in identifying
a subset of patients who responded poorly to treatment. The conformational analysis
of exon 9 of the samples so far reviewed has shown no detectable conformational
changes.
Conclusions This is the first report of the analysis for Fas gene alterations in
prostate malignancy. Our data suggest that expression of the Fas pathway is unaltered
following androgen resistance, and no conformational changes are noted in the exon
critical to the induction of apoptosis, suggesting a functional Fas receptor which may
be exploited therapeutically.
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RESPONSE OF HUMAN DNA REPAIR DEFECTIVE CELL
LINES TO DNA INTERSTRAND AGENTS PH Clingen*, EE
Denholm, IU De Silva, A Hockey and JA Hartley, CRC Drug DNA Interaction
Research Group, Dept of Oncology, Royal Free and University College
Medical School, 91 Riding House Street, London W1P 8BT, UK
DNA interstrand crosslinking (ICL) agents are integral components of chemothera-
peutic protocols utilised in the treatment of many human cancers. Mechlorethamine
and melphalan are major groove binding alkylating agents capable of forming both
monoadducts and ICLs. The importance of ICLs for cytotoxicity is reflected by
comparison with their monofunctional derivatives which produce indistinguishable
patterns of monoalkylation but which do not form ICLs. By using growth inhibition
assays (MTT) bifunctional mechlorethamine and melphalan were approximately 500
and 40 fold more toxic than their respective monofunctional counterparts in normal
human fibroblasts (1BR.3). The exact mechanism by which ICLs are processed in
human cells is currently unknown. Data from model yeast and rodent DNA repair
defective cells indicate that nucleotide excision repair (NER), especially the XPF-
ERCC1 exinuclease activity and recombination systems are necessary for their repair.
In contrast, comparison of cytotoxicity in a panel of human DNA repair defective
fibroblasts including cells from NER defective xeroderma pigmentosum complemen-
tation groups A (XP1TUF), C (XP14BR), F (XP24BR) and G (XP125LO) and
radiosensitive ataxia-telangiectasia cell lines (AT1BR, 290BR) and a cell line with a
defect in DNA ligase IV (180BR) show no marked sensitivity to mechlorethamine or
melphalan. All cell lines so far examined, demonstrated normal levels of unhooking of
ICLs as measured using a modified ‘comet assay’. We found no obvious overlap
between DNA repair pathways for processing ICLs in model lower eukaryotic cell
systems and in the human cell lines treated with mechlorethamine or melphalan. The
hypothesis is that human Fanconi anemia gene products compensate for the repair
defects in the panel of cells investigated. Fanconi anemia (FA) is a recessively trans-
mitted genetic disease characterised by marked sensitivity to crosslinking agents.
Current investigations aim to identify the role of FA proteins in the repair of ICLS.
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DEFINING THE PATHWAYS INVOLVED IN THE INITIATION
AND RESOLUTION STEPS OF DNA INTERSTRAND
CROSSLINK REPAIR PJ McHugh* and JA Hartley, CRC Drug-DNA
Interactions Research Group, Dept Oncology, Royal Free and University
College Medical School, UCL, 91 Riding House Street, London W1P 8BT, UK
We have previously reported that DNA double-strand breaks (DSBs) are a key inter-
mediate generated during the repair of interstrand crosslinks, the toxic lesion
produced by alkylating anticancer agents. In the yeast Saccharomyces cerevisiae these
crosslink-associated DSBs are primarily repaired by homologous recombination with
non homologous end-joining (NHEJ) acting as a minor, salvage pathway. The key
activity required for homologous recombination in yeast is the product of the RAD52
gene, and DSB repair is almost eliminated in strains where this gene is disrupted
(rad52 cells). The RAD52 epistasis group has five other members RAD51, 54, 55, 57
and 59, but unlike RAD52 none of these genes are indispensable for all homologous
recombination repair activities but show varying contributions depending on the
substrate. Consequently we have investigated the relative role of several of these
factors in the repair of nitrogen mustard crosslink associated DSBs. In addition to
RAD52 only RAD54 is absolutely required for DSB repair, and cells lacking the rad51
and rad59 genes show more minor repair defects. This can be explained in terms of
the recent observation that RAD54 is absolutely required for sister chromatid
exchanges in haploid cells, and rad51 and rad59 are partially redundant for mitotic
homologous recombination. A further activity investigated in this study was MRE11,
a gene involved in both homologous recombination and NHEJ. Mre11 deficient cells
demonstrate a level of hypersensitivity to nitrogen mustard and DSB repair defect
indistinguishable to that seen in rad52 cells indicating that during ICL DSB repair
Mre11 plays an indispensable role in the homologous recombination pathway.
We have also investigated the origin of the crosslink associated DSBs, and surpris-
ingly found that they still formed in cells defective in nucleotide excision repair
(NER), the main activity required for the excision of nitrogen mustard crosslinks. To
establish that the 5¢ and 3¢ endonuclease activities of the NER apparatus could not act
independently to initiate DSB formation we generated a strain defective in both these
activities (rad1 rad2 mutant). DSBs formed with the same frequency in this mutant as
the parental, repair wild-type strain. Surprisingly, examination of the repair of DSBs
in NER mutants indicated they are completely unable to repair these breaks, indi-
cating that the ICL still persists in association with the DSB. The DSB apparently
cannot be repaired until the crosslink is first eliminated. This suggests that DSBs form
as a prerequisite to NER, and that the excision of a crosslink is contingent upon the
formation of a strand break in order to permit access to the adduct.
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INVESTIGATION OF DOUBLE STRAND BREAK REPAIR
PROFICIENCY AND FIDELITY IN TESTICULAR GERM CELL
TUMOURS (TGCT) Rebecca E. Foster* and Christine M Chresta, School of
Pharmacy, University of Manchester, Manchester M13 9PL, UK
Testicular cancer is the commonest solid tumour in young men. It is unique in its
sensitivity to current chemotherapy regimes. We have shown that chemosensitivity is
related to a low threshold for apoptosis activation (1). Levels of etoposide &
bleomycin-induced DNA damage that are sub-lethal to normal human fibroblasts and
bladder tumour cells rapidly activate apoptosis in TGCT. Significantly TGCT cells are
preferentially sensitive to activation of apoptosis by agents that directly damage DNA.
We demonstrate here that the microtubule poison Paclitaxel induces similar levels of
apoptosis in TGCT and transitional cell carcinoma of the bladder cell lines. Two hour
treatment with 180 nM Paclitaxel resulted in approximately 30% apoptosis in both
cell types 24 hours after drug treatment. This specific hypersensitivity to agents which
directly damage DNA suggests that TGCT may be compromised in DNA repair.
We have investigated three mechanism of DNA strand break repair, single strand
break repair and the two types of double strand break repair, non-homologous end-
joining and homologous recombination repair. DNA strand break repair proficiency
and fidelity in TGCT has been compared to that of cell lines from transitional cell
carcinoma of the bladder and normal human fibroblasts. Alkaline elution demon-
strated that TGCT are equally as proficient as other cell types in single strand break
repair with less than 5% breaks remaining just one hour after etoposide or bleomycin
treatment. We could not directly quantify chemotherapy-induced DNA double strand
breaks in TGCT because neutral elution requires higher doses of damaging agents and
these induce rapid apoptosis in TGCT. We have therefore used a shuttle plasmid assay
to investigate direct end-joining of double strand breaks generated by a restriction
endonuclease. Fidelity of end-joining was found to be similar in all cell types (84±9%
in fibroblasts and 84±9% & 88±6% in the TGCT cell lines 833 K & GCT27 respec-
tively). Surprisingly rejoining frequency was 2–3 fold higher in TGCT (22 & 28%)
than normal human fibroblasts (9%). Enhanced non-homologous end-joining may be
related to overexpression of p53 in TGCT cells. It has recently been reported that p53
directly enhances rejoining of DNA strand breaks with cohesive termini (2). We are
currently investigating if sensitivity to DNA strand break-inducing agents is related to
reduced efficiency of homologous recombination repair since p53 inhibits the homol-
ogous repair pathway. p53 associated with Rad51, a protein involved in homologous
recombination repair of double strand breaks, and has been shown to inhibit Rad51
activity. The high levels of p53 seen in the TGCT cells may therefore reduce homolo-
gous recombination repair.
1 Chresta et al (1996) Cancer Res. 56: 1834–1841
2 Tang et al (1999) Cancer Res. 59: 2562–256564 Poster Presentations
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MEASUREMENT OF RESISTANCE TO THIOPURINE DRUGS
IN CELLS WITH DEFECTIVE MISMATCH REPAIR
LA Hogarth*, EC Matheson, L Minto, MA Little and AG Hall, LRF, Molecular
Pharmacology, CRU, Medical School, Newcastle NE2 4HH, UK
Errors occurring during normal DNA synthesis may produce mismatched base pairs.
The mismatch repair (MMR) pathway primarily functions to correct DNA replication
errors to avoid accumulation of mutations. The thiopurine drugs (6-mercaptopurine,
6-MP and 6-thioguanine, 6-TG) undergo intracellular activation to give cytotoxic
thioguanine nucleotides which are incorporated into the DNA of dividing cells in
place of guanine. Cell death is thought to result from futile attempts to repair the drug
mismatch and defects in DNA mismatch repair have been identified as a potential
cause of resistance to thiopurine drugs.
Risinger et al., (1998) have transfected the HEC-1-A (endometrial carcinoma) cell
line, which is defective in the mismatch repair protein PMS2, with wild type PMS2.
We have shown that the HEC-1-A cell line is more resistant to both 6-thioguanine (6-
TG) and 6-mercaptopurine (6-MP) than the PMS2 transfected HEC-1-A cell line
(WT1) using the sulphurhodamine B assay. Compared with the HEC-1-A cell line the
WT1 cell line has been shown, by western blotting, to have increased protein expres-
sion of PMS2 and also increased repair activity using a functional assay for DNA-
mismatch repair (Thomas et al, 1995). Currently, we are investigating the sensitivity
of these cells to 6-MP and 6-TG by measuring clonogenic survival and apoptosis.
Sensitivity to 6-TG and 6-MP is also being compared with incorporation of these
drugs into the DNA in order to assess the role of MMR in determining the ability of
the cells to respond to drug incorporation.
Risinger JL, Umar A, Glaab WE, Tindall KR, Kunkel TA and Barrett C (1998)
Cancer Research 58: 2978
Thomas DC, Umar A and Kunkel TA (1995) A Companion to Methods in
Enzymology 7: 187
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HIGH THIOPURINE METHYLTRANSFERASE EXPRESSION
CONFERS DIFFERENT LEVELS OF RESISTANCE WITH 6-
THIOGUANINE COMPARED TO 6-MERCAPTOPURINE S Coulthard*, L
Hogarth, L Minto, C Redfern and A Hall, LRF Molecular Pharmacology
Group, 2nd Floor, Medical School, Newcastle University NE2 4HH, UK
Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood.
Current treatment results in long term survival in over 70% of cases. In previous
studies it has been found that thiopurines given as part of continuing therapy are key
agents in preventing relapse. However optimal administration during continuing
therapy is often not achieved. Variations in the level of thiopurine methyltransferase
(TPMT) activity appear to be a major molecular determinant of the extent of
thiopurine metabolism.
In order to help understand the effect of TPMT activity directly on the metabolism
of the thiopurine drugs, wild-type TPMT cDNA was cloned into a Muristerone-
inductible expression vector and transfected into an embryonic kidney cell line,
EcR293 (InvitrogenR). The insect hormone analogue, Muristerone A, (MA) activates
gene expression via an ecdysone receptor in these cells. TPMT expression was
induced in these cells in order to elucidate sensitivity of these cells to 6-thioguanine
(TG) and 6-mercaptopurine (MP).
Optimal induction was obtained using 3 mM MA, which gave a TPMT activity of
2.7 nmol/hr/mg of protein. Activity was stable for 3 days. Assays for clonogenicity
and cell proliferation (using the Sulforhodamine B (SRB) assay) were used to study
the effect of TPMT expression on cellular properties. Clonogenic assays showed little
difference in sensitivity to either drug in the TPMT expressing cells, (IC50=1.5 mM
for TG and IC50=1.2 mM for MP) and the non-expressing cells (IC50=1.6 and 1.5 mM
for TG and MP respectively). Using the SRB assay those cells expressing TPMT
showed a slight difference in potency between the TG and MP (IC50=3.9 mM and 1.2
mM respectively). However, the non-expressing cells were more than 7 fold more
sensitive to TG than MP. (IC50 = 2.2 mM and IC50 = 15.0 mM respectively).
This difference in sensitivity may be due to differences in metabolism. MP is
converted into methlythioinosine monophosphate (a strong inhibitor of de novo purine
synthesis) by TPMT, thereby making high TPMT expressing cells more sensitive to
MP than the non-expressing cells. These data suggests that the effect of the thiopurine
drugs is not solely due to the incorporation of fraudulent bases into DNA.
We should like to thank the Leukaemia Research Fund for supporting this work
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GLUTATHIONE HOMEOSTASIS IN BUTHIONINE
SULFOXIMINE SENSITIVE AND RESISTANT
NEUROBLASTOMA CELL LINES MC Case* and AG Hall, LRF Lab, CRU,
Medical School, Newcastle NE2 4HH, UK
Neuroblastoma is the most common extracranial tumour of childhood. Metastatic
disease is associated with a poor prognosis using currently available therapy. Recently
it has been reported that many neuroblastoma cell lines are sensitive to exposure to
buthionine sulfoximine (BSO) an inhibitor of gamma-glutamyl cysteine synthetase
(GCS), the rate limiting enzyme in glutathione (GSH) synthesis at concentrations
10–100 times below the 3,000 to 8,000 mM peak plasma levels reported in human
trials. We have investigated the mechanisms underlying this chemosensitivity.
The sulforhodamine B (SRB) assay confirmed previous reports that some cell lines
(eg SHEP, SHEP tet 21 and IMR32) were very sensitive to BSO (IC50 <16 mM) whilst
the SKNBE cell line was resistant to all concentrations tested (IC50 >2048 mM).
Another cell line tested, SHSY5Y, was of intermediate sensitivity. Unlike previous
reports there was no correlation with MYCN copy number. BSO sensitivity was
dependant on the length of time cells were in culture prior to drug exposure; some cell
lines (eg SHEP tet21) were killed by BSO however long they were left prior to drug
exposure, some (eg SKNBE) were resistant to BSO at all time points tested and some
(eg IMR32) gained resistance to BSO as they become more confluent. We speculated
that this varied response to BSO could be due to the ability of different cell lines to
synthesise and maintain cellular GSH levels. In BSO resistant SKNBE cells GSH
levels rose as cells became more confluent. Real time PCR demonstrated a corre-
sponding fall in levels of GCS mRNA (heavy and light chain), suggesting that the rise
in GSH was due to a decrease in utilisation or export rather than an increase in
synthesis. In BSO sensitive SHEP tet 21 cells GSH levels fell as cells became more
confluent and the levels of GCS mRNA were low at all time points tested, suggesting
a deficiency in GSH synthesis. In all cell lines tested, addition of BSO led to depletion
of GSH-down to 10% of resting levels in the resistant cell lines and to <1% in the
sensitive cell lines. Levels of GCS mRNA rose markedly after BSO exposure.
These results suggest that the control of GSH homeostasis differs between BSO
sensitive and resistant cell lines, an observation which may have important implica-
tions for therapy. Supported by the Neuroblastoma Society and NECCRF.
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GLUTATHIONE DEPLETING AGENT BSO SENSITIZES
CHOLANGIOCARCINOMA TO RADIOTHERAPY
MC Okaro*1&2, FE Cotter2, BR Davidson1, 1University Dept Surgery RF &
UCMS London NW3 2PF & 2Dept Exp. Hematology, St Barts. and The R L S
of Medicine London E1 2AD, UK
Cholangiocarcinoma (CCA) is resistant to the apoptosis inducing effects of radio-
therapy and chemotherapy. Glutathione, an important anti-oxidant, is produced in the
liver and secreted in high concentrations into the bile (8–10 mm). Reduced
glutathione has been shown to inhibit apoptosis by alter the redox state of vicinal
thiols located in the permeability transition pore complex (PTPC) of the mitochondria
and also by the neutralizing reactive oxygen species (ROS) generated in the mito-
chondria. The effect of glutathione depletion of the sensitivity of CCA to radiotherapy
has not been established.
Egi-1 and Tfk-1 human cholangiocarcinoma cell lines, were used to study the
effects of glutathione depleting agent BSO on the rate and amount of apoptosis
following stimulation with UV light and high dose radiotherapy (500–1000c Gy) over
72 hrs. The thiol-replenishing agents N-Acetylcysteine and chloromethyl-x-rosamine
(CMX-Ros) were used to counter the effects of BSO.
Apoptosis was monitored by an established method, measuring the collapse in the
inner mitochondrial membrane potential (DY m) detected at single cell resolution by
flow cytometry using the DY m sensitive lipophilic flourochrome DiOC6 (3) and by
the annexin V assay.
Depleting cholangiocarcinoma cells of glutathione using BSO had a significant
effect at sensitizing cells of the DNA damaging and oxidative effects of UV light and
radiotherapy. There was a larger (3-fold increase, P < 0.01) and accelerated rate in the
collapse of mitochondrial function and plasma membrane disruption (apoptosis). This
effect was both time and dose dependent as well as totally reversible.
These results show that the control of apoptosis in cholangiocarcinoma is highly
dependent on the redox state of the cell and suggests that glutathione may be playing
an important part in contributing to radioresistance in cholangiocarcinoma. Altering
the redox state within the biliary tree may be one way of increasing the efficacy of
radiotherapy in the treatment of this disease.Poster Presentations 65
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FORMATION OF ATYPICAL CISPLATIN DNA ADDUCTS IN
CERTAIN CANCER CELLS A Azim-Araghi*1, KA Wright, CJ
Ottley2, DG Pearson2, PR Twentyman3, MJ Tilby1, 1Cancer Research Unit,
University of Newcastle, Newcastle Upon Tyne, NE2 4HH, 2Geology Dept,
University of Durham, 3UKCCCR, Lincoln’s Inn Fields, London, UK
The adenocarcinoma lung cancer cell line Mor was 3 fold more resistant to cisplatin
than the small cell lung cancer cell line H69 (1). To investigate the level of drug-target
interaction in these cell lines, they were exposed to a range of concentrations of
cisplatin (2 h), DNA extracted, and adduct levels determined using a competitive
ELISA technique based on a monoclonal antibody (2). For the same drug exposures,
the sensitive H69 cells consistently accumulated approximately 2 to 3 fold more
adducts than the resistant cell line. However, when the total amount of cisplatin bound
to DNA was quantified by atomic absorption spectrometry (AAS) or inductively
coupled plasma mass spectrometry (ICP-MS) the difference in adduct levels between
the two cell lines was less marked.
In contrast to the total Pt measured by AAS and ICP-MS, the ELISA method deter-
mined only immunoreactive adducts. Adducts formed in pure solution and in cells
were previously found to be equivalent (1). The amount of adducts needed to cause
50% reduction in immunoassay signal were calculated from the results of all 3 tech-
niques. This value was consistently >2-fold higher for adducts formed in Mor cells
than for adducts formed in H69 cells or on purified DNA. (Table).
Expt Adducts (fmole per well) causing Ratio
50% reduction in assay signal Mor/H69
H69 Mor
1# 2.6 7.5 2.9
2# 2.3 12.9 5.6
3# 1.9 6.6 3.5
4* 1.2 2.4 2.0
5* 1.1 3.3 3.0
6* 0.7 1.5 2.1
Each value represents the mean of 2–4 separate samples for each cell line.
# AAS *ICP-MS
If ELISA detects the predominant Pt-DNA adducts, a 2-fold change in overall
immunoreactivity indicates a considerable difference in some aspect of Pt-DNA
adduct structure in the Mor cells. ICP-MS detection limits of <1pg Pt/g will permit
future analysis of samples exposed to lower and more clinically relevant drug levels.
1 Tilby et al (1991) Cancer Res. 51: 123
2 Twentyman et al (1992) Cancer Res. 52: 5674
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IN VITRO/IN VIVO CORRELATIONS OF CISPLATIN-DNA
ADDUCT LEVELS IN LEUCOCYTES OF CHILDREN GJ Veal1,
C Dias1, AV Boddy1, E Price2, A Parry2, J Hale2, ADJ Pearson2, DR Newell1
and MJ Tilby1, 1Cancer Research Unit and 2Department of Child Health,
University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
It is generally accepted that the antitumour activity of cisplatin results from its inter-
action with DNA, resulting in the formation of platinum (Pt)-DNA adducts. In addi-
tion, clinical response to cisplatin has been reported to correlate with levels of
Pt-DNA adducts in peripheral blood leucocytes (PBLs) induced by therapy.1 Despite
reports that Pt-adduct levels formed in vivo are related to cisplatin exposure (AUC of
unbound cisplatin in plasma),2 recent findings in a paediatric patient population
suggested that pharmacokinetic variation could only account for a small proportion of
the interpatient variation in adduct levels.3 The present study investigates possible
relationships between levels of Pt-DNA adducts determined in vivo, levels of DNA
adducts formed following incubation of pretreatment blood samples with cisplatin in
vitro and the pharmacokinetics of cisplatin in children with cancer.
Pt-DNA adducts were measured in PBLs isolated from 7 children at 0, 6, 24 and 
48 h following the start of administration of cisplatin (50–100 mg/m2) as a 24 h intra-
venous infusion. Pretreatment samples of whole blood were also incubated with 
50 mM cisplatin for 1 h prior to isolation of PBLs. Adduct measurements were
performed by ELISA and total and unbound platinum concentrations at 0, 1, 2, 6, 24
and 48 h determined in plasma and plasma ultrafiltrate samples respectively by
Atomic Absorption Spectroscopy (AAS).
A strong correlation (r2=0.90) was observed between in vivo Pt-DNA adduct
AUC0–48 h and  in vitro Pt-DNA adduct levels normalised to cisplatin dose. No signifi-
cant correlation was seen between in vivo Pt-DNA adduct AUC0–48 h and free
(unbound) Pt AUC0–48 h (r2=0.08) or total Pt AUC0–48 h (r2=0.07) in plasma, indicating
that cellular factors play a more important role than pharmacokinetic variation in
determining cisplatin-DNA interactions in vivo. These preliminary results suggest that
in vitro adduct levels following a 1 h incubation with cisplatin are a good predictor of
Pt-DNA adduct levels formed in vivo and hence potentially of clinical response to
cisplatin in children.
1 Reed E, Parker RJ, Gill I et al (1913) Cancer Res 53: 3694–3699
2 Schellens JHM, Ma J et al (1996) Br J Cancer 73: 1569–1575
3 Peng B, Tilby MJ, English MW et al (1997) Br. J. Cancer 76: 1466–73
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PRECLINICAL COMBINATION STUDIES IN HUMAN OVARIAN
CARCINOMA CELL LINES WITH THE NOVEL PLATINUM
COMPLEX, ZD0473 (C/S-AMMINEDICHLORO [2-METHYLPYRIDINE]
PLATINUM(II) AND PACLITAXEL PM Rogers*1, F Boxall1, CP Allott2, T
Stephens2, and LR Kelland1, 1CRC Centre Cancer Therapeutics, Institute of
Cancer Research, Sutton, Surrey SM2 5NG & 2AstraZeneca, Alderley Park,
Macclesfield, Cheshire, UK
ZD0473 is a novel “sterically hindered” platinum complex targeted to circumvent
classical resistance mechanisms to cisplatin, especially resistance mediated by
increased thiol-containing molecules such as glutathione and metallothionein.
ZD0473 was shown to circumvent acquired cisplatin resistance in various human
ovarian carcinoma cell lines and xenografts resulting in its selection for clinical trial.
Myelosuppression was the dose-limiting toxicity observed in the initial phase I trial
using intravenous infusion every 3–4 weeks. The drug is now undergoing phase II
evaluation. The aim of this in vitro study was to determine the potential of combining
ZD0473 with the widely used drug paclitaxel, in the clinic. Four human ovarian carci-
noma cell lines have been used: two parent cisplatin-sensitive lines, CH1 and A2780;
a 15-fold acquired cisplatin resistant subline, A2780cisR; and an A2780 subline stably
transfected with the E6 human papillomavirus gene thereby disabling the wild-type
p53 function of the parental line, A2780 E6. Growth inhibition (using the sulforho-
damine B assay) has been determined for ZD0473 alone, and combined either simul-
taneously or administered sequentially for 24 hours with paclitaxel. The effect of the
drug combinations has been analysed using median effect analysis. ZD0473 alone (96
hour continuous exposure) exhibited potent growth inhibition against these cell lines
with IC50 values mM) of 3.7 for A2780, 15.6 for A2780cisR, 8.6 for A2780E6 and 3.3
for CH1. Hence. A2780cisR was only 4.2-fold cross-resistant to ZD0473 in these
studies. Paclitaxel alone also conferred potent growth inhibition with lC50 values in
nM of 2.5 for A2780, 3.5 for A2780cisR, 20.8 for A2780E6 and 3.1 for CH1. When
exposed concomitantly with paclitaxel the combination index (CI) values at 50% frac-
tion affected were synergistic for all 4 cell lines (A2780 CI of 0.49, A2780cisR CI of
0.55, A2780E6 CI of 0.41, CH1 CI of 0.69). However, when ZD0473 was applied for
24 hours before paclitaxel for 24 hours the effect was additive in A2780 (CI of 1.0)
whilst synergistic effects were obtained in the other 3 cell lines (A2780cisR CI of 0.4,
A2780E6 CI of 0.51 and CH1 CI of 0.61). When cells were exposed to paclitaxel for
24 hours followed by ZD0473 for 24 hours a strong synergistic effect was only
observed in A2780cisR (CI of 0.37) with the other cell lines giving weak synergism
(A2780E6 CI of 0.89), an additive effect (A2780 CI of 1.1) or an antagonistic effect
(CH1 CI of 2.4). These data indicate that, depending upon the cell line, the sequence
in which ZD0473 and paclitaxel are administered is of importance in determining
growth inhibition when combined.
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PROSPECTIVE COHORT STUDY OF THE USE OF
MAGNESIUM SUPPLEMENTATION WITH CISPLATIN
CHEMOTHERAPY, JW Adlard*1, J Watters1, 1Yorkshire Centre for Clinical
Oncology, Cookridge Hospital, Leeds LS16 6QB, UK
Cisplatin chemotherapy can cause glomerular injury leading to decreased glomerular
filtration rate and tubular damage manifesting as urinary electrolyte wasting, particu-
larly of magnesium. The aim of the study was to assess the effectiveness of routine
magnesium supplementation in preventing hypomagnesaemia in patients receiving
cisplatin-containing chemotherapy. 85 consecutive patients were evaluated in this
prospective cohort study. Eligible patients were those with adequate renal function,
who had not previously received cisplatin-containing chemotherapy. Renal function
and electrolytes including serum magnesium levels were measured prior to each cycle
of chemotherapy. Intravenous magnesium chloride supplementation was given
routinely with each cycle. Doses of magnesium chloride per cycle varied from 8 mmol
to 72 mmol dependent on the particular chemotherapy regimen, though most patients
(66%) received 16 mmol per cycle. Continuous oral magnesium glycerophosphate
supplementation (8 mmol three times daily) was given from the following cycle when
serum magnesium levels fell below 0.65 mmol/l.
A total of 264 cycles of cisplatin-containing chemotherapy were given to the 85
patients. Serum magnesium level fell significantly from the second cycle of
chemotherapy onwards. Mean serum magnesium prior to cycle 1 = 0.77 mmol/l (95%
C.I. 0.752–0.787) and prior to cycle 4 = 0.695 mmol/l (95% C.I.0.663–0.728)
P<0.001. Hypomagnesaemia (<0.65 mmol/l) occurred in 26% of patients and compli-
cated 14% of all chemotherapy cycles. Larger doses of intravenous magnesium used
with some regimens such as BEP (Bleomycin, Etoposide and Cisplatin) given over
several days did not appear to protect against hypomagnesaemia. There were no defi-
nite recorded symptomatic episodes. There were no other significant changes detected
in renal indices or electrolytes. Continuous oral magnesium supplements appeared
promising in improving hypomagnesaemia occurring despite intravenous supplemen-
tation. The cost of cisplatin for the duration of the study was approximately £9900,
compared with £1500 for the intravenous magnesium chloride and £630 for oral
magnesium supplementation.
Hypomagnesaemia remains common despite current intravenous magnesium
supplementation, though is rarely symptomatic. Oral magnesium supplements may
help maintain magnesium levels, but add to the costs of treatment and are of uncertain
benefit in asymptomatic patients.66 Poster Presentations
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HYPERSENSITIVITY REACTIONS TO CARBOPLATIN
VR Bulusu*1, F Ives1, E Sugden2, 1Oncologycentre,
Addenbrooke’s Hospital, Cambridge CB2 2QQ and 2Dept of Clinical
Oncology, Churchill Hospital, Headington, Oxford OX3 7LJ, UK
Aim 1. To characterise the clinical features of hypersensitivity reaction (HSR) to
carboplatin. 2. To correlate the relationship of the severity and duration of HSR to the
carboplatin infusion rate and concentration and time interval between initial exposure
and subsequent rechallenge with carboplatin.
Material and Methods A proforma has been developed to document the clinical
features of HSR to carboplatin. The HSR was graded in to I, II and III on the basis of
the severity of symptoms. 24 patients (19-ovarian cancer, 3-fallopian tube cancer, 1-
primary peritoneal cancer, 1-adenocarcinoma with unknown primary) who have expe-
rienced a HSR to carboplatin were included in the study. The overall incidence in all
patients treated was 4.5% and in patients who were rechallenged with carboplatin was
10.5%. The mean age was 57.8 years (range 33–75 years). 6 patients had prior history
of an allergic diathesis. The time interval, duration and concentration of carboplatin
infusion, the grade and duration of reaction, the clinical features, and the management
were documented.
Results The mean time interval between the initial exposure and to carboplatin and
the subsequent development of HSR was 26.5 months (range 5–96 months). 50%
(12/24) have developed the HSR on the 2nd cycle of the rechallenge. The mean dura-
tion of HSR was 44 min (range 10–180 min). The most common symptoms were
itchy hands, facial flushing, generalised erythema, palpitations and nausea. Grade 1
reaction was noted in 45%, grade II in 25% and grade III in 30% of patients. There
was no correlation between the time interval, infusion rate, drug concentration and the
severity of HSR. The mean time of onset of symptoms (n=10) was 14.5 min (range
5–20 min). No patient developed HSR after completing the infusion. No ITU admis-
sion was required. None of the reactions were fatal. All patients had their infusion
stopped, and treated with iv hydrocortisone and antihistamine, and oxygen as
required. 9 patients were rechallenged with a platinum compound and 6/9 (66%)
developed a HSR despite full steroid and antihistamine cover.
Conclusions We have highlighted the clinical features and the pattern of HSRs to
carboplatin. Patients who are rechallenged are at a significantly higher risk of devel-
oping a HSR. Hypersensitivity typically occurred on the 2nd cycle of rechallenge.
Relapsed ovarian cancer patients to be rechallenged with carboplatin should be made
aware of the possibility of a HSR. Patient education regarding the symptom recogni-
tion may help prompt diagnosis and treatment. Chemotherapy nurses managing these
patients should be equally aware of the clinical features and management of the HSRs.
We do not recommend re challenge with carboplatin in patients who have had a prior
HSR.
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TOXICITY, CELLULAR UPTAKE AND DNA CROSSLINKING
STUDIES ON THE NOVEL BIOREDUCTIVE ANTICANCER
DRUG RH1 TH Ward*1, Nic Coe1, R Hargreaves1 J Butler1 and AT McGown1,
1CRC Drug Development Group, Paterson Institute, Christie Hospital
Manchester M20 4BX, UK
DT-diaphorase; (EC. 1.6.99.2) is an obligate two-electron reductase that reduces
quinones to hydroquinones. With certain quinone anticancer drugs, this two-electron
reduction can produce a more biologically reactive species which can cross link DNA.
DT-diaphorase has been shown to be over expressed in many tumours relative to the
normal tissue and consequently represents a target for bioreductive anti-cancer drugs.
RH1 (2,5-diaziridinyl-3-[hydroxymethyl[-6-methyl-1,4-benzoquinone) is a novel
bioreductively activated DNA crosslinking agent which is an efficient substrate for
DT-diaphorase. This agent has been shown to be effective in a variety of xenograft
models and in particular, against ovarian tumours. RH1 is currently to undergo Phase
I/II trials as a joint collaboration between the CRC and the NCI. The toxicity, cellular
uptake and DNA crosslinking ability of this drug has been investigated in diaphorase
rich (H460) and diaphorase deficient (BE) cell lines. In addition a comparison
between this drug and other clinical DNA crosslinking anticancer agents has been
made using cultures of primary ovarian cancer cells. Uptake of 3H RH1 was shown to
be both time and concentration dependent. Uptake appeared maximum after 2 hrs and
correlated well with DNA crosslinking as measured by the comet assay. DNA
crosslinking could be detected at concentrations of drug as low as 10 nM after only 2
hrs exposure. The time dependency of DNA Crosslinking showed a rapid initial phase
over the first 4 hrs exposure reaching a maximum within 8 hrs. The DNA crosslinking
activity of three clinically used anti-cancer drugs (Melphalan, mitomycin C and CisPt)
in cultures of primary ovarian cancer cells was compared to RH1. The Comet
crosslinking assay showed that DNA crosslinking occurred at a significantly lower
concentration (1003) with RH1 than with any of the other drugs used. Furthermore
the amount of initial crosslinking produced by all drugs appeared to decrease on incu-
bation in drug free medium overnight suggesting possible repair of the DNA adducts.
Cytotoxicity assays comparing these and other clinical anticancer drugs showed that
RH1 was 10 times more toxic than taxol and 50 time more toxic than mitomycin-C in
these cells. Clearly RH1 represents a potent bioreductive anticancer drug and may
prove effective in the treatment cancers, particularly those over expressing DT-
diaphorase.
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EVIDENCE FOR ENHANCED ALKYLATION OF G-RICH
REGIONS OF DNA BY MELPHALAN IN CELLS COMPARED
TO PURE SOLUTION H McCartney* and MJ Tilby, Cancer Research Unit,
University of Newcastle, Newcastle Upon Tyne NE2 4HH, UK
Monoclonal antibodies MP5/73 (1) and Amp4/42 (2) appeared to recognise respec-
tively, N7 guanine adducts formed by melphalan and the corresponding alkali-induced
formamidopyrimidine ring-opened structure. However, analysis of DNA extracted
from drug-treated cells implied that adducts recognised by MP5/73 and Amp4/42
were not equivalent and that adducts formed in cells differed from those formed in
vitro.
Denatured DNA was reacted with 3H-melphalan and exposed for various periods
to alkali. Immunoreactivities of adducts to each antibody were determined by compet-
itive ELISA. Half-lives for loss of MP5/73 immunoreactivity were ca. 66 and 11 min.,
however, immunoreactivity to Amp4/42 increased with half-lives of ca 23 and <2
mins, in 0.01 and 0.1 M NaOH respectively. This difference in rates confirmed a
difference in properties of adducts recognised by each antibody. At 100 °C, pH7, the
rate of loss of immunoreactivity of adducts on RNA was approximately 10 times
slower than the rate for adducts on DNA (t1#fr2 = 68 and 6 mins for RNA and DNA
respectively). The effects of alkali and heat both rule out the involvement of phospho-
triesters in antibody recognition. To test the hypothesis that local DNA sequence
influenced the immunoreactivity of adducts, synthetic DNA oligomers were cova-
lently immobilised to wells of 96-well plates and exposed to a range of melphalan
concentrations. The binding of Amp4/42 and MP5/73 to the wells was investigated
+/– prior incubation with 0.1 M NaOH. All sequences containing guanine showed the
formation of adducts recognised by antibody MP5/73. However, adducts on oligo dG
were recognised very poorly by Amp4/42. These results were confirmed by competi-
tive ELISA experiments.
In drug-treated cells, adducts recognised by Amp4/42 formed a 10-fold smaller
proportion of the total adducts than for DNA alkylated in pure solution (2). The
present results indicate that this resulted from a greater proportion of the alkylation in
cells occurring in G-rich regions. Unlike previous comparisons of sequence dependent
DNA alkylation in vivo and in vitro, the immunoassay data reflects the properties of
the total cellular DNA rather than a specific small region. The results could indicate
that in cells, DNA alkylation occurs predominantly in regions associated with a
specific chromatin organisation (e.g. telomeres). It will be of interest to identify these
regions and to determine the rate DNA repair.
1. Tilby et al (1987) Cancer Res. 47: 1542
2. Tilby et al (1995) Carcinogenesis 16: 1895
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ANTI-TUMOUR PROPERTIES OF NOVEL
DIAZIRIDINYLQUINONES Angela M Di Francesco1,2, Robert
HJ Hargreaves2, Timothy W Wallace3, Stephen P Mayalarp4, Ali Hazrati5,
John A Hartley5 and John Butler1,2, 1Departments of Biological Sciences and
3Chemistry, Salford University, Salford M5 4WT, UK, 2CRC Section of Drug
Development, Paterson Institute for Cancer Research, Christie Hospital NHS
Trust, Manchester M20 9BX, UK, 4PE Biosystems, & Kingland Grange,
Warrington WA1 4SR, UK, 5CRC Drug-DNA Interactions Research Group,
Department of Oncology, Royal Free and University College Medical School
(UCL), London W1P 8BT, UK
Diaziridinylquinones (DQs) have been extensively studied as potential anti-tumour
agents, which are bioreductively activated to form toxic species. DQs can target the
obligate two-electron reducing enzyme DT-diapohrase (DTD), which is over-expressed
in some breast, colon, ovarian and non small cell lung cancers (NSCLC). Depending
upon the chemical structure of diaziridinylquinones, DNA strand breaks, monoalkyla-
tions of DNA and proteins, and DNA cross-links can be produced after bioactivation.
2,5-diaziridinyl-3-phenyl-1,4-benzoquinone (PDZQ) is a known DNA cross-linking
agent with cytotoxicities ranging from 2 to 16 nM (IC50 values) in different cell lines.
The present study has so far concentrated on ester derivatives of PDZQ which appear to
be as much as 70 times more toxic than PDZQ in colon, lung, ovarian and leukaemia
cell lines. Although these compounds did not produce high toxicity differentials
between DTD-rich and deficient cell lines, they were also found to be substrates for the
enzyme. Two ester isomers were selected for more detailed investigations. They were
shown to be cleaved by esterases to form a stable meta-phenol and an unstable para-
phenol. Flow cytometry studies on A2780 cell line, showed that after overnight treat-
ment at 10´IC50 concentrations, PDZQ produced a much stronger block in G2-M than
the two esters and the meta-phenol. On the other hand a plasmid assay on the A2780
cell line showed that at 1 mM concentrations and after chemical reduction, the meta-
phenol and the two esters were much better DNA cross-linkers than PDZQ. This
finding was confirmed by a COMET assay performed at 50 nM concentrations in the
same cell line. An apoptosis assay on A2780 cell line using fluorescein-12-dUTP, did
not detect any evidence for extensive apoptosis with any of the compounds tested. It is
therefore not possible at this stage, to derive a clear mechanism which can explain the
difference in the cytotoxicities of PDZQ and the phenol/esters. However, the overall
conclusion so far is that the toxicities are not simply due to the differences in DNA
cross-linking efficiencies. The similarity between both the structures of the meta and
para-phenols and those of known kinase inhibitors, would suggest a possible involve-
ment of kinases. Further studies are therefore underway to investigate the role of
kinases in the cytotoxicities of these phenols and esters.
The funding for this project comes from the Association for International Cancer
Research.Poster Presentations 67
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COMBINATORIAL PARALLEL SYNTHESIS AND EVALUATION
OF CELL GROWTH INHIBITORY PROPERTIES OF
SUBSTITUTED CHALCONES NJ Lawrence,1* D Rennison,1,2 AT McGown,2
S Ducki,1,2 LA Gul1 and N Khan1, 1Dept Chemistry, UMIST, PO Box 88,
Manchester M60 1QD, UK: 2. CRC Section of Drug Development, Paterson
Inst., Manchester M20 4BX, UK
A series of 644 chalcones was prepared by solution phase parallel combinatorial
synthesis using the Claisen-Schmidt base-catalysed aldol condensation of substituted
acetophenones and benzaldehydes. The cytotoxicity of these chalcones was deter-
mined directly from the crude products in 96 well microtitre testplates. This method
revealed seven chalcones of IC50 less than 1 mM of which 4-hydroxy-2,4,6,3¢-tetram-
ethoxychalcone was the most active [IC50 (K562) 30 nM].
In total, 23 substituted acetophenones were applied in this study along with 28
substituted benzaldehydes (selected randomly) to afford 644 chalcones. This provided
16 hits, a ‘success’ rate of 2.5%. The saving in time is impressive. The 644 chalcones
were prepared and evaluated in approximately 20 days. We estimate that it would take
approximately 850 days to prepare and test the same number of chalcone in a conven-
tional serial manner. The most active compound 4-hydroxy-2,4,6,3’-tetramethoxy-
chalcone is impressively cytotoxic (IC50 30 nM) and presents a compound of great
potential. We will report on its mode of action and its potential use as a drug to target
tumour vasculature. The method clearly shows that in vitro cell growth inhibition can
be used as an assay for high throughput screening.
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SYNERGISTIC EFFECTS BETWEEN LY294002, A SPECIFIC
PI-3 KINASE INHIBITOR AND DOXORUBICIN IN MDA-MB-
231 BREAST CANCER CELLS LSM McCarragher1, KA Al-Sakkaf2, BL
Brown1 & PRM Dobson2, 1Department of Human Metabolism and Clinical
Biochemistry; 2Institute for Cancer Studies, Sheffield University Medical
School, Sheffield, UK
The need for new approaches to cancer therapy is clear and cellular signalling path-
ways offer special targets. These novel modalities could overcome, at least in part, the
major problems which occur with the current generation of drugs. Although it should
be possible to use anti-signalling agents as the drugs of choice, the aim of this work
was to investigate possible synergistic reactions between signalling drugs and ‘clas-
sical’ chemotherapeutics, with the objective of lowering the doses of DNA-damaging
drugs. The PI-3 kinase pathway is a major survival pathway expressed in the majority
of cancers including those of the breast. We investigated the possible synergistic
effects of two different treatments, LY294002, a specific PI-3 kinase inhibitor and
doxorubicin, a classical cytotoxic agent. The aim of this study was to achieve a similar
effect seen using a high dose of doxorubicin, but using a much lower dose of the drug
in order to reduce its non-specific cytotoxicity, in combination with a low dose of
LY294002. MDA-MB-231 breast cancer cells were preincubated with LY294002 (1
mg/ml) for 30 minutes followed by 8–1000 ng/ml doxorubicin for 48 hours. Growth
inhibition was assessed by measuring cell numbers using a Coulter counter. Cell cycle
analysis was carried out using flow cytometry and the In Situ Nick Translation assay
was used to detect DNA fragmentation (used as a monitor of apoptosis). Drug synergy
was detected with lower doses of doxorubicin (8 & 10 ng/ml) giving a percentage
growth inhibition of 45% as single treatments and 61% and 72% respectively in the
presence of 1 mg/ml LY294002 (4.3% growth inhibition as a single treatment).
Significant differences were seen between doxorubicin alone and in combination with
LY294002 (F=7.29; P<0.01) suggesting synergistic affects. Growth inhibition, as a
measure of percentage loss of control, was supported by cell cycle analysis showing
enhanced G2 arrest. At these low doses of doxorubicin, DNA fragmentation was not
detected. This study supports the investigation of the inhibition of survival pathways
as direct targets for cancer therapy.
We are grateful to Yorkshire Cancer Research for funding.
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ZOLEDRONATE INDUCES APOPTOSIS OF BREAST
CANCER CELLS IN VITRO IN COMBINATION WITH
PACLITAXEL AND TAMOXIFEN: EVIDENCE FOR SYNERGISTIC
EFFECTS S Jagdev*1, P Croucher2, R Coleman1, 1Weston Park Hospital,
Sheffield, 2University of Sheffield, Sheffield, UK
Bisphosphonates are widely used in the treatment of breast cancer-induced bone
metastases both alone and in combination with other antineoplastic therapies. In the
adjuvant setting, recent clinical data suggest that the use of bisphosphonates may
affect the development of extra-skeletal as well as skeletal metatstases. We have
previously shown that the potent third generation bisphosphonate zoledronate signifi-
cantly reduces MCF7 and MDA 231 cell number and induces apoptosis in a dose-
dependent fashion in vitro. We have also recently demonstrated that these effects on
breast cancer cell apoptosis may be mediated via inhibition of enzymes of the meval-
onate pathway. The aim of this present study was to investigate the effects of short
term exposure to zoledronate on MCF7 breast cancer cell apoptosis. We also investi-
gated the effects of combining zoledronate with tamoxifen and with taxol on at clini-
cally relevant concentrations on breast cancer cell apoptosis. MCF7 cells were
exposed to zoledronate (100 mM) for 2, 6, 24 and 72 hours. There was a significant
increase in the proportion of apoptotic cells, as measured by a flourescence in situ
nick translation assay, after 2 and 6 hours of exposure to zoledronate with a corre-
sponding reduction in healthy cell number compared with control. Treatment with a
combination of zoledronate (10 mM) and taxol (2 nM) resulted in a four-fold increase
in the levels of apoptosis compared with either drug alone. The combination of zole-
dronate (10 mM) and tamoxifen (0.01 mM) resulted in a greater than two-fold increase
in the proportion of cells showing changes in nuclear morphology characteristic of
apoptosis. These data suggest that exposure to zoledronate for as short a period as two
hours is effective in inducing significant levels of MCF7 cell apoptosis. The combina-
tion of zoledronate and taxol may have additive effects on breast cancer cell apoptosis
and there may be evidence for a synergistic effect when tamoxifen and zoledronate are
combined. These observations warrant further in vitro and in vivo investigation.
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SELECTIVE TARGETING OF THE NOVEL
CYCLOPENTA[g]QUINAZOLINE-BASED THYMIDYLATE
SYNTHASE (TS) INHIBITORS CB300638 AND CB300907 TO a-FOLATE
RECEPTOR OVER-EXPRESSING CELLS IN VITRO D Theti*, C Melin, V
Bavetsias, L Skelton and AL Jackman, CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, Sutton, Surrey, UK
The a-isoform of the folate receptor (a-FR) is a high-affinity, low-capacity trans-
porter of folic acid and reduced-folate co-factors (Kd=0.1–1 nM) when upregulated or
constitutively over-expressed. Although levels of the a-FR are either absent or present
at low to moderate levels in normal tissues, the receptor can be constitutively over-
expressed to very high levels in some solid tumours e.g. in ovarian with high inci-
dence. Thus, over-expression of the a-FR may be an exploitable property of some
tumours, allowing the selective delivery of chemotherapeutic agents into tumour cells
and consequent inhibition of intracellular targets such as TS. Quinazoline-based TS
inhibitors such as raltitrexed (RTX) and ZD9331 bind to the a-FR with high affinities
(close to that of folic acid), but preferentially utilise the ubiquitously expressed
reduced-folate carrier (RFC) to gain entry into cells (Km’s=1–2 mM). However,
compounds with lower affinities for the RFC, but high affinities for the a-FR are
predicted to be highly selective for a-FR over-expressing cells compared with normal
tissues. The pure 6S-isomers of the novel cyclopenta[g]quinazoline-based compounds
(with dipeptide-based ligands), CB300638 and CB300907 are potent TS inhibitors
(Kiapp=0.52 and 0.16 nM respectively) with low affinities for the RFC (Km’s>100
mM) and high affinities for the a-FR (close to that of folic acid). Consistent with these
data, under physiological conditions of reduced-folates (20 nM leucovorin; LV),
CB300638 and CB300907 are ~250-fold more potent against A431-FBP cells (trans-
fected with the a-FR) (IC50=4 and 15 nM respectively) compared to neo-transfected
A431 cells (IC50=800 and 1500 nM respectively). A 160-fold reversal in the activities
of these compounds against A431-FBP cells in the presence of 1 mM folic acid is
consistent with compound uptake via the a-FR. Under the same conditions, the quina-
zoline-based compound CB3717 which has a moderate affinity for the RFC (Km=43
mM) and high affinity for the a-FR (higher than that of folic acid) is less selective for
A431-FBP cells over A431 cells (IC50=270 and 1500 nM respectively). CB300638
and CB300907 have IC50’s of ~ 1000 nM in non-a-FR expressing cell lines. However,
human KB cells which constitutively over-express the a-FR are highly sensitive to
these agents, with IC50’s ranging from 3.7–24 nM, which increases by up to 100-fold
in the presence of 1 mM folic acid. This is in contrast with ZD9331 and RTX, which
have similar activities in the presence and absence of 1 mM folic acid. Together, these
data suggest that in the over-expressed-state, the a-FR can be exploited to selectively
deliver TS inhibitors into tumour cells and that CB300638 and CB300907 are two
examples of compounds with these properties.68 Poster Presentations
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USE OF cDNA ARRAY METHODOLOGY TO ASSESS
RESISTANCE TO TS INHIBITORS AND POTENTIAL FOR CO-
EXPRESSION OF IMPORTANT ONCOGENES W Wang*, J Cassidy and HL
McLeod, Dept of Medicine and Therapeutics, University of Aberdeen,
Foresterhill, Aberdeen AB25 2ZD, UK
Thymidylate synthase (TS) catalyses the de novo synthesis of dTMP from dUMP and
is an attractive target for the design of anticancer drugs. TS inhibitors (e.g. 5-fluo-
rouracil [5FU] and tomudex [TDX]) have been used for treatment of various kinds of
human cancers. Chemoresistance is still a major barrier to the clinical use of these
agents. The development of cDNA array techniques makes it possible to quantitate the
expression of thousands of genes in a single experiment. This technique has been used
to analyze aberrant gene expression in a variety of human cancers. In this project, the
expression patterns of 1176 genes was observed from 5 pairs of TS inhibitor resistant
cell lines (colorectal cancer: H630-TDX, H630–5FU and RKO-TDX; breast cancer:
MCF-7-TDX; lymphoblast: W1L2-TDX). The aim of this work is the analysis of
global gene expression patterns in drug resistant cell lines to identify potential molec-
ular targets for drug development. Expression of 20–35% genes on the array was
detected in the different cell lines. The expression levels of drug resistant cell lines
were compared with those of parent cell lines. Since the variation of 95% genes from
the same cell line was lower than 2-fold, this standard was used to judge over- or
under-expression. cDNA array results demonstrated that gene expression patterns
were highly variable between different cell lines and more genes were overexpressed
in 5FU resistant H630 cell line than the TDX resistant cell lines. Only TS mRNA is
overexpressed in all of the drug-resistant cell lines (1.8 to 4.5 fold). Northern blotting
analysis confirmed the cDNA array results. TS protein is overexpressed in every resis-
tant cell line and at much higher level comparing to mRNA. This suggests that post-
transcriptional and translational manipulations are also involved in the TS
dysregulation. Southern blotting indicates that TS overexpression is derived from
gene amplification. c-yes oncogene, situated 50 kb away from TS, was also amplified
and the overexpression of c-yes mRNA and protein was detected in 4/5 drug-resistant
cell lines. Unexpectedly, c-yes gene was amplified, but mRNA and protein down-
regulated, in the drug-resistant lymphoid cell line W1L2. Conclusions: 1. cDNA array
is a reliable measure for molecular genetic analysis of drug resistance. 2. TS appears
to drive gene amplification, carrying along adjacent genes such as c-yes oncogene.
Overexpression of the latter may confer the drug resistant tumour more aggressive
biological behavior. 3. Some as yet unknown factors block the expression of C-Yes in
drug-resistant non-malignant cell line W1L2.
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CASSETTE DOSING IS A VALID APPROACH TO EVALUATE
THE PHARMACOKINETICS OF TRISUBSTITUTED PURINES
SUCH AS OLOMOUCINE, ROSCOVITINE AND BOHEMINE FI Raynaud,
BP Nutley, PM Goddard, P Fischer, S McClue, D Lane and P Workman, CRC
Centre for Cancer Therapeutics, The Institute of Cancer Research, 15
Cotswold road, Sutton, Surrey, UK; *Cyclacel Limited, Dundee Technopole,
James Lindsay Place, Dundee, UK
Pharmacokinetic analysis is frequently a bottleneck in drug development. Cassette
dosing or cocktail dosing allows high pharmacokinetic throughput by administering to
animals a combination of analogues. The use of liquid chromatography mass spec-
trometry (LC-MS/MS) with multiple reaction monitoring allows the specific and
sensitive measurement of the compounds in the same sample. In order to validate the
use of cassette dosing, Balb C– mice were injected with either a mixture of
olomoucine, roscovitine and bohemine each at 16.6 mg/kg, or with the individual
compounds at 50 mg/kg. Separation of the 3 compounds and the internal standard, 
6 benzylaminopurine was achieved on 5 cm ABZ+ column with a flow rate of 
0.6 ml/min with a 3 minutes gradient of 20–100% methanol in formic acid. Selected
reaction monitoring of the appropriate parent ions and daughter fragments was
subsequently performed. A standard curve was produced in mouse plasma.
Pharmacokinetic parameters were calculated using non-compartmental analysis. The
pharmacokinetic parameters estimated derived from compounds dosed in cocktail
showed that the overall ranking of the compounds was maintained; roscovitine having
the highest AUC and the lowest clearance. Furthermore, the pharmacokinetic parame-
ters of drugs in combination showed highly significant correlation with that of drugs
alone (spearman test r= 0.90 for olomoucine, r=0.87 for bohemine and r=0.99 for
roscovitine). The results suggest that cassette dosing is a valid approach to evaluate
the pharmacokinetics of trisubstituted purine analogues. Our data suggest that roscov-
itine, which is the most potent analogue of the 3 compounds and shows the best phar-
macokinetic profile, is a suitable pharmacokinetic standard for cassette dosing of
trisubstituted purine derivatives. This work was supported by the Cancer Research
Campaign and Cyclacel Ltd.
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OXALIPLATIN (L-OHP) DOES NOT INFLUENCE THE
PHARMACOKINETICS OF 5-FLUOROURACIL (5-FU) SP
Joel1, F Richards2, F Halstead2, M Seymour2, ICRF Depts of Medical
Oncology, St Bartholomew’s Hospital, London and Cookridge Hospital Leeds,
UK
Background The combination of 5-FU and L-OHP is used increasingly in the treat-
ment of colorectal cancer (CRC). We have previously suggested that L-OHP may alter
the pharmacokinetics (PK) of 5-FU, based on a between-patient comparison (ASCO
1998, ABS 777). This has been investigated further in a crossover study.
Patients/Methods Ten patients with advanced CRC received, in random order two
weeks apart, two cycles of chemotherapy using the Modified de Gramont (MdG) and
Oxaliplatin-MdG (OxMdG) regimens, defined as follows: MdG: 350 mg leucovorin
(LV) i.v. infusion over 2 hrs; then 5-FU 400 mg/m2 i.v. bolus over 5 minutes; then 5-
FU 2400 mg/m2 i.v. infusion over 46 hours. OxMdG: the same as MdG, except for the
addition of L-OHP 85 mg/m2 i.v. infusion over 2 hours concurrent with LV. Blood
samples were taken at ten timepoints out to 4 hours, and at 24 hours. Samples were
immediately cold-spun and the plasma frozen. Plasma 5-FU was determined by HPLC
analysis. 5-FU PK were derived using a 1 compartment model with linear and non-
linear elimination pathways, as previously described (Br J Cancer 70:724–8, ‘94).
The Km of the non-linear pathway was set at 1.95 mg/mL (15 mM), representing dihy-
dropyrimidine dehydrogenase catabolism. The AUC0–24 was determined by the trape-
zoidal method.
Results The mean 5-EU concentration-time curves with and without L-OHP are
virtually identical. PK data are summarised in the table (values ± s.d.). There are no
differences in any PK parameter for 5-FU with or without L-OHP (paired t-test
>0.10).
Table 1. 5-FU PK ± L-OHP (Mean ± SD)
Vd Vmax Kelim AUC0–24
(L) (mg/ml.hr–1) (hr–1)( mg/ml.hr–1)
5-FU alone 17.3 ± 4.9 87.3 ± 10.1 3.7 ± 0.8 23.5 ± 4.0
5-FU + L-OHP 17.0 ± 7.8 81.7 ± 6.4 3.8 ± 0.6 24.8 ± 4.8
Conclusions Using a within patient comparison L-OHP does not influence the PK
of 5-FU administered using this schedule. These data confirm our previous finding
that, with meticulous sampling and assay techniques, 5-FU PK show only moderate
interpatient variability.
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FACTORS INFLUENCING THE PHARMACODYNAMICS OF
THE HPMA DOXORUBICIN COPOLYMER, PK1 R Mikaty and
PM Loadman, Clinical Oncology Unit, University of Bradford, Bradford BD7
1DP, UK
PK1 is a synthetic N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-
doxorubicin (Dox) conjugate which is currently undergoing Phase II trials in the UK.
The activity of PK1 is dependent on endocytosis of the polymer and the release of
Dox from the conjugate via thiol dependent proteases. Murine colon tumours
MAC15A and MAC26 have previously been shown to have differing responses to
PK1 thought to be due in part to differences in enhanced permeability and retention
(EPR) and release profile of doxorubicin in vivo (Clin. Can. Res., 1999, 5 3682–88).
In order to address in more detail the factors which influence the pharmacodynamics
of PK1, we investigated both the lysosomal protease expression and the in vitro Dox
release from the polymer in a wide range of murine tumours. We also investigated the
anti-tumour response in the tumour with the highest protease expression to confirm
whether increased protease expression in tumours would lead to increased activity of
PK1 in vivo.
Dox was measured by an established HPLC assay and the lysosomal cysteine
protease activity by combining specific inhibitors with the measurement of naphthyl-
amide cleavage from specific protease substrates. Lysosomes were prepared from
tumour homogenates by differential centrifugation.
The rate at which Dox is released from the tumour preparations including MAC
32, 13, 31 26, 15A, 16A and MAC29, varied greatly from 1242 ng/h/mg protein in the
MAC 30T to <100 ng/h/mg from the less responsive MAC 26. Lysosomal expression
of cathepsin H, L and B varied between tumour type with MAC30T again having the
greatest activity of cathepsin H (830 ± 10 ´ 10–5 U/mg) cathepsin L (144 ± 20 ´ 10–5
U/mg) and cathepsin B (115 ± 9 ´ 10–5 U/mg). These data were supported by immuno-
histochemical observations.
In vivo anti-tumour activity against the high cathepsin expressing MAC30T grown
in NMRI mice was impressive (6 days growth delay p<0.05, PK1 40 mg/kg iv) when
compared to Dox alone (10 mg/kg iv) where no significant growth delay was seen
compared to controls (p>0.05). EPR in MAC30T measured by an established Evans
Blue assay showed that the EPR effect was not as great as shown previously with the
responsive MAC15A (Clin. Can. Res., 1999, 5 3682–88).
We have shown that protease expression is clearly going to influence the pharma-
codynamics of PK1 but must be considered in conjunction with the EPR properties of
a tumour.Poster Presentations 69
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DESIGN, SYNTHESIS AND DEVELOPMENT OF NOVEL
INHIBITORS OF HUMAN DNA-TOPOISOMERASE I
DJ Minchera*, G Kaya, JEL McDonalda, A Turnbulla, MC Bibbyb and JA
Doubleb, aSchool of Life Sciences, Napier University Edinburgh EH10 5DT,
UK, bClinical Oncology, University of Bradford BD7 1DP, UK
We have shown that anthraquinones conjugated to amino acids via conformationally-
flexible simple spacer groups such as polymethylenic chains affords a library of novel
topoisomerase inhibitors (coded NU:UB) with broad spectrum anti-tumour activity
both in vitro and in vivo. [DJ Mincher, A Turnbull, MC Bibby, JA Double, PS
Gilmour, G Lowe, G Kay and ID Hickson, Br. J. Cancer (1999), 80, 50]. The majority
of conjugates bind to DNA by mixed modal part intercalative, part minor groove
binding mechanisms and show dual inhibitory effects against topo I and topo II a and
b isoforms. Towards defining the structural requirements for topo I vs. topo II selec-
tivity, we now show that the conformation of the spacer group can act as a ‘molecular
switch’ between topo I and II. For example, the conformationally unrestrained
butyl-spaced L-Phe conjugate NU:UB 77 is a catalytic inhibitor of topo II (inhibition
of pBR 322 plasmid DNA-relaxation complete at 25 mM and 50 mM,  a and  b
isoforms respectively) but does not stimulate enzyme mediated DNA cleavage. In
stark contrast the conformationally restricted L-Phe analogue NU:UB 150
containing a rigid 1,4 diaminocyclohexane spacer, does not inhibit either topo II or
topo I mediated DNA relaxation. NU:UB 150 does, however, stimulate topo I medi-
ated cleavage of DNA (45% nicked plasmid DNA at 25 mM) in a manner analogous
to camptothecin. We conclude that the switch from topo II to topo I observed between
NU:UB 77 and NU:UB 150 is directly related to the concomitant switch between prin-
cipally intercalative binding (QE50 2.5 mM; QH50 4.8 mM) shown by NU:UB 77, and
the principally groove binding (QE50 6.5 mM; QH50 2.32 mM) mechanisim observed
for NU:UB 150 (as shown by fluorescence quenching experiments). The modulation
of the DNA binding mode by design of appropiate conformationally restricted
spacers, which direct the ligand to the minor groove, favours the design of new topo I
inhibitors. NU:UB 150 has shown notable in vitro activity against the highly refrac-
tory MAC15A murine adenocarcinoma cell line [IC50 3.5 mM (camptothecin 2.0
mM)]. The pattern of cell kill shown by a series of analogues of the prototype topo I
inhibitor NU:UB 150 is correlated to the expression of the enzyme and formation of
cleavable complexes in the MAC15A cell line. The data is valuable for the design of
clean inhibitors of topo I which do not suffer from disadvantages of the structural
lability of the camptothecin family.
P162
NOVEL DUAL TOPOISOMERASE (I AND II) INHIBITORS
DISPLAYING HIGH SELECTIVITY IN COLON CARCINOMA
DJ Minchera*, A Turnbulla, S Petterssona MC Bibbyb and JA Doubleb, aSchool
of Life Sciences, Napier University Edinburgh EH10 5DT, UK, bClinical
Oncology, University of Bradford BD7 IDP, UK
We have shown that spacer-linked anthraquinone-amino acid/peptide conjugates
exhibit a spectrum of inhibitory activity against DNA-topoisomerase enzymes in vitro
and broad-spectrum cytotoxicity in panels of human and animal tumour cell lines.
[International Patent No. WO: 99/65886 publ. 23 Dec 1999]
The (propyl-spaced) L-proline conjugate NU:UB 31 and the (butyl-spaced) L-
proline conjugate NU:UB 43 have emerged as dual inhibitors of human DNA topo-
isomerase I and the individual isoforms (a and b) of topoisomerase II. Their dual
inhibiting activity may allow circumvention of drug resistance mechanisms associated
with changes in expression of one of the proteins. The pattern of enzyme inhibition is
complex because the conjugates exhibit characteristics of both pure catalytic
inhibitors and topoisomerase poisons. NU:UB 31 and 43 each inhibited topo I-medi-
ated relaxation of plasmid pBR322 DNA (IC50 50 mM) and topo II-mediated DNA-
relaxation [IC50 10 mM (a-isoform); IC50 25 mM (b-isoform)]. The conjugates are also
able to stimulate topoisomerase-mediated cleavage of plasmid DNA for example,
NU:UB 31 (at 10 mM) produced 62% nicked DNA compared to camptothecin which
gave 90% cleavage at 10 mM concentration. Unlike camptothecin, however, both
NU:UB 31 and 43 antagonised the cleavage reaction at higher concentrations. Greater
levels of DNA cleavage were observed with topo I than either topo IIa or IIb at equiv-
alent drug concentrations.
In Vitro chemosensitivity data from a broad range of tumour cell lines has now
indicated high selectivity for colon cancer in which topo I levels are commonly over-
expressed. NU:UB 31 (typically had IC50 values in the 3–5 mM range and NU:UB 43,
containing the longer spacer, had IC50 values between 1 and 4 mM against a panel
which include COLO 205; HCC-2998; HCT-116; HCT-15; HT29; KM12; SW-620.
Intrinsic topo I levels in this panel varied by no more than 2-fold but overall log-linear
correlations between NU:UB-induced cleavable complexes and growth inhibition
indicate the importance of cleavable complexes and complex stabilisation in the
mechanism of cell kill in this panel of cell lines. The pattern of cell kill, and topo-
mediated DNA cleavage are correlated to the 3-dimensional structures of NU:UB 31
and NU:UB 43 and to the p53 status of the cell lines.
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IN VITRO ACTIVITY OF XR5944, A DUAL TOPOISOMERASE
I AND II INHIBITOR B Kofler1, W Dangerfield1, L Smith1, AJ
Stewart1, S Okiji1, BC Baguley2, WA Denny2, P Charlton1, 1Xenova Ltd,
Slough SL1 4EF, UK, 2Auckland Cancer Society Research Centre, University
of Auckland, NZ
Topoisomerases are enzymes involved in the resolution of topological problems
arising during the processes of DNA replication and recombination. Topoisomerase I
(Topo I) cleaves single stranded DNA whilst topoisomerase II (Topo II) cleaves
double stranded DNA. Both enzymes are thus essential for the viability of all eukary-
otic cells.
Inhibition of topoisomerases is a mechanism by which many established anti-
cancer agents function. For example camptothecins and etoposide target Topo I and
Topo II respectively. However the efficacy of compounds, which only target a single
enzyme, is often impaired due to the development of resistance resulting from alter-
ations of expression levels of that enzyme. Several agents have been recently reported
which are dual inhibitors of Topo I and Topo II (DACA/XR5000 (acridine carbox-
amide) and TAS-103 (quinoline derivative)) and are proposed to avoid this atypical
drug resistance. Here we describe the in vitro properties of a novel bisphenazine,
XR5944 which is also a dual topoisomerase inhibitor.
XR5944 was shown to be an exceptionally potent cytotoxic agent in a range of
tumour cell lines of various origin (lung, colon, breast, ovarian, leukaemic). IC50S for
XR5944 were typically sub-nanomolar making XR5944 considerably more potent
than either XR5000 or TAS-103 and indeed superior to many current clinical agents
(Doxorubicin, Topotecan, Paclitaxel). Studies with cell lines displaying atypical drug
resistance revealed that XR5944 retained the activity seen in the corresponding
parental cell line hence avoiding this mechanism of resistance. XR5944 also retained
significant potency in P-glycoprotein (P-gp) and Multidrug Resistant Protein (MRP)
expressing cell lines.
Purified enzyme assays, designed to look at formation of topo-dependant stabilised
cleavable complexes, confirmed that XR5944 poisoned both Topo I and Topo II
although XR5944 may have a preference for Topo I. Slight differences in cleavage
patterns to TAS-103 and XR5000 indicated that there may be subtle differences in
mechanism of action between the three stated molecules. However as with the cyto-
toxicity assays XR5944 appeared to be more potent than XR5000 or TAS-103 and the
action of XR5944 on both Topo I and Topo II may be due to its ability to intercalate
DNA as shown by DNA unwinding assays.
In summary, the combination of potency and dual activity of XR5944 makes this
molecule a promising candidate for anticancer treatment.
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THE IN VIVO ANTITUMOUR ACTIVITY OF XR5944, A
NOVEL, POTENT TOPOISOMERASE INHIBITOR
H Lancashire, DE Bootle, MB Baker, P Mistry, C Liddle, W Dangerfield, WA
Denny1, PA Charlton, Xenova Ltd, Slough SL1 4EF, UK, 1Auckland Cancer
Society Research Centre, University of Auckland, NZ
Inhibitors of topoisomerase are widely used in the treatment of cancer. Such treat-
ments include inhibitors of topoisomerase I (camptothecin analogues), or topoiso-
merase II (etoposide and doxorubicin). Recently, several compounds have been
demonstrated to have activity against both topoisomerase I and II (e.g. XR5000, into-
plicine and TAS-103). This approach has the advantage of avoiding drug resistance
due to alterations in cellular levels of either of the two enzymes, and may also allow
the drug to act at several points in the cell cycle. We report here a novel bis-phenazine,
XR5944, which is also an inhibitor of both topoisomerase I & II. In vitro, XR5944
demonstrated exceptional activity when tested against a panel of human cell lines, and
exhibited greater potency than several other topoisomerase inhibitors (e.g., topotecan,
doxorubicin, etoposide and TAS-103). In addition, XR5944 was unaffected by atyp-
ical drug resistance, and retained potent activity in cell lines overexpressing P-glyco-
protein (P-gp) or Multidrug Resistance Protein (MRP). In the present study, we have
evaluated the in vivo activity of XR5944.
In a hollow fibre model, XR5944 was active against a panel of human tumour cell
lines. In this model, where cells are grown in ‘cell max’ fibres which are implanted
subcutaneously or intraperitoneally into female CD1 nude mice, XR5944 (5 mg/kg
i.v. qdx5) evoked almost complete inhibition (77–94%) of proliferation against three
human cell lines (H69 SCLC, HT29 colon and HCT-15 colon). In comparison, TAS-
103 induced a 13–66% inhibition at its MTD, using the same schedule.
This exceptional activity of XR5944 translated well to solid human tumour
xenograft models. Treatment of female CD1 nude mice bearing H69 SCLC xenografts
with XR9544 (5 mg/kg iv. q4dx3) caused tumour stasis for >20 days, whilst 10–15
mg/kg i.v. q4dx3 induced complete tumour regression. In contrast, topotecan (20
mg/kg i.v. q4dx3) only slowed the tumour growth rate compared with control animals.
In the resistant HT29 colon carcinoma model, XR5944 (15 mg/kg i.v. q4dx3) induced
tumour regression, whereas TAS-103, dosed at its MTD, (45 mg/kg i.v. q7dx3) only
induced a delay in tumour growth, compared with control tumours. In all studies,
XR5944 was well tolerated at all the efficacious doses and schedules used.
These data show that XR5944 exhibits exceptional antitumour activity, and good
tolerance at efficacious doses, making it a promising compound for further develop-
ment.70 Poster Presentations
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MODULATION OF TOPOISOMERASE IIa EXPRESSION AT
CONFLUENCE BY MINOR GROOVE BINDERS B Tolner, JA
Hartley and D Hochhauser, Royal Free and University College Medical
School, University College London, 91 Riding House Street, London W1P
8BT, UK
This study aims to understand processes involved in cellular alteration of topoiso-
merase IIa (top2a) gene expression at confluence and how this is altered in tumour
cells. The expression of top2a is regulated by cellular proliferation with transcrip-
tional downregulation in confluent cells. Confluence induced downregulation is
modulated through the inverted CCAAT box 2 (ICB2) at position –108 to –104 (J.
Biol. Chem. 271: 16741–7, 1996) and may increase resistance to poisons such as
etoposide. We examined the DNA-protein interactions within the top2a promoter in
exponential and confluent phase NIH3T3 cells. Using electrophoretic mobility shift
assay and in vitro DNase I footprint experiments, ICB2 was shown to bind the tran-
scription factor NF-Y in nuclear extracts from cells growing in both exponential and
confluent conditions. However, a distinct difference in antibody supershift (NF-YA
and B) patterns and ICB2 footprinting was observed when comparing extracts from
exponential and confluent phase cells. This suggests involvement of an additional
factor (to NF-YA and B) which is expressed at confluence and results in top2a down-
regulation via ICB2. The DNA minor groove binding agents distamycin, Hoechst
33342 and Hoechst 33258 were demonstrated to occupy regions surrounding the
inverted CCAAT box in the top2a promoter and displaced proteins binding to this box
when incubated with cell extracts. Addition of both Hoechst 33342 and Hoechst
33258 to NIH3T3 cells at confluence resulted in increased expression of top2a.
Therefore, DNA binding drugs which block transcription factor activation of the
promoter may deregulate top2a and this strategy may be of value in modifying gene
expression and modulating chemosensitivity.
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ACTIVATION OF CB 1954 BY NQO2 – A NOVEL AND DIRECT
ANTI-TUMOUR THERAPY Richard J Knox*, Roger G Melton,
Surinda K Sharma and Philip J Burke, Enzacta Group Plc, Porton Down
Science Park, Salisbury SP4 OJQ, UK
A novel prodrug activation system has been discovered that is endogenous in human
tumor cells. A latent enzyme-prodrug system is switched on by an engineered non-
biogenic, small molecule co-substrate. This ternary system is inactive if any one of the
components is absent. CB 1954 [5-(aziridin-l-yl)-2,4-dinitrobenzamide] is an anti-
tumor prodrug that is activated in certain rat tumors via its 4-hydroxylamine deriva-
tive to a potent difunctional alkylating agent. However, human tumor cells are
resistant to CB 1954 because they are unable to catalyze this bioactivation efficiently.
A human enzyme has been discovered that can activate CB 1954 readily and shown it
to be commonly present in human tumor cells. The enzyme is NQO2 (NAD(P)H
quinone oxidoreductase 2) but its activity is normally latent and a non-biogenic co-
substrate such as NRH [nicotinamide riboside (reduced)] is required for enzymatic
activity. There is a very large (100–3000-fold) increase in CB 1954 cytotoxicity
towards either NQO2-transfected rodent or non-transfected human tumor cell lines in
the presence of NRH. A large anti-tumour effect is observed against human tumour
xenografts treated with CB 1954 and NRH in vivo. There was no significant anti-
tumour effect when these agents were administered separately.
Other reduced pyridinium compounds can also act as co-substrates for NQO2. In
particular, l-carbamoylmethyl-3-carbamoyl-1,4-dihydropyridine was shown to be a
co-substrate for NQO2 with greater stability than NRH, with the ability to enter cells
and potentiate the cytotoxicity of CB 1954. In vivo, the combination of this compound
with CB 1954 produced an even greater anti-tumour effect than that achieved with CB
1954 and NRH. Further, this agent is synthetically accessible and suitable for further
pharmaceutical development.
NQO2 is a novel target for prodrug therapy and has a unique activation mechanism
that relies on a synthetic co-substrate to activate an apparently latent enzyme. Our
findings may reopen the use of CB 1954 for the direct therapy of human malignant
disease.
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A NOVEL NITROREDUCTASE FOR CB 1954 ACTIVATION IN
CANCER GENE THERAPY GM Anlezark1, T Vaughan2, NP
Michael3, NP Minton1, H Murdoch1, MA Sims1, E Fashola-Stone1, S Wigley1,
1Centre for Applied Microbiology and Research, Porton Down, Salisbury SP4
OJG, 2Dept of Biology, Univ of York YO10 5YW; 3Nycomed-Amersham,
Cardiff Laboratories CF4 7YT, UK
A novel nitroreductase that can activate the prodrug CB 1954 has been isolated from a
Bacillus species by ammonium sulphate precipitation and ion exchange chromatog-
raphy. The N-terminal protein sequence identified the encoding gene as a homologue
of a hypothetical NAD(P)H oxidoreductase of B. subtilis. The gene was obtained as a
PCR product by reverse genetics, cloned and the entire nucleotide sequence deter-
mined. The recombinant protein was overexpressed in an E. coli host, and its proper-
ties compared with those of the previously known E. coli B nitroreductase (NTR) and
Walker DT-diaphorase (DTD) both of which activate CB 1954. The new protein
reduced the prodrug CB 1954, and HPLC analysis of the products demonstrated that
only the cytotoxic 4-hydroxylamine derivative was formed. In this property it more
closely resembles DTD than NTR. Its affinity for CB 1954 and turnover of the
substrate were higher than that of NTR or DTD. In common with both DTD and NTR
it could use the quinone, menadione as electron acceptor and its activity with this
substrate was potently inhibited by dicumarol. However, in contrast to the other
enzymes it showed a marked preference for NADPH as cofactor and therefore could
not be classified as a DT-diaphorase (EC 1.6.99.2). It also used the flavin FMN as
acceptor with high affinity, and FAD, although with a four fold lower affinity. It is a
flavoprotein with a monomeric molecular mass of 21.5 kDa by calculation from the
deduced protein sequence and SDS-PAGE. In in vitro cytotoxicity tests an enhanced
cytotoxicity of CB 1954 was demonstrated when V79 cells were incubated with
prodrug, NADPH and enzyme. The improved properties of this enzyme compared
with those of the previously known NTR and DTD indicate that it may overcome their
limitations for applications in cancer gene therapy.
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SYNTHESIS AND ANTI-CANCER ACTIVITY OF DT-
DIAPHORASE ACTIVATED NAPHTHOQUINONE PRO-
DRUGS AND COMPARISON WITH EO9 G Steans1,2, PM Loadman1, DJ
Maitland2 and RM Phillips1, 1Clinical Oncology Unit; 2Chemistry and Forensic
Science, University of Bradford, Bradford BD7 1DP, UK
The indoloquinone EO9 was developed as a potential DT-diaphorase (DTD,
NAD(P)H:Quinone oxidoreductase, EC 1.6.99.2) directed bioreductive anti-cancer
drug. EO9 was selected for clinical trial due to its unique mode of action, selectivity
and potency, both in vitro and in vivo. 3 partial remissions were seen in Phase I trials,
but these results were not replicated in Phase II. The failure in the clinic is thought to
be due to inadequate drug delivery to the tumour as a result of rapid pharmacokinetic
elimination in conjunction with poor penetration through multicell layers (Phillips et
al., 1998, Br J Cancer 77; 2112). The aims of this project were to develop a drug with
similar properties to EO9 in terms of bioreductive activation by DTD but with
improved pharmacological characteristics in terms of drug delivery. From a series of
12 substituted naphthoquinones, 3 were identified as having comparable biochemical
and cytotoxicity profiles to EO9. These were the compounds GS2 (2-aziridinyl-5-
hydroxy-1, 4-naphthoquinone),GS3 (2,3-diaziridinyl-5-hydroxy-1,4-naphthoquinone)
and GS12 (2-aziridinyl-6-hydroxymethyl-1,4-naphthoquinone). GS3 was comparable
to EO9 in terms of substrate specificity for purified human DTD (13.02 ± 2.51 and
19.9 ± 0.5 mmol/min/mg respectively, whilst GS2 and GS12 were considerably better
substrates (208.9 ± 5.9 and 199.8 ± 6.0 mmol/min/mg respectively) for DTD than
EO9. Sensitivity to 3 DTD rich cell lines (H460, A549, HT29) and the DTD deficient
cell line (BE) was determined following a two hour drug exposure using the MTT
assay. Selectivity ratios (IC50 BE/IC50 H460) were 250 (GS2), 231 (EO9), 149 (GS3)
and 71 (GS12). Similar results were seen with the remaining 2 cell lines.
Pharmacological properties were determined by assessing the stability of compounds
in murine whole blood at 37°C in vitro by HPLC analysis. EO9 has a half life of 9 ± 4
min. in whole blood suggesting that the rapid elimination of EO9 in vivo is due in part
to metabolism by the blood. GS3, GS12 and GS2 have half lives in murine whole
blood of 589 ± 36, 55 ± 1 and 31 ± 2 min respectively. These results suggest that GS3
in particular may have improved pharmacological properties in terms of decreased
pharmacokinetic elimination rates in vivo over EO9. In addition, GS3 retains the
desirable properties of EO9 with regards to DTD activation and selectivity for DTD
rich cells. Further studies are required to determine whether or not these results trans-
late into improved anti-tumour activity in vivo compared with EO9.Poster Presentations 71
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A PHASE I DOSE ESCALATION TRIAL AND PHARMACO
KINETICS OF THE GDEPT PRODRUG CB1954 C Palmer, 
G Chung-Faye, R Barton*, D Ferry, J Clark, J Baddeley, D Anderson, 
L Seymour, DJ Kerr, CRC Institute for Cancer Studies, University of
Birmingham, Edgbaston, Birmingham B15 2TA, UK
CB1954 (5-(aziridin-l-yl)-2,4-dinitrobenzamide) is a substrate for the bacterial
enzyme nitroreductase which converts it into a potent bifunctional alkylating agent.
CB1954 is therefore a candidate prodrug in Gene Directed Enzyme Prodrug Therapy
(GDEPT) protocols.
CB1954 was administered by bolus intravenous injection on a three weekly cycle.
26 patients (age range 23–78, median age 62) received between one and six doses of
drug. 19/26 (73%) patients were male. 13/26 (50%) of cancers were colorectal, 3/26
(12%) gastric, 12% oesophageal and 12% mesothelioma. The first dose level explored
was 3 mg/m2, no significant toxicity was seen until the fifth dose level of 24 mg/m2.
Toxicity of intravenous CB1954
Dose level (mg/m2) Number of patients Toxicity
24 4 Diarrhoea (G2)
30 5 ALT/AST (G3)
37.5 3 Diarrhoea (G4)
Dehydration (G4)
ALT/AST (G2)
The maximum tolerated dose (MTD) was 37.5 mg/m2 with gastrointestinal and
hepatic dose limiting toxicity. No alopecia, haematological toxicity or nephrotoxicity
was seen. Pharmacokinetics of CB1954 indicated a linear relationship between dose
and area under the data (AUD) for 3 to 24 mg/m2 but there appeared to be a non-linear
effect at the higher doses. The median elimination half-life was 51 minutes and less
than 5% of the drug appeared unchanged in the urine. From in vitro studies of cells
expressing nitroreductase, the IC50 of CB1954 is between 0.1 and 10 mM. At a dose of
30 mg/m2, the serum levels were greater than 1 mM for 2 hours and greater than 0.1
mM for more than 4 hours. One patient with colorectal cancer had a fall in carcino-
embryonic antigen (CEA).
In conclusion, CB1954 is a well tolerated prodrug for the GDEPT approach. We
are now conducting phase I trials of IV CB1954 plus virally delivered nitroreductase
in patients with liver metastases.
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IN VITRO & IN VIVO STABILITY OF PURIFIED MFE 23::CPG2
FUSION PROTEIN FROM PICHIA PASTORIS J Bhatia, SK
Sharma; BR Pedley; G Boxer; L Robson; RHJ Begent and K Chester, CRC
Targeting and Imaging Group, Dept of Oncology, RFUCMS, UCL, Royal Free
Campus, London NW3 2PF, UK
The efficiency of antibody directed enzyme prodrug therapy (ADEPT) has been demon-
strated in animal studies and in clinical trails1. A new approach to achieving ADEPT
involves the use of recombinant MFE-23::CPG2 fusion protein expressed in Pichia
pastoris. MFE-23 is a phage-derived single chain Fv antibody reactive with carcinoem-
bryonic antigen (CEA)2. CPG2 is carboxypeptidase G2, an enzyme that cleaves gluta-
mate to activate a prodrug. MFE-23::CPG2 was initially expressed in E. coli, purified
using CEA-affinity chromatography and shown to specifically localise to a tumour with
favourable tumour to normal tissue ratios after 48 hr of injection; these results showed
significant improvement over those obtained with a chemical conjugate of CPG2 with
anti-CEA3. However, E.coli-expressed MFE-23::CPG2 gave low yields (0.5–1.0
mg/ml). To obtain greater yields and improve the ease of purification, MFE-23::CPG2
with a hexahistidine tag was expressed from the yeast Pichia pastoris. This resulted in a
100-fold increase in yield using purification with immobilised metal affinity chromatog-
raphy. Specific enzyme activity of the fusion protein was 81 U/mg. Immunoreactivity to
CEA was confirmed by ELISA and the presence of glycosylation by lectin binding. In
vitro stability was assessed by SDS-PAGE, western blotting, enzyme activity, size
exclusion and ELISA. These showed that MFE-23::CPG2 was stable when stored at
–80°C for more than a year. In vivo stability was determined by sub-millimetre biodis-
tribution of 125I-labelled MFE-23::CPG2 in nude mice bearing colorectal tumour
xenografts. This revealed that the fusion protein penetrated well into the tumour mass
and selectively targeted viable regions as early as 4 hr after injection. Furthermore, using
125I-labelled MFE-23::CPG2, a novel approach was developed to investigate the in vivo
stability in LS174T xenografts. This involved homogenising the isolated xenograft and
separating the proteins by SDS-PAGE. The 125I-labelled MFE-23::CPG2 within the
homogenised tumour mass was visualised using autoradioluminography. This test
showed that the radiolabelled product was intact 4 hr after injection. At this time point,
in the same animal model, the tumour: plasma ratio of CPG2 enzyme activity obtained
with MFE-23::CPG2 was 19:1. The results confirm that Pichia pastoris expressed
MFE-23::CPG2 is stable in in vivo human colorectal xenograft models. The fusion
protein is at present being prepared for a phase I clinical trial.
Research funded by the Cancer Research Campaign and the Ronald Raven Chair
in Oncology Trust.
1 Napier et al. (2000) Clinical Cancer Research 6: (2000)
2 Chester et al. (1994) Lancet 343: 455–456
3 Bhatia et al. (2000) Int J Cancer 85: 571–577
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MUTATING ADEPT ENZYME CPG2 TO REDUCE ITS
IMMUNOGENICITY DIR Spencer1*, D Purdy2, N Minton2 NR
Whitelegg3, AR Rees3, RHJ Begent1 & KA Chester1, 1CRC Targeting &
Imaging Grp., Dept Oncology, RFUCMS, UCL, London NW3 2PF, 2CAMR,
Salisbury SP4 OJG, 3Dept. Biol. Biochem, Bath Univ., Bath BA2 2AY, UK
Background Carboxypeptidase G2 (CPG2) is an enzyme derived from Pseudomonas
aeruginosa that natively cleaves c-terminal glutamic acids from peptides. No equiva-
lent exists in humans and hence this enzyme has been used successfully for antibody
directed enzyme prodrug therapy (ADEPT) in the treatment of drug resistant epithe-
lial carcinomas. These express novel tumour markers that can be targeted selectively
with antibodies. However, CPG2 is immunogenic in humans. Previously a phage
display library representing the immune response of mice immunised with CPG2 was
used to epitope map a region of CPG2 that is immunogenic in humans. Two antibody
single chain fragments (scFvs) bound to this region, CM79 and CM12. Using surface
enhanced laser desorption ionisation affinity mass spectrometry (SELDI-AMS) this
region of CPG2 was defined as incorporating the c-terminus and two loops from
sequentially remote sequences bound to both CM79 (c-terminus and one loop) and
CM12 (c-terminus and both loops). Mutating this region to epitopes no longer recog-
nised by CM79 and CM12 may result in CPG2 variants with decreased immuno-
genicity.
Results Using the epitope information from CM79 and CM12 binding to CPG2 we
have produced, using recombinant technology, a series of CPG2 mutants where each
amino acid of a selected epitope region was in-turn replaced with alanine. Two vari-
ants were produced with an epitope region replaced with sequences based on human
peptides modelled to have similar conformation to the native sequence. These CPG2
mutant variants were tested for enzyme activity by a spectrophotometric assay and for
CM79 and CM12 antibody binding by ELISA. Out of 15 CPG2 variants tested one of
the alanine mutations where arginine 162 was replaced with an alanine resulted in a
CPG2 variant that completely lost CM79 binding activity and but still retained some
CM12 binding activity. The CPG2 variant retained enzyme activity. This new variant
of CPG2 is the first to prove that immunogenic sites of this clinically important
enzyme can be removed without significantly losing enzyme activity.
Discussion Modifying the principle immunogenic sites on CPG2 may reduce
overall immunogenicity but also gives potential to have alternative versions of the
enzyme which can be given to patients who have developed an immune response to
the original CPG2.
This work is supported by the Cancer Research Campaign and The Ronald Raven
Chair in Oncology Trust.
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IN VIVO CHARACTERISTICS OF AN ENGINEERED FUSION
PROTEIN FOR USE IN ADEPT SK Sharma*1, RB Pedley1, J
Bhatia1, N Minton2, KA Chester1 and RHJ Begent1, 1CRC Targeting and
Imaging Group, Royal Free and UCL Medical School, London NW3 2PF,
2CAMR, Porton Down, Salisbury, Wilts, UK
Antibody directed enzyme prodrug therapy (ADEPT) has shown feasibility as a treat-
ment for cancer. ADEPT has the potential to generate high concentrations of cytotoxic
agent selectively at tumour sites. To realise this potential, the targeted enzyme must be
present in high concentrations at the tumour sites and be rapidly cleared from blood
and normal tissues before prodrug administration. To achieve this, a biologically
active recombinant fusion protein, comprising an anti-CEA scFv MFE-23) antibody
fused to an enzyme carboxypeptidase G2 (CPG2), has been constructed for use in the
next ADEPT system. This fusion protein has been expressed in Pichia pastoris and is
stable in vitro and in vivo. Biodistribution studies of enzyme activity measurements
were performed in nude mice bearing the human colon carcinoma xenograft LS174T,
using an hplc assay. MFE::23-CPG2 fusion protein (1000 units/kg) was given intra-
venously into the tail vein, and showed localisation in tumours at earlier time points
than was observed with the A5B7-F(ab¢)2-CPG2 conjugate. MFE-23::CPG2 cleared
rapidly from plasma within 6 hours after injection (0.0052+/–0.001 units/ml plasma)
but enzyme activity persisted in tumours (1.3 +/–0.2 units/g tumour at 6 hrs), resulting
in a tumour to plasma ratio of 250:1. Tumour to liver, kidney, lung and spleen ratios
were 254, 245, 158 and 160 respectively. This allowed prodrug to be given at 6 hours
after fusion protein injection, resulting in significant growth delay of the tumour with
no toxicity in mice.
The rapid clearance from blood and normal tissues combined with selective
enzyme retention in tumours observed with MFE-23::CPG2 fusion protein gives the
potential to deliver multiple cycles of ADEPT for greater clinical efficacy before
development of immune response to CPG2.
Supported by the Cancer Research Campaign.72 Poster Presentations
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INFLUENCE OF TUMOUR CELL RESPONSE AND NUCLIDE
SELECTION ON THE EFFICACY OF RIT JLJ Dearling, AA
Flynn, C Pagoulatos, GD Wilson, M Woodcock, E Denholm, J Hartley, RHJ
Begent and RB Pedley, CRC Targeting and Imaging Lab, Dept of Oncology,
RFUCMS, Royal Free Campus, Hampstead, London NW3 2PF, UK
Introduction Radioimmunotherapy (RIT) uses antibodies, labeled with a radio-
nuclide, to deliver a therapeutic dose of radiation selectively to cancer deposits.
Treatment efficiency depends on a number of factors but is ultimately determined by
the number of surviving cells. In this study we used a mathematically defined para-
meter, the biologically effective dose (BED), to relate the number of surviving cells to
absorbed dose and its pattern of delivery. The dose delivered to the tumour was calcu-
lated for a range of radionuclides (90Y,  131I, 32P, 186Re, 188Re, 64Cu) linked to a tumour
specific anti-CEA IgG.
Methods The response of three human colorectal cancer cell lines (SW1222,
LOVO and LS174T) was characterised by the in vitro measurement of radiosensi-
tivity, rate of repair and proliferation using clonogenic assay, comet assay and flow
cytometry respectively. True dose was calculated for each cell type and radionuclide
and was standardised to a typical dose received by bone marrow during radiotherapy
(4 Gy).
Results The results are summarised in the table below.
SW1222 LOVO LS174T
Radiosensitivity (a/b (Gy)) 310.48 14.68 12.26
Repair half life (minutes) 8.32 16.77 4.13
Rate of proliferation (Tpot (hours)) 12.96 10.44 11.90
BED (Gy) 32P 20.86 10.78 10.91
64Cu 5.84 3.74 3.74
The SW1222 cells were found to be considerably more radiosensitive than the other
two lines. Repair half-lives were within the normal range (5–55 minutes) and the rates
of proliferation of the three lines were similar. The highest BED was for 32P and the
lowest was for 64Cu. Nuclides with shorter half-lives tended to have a higher relative
effectiveness (RE) but deliver their dose over a shorter period of time, their net thera-
peutic effect being less than that of the longer lived nuclides.
Discussion and Conclusions The mathematical model predicted that SW1222 was
the most responsive cell line to RIT, was confirmed in comparative therapy experi-
ments in vivo. It also showed that radionuclides with longer half-lives were the most
therapeutically effective. The model can now be used to optimize RIT by matching
radionuclides with antibodies and tumour type.
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RADIOLABELLING OF CAMPATH-1H MONOCLONAL
ANTIBODY (Mab) WITH 111INDIUM USING DOTA-MALEIMIDE AS
THE CHELATING AGENT P Hadjiyiannakis*1, G Hale2, A Hall1, G Harden1, R
Clutterbuck1, R Brooks1, VR McCready1, A Horwich1, MJS Dyer1, 1: The Institute
of Cancer Research and 2:The Therapeutic Antibody Centre, Oxford, UK
Background The therapeutic unconjugated humanised IgG1 CD52 Mab,
CAMPATH-1H has reduced efficacy against lymphomatous nodes, which can be
treated with radioimmunotherapy. A stably radiolabelled Mab, with preserved
immunoreactivity, is a prerequisite for such work. 111Indium (111In) is a better imaging
agent than 131Iodine (131I). 111In-Mab is used to predict the biodistribution of Mabs
labelled with 90Yttrium (90Y). The latter emits higher energy beta particles than 131I
which potentially allow a more homogeneous dose to be delivered in large masses.
Macrocyclic chelating agents such as DOTA (1,4,7,10-tetraazacyclododecane-
N,N,N,N tetraacetic acid) have higher stability for both 111In and 90Y than DTPA
(diethylene triamine pentaacetic acid).
Aim To radiolabel CAMPATH-1H with 111In for experimental and clinical use.
Methods A two step conjugation methodology was employed. Two thiols were
incorporated per antibody molecule using N-Succinimidyl 3-(2-pyridyldithio)propi-
onate (SPDP) followed by reduction with dithiothreitol. DOTA-maleimide was incu-
bated with 111In (in 0.2 M HCl) for a minimum of two and half hours at 47°C using 0.1
M ammonium acetate buffer pH7.4, on a magnetic stirrer/hot plate. The DOTA: 111In
molar ratio was 250:1. (For 90Y (in 0.05 M HCl) 0.025 M ammonium acetate buffer
pH5.4 was used, at 100–250:1 DOTA: 90Y, for 45 mins at 47°C). The 111In-DOTA-
maleimide was reacted with thiolated Mab (molar ratio 2:1 DOTA: Mab) for one hour
at room temperature, followed by a 10 fold excess DTPA (in 0.1 M ammonium acetate
buffer pH 5.0) strip for 90 minutes at room temperature to remove any loosely bound
111In. The final purification step was via a Microcon microconcentrator (50 kD cut
off). Ascorbic acid (10 mg) in PBS (pH 7.4) was added as a radioprotectant.
Results >80% of the 111In was incorporated by the DOTA-maleimide. Significant
differences (p<0.05) were seen by varying DOTA: 111In molar ratios, length of incubation,
and temperature of incubation. The DOTA-maleimide retained its reactivity for thiols
when incubated for up to 6 hrs at 47°C. Labelling efficiency of the whole procedure was
50% with specific activity of 58 MBq/mg. Protein recovery was 73% for the microcon-
centrator. The radiochemical purity of the 111In-Mab was 95% by size exclusion HPLC.
Immunoreactivity was >80% as assayed by two affinity HPLC methods. The radiola-
belled antibody was stable to DTPA challenge and plasma (both in-vivo and in-vitro).
Discussion Biodistribution of 111In-CAMPATH-1H was investigated in SCID/Nod
mice bearing human lymphoma xenografts. There was a high tumour uptake (15%
injected activity per gram tumour) with a favourable therapeutic ratio, once Fc recep-
tors were blocked with normal human immunoglobulin. Human studies are planned.
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COMPLETE REGRESSION OF POST-TRANSPLANT
LYMPHOPROLIFERATIVE DISEASE WITH EPSTEIN BARR
VIRUS SPECIFIC ALLOGENEIC CYTOTOXIC T CELLS T Haque1, C
Taylor*1, GW Wilkie1, P Murad1, S Beath2, P McKiernan2, DH Crawford1,
1Basic & Clinical Virology Group, University of Edinburgh, EH9 1QH, 2Liver
Unit, Birmingham Children’s Hospital, B4 6NH, UK
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T lymphocyte (CTL) have
recently been used to treat or prevent EBV associated post-transplant lymphoprolifer-
ative disease (PTLD) as a form of adoptive immunotherapy. In a UK-wide multicentre
trial, we are generating a bank of polyclonal EBV-specific CTL lines from healthy
blood donors. As PTLD lesions are aggressive and rapidly growing, these CTLs are
ready for infusion if the disease arises. These lines are selected for transplant patients
on the basis of best HLA match, and on specific killing of patient’s cells in in vitro
cytotoxicity assays. Here we report the first successful regression of PTLD in a solid
organ transplant recipient using partially HLA-matched EBV-specific CTL grown
from an unrelated healthy blood donor.
Withdrawal of immunosuppression had failed to treat an EBV positive PTLD in an
eighteen month old liver and bowel transplant recipient. One infusion of EBV-specific
CTL was given at a dose of 106 cells/kg body weight.
The patient’s tumour showed signs of regression within a week. There was no toxi-
city associated with the infusion and no evidence of graft versus host disease. The
EBV load in peripheral blood dropped to undetectable levels within one week.
Limiting dilution analysis (LDA) assays showed no CTL precursor (CTLp) activity
before the infusion and high numbers of CTLp at 4 hours and 24 hours post CTL infu-
sion. There was a reversal of the CD4/8 ratio in peripheral blood and an increase in the
percentage of HLA-DR positive CD8 cells. Allospecific IgM against the donor CTL
was detected at 6 weeks after infusion. The patient has been in complete remission for
eight months.
Allogeneic CTL infusion to treat more PTLD patients is currently underway. If
successful in clinical trials, the use of allogeneic antigen-specific CTLs could become
an important addition to tumour therapy.
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DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS
WITH RELAPSED METASTATIC BREAST CANCER – A
PHASE ONE CLINICAL TRIAL FE Nussey*1, I Downing2, M Waterfall1, J
Campbell2, N Hunter2, J Parker3, J Innes2, K Samuel2, Gordon Cook2, ML
Turner4, RCF Leonard1, University of Edinburgh, Department of Oncology,
Western General Hospital, Crewe Road, Edinburgh EH4 2XU, 2Scottish
National Blood Transfusion Service, Edinburgh, 3 Biomira Inc’, Edmonton,
Canada, 4University of Edinburgh, John Hughes Bennett Laboratory, Western
General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
Human MUC-1 is a high molecular weight trans-membrane glycoprotein which is
expressed on most epithelial cells, but in breast cancer there are alterations in distrib-
ution and intensity of expression, as well as changes in carbohydrate structure.
Dendritic cells (DC’s) are potent antigen processing and presenting cells which, when
pulsed with MUC-1 tumour antigens are able to induce MHC restricted antigen
specific CD4 and CD8 positive T cells in vitro. DC’s are the only antigen presenting
cells known to induce and specifically prime naive cytotoxic T lymphocytes.
Since August 1999 DC’s have been produced by co-culture, in the presence of
GM-CSF and IL4, of monocytes derived from the buffy coat of 6 patients with
relapsed metastatic breast cancer (BC). These cells were then pulsed with liposomal
MUC-1 (“Biomira Inc”) and returned to the patients by subcutaneous injection. Each
patient received one or two injections depending on the number of cells produced, but
all received a dose equivalent to between 0.07 and 0.13´106 CD1a positive cells per
kilogram. Patients were observed overnight and followed up at 7, 14, 28 days and 3
months following the completion of therapy. Disease status was assessed at entry to
the study and at 28 days and 3 months. There was no acute toxicity noted. Fatigue
(lasting median 2.5 days) was reported in 4 patients; grade 1 in 3 and grade 2 in 1.
There were no grade 3 or 4 toxicities noted. All patients have now completed follow
up of minimum 28 days and maximum 3 months. At one month one patient had stable
disease after prior progression, two had continuing stable disease and three experi-
enced further progression.
We have demonstrated feasibility and tolerability of the first two dose levels. It is
projected that a further 3 patients at each of two dose levels will be entered into the
study. In order to escalate the dose of DC’s given to these patients monocytes will be
collected by a 2–3 hour leucopheresis. Further, larger, clinical studies are requested to
assess potential theraputic benefit. Studies of the specific humoral and cellular
immune responses in these patients are in progress.
This work is supported by a grant from “The Melville Trust for the Care and Cure
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THE ROLE OF COMPLEMENT IN ELIMINATING TUMOUR
CELLS FROM GUINEA PIGS* KS Kan1, CY Yu1 & GT
Stevenson2, 1School of Biological & Applied Sciences, University of North
London, Holloway, London N7 8DB, 2Tenovus Research Laboratory,
Southampton University Hospital, Tremona Road, Southampton SO16 6YD,
UK
The role of complement in removing leukaemic cells from the guinea pigs was studied
using two different approaches. In the first approach, normal strain 2 and abnormal
C3-deficient guinea pigs were employed. In this study, 0.2 ´ 105 L2C leukaemic B
lymphocytes were inoculated into two groups of ten strain 2 and ten C3-deficient
animals. Twenty four hours after the inoculation, they were injected intravenously
with 1 mg of anti-idiotypic mouse/human chimeric FabFc2 antibody in which the Fcg
is of human origin. The profiles of survival were found to be similar between the two
groups and their life-span was prolonged by an average of 14 days as compared with
the control. In the second approach, the disulphide bonds at the hinge of the FabFc2
antibody were disrupted by DTT reduction followed by alkylation with N-ethyl-
maleimide. This procedure rendered the Fcg incapable of activating complement. The
inability of the open-hinge FabFc2 antibody to activate complement lysis was
confirmed by the 51Cr release assay on the L2 C cells. Twenty four hours after inocu-
lating the L2C cells into two groups of ten leukaemic strain 2 guinea pigs, the animals
were injected intravenously with 1 mg of either closed-hinge or open-hinge FabFc2
antibody. The profiles of survival were also found to be comparable between the two
groups and their life-span was prolonged by an average of 7 days. These observations
indicate that complement does not play a significant role in eliminating leukaemic
cells in guinea pigs.
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THE RELATIONSHIP BETWEEN LYMPHOCYTES OF THE
CD103 PHENOTYPE AND E-CADHERIN EXPRESSING
BLADDER CANCERS *J Cresswell, H Robertson, JA Kirby and DE Neal,
Dept of Surgery, The Medical School, Newcastle University, Newcastle upon
Tyne, UK
Background CD103 is a marker of the a subunit of the intra-epithelial lymphocyte
integrin aEb7; the principle ligand for this molecule is the epithelial adhesion molecule
E-cadherin. Expressed by most intra-epithelial lymphocytes of the gut, to our knowl-
edge this is the first report of CD103+ lymphocytes in human bladder.
Aim To demonstrate the presence of lymphocytes bearing this integrin in normal
and cancerous human bladder and to investigate the relationship with E-cadherin
expression.
Methods Cryostat sections of normal bladder and Transitional Cell Carcinomas
(TCC) were treated with antibodies specific for CD103 and E-cadherin. Visualisation
was performed by immunoperoxidase and alkaline phosphatase development. Dual
staining was used to assess the relationship between the antigens.
Results A few CD103+ lymphocytes were found in normal bladder confined to the
epithelium and lamina propria. In 20 TCC sections examined, E-cadherin expression
varied in accordance with the histological grade. CD103+ lymphocytes were found
predominantly in the stroma surrounding the tumours, although some cells were noted
to be infiltrating the periphery of tumour islands. Dense aggregates of E-cadherin
positive tumour cells were shown to be minimally infiltrated by CD103+ cells.
Conclusion Lymphocytes of the CD103+ phenotype were observed in normal
bladder and cancer specimens; however, aggregation of these cells was predominantly
observed in the stroma surrounding tumour cells. It is possible that immune evasion
strategies utilised by the tumour cells prevent infiltration by CD103+ T cells.
Alternatively, the dense homotypic adhesion between E-cadherin positive tumour cells
may mask the epitope required for CD103 interaction. Further studies are underway to
examine the functional significance of this pattern of antigen distribution.
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EXPRESSION OF THE NOVEL PRO-INFLAMMATORY
POLYPEPTIDE EMAP-II IN LUNG TUMOURS: ASSOCIATION
WITH INFLAMMATORY INFILTRATES MPR Tas, L Jones, W Ward, C
Clelland1 and JC Murray*, University of Nottingham Laboratory of Molecular
Oncology, CRC Department of Clinical Oncology and 1Department of
Histopathology, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
The novel pro-inflammatory polypeptide EMAP-II (endothelial monocyte-activating
polypeptide-II) modulates the behavior of endothelial cells, monocytes and granulo-
cytes in vitro. Injection in vivo induces an acute inflammatory response and tumour
regression in mice. Biologically active EMAP-II is detected in supernatants of
cultured tumor cells; however, little is known about its expression by tumours in vivo.
We studied EMAP-II distribution and processing in normal human lung and lung
tumours, and its relationship to the presence of inflammatory infiltrates.
Immunohistochemistry was performed with polyclonal antibodies against recombi-
nant human protein, and immuno-blotting with the same antibodies was used to assess
the conversion of EMAP-II to processed forms. Neuroendocrine differentiation was
assessed by immunohistochemical staining for N-CAM, and sections were scored for
the presence of inflammatory infiltrates. In normal lung only alveolar macrophages
were positive for EMAP-II expression. In lung carcinoids, which were devoid of
inflammatory infiltrates, tumour cells were strongly positive for EMAP-II, occurring
primarily as the 34 kDa cytoplasmic form. In small cell lung cancers (SCLC), all of
which contained inflammatory infiltrates, there was weak, diffuse staining of some
tumour cells, and stronger staining of tumor stroma. In these tumors, EMAP-II
occurred primarily as a 26–28 kDa processed form, normally found in the extracel-
lular compartment. The stroma of adenocarcinomas and squamous cell carcinomas
also showed diffuse staining. We conclude that (i) EMAP-II expression and
processing in lung tumours depends upon histological type, and (ii) recruitment of
inflammatory cells into lung tumours is associated with the presence of processed
forms of EMAP-II, and not with expression of EMAP-II per se.
This work is supported by the Cancer Research Campaign
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PROSTATE ADENOCARCINOMA CELLS RELEASE PRO-
INFLAMMATORY POLYPEPTIDE EMAP-II IN RESPONSE TO
STRESS G Barnett, MPR Tas, A-M Jakobsen, K Rice, J Carmichael, and JC
Murray*, University of Nottingham Laboratory of Molecular Oncology, CRC
Department of Clinical Oncology, City Hospital, Hucknall Road, Nottingham
NG5 1PB, UK
Endothelial-monocyte activating polypeptide-II (EMAP-II) is a pleiotropic effector of
endothelial cells, monocyte/macrophages and neutrophils, first described in super-
natants of murine tumour cells. It induces coagulation, E- and and P-selectin expres-
sion, and release of von Willebrand factor from endothelial cells in vitro, is
chemotactic for neutrophils and monocytes, and induces release of myeloperoxidase
activity from neutrophils in vitro. Local injection of EMAP-II evokes an acute inflam-
matory response in the mouse footpad, and haemorrhage, inflammatory infiltration,
and regression of tumours. EMAP-II occurs intracellularly as a 34 kDa precursor,
which can be proteolytically cleaved and released in an active 20–22 kDa form, by an
unknown mechanism. The amino acid sequence at the cleavage site, and the observa-
tion that apoptotic cells release EMAP-II, suggests the involvement of a caspase-like
enzyme. We have studied the effects of chemical and physiological stresses on the
processing and release of EMAP-II by the human prostate adenocarcinoma cell lines
LNCaP and DU-145. We first demonstrated by RT-PCR that both cell lines express
EMAP-II transcripts. We then used western blotting with polyclonal antibodies raised
against recombinant human EMAP-II to detect and characterise the EMAP-II
polypeptides. Both cell lines expressed EMAP-II primarily as a cytoplasmic 34 kDa
form. The cells were then treated with agents known to induce apoptotic or necrotic
cell death, and the relationship between form of cell death, and EMAP-II processing
and release was examined. In response to inducers of apoptosis (etoposide, camp-
tothecin, ionomycin, and thapsigargin) EMAP-II was processed to a 26–28 kDa inter-
mediate and released. Etoposide and ionomycin treatment also led to the appearance
of the 20–22 kDa form. Antimycin-A and saponin, which induce necrosis, also stimu-
lated release and processing of EMAP-II. Hypoxia (2.5% O2), which induces
primarily necrotic cell death in these cell lines, caused the release of biologically
active EMAP-II. We conclude that EMAP-II may become biologically available and
active in prostate tumours following a variety of stresses. The release of EMAP-II
may have implications for the physiology of tumours as well as their response to treat-
ment.
This work is supported by the Cancer Research Campaign and the Association for
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A MODEL TO PREDICT BIOCHEMICAL (PSA) CONTROL
AFTER RADICAL RADIOTHERAPY WITH INITIAL
ANDROGEN SUPPRESSION FOR CLINICALLY LOCALISED PROSTATE
CANCER DP Dearnaley, C Parker, A Norman, R Huddart, A Horwich, Royal
Marsden Hospital and Institute of Cancer Research
Introduction Phase III studies have demonstrated the clinical benefit of combining
short course neo-adjuvant androgen deprivation (NAD) with radical radiotherapy
(RT) for clinically localised prostate cancer. We have developed a nomogram to
predict the likelihood of PSA control.
Patients and Methods 517 men with histologically proven ca prostate were
treated with 3–6 months NAD (LHRHa + 3 weeks cyproterone acetate) and radical
prostate radiotherapy (64 Gy in 6#fr1/2> weeks) between 1988–98. Median
presenting PSA was 20 ng/ml and 56% of patients had T3/T4 disease. Gleason Scores
of 2–4, 5–7, 8–10 were reported in 14%, 66%, and 20% of cases respectively. PSA
failure was defined by two consecutive rises in PSA ³ 2 ng/ml, and the time of failure
taken as the date of first PSA value ³ 2 ng/ml or date of restarting normal treatment.
Univariate/multivariate (MV) analysis of pre-treatment factors was performed and a
nomogram constructed to predict PSA failure free survival probability.
Results After a median follow-up of 35 months, 224 men had developed PSA
failure. Clinical T stage, presenting PSA and histological grade were all highly predic-
tive of PSA failure on MV analysis. The nomogram gave the maximum coefficient
(PSA>50) the value of 100. The score for an individual patient is given by the summa-
tion of T stage (T1,2=0: T3,4=29), PSA (<10 ng/ml=0: 10–19 ng/ml=12: 20–49
ng/ml=37: >50 ng/ml=100) and histology (Gleason 2–4=0: 5–7=42: 8–10=79) values.
Patient Score 0 50 100 150 200
2 year PSA failure free Survival (%) 91 83 69 50 20
5 year PSA failure free Survival (%) 74 55 31 11 6
Conclusion These results are at least equivalent to those reported using surgery or
higher doses of RT alone. Simple graphical display of the nomogram can inform both
clinician and patient of the likely outcome of treatment.
P182
A POSSIBLE ROLE FOR INTERMITTENT ANDROGEN
SUPPRESSION (IAS) IN THE EARLY MANAGEMENT OF
LOCALISED PROSTATE CANCER D Farrugia*1, W Ansell1, F Chinegwundoh2,
G Williams2, P Wilson1 and RTD Oliver1, Departments of Medical Oncology1 and
Urology2, St Bartholomew’s Hospital, London EC1A 7BE, UK
IAS has been shown to be a feasible strategy in the management of advanced prostate
cancer. Several phase II studies including over 200 patients (pts) showed that repeated
remissions can be induced with successive cycles on and off treatment, thus reducing
the duration of side effects from androgen suppression (AS) without compromising
the duration of disease control or survival (Gleave M et al. 1998, Prostate Cancer and
Prostatic Diseases, 1:289). In localised disease (LD), debate continues over the roles
of radical surgery (S) and radiotherapy (RT), as well as the role of early AS versus
“watchful waiting”. We studied 31 pts in 3 groups with LD (≤T3N0M0) who had
either RT followed by observation (group A, n=7), S/RT with concurrent IAS (group
B, n=11), or IAS alone as primary therapy (group C, n=13). AS consisted of either
LHRH analogue alone (LHRHA) or combined androgen blockade (CAB). Pts stopped
AS when PSA had normalised with no clinical evidence of residual disease, and
remained off treatment until clinical recurrence or elevation of PSA >20 ng/ml when
AS was again introduced. Pts achieving PSA and clinical remission again stopped AS
until relapse. Results in the 3 categories are summarised below:
Patient Characteristic Treatment Category
ABC
No. of patients/median age 7/65 11/63 13/69
Median ± range baseline PSA (ng/ml) 18 (14–58) 58 (1.6–242) 27 (5.3–166)
Type of AS: LHRHA/CAB – 6/5 5/8
Duration on/off primary AS1 – 12/25 9/9
Response: CR/PR/NR/NE – 11/0/0/0 12/1/0/0
Time to progression (1) 29 37 212
Relapsed pts starting AS/still on Rx 7/0 7/3 9/5
Duration on/off As for relapse 10/20 13/15 7/33
Response: CR/PR/NR/NE 5/2/0/0 3/2/0/2 6/2/1/0
Time to progression (2) 33 28 342
Median follow-up (range)/no. dead 89(31–244)/2 59(12–115)/1 35(15–134)/1
1= Durations are median in months; 2=differences not significant
Thus disease control was equivalent for primary IAS alone (C) and radical RT
alone (A), but combined treatment may be superior. Only 33% of time was spent on
AS in groups B and C. Whether combined IAS + RT up front is superior to IAS alone
with delayed RT is under investigation in a prospective study.
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EVALUATION OF THE OPTIMAL COPLANAR FIELD
ARRANGEMENT FOR USE IN THE BOOST PHASE OF DOSE
ESCALATED CONFORMAL PROSTATE RADIOTHERAPY VS Khoo*1, JL
Bedford2, S Webb2, DP Dearnaley1, 1Academic Unit of Radiotherapy, and the
Joint Department of Physics, ICR & Royal Marsden NHS Trust, Sutton SM2
5PT, UK
Introduction The aim was to determine the optimal coplanar beam arrangement for
use in the boost phase of conformal prostate radiotherapy from 64 Gy to 74 Gy for a
variety of three-field (3F), four-field (4F) and six-field (6F) plans. The boost phase
planning target volume was altered from that used for the first 64 Gy and comprised
the prostate gland alone without a planning margin.
Methods In ten patients, three optimised plans (3F 0°,90°,270° plan, 4F
45°,90°,270°,315° plan, and 6F 40°,90°,115°,245°,270°,320° plan) were selected
from a variety of plan arrangements and compared with the following reference plans:
3F (0°,120°,240°) plan, 4F (0°,90°,180°,270°) plan, 6F (55°,90°,125°,235°,
270°,305°) and 6F (50°,90°,130°,230°,270°,310°) plans. All plans were for 6 MV
photons. Beam weightings were inversely optimised for each patient. Plans were
compared by means of rectal volumes irradiated to greater than 50% (V50), 80% (V80),
and 90% (V90) of the prescribed dose. Irradiated volumes were also measured for the
bladder (V90) and femoral heads (V70).
Results All selected 3F, 4F and 6F plans gave lower rectal V80 and V90 than their
corresponding reference plan. The 3F (0°,90°,270°) plan consistently provided greater
rectal sparing at V50 to V90, with acceptable bladder and femoral head doses, compared
to the other plans in the study. When the 6F (50°,90°,130°,230°,270°,310°) plan used
at our institution for the boost phase was compared to the 3F (0°,90°,270°) plan, there
were reductions of rectal V50 from 20.8 ± 5.2% to 12.6% ± 5.1%, rectal V80 from 8.7 ±
2.9% to 6.5 ± 3.1%, and rectal V90 from 5.5 ± 2.1% to 3.9 ± 2.0% (all p < 0.001). The
bladder V90 and femoral head V70 were equivalent.
Discussion Using a reduced planning target volume for the boost phase, the 3F
beam arrangement using coplanar gantry angles of 0°, 90°, and 270° provided the best
rectal sparing at the high dose regions with acceptable bladder and femoral head
doses. This plan significantly improved on the 6F 40/40 plan being used at our institu-
tion. It is anticipated that this 3F plan would provide the least increase in high dose
rectal irradiated volume when combined with any phase 1 plan. These plans were
individually inversely optimised using conformal shaped blocks. Similar results were
found when the beam weightings were standardised thereby providing a class solu-
tion. Other factors may impact on the practicability of implementation such as differ-
ences in multileaf collimator (MLC) shaping vs shaped blocks. MLC leaf widths (1
cm vs 3–5 mm), limitations in MLC orientation using integral wedges and these will
need to be addressed.
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OPTIMISATION OF 3-, 4-, AND 6-FIELD COPLANAR BEAM
ORIENTATIONS FOR USE IN CONFORMAL DOSE
ESCALATION OF PROSTATE RADIOTHERAPY, VS Khoo*1, JL Bedford2, S
Webb2, DP Dearnaley1, 1Academic Unit of Radiotherapy, and the Joint
Department of Physics, Institute of Cancer Research & Royal Marsden NHS
Trust, Sutton SM2 5PT, UK
Introduction We have evaluated the optimal coplanar beam arrangement for use in dose escalated
conformal prostate radiotherapy. Two different clinical target volumes: prostate only (PO) and
prostate plus seminal vesicles (PSV), a variety of three-field (3F), four-field (4F) and six-field (6F)
plans and the impact of two different doses (64 and 74 Gy) were studied. Methods: Series of 3F, 4F
and 6F plans were created for PO and PSV volumes in each of ten patients. The optimal plan for
each of 3F, 4F and 6F were chosen from a variety of symmetrically and asymmetrical field
arrangements and compared to their respective reference plans: 3F 0°, 120°, 240° plan, 4F 0°, 90°,
180°, 270° (box) plan, and 6F 55°, 90°, 125°, 235°, 270°, 305° plan (plan designated 35/35
describes the angle of the oblique beams (ant/post) from the mid-coronal plane). Comparisons
were performed using the rectal volume irradiated to greater than 50% (V50), 80% (V80), and 90%
(V90) of the prescribed dose, femoral head (FH) V70 and bladder (B) V90, normal tissue complica-
tion probability (NTCP) for rectum (R), B, and FH. Over 1800 plans were computed.
Results The mean statistics (±1SD) for the best 3F, 4F, and 6F plan were compared with their
respective reference plans:
Plan Type Reference 3F, 4F, and 6F plans Optimised 3F, 4F, and 6F plans
3F 4F 6F 3F 4F 6F
PO Group % 0,120,240 box 35/35 0,90,270 35,90,270,325 50/25
R V50 51.3 ± 10.4 66.7 ± 14.6 40.9 ± 7.8 31.7 ± 6.6 49.8 ± 11.0 38.8 ± 7.7
R V80 35.2 ± 8.0 26.0 ± 5.8 26.3 ± 5.9 22.8 ± 5.5 24.0 ± 5.4 24.4 ± 5.3
R V90 30.3 ± 7.1 21.4 ± 5.2 21.7 ± 4.6 18.4 ± 5.7 19.5 ± 5.4 18.6 ± 4.9
R NTCP 64 Gy 2.0 ± 0.8 1.3 ± 0.5 1.3 ± 0.4 0.8 ± 0.3 0.9 ± 0.3 0.8 ± 0.2
R NTCP 74 Gy 8.9 ± 3.1 6.0 ± 2.1 6.2 ± 1.9 4.1 ± 1.5 4.5 ± 1.5 3.8 ± 1.2
B V90 9.9 ± 5.3 10.1 ± 5.3 8.9 ± 4.5 9.3 ± 5.1 8.5 ± 4.5 8.9 ± 4.5
FH V70 0.0 ± 0.0 0.1 ± 0.4 16.7 ± 23.2 0.6 ± 1.9 1.3 ± 2.6 7.4 ± 19.7
FH NTCP 74 Gy 0.0 ± 0.0 0.0 ± 0.1 4.4 ± 13.2 0.1 ± 0.1 0.0 ± 0.1 1.4 ± 4.2
3F 4F 6F 3F 4F 6F
PSV Group % 0,120,240 box 35/35 0,90,270 20,90,270,340 65/30
R V50 83.8 ± 7.5 93.4 ± 7.6 74.8 ± 9.4 56.6 ± 6.5 82.2 ± 8.1 78.5 ± 8.4
R V80 65.7 ± 9.0 47.3 ± 5.5 49.4 ± 5.6 41.9 ± 5.8 44.2 ± 5.0 47.5 ± 6.3
R V90 58.8 ± 8.8 41.6 ± 5.1 42.3 ± 4.8 35.5 ± 5.9 37.0 ± 6.7 40.1 ± 6.8
R NTCP 64 Gy 5.7 ± 1.8 3.1 ± 0.7 3.7 ± 0.7 2.3 ± 0.6 2.4 ± 0.6 3.0 ± 1.0
R NTCP 74 Gy 21.4 ± 5.3 13.2 ± 2.3 15.1 ± 2.5 10.2 ± 2.4 10.6 ± 2.1 12.6 ± 3.5
B V90 19.5 ± 9.3 19.0 ± 9.5 15.7 ± 7.5 18.0 ± 8.9 18.5 ± 9.4 17.1 ± 8.6
FH V70 0.0 ± 0.0 0.0 ± 0.0 37.5 ± 25.4 3.4 ± 6.9 1.3 ± 3.0 3.9 ± 10.6
FH NTCP 74 Gy 0.0 ± 0.0 0.0 ± 0.0 9.1 ± 23.1 0.3 ± 0.4 0.0 ± 0.0 0.6 ± 1.8
Conclusion The optimal rectal sparing field arrangement with acceptable bladder and FH
doses was a 3F plan with coplanar angles of 0°, 90°, and 270°. This finding was consistent for
both PO and PSV volumes, and when dosed to either 64 Gy or 74 Gy. However, if the target
volumes (using 1 cm margins) remained unchanged to 74 Gy, the irradiated rectal volumes were
high and rectal NTCPs were predicted to increase by 4–5 fold. Therefore, it is prudent to reduced
planning volumes for dose escalation to 74 Gy.Poster Presentations 75
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USE OF A DEPTH HELMET TO ASSESS AND IMPROVE
ACCURACY OF A GTC STEREOTACTIC RADIOTHERAPY
FRAME KE Burton1, D Whitney2, DS Routsis1, SJ Thomas2, RJ Benson1, NG
Burnet1*, Departments of 1Oncology and 2Medical Physics, Addenbrooke’s
Hospital, Cambridge CB2 2QQ, UK
The value of using the GTC stereotactic radiotherapy frame is in improving accuracy
of relocation for high precision radiotherapy. We sought to measure and improve the
accuracy of our system, by use of a depth helmet. This consists of a perspex hemi-
sphere with a set of 24 measuring portals. This attaches to the stereotactic frame once
the patient is in the treatment position. A measuring rod is used to measure the
distance from scalp to helmet.
Measurements were taken at the initial fitting, localisation and verification CTs,
and for each treatment fraction for 20 consecutive patients, a total of 291 episodes.
The localisation CT data were used as the reference set. The frame was refitted until
the recorded measurements were within acceptance criteria: no worse than 1 reading
>2 mm or 3 readings >1.5 mm. After the treatment course, each depth measurement
was entered into a spreadsheet to calculate the vector displacements of the isocentre.
The mean displacements (and standard deviations) for the whole sample together
were left-right 0.002 mm (0.620 mm), anterior-posterior 0.116 mm (0.532 mm) and
superior-inferior 0.229 mm (0.594 mm). The maximum 95% confidence intervals
were 1.22, 1.16, and 1.39 mm for left-right, anterior-posterior and superior-inferior
dimensions respectively. Only 1% of treatments had a displacement exceeding 2 mm.
These did not necessarily occur in the same patient or direction.
Use of all suitable measurements, together with the spreadsheet, gave greater reli-
ability and true evidence of the variation of isocentre position. Variations caused by
differences in pressure applied to the measuring rod are removed by calculation of the
vector displacements in the left-right and anterior-posterior dimensions. Measurement
of the depth onto the occipital plate, which supports the back of the head, proved a
useful tool in repositioning the occipital plate in 1 case where it came loose.
Comparison of measurements to the reference data set without the spreadsheet, on
which the acceptance criteria are based, suggest much greater discrepancies than actu-
ally occur in the isocentre position calculated from vector displacements.
Errors attributable to the patient’s relocation within the frame are very small using
this system. Use of the helmet, and spreadsheet to calculate real isocentre movements,
confirm the accuracy for individual patients. Therefore, we are introducing use of the
spreadsheet so that the true vector displacements are calculated prior to the treatment
fraction, and acceptance criteria will be based on these results. Considering the 95%
confidence intervals, which are all ≤ 1.39 mm, with other potential errors, we now use
a CTV-PTV margin of 3 mm for this high precision technique.
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RADIOTHERAPY FOR PREVENTION OF HORMONE-
INDUCED GYNAECOMASTIA AND MAMMALGIA IN
ADVANCED PROSTATE CANCER RSD Brown1, JF Money-Kyrle1, HA
Payne1 and GM Duchesne2, 1Middlesex Hospital, Mortimer Street, London
W1N 8AA, 2Peter MacCallum Cancer Institute, Melbourne Australia
Purpose Low-dose diethylstilbestrol (DES 1 mg) therapy may produce a sustained
response in advanced prostate cancer but causes gynaecomastia and nipple tenderness.
We have reviewed our experience with prophylactic nipple irradiation in preventing
this complication.
Patients and Methods Fifty-nine patients with relapsed prostate cancer due to
commence DES 1 mg were treated with short distance 60Co g rays using an applied
dose of 15 Gray in 3 fractions to a 6 cm circular nipple field. Each patient was exam-
ined and scored for mammalgia and gynaecomastia pre-radiotherapy, and at 3, 6, and
12 months post-radiotherapy.
Results 41/59 patients had neither gynaecomastia nor mammalgia prior to radio-
therapy and 36 (88%) of these remained unaffected. 5/41 patients developed gynaeco-
mastia or mammalgia despite prophylactic radiotherapy. No patient developed more
than mild to occasional mammalgia (Grade I) or questionable gynaecomastia (Grade
I). For patients with pre-existing gynaecomastia or mammalgia (18/59), stabilisation
occurred in 14/18 (78%), improvement occurred in 3/18 patients (17%) and progres-
sion occurred in 1 patient (5%). No acute side effects were noted from radiotherapy
treatment.
Conclusion Prophylactic nipple irradiation is an effective modality in preventing 1
mg DES-induced gynaecomastia and mammalgia in patients with advanced prostate
cancer. The effectiveness and low acute side effect rate suggest the possibility of
considering prophylactic nipple irradiation in earlier stage adjuvant treatment of
prostate cancer if other drugs that causes similar breast changes (e.g. oral anti-
androgen therapy) are to be considered. Long term follow up would be needed to
check for late effects.
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POLYMORPHISMS IN TNFµ AND RISK OF BLADDER
CANCER, H Marsh*1,2, N Haldar1, M Bunce1, S Marshall1, A
Harris2, K Welsh1, 1Tissue Typing Laboratory Churchill Hospital, Oxford OX3
7LJ, 2ICRF, John Radcliffe Hospital, Oxford OX3 9DU, UK
Introduction TNFµ is known to play a key role in the regulation of the angiogenic
enzyme thymidine phosphorylase (1) and TNFµ deficient mice have a greatly reduced
tumour growth and tumour induction in response to chemical carcinogens. (2). There
are at least 14 known polymorphisms in and around TNF and several of these poly-
morphisms have been implicated in a number of conditions including malignant,
inflammatory and granulomatous disease. (3).
Aims We set out to assess the association between TNFµ polymorphisms and the
risk of bladder cancer by determining the frequency of TNF polymorphisms in
bladder cancer patients and a control population.
Methods We looked for 12 polymorphisms in 100 bladder cancer patients and 100
controls (renal donors — no malignancy). DNA was extracted from peripheral blood
and amplified by PCR using sequence specific primers. PCR products were then elec-
trophoresed in 1% agarose gels and visualised with UV illumination.
Results Initial results have shown a highly significant association with 2 polymor-
phisms in TNFµ. At locus –488, GA was found in 30% of patients compared with
11% of controls, p=0.0005 (p=0.006 with bonferoni correction) and at –238 GA was
found in 1% of patients compared to 15% of controls p=0.0003 (p=0.004 corrected).
Conclusions and significance This preliminary result shows a highly significant
association between 2 TNF polymorphisms and bladder cancer. It must be confirmed
with a second set analysis and the remaining TNF polymorphisms must be assessed. If
correct then we will follow this up with functional studies. Ultimately this work could
lead to new methods of detecting patients at risk of bladder cancer and new thera-
peutic techniques such as TNF antagonism.
1 Leek RD et al (1998) Br J Cancer 77: 2246
2 Moore RJ et al (1999) Nat Med 5; 7:828
3 Mulligan CG et al (1999) Genes and Immunity 1: 137
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THE GENETIC BASIS OF ADENOCARCINOMA OF THE
BLADDER WITH SPECIAL EMPHASIS ON THOSE ARISING
IN “CLAM” BLADDERS, Appanna TC*1, Croft J2, James S2, Parry EM2, Parry
JM2, Stephenson TP1, 1Department of Urology, University Hospital of Wales,
Cardiff, 2Centre for Molecular Genetics and Toxicology, U.W.C.S., Swansea,
UK
Introduction Since its introduction in 1982 the “clam” enterocystoplasty has become
widely used for the treatment of detrusor hyperreflexia and instability. Over 400 oper-
ations a year are being performed in the U.K. There is thought to be a significant risk
of malignancy in these bladders and in our unit alone there have been four such
tumours. They were all highly aggressive adenocarcinomas in the native bladder
segment. Filmer reported a latency period of between 5 and 29 years for tumour
development. There are potentially over 4000 patients in the U.K. alone at risk a lot of
whom are quite young. Ideally we would like to identify those most at risk so that we
could follow them up more closely. Our first aim therefore is to identify genetic irreg-
ularities peculiar to these tumours as reference points.
Materials and methods DNA is extracted from the slides of 2 clam tumours that
we have had and 2 de novo adenocarcinomas of the bladder using a commercially
available kit (PROMEGA). DNA has also been extracted from biopsy samples taken
from the bladder remnant of clam patients. The DNA is then subjected to a technique
called Comparative Genomic Hybridisation (CGH). Firstly the DNA is nick translated
with a fluorescent marker (Fluoro Green) and then competitively hybridised with
control DNA to a normal human metaphase spread. The hybridisation is visualised by
the use of 2 different fluorochromes. The ratio of fluorescence intensities along each
chromosome reflects the relative ratios of test and reference sequences. We can there-
fore show amplifications and/or deletions anywhere in the chromosomal series.
Results The analysis of the tumours has shown several amplifications most
notably on 8 p on the clam tumours and 21 q common to both clam and de novo
adenocarcinomas. Biopsies from clam patients without tumour show greater genetic
instability nearer the bowel to bladder anastamosis than those from further away.
Discussion The spectre of the possibility of clam cancer still hangs over us. We
need to be able to try and predict which patients are most at risk. If we can identify a
sequence of DNA changes leading to tumour formation then we can use them as indi-
cators for the clam patients. If any of them develop similar DNA changes then they
will require closer follow up.76 Poster Presentations
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CYCLOOXYGENASE2 EXPRESSION IN SUPERFICIAL
TRANSITIONAL CELL CARCINOMA OF BLADDER
P Maheshkumar1*, JE Martin2, VH Nargund1 and DM Berney2, Dept of
Urology and 2Dept of Histopathology and Morbid Anatomy, Barts and The
London NHS Trust, London, EC1A 7BE, UK
Objectives Cyclooxygenases (Cox) catalyse the synthesis of prostaglandins from
arachadonic acid. Two isoforms of Cox exist, Cox1 and Cox2. Cox1 is constitutively
expressed and has a physiologic role in the cell metabolism. Cox2 is induced by
various stimuli such as growth factors, carcinogens and tumour promoting phorbol
esters. The constitutive isoform of Cox1 is essentially unaffected by these factors.
Previous studies have shown that Cox2 is increased in invasive bladder cancer.
Animal studies have also shown the anti tumour effects of Piroxicam (NSAID) in
spontaneous canine transitional cell carcinoma (TCC) bladder. Recently, selective
Cox2 inhibitors have been approved for clinical use in the UK, they have fewer side
effects than traditional NSAID’s. The purpose of this study was to determine the Cox2
expression in superficial TCC bladder and any possible relationship with grade, stage
or disease progression.
Materials Formalin fixed tumour tissues (n=169) were obtained for all newly
diagnosed superficial bladder cancer between 1982 to 1988. These were evaluated for
Cox2 expression by immunohistochemistry following microwave antigen retrieval.
Results
TCC-grade and stage Cox2 +ve Cox2 –ve
pTa (n=120) 37 (31%) 83 (69%)
pT1 (n=49) 13 (27%) 36 (73%)
G1 (n=66) 19 (29%) 47 (71%)
G2 (n=62) 21 (34%) 41 (66%)
G3 (n=41) 10 (24%) 31 (76%)
Cox2 expression is seen in a small proportion of superficial TCC and is unrelated to
grade or stage. Subset analysis of those TCC’s that subsequently progressed (n=39)
also did not reveal any association with Cox2 expression.
Conclusions COX2 expression does not provide useful diagnostic or prognostic
information in superficial TCC. The biological role of this enzyme in superficial TCC
bladder cancer remains unclear.
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LOSS OF HETEROZYGOSITY ON CHROMOSOME 9 AS A
POTENTIAL MARKER OF RECURRENCE AND
PROGRESSION IN BLADDER CANCER J Edwards*1, P Duncan1, JJ
Going2, AD Watters1 and JMS Bartlett1, Dept of Surgery1/Dept of Pathology2,
Glasgow Royal infirmary, Glasgow G31 2ER, UK
Approximately two thirds of patients diagnosed with superficial transitional cell carci-
noma (TCC) of the urinary bladder will recur within 2 years. It was recently reported
that loss of chromosome 9 in primary TCC identifies a subset of patients at high risk
of recurrence (Bartlett et al. 1998, BJC. 77 (12), 2193–2198).
This study explores in further detail genetic alterations at chromosome 9 as
possible predictors of recurrence and/or progression. Forty-seven patients with full
follow-up were retrospectively selected and categorised into 2 groups, (non-recurrent
TCC of the bladder (NR, n=18) or recurrent TCC of the bladder (REC, n=29). The
REC group was further divided into recurrer non progressors (RNP, n=18) and
recurrer progressors (RP, n=11). Patient DNA was microdissected and extracted from
archival normal/tumour tissue sections and analysed for loss of heterozygosity (LOH)
at 9 loci on chromosome 9. Fluorescent PCR was performed and genotyping carried
out on a Perkin Elmer AB1377™ sequencer.
The level of LOH in primary tumours of the patient groups was studied. In the NR
group 83% of patients exhibited at least one LOH at the loci tested, this ranged from
1/9 loci per patient to 6/9 loci per patient, 0 patients had LOH at all loci tested. In the
REC group 100% of primary tumours exhibited at least one LOH at the loci tested, this
ranged from 1/9 loci per patients to 9/9 loci tested per patient. LOH at all loci tested
was seen in 24% of REC patients. A significant difference between the NR and REC
(p=0.04) group was observed. However when the REC group was sub divided and
compared a significant difference was only seen between the primary NR and RNP
tumours (p=0.03). When LOH at individual loci was compared no difference was
found between groups, except when the markers spanning 9q34 were investigated, as it
was noted that 11% of NR primary tumours lost this region compared to 51% of REC
primary tumours (p=0.01). The total level of LOH in NR tumours was 33% compared
to 70% in the REC patients. The level of LOH inpatients recurrent tumours was also
investigated. There was no increase in level of LOH observed with repeated tumour
recurrences in the RNP group. However the level of LOH increased at the tumour
recurred and progressed in the RP group, the level of LOH observed in the post inva-
sive tumours was 61% compared to 37% in the primary tumour (p=0.003).
A higher rate of LOH, in particular at 9q34 is seen in primary tumours of REC
patients when compared to NR patients, however only LOH at all informative markers
on chromosome 9 was demonstrated to predict recurrence. LOH at multiple loci on
chromosome 9 implies that more than one tumour suppressor gene located on chro-
mosome 9 is involved in recurrence of TCC of the urinary bladder.
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A PHASE I/II STUDY OF SYNCHRONOUS
CHEMORADIOTHERAPY FOR POOR PROGNOSIS LOCALLY
ADVANCED BLADDER CANCER SA Hussain*1,2, DD Moffitt1, JG Glaholm2,
D Peake2, DMA Wallace2, ND James1,2, 1CRC Institute For Cancer Studies,
University Hospital Birmingham, 2Queen Elizabeth hospital, Edgbaston,
Birmingham, UK
Purpose To investigate synergy between radiotherapy and synchronous chemo-
therapy using 5-fluorouracil (5-FU) and Mitomycin-C (MMC) and evaluate the toxi-
city and activity in patients with muscle invasive bladder cancer in a phase I/II study.
Method Patients with T2-T4 NO/Nx MO muscle invasive bladder cancer were
entered into this single centre study. Patients received 55 Gy/20 fractions/4 weeks of
radiotherapy. Concurrent chemotherapy was given with MMC 12 mg/m2 day 1 and 5-
FU 500 mg/m2/24 hours weeks one and four of radiotherapy for five or seven days on
each occasion. Primary end point for phase-I part of the study was toxicity. Primary
end point for phase II part of the study was pathological response rate at 3 months,
secondary endpoints for both parts were toxicity, disease-free and overall survival.
Dose escalation was carried out by increasing the duration of continuous infusion of
5-FU chemotherapy from 10 to 14 days after 20 patients.
Results A total of 31 patients have entered the trial from March 1998 to December
99 (22 5-day, 9 7-day schedule). Date of censor was 6th February 2000. Median age
was 68 (range 58–79) years, 23 males and 8 females; 2 patients were node positive; T2
9 (29%), T3a 4 (12%), T3b 9 (29%), T4 9 (29%), TCC grade 2, 8 (26%) and grade 3,
23 (74%); 14/31 patients had hydronephrosis. Toxicity was mild to moderate with the
5-day schedule (NCI-CTG grade 3: thrombocytopenia 2/22; diarrhoea 2/22). More
severe toxicity was seen with the 7-day schedule (NCI-CTG grade 3: leucopenia 1/9;
diarrhoea 2/9; cystitis 2/9). 4/9 patients failed to complete planned therapy. There was
1 death on treatment from stroke, probably unrelated to therapy. We have now
reverted to the 5-day schedule for an extended phase II study. Of 17 patients with the
5-day schedule eligible for local response assessment, pathological complete response
at 3 months was 70%; 3 patients were not evaluable due to metastatic spread. 9
patients received the 7-day regimen, of the eight patients due for response assessment
the 3 month pathological response rate was 6/7 (84%) pathological CR (3) 42% +
pathological PR (3) 42%. Actuarial 12-month survival was 57%. Of patients still alive
from either schedule, 16/18 retain a functioning bladder at median follow up of 13.6
months.
Conclusion Chemoradiotherapy with the 5-day schedule is feasible in the manage-
ment of elderly patients. The regimen has encouraging activity with acceptable toxi-
city in poor prognosis patients. A randomised trial using the 5-day schedule compared
to radical radiotherapy alone is being launched.
Key words Bladder cancer Chemoradiation Organ preservationPoster Presentations 77
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LOCAL ANAESTHETIC PHOTODYNAMIC THERAPY FOR
SUPERFICIAL BLADDER CANCER: EARLY CLINICAL
RESULTS D Shackley*1,2, C Whitehurst1, JV Moore1, A Gilhooley2, CD Betts2
and NW Clarke2,3, 1CRC Department of Experimental Radiation, Oncology,
Paterson Labs, Christie Hospital Manchester M20 4BX; 2Department of
Urology, Hope Hospital, Salford M6 8HD. 3Department of Urology, Christie
Hospital, Manchester M20 4BX, UK
Introduction Photodynamic therapy (PDT) is a potential new treatment for bladder
tumours. Presently, this requires a general anaesthetic (GA), bladder irrigation and
rigid cystoscopy. We have developed a system whereby PDT is given via a flexible
cystoscope under local anaesthetic (LA) in a clinic environment. This system may
help treat patients who cannot have a GA. We present our initial clinical results.
Patients and Methods Eight patients (five men, three women; mean age 75, range
66–83) with recurrent superficial bladder cancer (stage Ta, grades 1–2) were sensi-
tised with 50 mls of intravesical 3% Aminolaeuvulinic acid (ALA) solution. After 4
hours, this was replaced by 40 mls of 2% lignocaine for 45 minutes and then by 150
mls of saline. 50 J/cm2 of 633 nm laser light was then delivered via a flexible cysto-
scope.
Results The procedure was well tolerated and painfree. Thereafter, bladder
frequency was noticed in all patients usually settling within 1 week. One patient had
irritability which lasted 4 weeks before settling completely. There were no skin photo-
sensitivity episodes nor post-PDT changes in objective bladder function tests. Serum
lignocaine levels were insignificant. Intravesical temperature measurements via a
thermocouple demonstrated no hyperthermic effect of the treatment. Independent
cystoscopic follow-up at 2 months showed 6 patients had a substantial response to
treatment (2 had a complete response and 4 had a partial response (>50% reduction in
size/numbers of visible tumours)). A smaller response was noticed in 1 of the
remaining 2 patients.
Conclusions Local anaesthetic bladder PDT is possible, safe and effective in
recurrent superficial TCC. Larger therapeutic studies are now possible under LA to
evaluate dose-response characteristics.
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A NEW HIGHLY SPECIFIC MONOCLONAL ANTIBODY
AGAINST PLACENTAL ALKALINE PHOSPHATASE (PLAP): A
POTENTIAL MARKER FOR AN EARLY DETECTION OF TESTIS TUMOUR
AME Nouri, AME, Dabare AANPM, Torabi-Pour N and Oliver RTD,
Department of Medical Oncology, The Royal London Hospital. Whitechapel
London E1 1BB, UK
The aim of this study was to develop specific monoclonal antibodies (Mab) against
human germ cell tumours. For this, the preparation of a single cell suspension
obtained from tumour tissue fragments (consisting of both tumour and normal
compartments) from a patient with seminoma was used as an immunogen. Spleen
cells from the immunised mice were used to develop Mabs. Analysis of tissue speci-
ficity, biochemical characteristics, as well as competitive studies were carried using
techniques which included immunocytochemical staining, dot blot and a Western blot
analysis for the identification of target antigen(s).
The results showed that: 1. The immunisation protocol led to the development of
107 hybridomas, 90 of which were negative against the original tissue biopsies. The
remaining 17 showed positivity against various tissue compartments. One chosen
Mab i.e. ATC2 showed specific staining on germ cell tumours but not on normal
tissues. It also showed positive staining with some human tumour cell lines. 2. The
nature of target antigen for ATC2 Mab was found to be PLAP based on:
a. Western blot analysis compared with commercially available PLAP.
b. Comparison of the data with another well-known anti-PLAP Mab i.e. H17E2
although the two Mabs recognised different antigenic epitopes.
c. Heat resistance characteristics.
d. HPLC analysis of the ATC2 target antigen and comparison with purified PLAP.
These data confirm the exquisite specificity of ATC2 for human germ cell tumours.
The results also showed that the target antigen for ATC2 Mab was PLAP, although the
antigenic epitope(s) was different from those recognized by H17E2 Mab. The ATC2
may prove to be useful for monitoring sera levels of PLAP in testis cancer patients. It
may also prove to be relevant for detecting cancer cells in semen of individuals
suspected of testis cancers particularly in those with equivocal ultrasound.
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THE EFFECT OF TREATMENT ON THE HEALTH OF LONG
TERM SURVIVORS OF TESTICULAR CANCER RA Huddart,
A Norman, D Coward, E Nicholls, G Jay, M Shahidi, A Horwich, DP
Dearnaley, Royal Marsden Hospital and Institute of Cancer Research
The long term effects of treatment are an important consideration when deciding treat-
ment options in cancers which are largely curable such as testicular cancer. To eval-
uate the effects of treatment on the health of survivors of testicular cancer we have
undertaken a cross-sectional study of patients treated at our institution with a
minimum of 5 years follow up. Patients completed general health and quality of life
questionnaires, underwent biochemical and hormonal profiles and clinical review. Of
1603 patients treated between 1982 and 1992; 1203 are alive and fulfilled study entry
criteria. Of these, 730 patients entered the study. Information on cardiovascular
disease (CVD) and health problems was obtained on a further 202 patients not under
regular review. To study treatment effects, patients were divided into four groups
according to clinical management; surveillance (S) (N=233), radiotherapy (RT)
(N=219), chemotherapy (C) (N=371) and both chemotherapy and radiotherapy
(C/RT) (N=123). Median follow up was (in years) S 11.0, RT 9.1, C9.2, C/RT 11.1.
There was an increase risk of CVD in patients receiving RT (relative risk (RR) 2.2;
p=0.026), C (RR 1.8, p=0.09), and C/RT (RR 2.0, p=0.08), compared to patients on
surveillance. This was associated with a trend to increased risk of hypertension in
patients receiving any treatment (14% v 9% for S p=0.1) and detectable biochemical
changes including lower serum Na+ (RT C/RT) and Mg2+ (C/RT); increased K+ (RT, C,
C/RT), creatinine, (RT, C, C/RT) and protein, (C, C/RT). There was no difference in
smoking history or cholesterol in these groups.
A trend to increase in non testicular second malignanacies was also seen in patients
receiving treatment, (RR: RT 1.9, C 1.6, C-RT 2.55 p=0.2). Chemotherapy treatment
was associated with an increased frequency of sensory peripheral neuropathy (C 20%,
S 7% p<0.001), Raynauds syndrome (C 22%, S1% p<0.001), tinnitus (C 24%, S 12%
p=0.066) and hearing changes (both objective and subjective p<0.001). Radiotherapy
was associated with a reduced WBC (median(´109) RT 6.2, S 6.9 p=0.005), Hb
(median(g/dl) RT 14.2, S 14.5 p=0.006) and Platelet counts (median (´109) RT 217, S
228p=0.053) and an increased risk of GI symptoms (RT 8%, S 3% p=0.03). There
were high levels of gonadal dysfunction in all groups (low testosterone 16%, raised
FSH 49%, raised LH 12%).
Long term survivors of testicular cancer treatment are at an increased risk of
cardiovascular disease, increased risk of second malignancy and other health effects.
This data will be helpful in the counselling of patients and definition of treatment and
follow up, particularly in patients with Stage I disease.
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PACLITAXEL CHEMOTHERAPY IN THE SALVAGE OF
MULTIPLY RELAPSED AND PLATINUM REFRACTORY
GERM CELL TUMOURS JN Staffurth1*, J Nichols1, RA Huddart1, DP
Dearnaley1, A Horwich1, 1Royal Marsden NHS Trust, Sutton, UK
70–80% of patients with metastatic germ cell tumour will be cured with initial plat-
inum-based chemotherapy. Although 40% of the relapsing patients will be salvaged
with either ifosfamide-based conventional regimens or high-dose chemotherapy,
patients with multiply relapsed or platinum refractory tumours have an extremely
poor outlook. We investigated paclitaxel combination chemotherapy in this patients
group.
From 1996–99, nine patients with platinum refractory or multiply relapsed germ
cell tumours have been treated at our centre with paclitaxel containing regimens. Five
patients received paclitaxel with cisplatin/carboplatin, the remaining four received
paclitaxel and ifosfamide, with cisplatin/carboplatin. All patients had a testicular
primary tumour, two seminomas and seven malignant teratomas. The median age of
the patient was 38 years (range, 30–49). 6 patients (66%) had ³2 metastatic sites.
Median number of previous platinum cycles was nine (range, 5–15). Six had received
high dose carboplatin and etoposide with peripheral stem cell rescue. Two patients
were late relapses.
One patient (11%) had a complete response to the paclitaxel regimen, with only
differentiated teratoma in the resected specimen; his response lasted seven months.
No other patients responded.
The major toxicity was haematological, 66% of the patients suffering grade III/IV
neutropenia.
Paclitaxel has previously been shown to have a single-agent response rates of
10–26% in salvage of selected patients with relapsed germ cell tumours, and can be
incorporated safely into combinations with ifosfamide and cisplatin. However, in our
experience of heavily pre-treated patients, only one patient had a complete response,
lasting only seven months.78 Poster Presentations
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LATE RELAPSE OF TESTICULAR GERM CELL TUMOURS
AND IMPLICATIONS ON LONG TERM FOLLOW UP
M Shahidi1, AR Norman2, J Nicholls3, DP Dearnaley1, RA Huddart1, A
Horwich1, 1Academic Unit of Radiotherapy & Oncology, Royal Marsden NHS
Trust and the Institute of Cancer Research, 2Department of Computing and
Information, 3Bob Champion Unit, Royal Marsden NHS Trust Downs Road,
Sutton, Surrey, UK
Testicular germ cell tumours (GCTs) are highly curable, however 10–30% of patients
relapse after initial treatment. The time course of relapse has implications for duration
of follow up. This study was undertaken to assess the time course of relapse and to
identify patients with higher risk of late relapse. A review was performed of 1264
patients with primary testicular germ cell tumors presenting to the Royal Marsden
Hospital between December 1979 and December 1993. In all 256 episodes of relapse
were documented (including 44 patients with multiple relapses). Relapse-free
survivals were calculated (table). 54 patients (16 seminoma; 38 NSGCT) relapsed
more than 2 years after initial presentation. A multivariate analysis of risk of relapse
after 2 years identified advanced disease to be the only patients (1 seminoma; 14
NSGCT) relapsing after 5 years, 14 had metastatic disease at presentation. Relapse are
rare in testicular GCTs and follow up to detect recurrence may not be needed beyond
5 years except in those presenting with metastatic non-seminomatous GCTs.
Relapse free survival (No of patients at risk)
2 year 5 year 10 year
Seminoma Stage 1 93.7% (344) 91.4% (314) 91.4% (158)
Seminoma Stage 2 85.7% (93) 81.0% (81) 80.0% (53)
Seminoma Stage 3–4 75.8% (25) 75.8% (24) 75.8% (19)
NSGCT Stage 1 79.9% (273) 76.6% (233) 76.6% (132)
NSGCT Stage 2 91.6% (144) 90.2% (127) 87.9% (74)
NSGCT Stage 3–4 81.4% (151) 76.9% (131) 74.5% (90)
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TEN YEAR REVIEW OF SURVIVAL OF PATIENTS WITH
ADVANCED NON-SEMINOMATOUS GERM CELL TUMOURS
(NSGCT): THE WESTON PARK EXPERIENCE SI Ahmed*, J George, JM
Coleman, CR Radstone, JM Horsman, MQ Hatton, RE Coleman, YCR
Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK
Germ cell tumours constitute 40% seminomas and 60% non-seminomas (NSGCT).
Surgery and cisplatin-based chemotherapy are the main treatment modalities for
metastatic NSGCT, resulting in a survival rate of 80–90%. In an attempt to target toxic
treatments to patients at highest risk, categorisation of patients into prognostic groups
has resulted in the International Germ Cell Cancer Collaborative Group (IGCCCG)
prognostic grouping. This grouping considers the site of the primary tumour, three
markers (AFP, bhCG, LDH) and the presence of non-pulmonary visceral metastases.
The 5 year survival for good, intermediate and poor prognosis patients were reported
to be 92%, 80% and 48% respectively1. Although BEP (bleomycin, etoposide,
cisplatin) remains the standard treatment for metastatic NSGCT, more intensive regi-
mens have been suggested for the intermediate and poor prognosis patients including
the POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin/dactinomycin,
cyclophosphamide, etoposide) regimen.
Aim & Objectives To determine survival rates of patients with advanced NSGCT
with respect to age at diagnosis, prognostic group and chemotherapy regimen, as
compared to those published by the IGCCCG.
Method A retrospective analysis of survival data of all patients with advanced
NSGCT treated at Weston Park Hospital, between January 1989 and November 1999
was undertaken. Data was obtained from the Trent Regional Testicular Tumour
Registry Database. Patients with stage I disease on surveillance were excluded.
Disease free (DFS) and overall survival (OS) were determined.
Results 143 male patients with NSGCT were identified. The proportion of patients
in the good, intermediate and poor prognostic groups were 76 (53%), 29 (20%) and 38
(27%) respectively. The 5-year OS for the good, intermediate and poor prognostic
groups were 95.8%, 77.5% and 57.1% respectively. This compares well with the
IGCCCG survival rates. The IGCCC prognostic group was the only statistically
significant variable impacting on DFS (p=0.002) and OS (p=0.004).
Conclusion 5 year survival rates at this single Cancer Centre were found to be
higher than those published by the IGCCCG in all groups, except the 5-year OS for
the intermediate prognostic group. The significantly better survival rate found in this
study, for the poor prognostic group may be due to the use of the POMB-ACE
regimen.
1 IGCCCG (1997) JCO 15: 594
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GENETIC ANALYSIS OF A POTENTIALLY PRE-MALIGNANT
PHENOTYPE IN OVARIES OF WOMEN WITH BRCA
MUTATIONS J Gale*, I Campbell, D Eccles, N Singh, P Englefield, CRC
Wessex Medical Oncology Unit, Southampton General Hospital,
Southampton, UK
Prophylactic oophorectomy specimens from six women were examined; five had
BRCA1 and one a BRCA2 mutation. Atypical features were identified, and microdis-
sected from sections of paraffin-embedded ovarian tissue; matching normal cells were
obtained from other areas of the same section. DNA was extracted from dissected
tissue and leucocytes for each individual, and examined using microsatellite PCR for
loss of heterozygosity (LOH) at candidate loci on all chromosome arms. Most
sections revealed inclusion cysts; for one individual there were also multiple areas of
microscopic malignancy. Material from the BRCA2 mutant showed no LOH.
Amongst the remaining samples the following LOH was detected.
Chromosome arm LOH inclusion cyst LOH microscopic malignancy
(n=9) (n=9)
2p 1 1
5p 1 –
5q 1 1
6q 2 4
7q – 1
8q 1 1
9p 2 –
9q – 2
11q 2 –
13q 3 1
15q 4 5
17q 4 5
Xq 1 –
LOH on 5q, 6q, 9p, 11q and 17q has been previously reported for benign, borderline,
and low grade malignant ovarian tumours. For all those chromosome arms demon-
strating LOH within areas of microscopic malignancy, losses have been previously
described in ovarian carcinoma. The data collected supports the concept of a histolog-
ical pre-malignant phenotype in the ovaries of women with BRCA1 mutations.
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A PHASE I STUDY OF SEQUENTIAL TOPOTECAN AND
INFUSIONAL ETOPOSIDE PHOSPHATE IN RECURRENT
OVARIAN CANCER Deplanque G, Propper D, Levitt N, Bates N, Jones P,
Flanagan E, Perry J, Joel S, Ganesan TS, ICRF Medical Oncology Unit,
Oxford Radcliffe Hospitals, Oxford OX3 7LJ, UK and ICRF Medical Oncology
Unit St. Bartholew’s Hospital, London EC1A 7BE, UK
Background Topotecan (T) and etoposide phosphate (EP) are both active single
agents in the treatment of recurrent ovarian cancer. Preclinical in vitro and in vivo
studies suggest that they may act synergistically in sequential combination when inhi-
bition of topoisomerase I> by T is followed by upregulation of the EP target, topoiso-
merase II. 
Study design Phase I study to determine the toxicity and maximum tolerated dose
(MTD) of the sequential combination of topotecan iv day 1 to 5 followed by 120 hrs
infusional etoposide phosphate (day 6 to 11) targeting specific plasma etoposide
concentrations. Pts were evaluated for response at 3 cycles and responding patients
received a maximum of six cycles. 
Patient characteristics A total of 18 pts have been entered into the trial and 10 pts are
evaluable for toxicity and response. Median age is 55.5 years (31 to 66). Pts were
treated in second line (2), third line (5) and fourth line (3). Eight pts were resistant to
platinum. All the pts in dose levels 1, 2 and 1/5 at dose level 3 had received paclitaxel
previously in addition to platinum.
Dose level Topo mg/m2 EP (mg/ml) Pts Response
1 1 2 2 2PR
2 0.85 2 3 1PR 2PD
3 0.85 1 5 (+4) 1PR 1SD 3PD (4NE)
(4) (0.85) (1.5) (4) (Not evaluable)
Toxicities 46 cycles have been administered. Myelosuppression was the dose
limiting toxicity (DLT). At dose levels 1 and 2, grade 4 neutropenia was observed in
all pts. At dose level 3, grade 4 toxicity was observed in 1/5 evaluable pts. Alopecia
(grade 2) and nausea and vomiting (grade 1) were the other toxicities observed. 
Efficacy 4 PR for an ORR of 40%, with PR seen at each dose level.
Conclusion Sequential T plus infusional EP is feasible and promising, and
warrants further investigation in recurrent ovarian cancer. The maximum tolerated
dose for phase II trials has not yet been reached.Poster Presentations 79
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WEEKLY CISPLATIN AND ORAL ETOPOSIDE AS
TREATMENT FOR RELAPSED OVARIAN CANCER T Meyer*,
AE Nelstrop, M Mahmoudi and GJS Rustin, Dept Medical Oncology Mount
Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK
van der Berg has previously reported high response rates to weekly cisplatin and oral
etoposide in patients with platinum refractory relapsed ovarian cancer (van der Berg
1996 Proc Am Soc Clin Onc 15: Abs 772). We analysed 42 women with relapsed,
advanced ovarian cancer who were treated using a similar regimen with cisplatin 60
mg/m2 on days 1,8,15,29,36 and 43 and oral etoposide 50 mg given from day 1–15
and day 29–43. In those who were responding and tolerating treatment (n=13) oral
etoposide 50 mg was continued for two further cycles days 1–21 repeated every 28
days. The regimen was given as 1st line relapse therapy in 9 patients, as 2nd line in 19,
3rd line in 7 and 4th line in 8 patients. The mean age of the patients was 57.1 years
(range 33.8–80.7). The median time since previous treatment with cytotoxic
chemotherapy was 120 days and the median time since previous platinum administra-
tion was 223 days. A median of 5 doses of cisplatin was given to each patient, with 17
receiving the full 6 doses. A median of 28 doses of etoposide was given.
33 patients were evaluable for response according to CA 125 criteria (as defined in
Rustin et al 1996 J Clin Oncol 14: p1545) giving an overall response rate of 39.3%
(30.2% if non-evaluable patients were included). The response rate in evaluable
patients declined with increasing numbers of previous treatments: 57.1% with 1 prior
treatment, 40% with 2, 33.3% with 3 and 20% with 4. The response rates in evaluable
patients who had received prior platinum chemotherapy within 6 months (median 121
days) prior to treatment was 41.7% (5/12), while in those who had received platinum
more than 6 months previously (median 366 days) the response rate was 35% (7/20).
Treatment was reasonably well tolerated with the only significant non-haematological
toxicity being nausea and vomiting in 4 patients experiencing greater than grade 2
toxicity. The number of patients experiencing haematological toxicity more than
grade 2 was as follows: haemoglobin 3, white blood count 12, platelets 6. 16 patients
had dose delays and 2 had dose reductions.
We conclude that this short but intensive regimen provides worthwhile response
rates, even in those patients who would ordinarily be considered refractory to plat-
inum, and has an acceptable toxicity profile.
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PRELIMINARY RESULTS OF A PHASE II STUDY OF
WEEKLY PACLITAXEL AND ETOPOPHOS CHEMOTHERAPY
IN PATIENTS WITH RELAPSED OVARIAN CARCINOMA SI Ahmed*, J
Higgins, T Briggs, SD Pledge, RE Coleman, YCR Department of Clinical
Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
Although the prognosis for advanced ovarian cancer has improved, the median time to
relapse remains around 18 months, often with platinum resistant disease. Paclitaxel
(Taxol™) is usually administered on a 3-weekly schedule. A number of small studies
have identified that weekly Taxol is feasible and has produced responses even after
recurrences or progression on standard Taxol-based regimens. Etoposide has shown
activity in ovarian cancer in the salvage situation. Etoposide phosphate (Etopophos™)
has been recently formulated allowing administration as 5 minute bolus injection.
Taxol and Etopophos may act synergistically.
Aim & Objectives This is an ongoing study to assess efficacy and tolerability of
weekly Taxol and Etopophos given over 12 weeks, in patients with recurrent ovarian
cancer. Principle end-points are response rate, time to progression, toxicity and assess-
ment of quality of life (EORTC QLC30 questionnaire).
Method Patients with recurrent disease following at least one platinum and/or
taxane based chemotherapy, were recruited to receive Taxol 60 mg/m2 and Etopophos
100 mg/m2 on a weekly schedule over 12 weeks in out-patients.
Results 13 patients have been recruited to date, all had relapsed within 12 months
of receiving platinum-based chemotherapy, thus likely to represent drug resistant
relapse. Six of these women had also previously received taxanes. Disease was
assessed with fortnightly CA125 and CT scanning of measurable disease at 12 weeks.
The main dose limiting toxicities were Gl toxicity and neutropenia. No patients
required cessation of treatment due to toxicity. There were 7 delays in treatment due to
grade III neutropaenia, no grade IV neutropenia was seen. 1 patient had progressive
disease during treatment. 3 patients died during treatment. 2 succumbed to non-
neutropenic pneumonia and 1 patient developed a pulmonary embolus. 3 patients with
bulky intra-abdominal recurrence prior to starting chemotherapy developed DVTs
requiring anti-coagulation. 4 patients have had radiological evidence of partial
response.
Conclusions In this small phase II study of weekly Taxol and Etopophos, the
regimen is well tolerated and responses have been seen in patients with probable drug-
resistant relapse. Weekly scheduling of taxanes may improve their efficacy particu-
larly in cases of drug-resistance. Recruitment to this study continues.
P203
PACLITAXEL AND CARBOPLATIN DOSE-INTENSITY AND
DURATION OF INFUSION IN THE TREATMENT OF OVARIAN
CANCER AV Boddy, MJ Griffin, JG Wright, JA Sludden, HD Thomas, K
Fishwick, R Plummer, M Highley, AH Calvert, Cancer Research Unit,
University of Newcastle upon Tyne, UK
The combination of carboplatin and paclitaxel is an active treatment for ovarian
cancer. While different infusion durations have been studied for paclitaxel, the
pharmacological and clinical effects of shorter infusions have not been explored
thoroughly.
Eighteen patients with ovarian cancer were treated on a study where the dose of
carboplatin was determined by GFR, to attain a target AUC or 6 or 7 mg/ml.min.
Paclitaxel dose was 175 or 200 mg/m2, administered over 1 hour or 3 hours. The order
of treatment was randomized at the first course, crossing over to the alternative dura-
tion of infusion for the second course. Blood samples were analyzed for carboplatin,
paclitaxel and for ethanol and Cremophor.
Overall the three-weekly schedule of administration of the combination of carbo-
platin and paclitaxel was well-tolerated. Also, there was no clinical difference in the
toxicities observed between courses where a 1 h infusion was used, compared to a 3 h
infusion. Pharmacokinetics of carboplatin indicated that the target AUC was achieved
(mean ± standard deviation 114±20% of target) in the majority of cases. Analysis of
paclitaxel pharmacokinetics did not show a difference in the AUC or time above a
pharmacological threshold for the two infusion durations. The peak concentration of
drug obtained at the end of the infusion (9.1 vs 4.5 mg/ml), and the plasma ethanol
concentration (40.0 vs 20.5 mg/dl) were higher following the shorter duration infu-
sion. Peak concentrations of Cremophor were not different between the two infusion
durations.
These data indicate that the combination of paclitaxel at a dose of 175 mg/m2 and
carboplatin at a target AUC of 6–7 mg/ml.min can safely be administered every 3
weeks. Also, paclitaxel can be given as a 1 h infusion with no clinical disadvantage
over a 3 h infusion and these durations of administration are pharmacologically equiv-
alent.
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PACLITAXEL IN PLATINUM-RESISTANT EPITHELIAL
OVARIAN CARCINOMA AM Wardley*, A Jenkins, DL Alison,
and TJ Perren, ICRF Dept. of Medical Oncology, St. James’ Hospital, Beckett
Street, Leeds LS9 7TF, UK
Platinum based regimens continue to be the mainstay for treatment of epithelial
ovarian carcinoma, and treatment of platinum-resistant disease typically results in low
response rates and short survival. First-line treatment with Paclitaxel/platinum combi-
nations has improved response rates and progression free survival. We performed a
retrospective analysis of the use of paclitaxel in 97 patients treated with second-line
paclitaxel at a single large cancer centre. Of these, 85 patients had progressive disease
on or within 3 months of platinum-based chemotherapy. Eleven (13%) patients died
before response could be assessed. There were no complete and 19 (22.5%) partial
responses, 23 (27%) with stable and 32 (37.5%) with progressive disease. The median
survival was 8 (95% CI, 4.75–11.5) months and the progression free survival was 2
(1.2–3.1) months. Patients aged 40 years or less had significantly worse progression
free survival and overall survival than older-patients. There was no difference
according to number of previous courses of platinum-based chemotherapy, but
patients who had received up to 2 previous chemotherapy regimens in total had PFS
1.5 (1.3–1.75) compared to 4.4 (2.6–6.2) months (p < .01), for patients who had
received ³ 3 previous chemotherapy regimens. The progression free survival of
patients with responsive disease (5.75 ± 0.25 months) was significantly greater than
those with stable disease (4.5 ± 0.5 months, p< .005), and both of these groups had a
highly significant improvement in PFS compared to patients with progressive disease
(1.3 ± 0.1 months; p< .0000). The overall survival of these groups was 18.8 ± 2.6, 12
± 1.4 and 5.1 ± 1 months (p< .0000, log rank). There is a clear survival advantage in
patients who respond to paclitaxel in terms of progression free and overall survival.
There appear to be a group of patients whose disease is more responsive to
chemotherapy. Paclitaxel is not a panacea for all patients with platinum-resistant
disease and there remains a need to find alternative treatments.80 Poster Presentations
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THE EX VIVO EFFECT OF HIGH CONCENTRATIONS OF
DOXORUBICIN ON RECURRENT OVARIAN CARCINOMA
MH Neale1, A Lamont2, IA Cree*1, 1Dept of Pathology, Institute of
Ophthalmology, Bath Street, London EC1V 9EL, 2Dept of Radiotherapy &
Oncology; Southend Hospital; Westcliff-on-Sea; Essex SSO ORY, UK
The toxicity of anthracyclines has largely prevented dose intensification, but the use
of liposomal preparations allows much higher intra-tumoural concentrations to be
achieved. However, it is uncertain how much this will improve response rates over
standard dose single agent anthracycline therapy. The ATP-based chemosensitivity
assay (ATP-TCA) has been used to develop new regimens for several tumour types, to
investigate the molecular basis of chemosenstivity, and shows considerable promise
as a clinical method for individualising chemotherapy (1).
In this study, we have used the ATP-TCA to determine the concentration respon-
siveness of tumour-derived cells to concentrations of doxorubicin achievable with
liposomal preparations. The 21 tumour samples included were obtained from 19
heavily pre-treated patients with recurrent ovarian cancer, and seven had previous
anthracycline exposure, four as part of the CAP regimen.
The results show >95% inhibition at clinically achievable concentrations in 12/21
tumours tested. Of the rest, 7 showed a plateau effect between 80 and 95% inhibition,
suggesting that there might be a subset of resistant cells present which could not be
killed by high concentrations of doxorubicin. Two tumours showed complete resis-
tance: neither of these had received previously anthracycline therapy. As it has been
suggested that gemcitabine might enhance anthracycline sensitivity in combination,
and we have had good results with gemcitabine modulation of alkylating agents in the
assay (2), we have tested the combination of doxorubicin + gemcitabine under assay
conditions in 11 tumours with little indication of improvement.
In conclusion, doxorubicin at concentrations achievable with liposomal prepara-
tions shows strong ex vivo activity against pre-treated recurrent ovarian cancer in just
over half of the cases tested.
1 Cree IA, Kurbacher CM (1997) Anti-Cancer Drugs 8: 541–8
2 Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL,
Plowman PN (1999) Br J Cancer 79: 1487–93
P206
OUTPATIENT CHEMO-RADIOTHERAPY FOR CERVIX
CANCER USING LOW DOSE CISPLATIN – PRELIMINARY
RESULTS OF A MULTICENTRE LGOG STUDY MEB Powell1 & PR Blake2,
on behalf of the London Gynae-Oncology Group, 1Dept of Clinical Oncology
Barts & TheLondon NHS Trust, 2Dept of Gynae-Oncology Royal Marsden
Hospital NHS Trust
Introduction In 1999 the National Cancer Institute issued a rare clinical announce-
ment stating strong consideration should be given to adding concurrent cisplatin based
chemotherapy to radiotherapy for cervix cancer. This was prompted by abstracts
describing five phase 3 studies (four have now appeared as peer reviewed papers)
using chemoradiation and showing a reduction in risk of death from cervix cancer by
30–50%. A criticism of these trials is the sub-optimal delivery of radiotherapy, with
median treatment times of 50, 58, 63 and 63 days. It is well recognised that protracted
treatment times can reduce local control rates and based on this, most UK clinicians
aim to complete treatment in less than 50 days.
Aims This study aimed to evaluate whether chemoradiation could be safely incor-
porated into UK style shorter radiation schedules.
Methods Any patient with cervix cancer suitable for radical radiotherapy, with a
GFR>50 ml/min, performance status ≤2. Pelvic radiotherapy to a dose of 45–50 Gy in
25–28 fractions was prescribed, followed by intracavitary brachytherapy delivering a
total dose to point A of 70–80 Gy. Cisplatin chemotherapy was given as an outpatient
either twice weekly (20 mg/m2) or once weekly (40 mg/m2). Toxicity was measured
using WHO criteria and response initially assessed clinically and radiologically at
three months post treatment. Follow-up was 3 monthly thereafter.
Results Since April 1998 over 50 patients with a median age of 50 (range 28–72)
have been treated. Some degree of neutropaenia occurred in 70% of patients with 27%
showing grade 3) or severe (grade 4) effects. Thrombocytopaenia occurred in 12%.
Median duration of treatment was 48 days (range 39–69). Treatment delays, mainly
due to neutropaenia, were necessary in 11 out of the first 20 patients treated. This led
to a change from twice weekly to once weekly cisplatin and a recommendation to use
white cell growth factors. Subsequently only 2 patients have needed a delay in treat-
ment. Preliminary data on response will be presented.
Conclusion Chemoradiotherapy using a weekly outpatient cisplatin containing
regimen is feasible to deliver and well tolerated by patients. Significant haematolog-
ical toxicity is a problem and without the use of white cell growth factors could lead to
unacceptable protraction of treatment which could ultimately compromise cure.
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CHEMO-RADIOTHERAPY FOR CARCINOMA OF THE
CERVIX – THE ADDENBROOKE’S EXPERIENCE SG Russell,
LA Burgess and LT Tan, Oncology Centre, Addenbrooke’s Hospital,
Cambridge CB2 2QQ, UK
Introduction Cisplatin-based chemo-radiotherapy (chemo-RT) has been advocated as
the treatment of choice for patients with advanced carcinoma (Ca) of cervix with a
survival advantage of 10–17% compared to radiotherapy (RT) alone. However acute
toxicity is a serious concern and may lead to delays in RT which could offset any
benefit from the addition of chemotherapy. This prospective audit assesses the acute
toxicity, and subsequent delays in RT, of chemo-RT for Ca cervix at Addenbrooke’s
Oncology Centre.
Methods Since May 1999, 25 patients have received chemo-RT for advanced Ca
cervix. The median age was 50 (range=32–69) years. The stage distribution was as
follows: Ib = 7, IIa = 2, IIb = 8, IIIb = 6 and IVa = 1.2 patients had positive pelvic
nodes. Patients received 45–50 Gy in 25 daily fractions to the pelvic using opposed
anterior and posterior fields (8/25 = 32%) or a 3/4 field brick technique (17/25 =
68%). Chemotherapy consisted of single agent cisplatin 40 mg/m2 given at weekly
intervals during external beam RT. On completion of external beam RT, all patients
proceeded to a single brachytherapy (BT) insertion to a total dose of 65–75 Gy to
point “A” at a dose rate of 1.07–1.48 Gy/hr.
Results 17 patients (68%) had gastrointestinal (GI) toxicity during chemo-RT.
Urological toxicity occurred in 3 patients (12%), haematological toxicity in 7 (28%)
while 14 patients (56%) complained of general malaise. 1 patient with hydronephrosis
had a temporary deterioration in renal function which improved after further chemo-
RT. Only 1 patient had Grade 3 or higher toxicity of any system – she developed
neutropaenic pyrexia following her second cycle of chemotherapy. 17 patients (76%)
completed the prescribed course of 5 chemotherapy cycles. In the remaining 8
patients, 1–3 cycles of chemotherapy were omitted for GI-toxicity (4), deteriorating
renal function (1) and visual disturbance (2). 1 patient died of intra-abdominal throm-
bosis during the second week of chemo-RT. Another patient sustained a massive
pulmonary embolus within days of her BT treatment. In both patients, chemotherapy
was not considered a significant contributory factor to death. None of the 24 patients
who completed the prescribed course of external beam RT experienced any delays in
RT.
Conclusions In our experience, chemo-RT for Ca cervix is reasonably well toler-
ated and does not result in delays in RT. We believe that the lack of RT delays in our
patients was achieved by the vigilance of the gynaecology oncology team and early
action, including delay/omission of chemotherapy, in patients experiencing toxicity.
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A STUDY OF THE SAFETY OF INCREASED FOLINIC ACID
(FA) RESCUE FOR METHOTREXATE (MTX) TOXICITY IN
PATIENTS WITH PERSISTENT TROPHOBLASTIC DISEASE (PTD)
R Agarwal*, S Strickland, M Foskett, IA McNeish, ES Newlands and MJ Seckl,
Dept. of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK
Introduction MTX (50 mg IM) on days 1, 3, 5 and 7 with FA rescue (7.5 mg PO, 30
hours post MTX) on days 2, 4, 6 and 8 (MTX-FA)1 is the standard treatment for low
and medium risk PTD, at Charing Cross Hospital (CXH). Although well tolerated,
some patients develop significant mucositis which may result in treatment delays or a
change to another chemotherapy regime. Increasing the dose of FA rescue to 15 mg
usually ameliorates mucositis. However, this may potentially increase the subsequent
risk of MTX resistance. Here we have explored the safety and efficacy of using an
increased dose of FA for rescue in those patients with significant mucositis.
Method All patients treated with MTX-FA for PTD at CXH, between 1/1/97 to
1/1/99 were included in the study. Patients who developed more than one mouth ulcer,
or an ulcer which failed to heal in time for the next course of treatment, had their FA
rescue increased to 15 mg. The response to treatment was monitored with twice
weekly serum human chorionic gonadotrophin (hCG) measurements. Patients who
developed a plateau or rising hCG on MTX-FA were defined as MTX resistant and
were changed to actinomycin D, if the hCG was below 100 iu/l; otherwise they were
treated with etoposide, MTX, actinomycin D alternating weekly with cyclophos-
phamide and vincristine. Since the completion of treatment all patients have been
monitored with regular serum and/or urine hCG to detect any relapses.
Results A total of 105 patients were followed for an average of 19.2 months from
the start of chemotherapy. Increased FA rescue was required in 43% (n=45) of these
patients due to mucositis. No other treatment changes in the MTX-FA regime were
necessary in either group due to mucositis or other toxicity. The risk of developing
MTX resistance was not significantly different between patients receiving 7.5 mg
(FA-7.5) or 15 mg FA rescue (FA-15) (38.3% and 37.7% respectively, p=0.95). The
relapse rates following chemotherapy were also similar in the two groups (1.7% with
FA-7.5 and 2% with FA-15, p=0.84). In addition, the total duration of chemotherapy
was not significantly different either (average of 108 days in the FA-7.5 group and 107
days in the FA-15 group, p=0.23).
Conclusion The use of 15 mg of FA rescue in patients with mucositis enables the
continuation of MTX-FA chemotherapy with minimal morbidity, without compro-
mising the safety or efficacy of the treatment. We currently recommend that all
patients being treated with MTX-FA should receive 15 mg folinic acid rescue.
1 Bagshawe KD, Dent J, Newlands ES, Begent RH and Rustin GJS (1989) The
role of low-dose methotrexate and folinic acid in gestational trophoblastic
tumours (GTT). Br J Obstet Gynaecol 96: 795Poster Presentations 81
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INCREASED ENDOGENOUS N-NITROSATION IN THE
HUMAN COLON: A RESPONSE TO RED AND WHITE MEAT?
AJ Cross*1, JRA Pollock2, SA Bingham1, 1MRC Dunn Human Nutrition Unit,
Hills Rd, Cambridge CB2 2XY, 2Pollock and Pool Ltd, Ladbroke Close,
Woodley, Reading RG5 4DX, UK
Diets containing high levels of red meat have been associated with an increased risk of
sporadic colorectal cancer. One possible mechanism is via elevated levels of faecal
apparent total N-nitroso compounds (ATNC), which have been shown in response to
increased red meat intake (Bingham, 1996, Carcinogenesis, 17, 515). These N-nitroso
compounds may be DNA-alkylating agents capable of causing mutagenic damage as
seen in animal models. This study was designed to elucidate whether this increase in
ATNC is unique to red meat or whether white meat produces similar effects.
Five healthy male volunteers were assigned to a randomised sequence of 15-day
dietary periods (60 g red meat/day, 420 g red meat/day, 420 g white meat/day) whilst
living in a metabolic suite. The diets were isocaloric, low in nitrate and heterocyclic
amines and deionised water was used for cooking and drinking.
Faecal samples were analysed on day 14, for ATNC by thermal energy analysis
(Pignatelli, 1987, Analyst, 112, 945).
Endogenous production of ATNC was significantly increased (p=0.012) on the
high red meat diet (293 ± 25 mg/day) when compared with the low red meat diet (123
± 25 mg/day). However there were no significant differences (p= 0.370) in faecal
ATNC when comparing the high white meat diet (88 ± 18 mg/day) with the low red
meat diet.
High levels of white meat do not therefore affect endogenous production of ATNC
in the human colon, whereas high red meat diets significantly enhance production of
these compounds. The effect of red but not white meat may explain epidemiological
associations with cancer risks.
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COLORECTAL MUCOSA ADENOMA FORMATION AND O6-
ALKYLGUANINE DNA-ALKYLTRANSFERASE LEVELS: A
CASE-CONTROL STUDY NP Lees*1,2, KL Harrison1,3, CN Hall2, GP
Margison1, AC Povey3, 1Paterson Institute Manchester M20, 2Dept of
Surgery, Wythenshawe Hospital, Manchester M23, 3School of Epidemiology
and Health Sciences, Medical School, Manchester M13, UK
Introduction The promutagenic adduct O6-methylguanine is found in the human
colon and rectum, and is repaired by O6-alkylguanine DNA-alkyltransferase (ATase),
inactivating the protein in the process (1). ATase is inducible in experimental animal
systems (2). Colorectal ATase activity is lower in those with K-ras GC®AT transition
mutations in colorectal cancer than in those with colorectal cancer lacking this muta-
tion (3). Very little is known about ATase activity associated with colorectal adenoma
formation where K-ras mutation may first occur. We sought to investigate ATase
activity in the non-neoplastic and adenoma bearing large bowel.
Methods With ethical approval and patients’ consent, mucosal pinch biopsies
were taken adjacent to small (<1 cm) and large (³1 cm) adenomas found during
colonoscopy and from the same bowel segment of age- and sex-matched controls, free
of neoplasms during complete colonoscopy. ATase activities of extracts were
measured by quantifying the enzyme-dependent transfer of [H3]-labelled methyl
groups from calf thymus DNA, an established technique. Matched pairs were assayed
simultaneously.
Results Comparing mean ATase activity: 1; in the rectum (n=70), 250±116
fmol/mg protein and in the colon (n=100), 203±120 fmol/mg protein, P<0.01. 2; in
small adenoma cases (n=22), 214±146 fmol/mg protein and in matched controls
(n=22), 199±116 fmol/mg protein, p>0.1. 3; in large adenoma cases (n=63), 250±112
fmol/mg protein and in matched controls (n=63), 207±117 fmol/mg protein, P<0.05.
Conclusions This is the first systematic study of ATase activity in benign
colorectal neoplasia. There is significantly higher ATase activity in the rectum, the
commonest site of large bowel neoplasia, than in the colon. There is evidence of
increasing ATase activity in normal colorectal mucosa associated with adenoma
progression. Further studies should address whether alkylating, or other, agents cause
ATase upregulation in the human large bowel.
Work was supported by a grant from the AICR. The laboratory is supported by
CRC.
1 Pegg AE, Dolan ME and Moschel RC (1995) Prog Nucleic Acid Res Mol Biol
51: 167
2 Chinnasamy N, Rafferty JA, Margison GP, O’Connor PJ and Elder RH (1997)
DNA Cell Biol 16(4): 493
3 Jackson PE, Hall CN, O’Connor PJ, Cooper DP, Margison GP and Povey AC
(1997) Carcinogenesis 18(7): 1299
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METABOLISM AND BIOAVAILABILITY OF THE
CHEMOPREVENTIVE AGENT CURCUMIN IN RATS
CR Ireson1*, S Orr3, DJL Jones1, S Donald1, MW Williams2, CK Lim1, RD
Verschoyle1, WP Steward2 and A Gescher1, 1MRC Toxicology Unit and
2Department of Oncology, University of Leicester and 3Human Tissue Bank,
De Montford University, Leicester, UK
Curcumin (diferuloylmethane) is the major constituent of the spice turmeric, a yellow
pigment that can be isolated from the rhizome of the Curcuma Longa plant. Whilst
there is substantial evidence for the cancer chemopreventive efficacy of curcumin in
animals, little is understood regarding its bioavailability and metabolism. Therefore
we studied the disposition of curcumin in rats in vivo and in rat and human hepato-
cytes in vitro. Rats received a single dose of curcumin either via the i.v. (40 and 10
mg/kg) or oral routes (0.5 and 2.5 g/kg). A sensitive HPLC method was developed for
the detection of curcumin. Following i.v. administration curcumin disappeared within
30 min from the plasma, and after gastric intubation only trace levels of parent
compound could be detected. The following metabolites were identified in the plasma
following i.v. administration using liquid chromatography-electrospray mass spec-
trometry in the selected ion monitoring mode: tetrahydrocurcumin (THC, m/z=371),
hexahydrocurcumin (HHC, m/z=373), hexahydrocurcuminol (HHCO m/z=375),
curcumin sulphate (m/z=447) and curcumin glucuronide (m/z=543). Following oral
administration only conjugates of curcumin could be detected in the plasma. To
confirm the identity of the conjugates, plasma extracts were incubated with either b-
glucuronidase or aryl sulphatase. In each case the size of the conjugate peaks was
reduced, with a concurrent increase in that of the parent compound. Hepatocytes were
isolated from rats and humans and incubated with curcumin (100 mM) for 1–2 hr.
Curcumin was metabolised to THC, HHC and HHCO, but only to a very slight degree
to its sulphate and glucuronide conjugates. The results suggest that i) the systemic
bioavailability of curcumin is poor, ii) the metabolism of curcumin in rat and human
hepatocytes is qualitatively similar, and iii) hepatic metabolites are only minor
biotransformation products of curcumin in vivo. It is possible that the metabolites of
curcumin play a role in its pharmacological activity.
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REGULATION OF UNCOUPLING PROTEIN-1 AND -2 GENE
EXPRESSION BY A LIPID MOBILIZING FACTOR ST Russell*1,
MJ Tisdale1 and C Bing2, 1Pharmaceutical Sciences Institute, Aston
University, Birmingham B4 7ET, 2Department of Medicine, University of
Liverpool, Liverpool L69 3GA, UK
Loss of adipose tissue is part of the syndrome of cancer cachexia, which occurs in
about 50% of all untreated cancer patients. We have recently isolated a lipid mobi-
lizing factor (LMF) from the urine of weight losing patients with cancer, which
produces direct triglyceride hydrolysis in isolated adipocytes. In vivo studies show
specific depletion of carcass lipid with increased oxygen uptake of brown adipose
tissue (BAT), providing evidence for both increased lipid mobilization and utilization.
In the present study LMF was purified from the urine of cachectic cancer patients by
a combination of ion-exchange and hydrophobic interaction chromatography, and
injected iv (8 mg protein, b.d) into exbreeder male NMRI mice. A decrease in overall
body weight of 11±2% was observed within 48 h, without an effect on food consump-
tion. There was a decreased size of the fat pads and accumulation of fat in the liver.
There was a decrease in serum glucose (58%; p<0.01), glycerol (54%; p<0.05) and an
increase of (10%) in nonesterified fatty acids. Northern blotting of BAT showed
increased UCP-1 mRNA levels in LMF treated mice (+96%; p<0.01) and increased
UCP-2 (+146%; p<0.05) mRNA in gastrocnemius muscle. UCP-3 mRNA was also
increased in gastrocnemius muscle (+110%) but this did not reach statistical signifi-
cance. There was a small elevation (+0.6 ± 0.2°C) in body temperature in LMF-
treated animals suggesting an increase in thermogenesis through increased UCP-1
activity. The effect of LMF maybe mediated through a beta-3 adrenoceptor, since
lipolysis in vitro was attenuated by the specific beta-3 antagonist SR59230A and LMF
significantly increased cyclic AMP levels in CHO K1 cells transfected with the
human beta-3 adrenoceptor. These results suggest that LMF may play an important
role in the increase of energy expenditure associated with tumour growth.82 Poster Presentations
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EFFECT OF A TUMOUR PRODUCED LIPID-MOBILISING
FACTOR ON ADIPOSE TISSUE AND SKELETAL MUSCLE
Islam-Ali B*, Tisdale MJ, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK
A lipid-mobilising factor (LMF) was purified from the urine of patients with cancer
cachexia using a combination of ion-exchange and hydrophobic chromatography. It
had the ability to directly induce lipolysis in isolated epididymal murine white
adipocytes. In order to study this effect initial studies were carried out using
membranes isolated from white adipose tissue taken from NMRI mice bearing an
experimental cachexia inducing tumour model, MAC16 adenocarcinoma, known to
produce LMF. Immunoblotting of membranes taken from mice with increasing
degrees of weight loss showed an upregulation of stimulatory G proteins (Gs) paralled
with a downregulation of inhibitory G proteins (Gi). A reversal of this effect was
observed in mice treated orally with EPA, a polyunsaturated fatty acid. Human
adipose tissue taken from cachectic cancer patients demonstrated an increase expres-
sion of Gs with a decrease in Gi. An increase in Gs was noted in white adipose tissue
taken from mice administered LMF. These changes are thought to be related to the
increased lipid mobilisation seen in cancer cachexia.
LMF also increased protein synthesis in vitro using C2C12 myoblast cells in a dose
dependent manner. Maximum stimulation in protein synthesis was achieved at 50 mg
of protein over a 24 hr period giving an increase of 41% in comparison to control. The
observed effects were partially attenuated by pre-treating the cells with propanolol (10
mM) and a polyclonal antibody raised to human Zinc-a2-glycoprotein (Zna2gp). The
increase in protein measured by tritiated phenylalanine incorporation, was attributed
to the stimulation of adenylate cyclase (AC). The effect of LMF was attenuated in the
presence of the adenylate cyclase inhibitor MDL12330A (20 mM) and the protein kinase
A inhibitor H8 (10 mM). Dibutyryl-cAMP (0.5 mM and 1 mM) and forskolin (25 mM)
increased protein synthesis and these responses were additive to LMF. Thus the
increase in protein synthesis appears to be mediated by AC possibly through a b-
adrenergic receptor.
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COPY NUMBER GAIN AT 12Q12–14 MAY BE ASSOCIATED
WITH POOR OUTCOME FOLLOWING THE
TRANSFORMATION EVENT IN NON-HODGKIN’S LYMPHOMA RE Hough,
JR Goepel, HE Alcock, BW Hancock, PC Lorigan, DW Hammond*, Institute
for Cancer Studies, Division of Oncology and Cellular Pathology, University
of Sheffield Medical School, Sheffield S10 2RX, UK
Diffuse large B cell lymphoma (DLBL) arising from follicle centre cell lymphoma
(FCL) is typically refractory to treatment and median survival is only one year
following transformation.
Paired samples of paraffin-embedded FCL and subsequent transformed DLBL
from the same patient were obtained in 24 cases. DNA was extracted from tumour
cells which had been microdissected from tumour sections. Tumour DNA was
compared to same sex reference DNA using comparative genomic hybridisation.
Gains on chromosomes 2q, 7p, 12q and 17q and losses on 5p and 8q were present only
in transformed DLBL. Gain at 12q12–14 was found in 12 of the 23 transformed
DLBL (adequate DNA could not be obtained in one case) and was not seen in the FCL
counterpart.
Of the 11 patients not demonstrating gain at 12q12–14 on transformation (Group
A), 6 were male and median age at presentation was 55 years. Five patients had stage
III-IV disease at diagnosis. Eight of the 12 patients demonstrating gain at 12q12–14 at
transformation (Group B) were male. The median age at presentation was 51 years
and 7 patients had stage III-IV disease. Mean time from diagnosis to transformation
was similar in both cohorts, 60 months for Group A and 56 months for Group B.
Median survival following transformation was 35 months for Group A and 23 months
for Group B (p.0.05). Salvage therapy was similar in both groups. A non-significant
trend was also observed in overall survival with median survival in Group A of 116
months and in Group B of 97 months.
Gain at 12q12–14 was present in 52% patients with histologically proven trans-
formed DLBL. These patients have a trend towards a poorer survival following trans-
formation. Amplification of a gene at this site may be associated with resistance to
currently used cytotoxic agents and radiotherapy, contributing to a more aggressive
clinical course.
Supported by Yorkshire Cancer Research.
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IDENTIFICATION OF NOVEL REGIONS OF AMPLIFICATION
AND DELETION WITHIN MANTLE CELL LYMPHOMA DNA BY
COMPARATIVE GENOMIC HYBRIDIZATION JE Allen*, JR Goepel, RE
Hough, S Bottomley, GA Wilson, HE Alcock, EA Vandenberghe, BW
Hancock and DW Hammond, Division of Oncology and Cellular Pathology,
University of Sheffield, UK
Mantle cell lymphoma (MCL) is a recently classified entity of non-Hodgkin’s
lymphoma which has an aggressive clinical course despite being previously consid-
ered to be low grade. We have used comparative genomic hybridization (CGH) to
characterise alterations in the frequency of DNA sequences corresponding to either
amplifications or deletions of specific chromosome regions in archival cases of MCL.
A series of local cases was compiled and a diagnosis of MCL confirmed by a combi-
nation of histological review by an expert pathologist and immunohistochemistry
using a cyclin D1 antibody (NCL-CYCLIN D1-GM; Novocastra laboratories). The
status of the BCL-1 locus was investigated by FISH and PCR. DNA was extracted
from formalin fixed, paraffin embedded biopsy material and used for CGH experi-
ments. The DNA from each case was labelled with SpectrumGreen-dUTP (Vysis) and
co-hybridised with DNA from a normal individual labelled with SpectrumRed-dUTP
(Vysis) to normal male metaphase target slides. Digital images of target metaphases
were analysed using Quips Software (Vysis). Regions of genomic imbalance were
identified in all cases examined (n=30). Chromosome regions with amplification in
several cases included 3q (21/30), 6p (19/30), 7p (7/30), 7q(8/30), 12p (8/30), 12q
(9/30) and 17q11.1q21 (8/30). 19 cases (63%) shared a common region of amplifica-
tion of 3q28q29 which was highly amplified in 3 cases, suggesting the possible pres-
ence of a MCL related oncogene in this region. Chromosome regions with deletions in
several cases included 1p13p32 (10/30), 5p13p15.3 (9/30), 6q14q27 (11/30), 8p
(7/30), 11q13q23 (8/30) and 13q (18/30). There was a minimal common region of
deletion in 10 cases (33%) at 6q25q26. This is of considerable interest, since although
deletions of 6q are frequently found in B-cell lymphoma, no MCL specific locus has
previously been identified. The 6q25 region may therefore contain a tumour
suppressor gene specifically involved in the development of MCL.
This work is supported by Yorkshire Cancer Research.
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DETECTION OF NOVEL TRANSLOCATIONS INVOLVING BCL
10, A TUMOUR SUPPRESSOR GENE BY FLUORESCENT IN
SITU HYBRIDISATION Achuthan R*1, Bell SM2, Horgan K1, Markham AF2,
MacLennan KA3, 1Department of Surgery, Leeds General Infirmary, Leeds
LS1 3EX, 2Molecular Medicine Unit and ICRF Cancer Medicine Unit, St
James’s University Hospital, Leeds LS9 7TF, UK
Aims BCL 10 is a novel tumour suppressor gene thought to play an important role in
tumour progression in multiple tumour types. This study aims to seek novel transloca-
tions of this gene using fluorescent in situ hybridisation (FISH) and to determine its
role as a candidate gene in the development of lymphomas.
Materials and methods Fluorescent in situ hybridisation (FISH) was performed
on metaphases of patients (n = 20) diagnosed with lymphomas using a specific probe
for BCL 10 gene to detect novel translocations. In addition DNA was extracted from
archival fresh frozen tissue of these 20 and a further 12 (total=32) patients diagnosed
as having lymphoma. DNA was also obtained from three normal nodes as control. We
performed single strand conformational polymorphism (SSCP) analysis on these to
seek mutations in the BCL 10 gene. Additionally direct 33P sequencing was performed
on selected cases.
Results FISH confirmed a novel translocation t(1;2)(p22;p12) involving the BCL
10 gene and the kappa immunoglobulin light chain region on chromosome 2 in a case
of extra nodal, marginal zone lymphoma (MALT type). Previously changes involving
this gene have only been reported to the immunoglobulin heavy chain region. In the
remaining 19 patients no other changes were identified involving BCL 10.
Interestingly we identified 3 cases (3/20) with recurrent breakpoints in the 1p3 region,
telomeric to the BCL 10 gene. This region harbours many candidate tumour
suppressor genes suggesting the involvement of one such gene in these cases. These
changes are being further characterised.
Analysis for identifying mutations BCL10 by SSCP revealed band shifts in the
exon 1 region of the gene. Direct 33P sequencing detected polymorphisms in the gene
however failed to detect mutations.
Conclusions Using FISH we have found a novel translocation involving the BCL
10 gene in a case of MALT lymphoma. Mutation analysis did not reveal any mutations
of this gene at the DNA level and analysis at the post transcriptional level is ongoing.
In view of the translocation identified it appears that the role of BCL 10 may be
limited to the pathogenesis of MALT lymphomas. We have incidentally identified
recurrent breakpoints in the 1p3 region and this may be of importance as this region
contains many candidate tumour suppressor genes. Further work is underway in this
direction.Poster Presentations 83
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ISOTYPE SWITCH VARIANTS REVEAL CLONALLY-RELATED
SUBPOPULATIONS IN DIFFUSE LARGE B CELL
LYMPHOMAS: INSIGHTS INTO THE BIOLOGY OF GERMINAL CENTRE
LYMPHOMAS CH Ottensmeier*1, BS Wilkins2, JW Sweetenham1 and FK
Stevenson3, 1CRC Wessex Oncology Unit, Dpt of Histopathology2, Molecular
Immunology Group Tenovus3, Cancer Sciences Division, Southampton
Medical School, Southampton SO16 6YD, UK
Primary diffuse large cell lymphomas (DLBCL) are aggressive tumors accounting for
~40% of B-cell malignancies. Their immunoglobulin (Ig) variable region genes of
heavy (VH) and light chain have undergone rearrangement and are commonly somati-
cally mutated. The majority of tumours show intraclonal variation indicating that
somatic mutation has continued post-transformation. Typically, cells of DLBCL
express Ig of a single isotype, but there are often accompanying cells which express
alternative isotypes. In order to probe the status of the isotype switch process in
DLBCL, we have investigated six cases for tumour-derived constant region tran-
scripts of all isotypes. Using PCR, cloning and sequencing, multiple VH gene products
were analyzed for each case. For each of the immunoglobulin isotypes separate PCRs
were then amplified and sequenced in separate assays. Following identification of the
tumour related VDJ segments, the presence of the major isotype expected from
immunohistochemical analysis was confirmed at the RNA level. A further 3–4 alter-
native isotypes were revealed in all cases, some of which were also demonstrable by
immunohistochemistry. All cases were somatically mutated with intraclonal variation.
In two cases, we found clearly distinct patterns of somatic mutation between isotypes,
consistent with independent evolution of the tumor sub-populations. There was clus-
tering of mutational patterns into either an IgMD/IgG3/IgA set, or an IgG1/IgA set,
indicating that switch to IgA can occur by different routes. We conclude that alterna-
tive isotype expression is evident in DLBCL, both at the RNA and protein levels. The
pattern of mutation indicates that switching is occurring in subpopulations of the
tumor after malignant transformation. The findings support the concept that isotype
switching may be a feature of DLBCL and illustrate the germinal centre origin of
these tumors. Additionally the findings demonstrate that the malignant cells can
respond to mechanisms, active in normal B cells without being able to achieve full
differentiation.
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PRIMARY NON-HODGKINS LYMPHOMA (NHL) OF THE
GASTRO-INTESTINAL (GI) TRACT – THE SHEFFIELD
LYMPHOMA GROUP (SLG) EXPERIENCE (1989–1998) Koh PK,* Horsman
J, Hancock H, Hancock BW, YCR University Department of Clinical
Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK
The GI tract is one of the commonest sites of extranodal lymphoma; the concept of
MALT (mucosa associated lymphoid tissue) origin and recognition of the role of
Helicobacter pylori has revolutionised clinical management. The SLG experience
reflects that of most other studies. Primary (Stage IE IIE) GI lymphoma was seen in 71
cases (comprising 45 (63%) stomach, 16 (23%) small intestine and 9 (13%) large
intestine) These cases accounted for 26% of all extranodal presentations and 6% of all
NHL seen by the group. Clinical presentation was most often (80%) dyspepsia/pain in
gastric lymphomas; intestinal lesions presented commonly (70%) with obstructive
features. Histopathology review (according to the Revised European American
Lymphoma (REAL) classification) showed that MALT lymphoma was the
commonest type (54% of all cases, 87% arising in the stomach). Diffuse large B cell
lymphoma accounted for 21% of cases, most frequently (60%) arising in the intestine.
Treatment was often surgery followed by observation or anti-helicobacter therapy (for
MALT tumour) or by combination chemotherapy (for diffuse large ‘B’ cell
lymphomas). Surgery was less often the primary treatment in stomach lymphomas
seen later in the study period. The 5 and 10 year survivals were 52% and 45% respec-
tively, comparable to results from other centres. In this small series univariate analysis
showed significantly better survival only for Stage I vs II. The survival for primary GI
NHL was similar to that for extranodal lymphoma, seen by the SLG, as a whole.
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PROGNOSTIC FACTORS FOR SURVIVAL IN MALIGNANT
LYMPHOMA – A RETROSPECTIVE ANALYSIS OF 1198
PATIENTS SEEN BY THE SHEFFIELD LYMPHOMA GROUP (SLG)
SE Low*, J Horsman, C Radstone, H Hancock, BW Hancock, YCR University
Department of Clinical Oncology, Western Park Hospital, Sheffield S10 2SJ,
UK
Many haematological, biochemical and immunological indices have been considered
important as prognostic markers in lymphoma, culminating in prognostic models such
as those of the International Prognostic Factors Project for aggressive non-Hodgkin’s
lymphoma and advanced Hodgkin’s disease (N. Eng. J. Med 1993; 329: 987 and
1998; 339: 1506, respectively).
We have retrospectively evaluated, by univariate analysis, putative markers that
were routinely recorded on patients seen by the SLG between 1970 and 1998. 1198
patients were evaluable for overall survival. Broad histological categories (Hodgkin’s
Disease and Non-Hodgkin’s Grade I and II – according to British National Lymphoma
Investigation classification) were used.
p values for Log Rank test for equality of Survival distributions
WCC WCN WCL Hb ESR LDH IgM Alb
HD * * * ***
<1.0¯ <11.5¯ <0.5¯ <35¯
NHL I ** * ** * ** ***
<1.0¯ <11.5¯ >50¯ High¯ Lower¯ <35¯
NHL II *** *** *** *** *** ** *** ***
High­ 2.6–5­ Lower¯ Lower¯ >20¯ High¯ <0.5¯ Lower¯
* p <0.05; ** p <0.01; *** p <0.001; HD – Hodgkin’s Disease; NHL – Non-
Hodgkin’s Lymphoma; WCC – Total white cell count; WCL – Lymphocyte
count (´ 109/L); Hb – Haemoglobin (g/dL); ESR – Erythrocyte Sedimentation
Rate (mm/Hr); LDH – Lactate dehydrogenase (U/L); IgM – Immunoglobin M
(g/L); Alb – Albumin (g/L).
In summary, on univariate analysis, significant adverse prognostic markers for all
or some histological categories were low serum albumin, low serum IgM, low haemo-
globin, low lymphocyte count, raised ESR, raised LDH and raised white cell count.
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EXPOSURE TO LOW CONCENTRATIONS OF ETOPOSIDE
REDUCES THE DIFFERENTIATION AND APOPTOTIC
CAPABILITY OF LEUKAEMIC CELL LINES WM Liu, PR Oakley and SP
Joel, ICRF Department of Medical Oncology, St Bartholomew’s Hospital,
London, UK
The development of secondary leukaemia following treatment with etoposide has
been highlighted in a number of studies. The risk of incidence appears to be schedule
dependent, although the exact mechanism of this secondary leukaemogenesis has not
been fully elucidated. We have investigated the effect of low etoposide concentrations
on the ability of cells to initiate apoptosis and undergo cellular differentiation in three
leukaemic cell lines.
The incubation of CEM and HL60 cells with a low concentration of etoposide (LC-
etoposide: 0.04 mM) had no effect on cell proliferation or cell cycle dynamics.
Following a continuous culture with LC-etoposide for 5-days, cells were allowed to
recover for one week in drug-free medium, then exposed to 0.3 mM etoposide for 4-
days (IC60). There was a significant increase in viability (%V) and decrease in apop-
tosis (%A) compared to cells without the pre-treatment with LC-etoposide (%V: 93.1
± 2.1% vs. 57.8 ± 5% and %A: 1.0 ± 0.4% vs. 8.5 ± 0.4%; p < 0.001), associated with
a decrease in bax-protein levels. Additionally, there was an 82% reduction in growth
factor-induced haemoglobinisation in K562 cells pre-treated with LC-etoposide
compared to K562 cells without (6.5 ± 4.8% vs. 40.1 ± 3.3%; p < 0.001). In contrast,
the pre-culture of cells with a low cisplatin-concentration did not suppress the cyto-
toxicity of subsequent exposure to cisplatin. Our data has shown that there was no
change in the karyotype in these cells, but a two-fold increase in the number of chro-
mosomal aberrations. Results also revealed that a 3-day-minimum duration of expo-
sure to LC-etoposide was required to induce this suppression in apoptosis and
differentiation.
These data confirm that etoposide can induce effects which are maintained in the
absence of drug and which subsequently affect apoptosis and differentiation. This cell
system may provide a model for the induction of chromosomal changes which can
give rise to secondary leukaemias.84 Poster Presentations
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LONG-TERM OTUCOME OF PATIENTS WITH ACUTE
LEUKAEMIA INM Micallef, AZS Rohatiner, M Carter, S Slater,
JAL Amess and TA Lister, ICRF Medical Oncology Unit and Dept of
Haematology, St. Bartholomew’s Hospital, London ECIA 7BE, UK
Between 1972 and 1988, 834 consecutive patients (pts., median age 48 years [yrs.],
range 15–81 yrs.) received treatment for newly diagnosed acute leukaemia, with cura-
tive intent. In 5 pts. treatment involved an allograft, in 5 pts. high-dose treatment
supported by autologous bone marrow transplantation. Patients were seen quarterly
for the first 5 yrs., and annually thereafter; only one patient was lost to follow-up. A
retrospective analysis was conducted to review outcome in the 101 pts. (12%) who
survived more than 10 yrs. from diagnosis (67/630 pts. [11%] acute myelogenous
leukaemia [AML], 34/204 pts. [17%] acute lymphoblastic leukaemia [ALL]). With a
median follow-up of 16 yrs. (range 10–28 yrs.), 88 of 101 pts. (88/834 of the total,
11%) are still alive. To date, 22 pts. have developed recurrent leukaemia, in 6 (AML 4,
ALL 2) after 5 yrs. (6, 8, 8, 9, 11 and 20 yrs. respectively). Seventy-one pts. continue
in first, 15 in second and 2 in third remission. Thirteen have died, 3 of leukaemia or of
treatment related toxicity, 4 of another malignancy, 3 of heart failure and 3 of unre-
lated causes. Twenty-six children are known to have been born from 29 pregnancies in
19 pts. (10 men, 9 women). One of the children has a chromosome 15 abnormality and
is developmentally delayed, another died shortly after birth with anencephaly and
multiple organ abnormalities, one has epilepsy. Eight women were documented to
have premature ovarian failure and 3 men had oligo or azoospermia. Twenty-one
subsequent malignancies have been observed (haematological 4, skin 3, cervix 3,
squamous cell 2, breast 2, gastrointestinal tract 2, lung 2, hydatidiform mole 1, astro-
cytoma 1, adenocarcinoma 1). Benign meningiomas have occurred in 2 pts.; both had
received cranial irradiation (one prophylactic, one both prophylactic and therapeutic
for CNS relapse). One additional pt. developed CNS radiation damage. Three pts. (all
with ALL) have persistent alopecia. Long-term follow-up of pts. who have survived
more than ten years following treatment for acute leukaemia reveals a significant
number of other malignancies (21%), late recurrences (6%) and complications
following cranial irradiation (4%). It is also clear that there is a persistent small risk of
death (3%) from recurrent leukaemia. These data show the value of long follow-up
and suggest that patients should not be discharged from the clinic.
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LONG TERM OUTCOME OR PATIENTS WITH INVASIVE
THYMOMA L Vini, N Fersht, RA ‘Hern, C Harmer, Dept of
Clinical Oncology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ,
UK
Aim This is a retrospective study aiming to assess the long term results of treatment
and outcome of patients with thymoma.
Patients Over the last 30 years, 107 patients with thymoma were treated at the
Royal Marsden Hospital. There were 56 men and 51 women with a median age at
diagnosis of 47 years (range 5–83 years). Sixty-one patients (58%) presented with
chest. Twenty-eight were asymptomatic when a mediastinal mass was found on a
routine chest radiograph. In 15 cases the diagnosis was made following thymectomy
for myasthenia gravis while in 3 the thymoma was discovered following investiga-
tions for red cell aplasia.
Results Tumours were staged according to Masaoka staging system: there were 2
stage I, 28 stage II, 32 stage III, 30 stage IVA and 15 stage IVB tumours. Initial
management included complete surgical resection in 25 cases, microscopically
incomplete resection in 38, surgical debulking in 18 and biopsy only in 26. Post-oper-
ative radiotherapy (20–60 Gy) was given to 65 patients and adjuvant chemotherapy to
38. With a median follow-up of 16 years (1–30 years) local recurrence occurred in 48
patients and distant metastases (mainly in bone and lung) in 15. Sixty patients have
died (there were 12 deaths of unrelated causes), 27 are alive with no evidence of
tumour progression and 17 are alive with disease. Overall 5 and 10-year survival was
55% and 38% respectively. Stage of disease (p<0.001), extent of surgery (p<0.01) and
adjuvant radiotherapy (p<0.01) were important prognostic factors for local recurrence
and survival.
Conclusions Surgical excision (total resection whenever possible) is the standard
treatment for thymomas. The effect of post-operative radiotherapy and chemotherapy
is not clear due to lack of prospective studies. Radiotherapy, however, seems to be of
value in advanced and incompletely resected tumours.
P223
LATE COMPLICATIONS OF MANTLE RADIOTHERAPY FOR
HODGKIN’S LYMPHOMA A Sibtain*, A Bradshaw, N Shah, PJ
Hoskin, Marie Curie Research Wing, Mount Vemon Hospital, Northwood HA6
2RN, UK
Aim To identify the rate and type of complications from mantle radiotherapy in the
treatment of Hodgkin’s Disease.
Design A retrospective review of the BNLI database for Hodgkin’s Disease
patients treated at Mount Vernon Hospital between January 1970 and December 1985.
Results In the 141 sequentially registered patients in the database, 39 complica-
tions in 28 patients treated to the mantle area or neck were found. 2 of these also
received radiotherapy to the para-aortic region. The median age at diagnosis was 37.5
(range 15–66). The median overall survival is 181 months. The treatment was
predominantly delivered using a cobalt machine with only 5 patients treated on a 4
MV and 5 MV linear accelerator. Treatment technique was by either direct field alone
(12 patients) or a direct field with a posterior mediastinal boost once or twice a week.
Three patients were treated with daily opposed fields. The midplane dose was
between 30 and 40 Gy, 12 patients receiving 40 Gy. In order to achieve this with low
energy beams and this treatment technique, anterior applied doses of over 50 Gy were
required in 13 patients.
The complications comprise 18 lung, 6 cardiac, 4 laryngeal, 5 second malignancy,
2 skin, 2 hypothyroidism, and one each of oesophageal stricture and jugular vein
thrombosis. 16 of the 28 patients have died, with treatment related events contributing
in 8 of these. Two bronchial carcinomas may have been incidental, leaving 6 patients
whose death was unequivocally related to treatment complication, a treatment related
mortality rate of 4.2%.
The median time of onset of complications from treatment was 89 months (range
8–332 m). The median time to cardiac complications was 143 months (range 67–237
m). The median time to lung complications was 61 months (range 8–303 m). Ten of
these developed early lung complications between 8 and 31 months, whereas the other
9 developed late complications between 89 and 303 months after treatment. The
second tumours seen were basal cell carcinoma at 90 months, lung carcinomas at 117
and 129 months, bowel carcinoma at 293 months and oesophageal carcinoma at 332
months. All were within the radiation field.
Conclusion An overall late complication rate after mantle radiotherapy for
Hodgkin’s disease of 28% and an absolute treatment related mortality of between
4.2% and 5.7% has been observed in this cohort of patients. This may reflect the use
of low energy beams weighted anteriorly with consequent high applied doses. Modern
techniques can be expected to produce a much lower treatment complication rate.